0001079973-24-000236.txt : 20240214 0001079973-24-000236.hdr.sgml : 20240214 20240214124835 ACCESSION NUMBER: 0001079973-24-000236 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 56 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240214 DATE AS OF CHANGE: 20240214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BION ENVIRONMENTAL TECHNOLOGIES INC CENTRAL INDEX KEY: 0000875729 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE CHEMICALS [2870] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 841176672 STATE OF INCORPORATION: CO FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19333 FILM NUMBER: 24635161 BUSINESS ADDRESS: STREET 1: PO BOX 323 CITY: OLD BETHPAGE STATE: NY ZIP: 11804 BUSINESS PHONE: (212) 758-6622 MAIL ADDRESS: STREET 1: PO BOX 323 CITY: OLD BETHPAGE STATE: NY ZIP: 11804 FORMER COMPANY: FORMER CONFORMED NAME: RSTS CORP DATE OF NAME CHANGE: 19930328 10-Q 1 bion_10q.htm FORM 10-Q
false --06-30 2024 Q2 0000875729 0000875729 2023-07-01 2023-12-31 0000875729 2024-02-01 0000875729 2023-12-31 0000875729 2023-06-30 0000875729 2023-10-01 2023-12-31 0000875729 2022-10-01 2022-12-31 0000875729 2022-07-01 2022-12-31 0000875729 bnet:SeriesAPreferredStocksMember 2022-09-30 0000875729 bnet:SeriesCPreferredStocksMember 2022-09-30 0000875729 us-gaap:CommonStockMember 2022-09-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000875729 bnet:SubscriptionsReceivableMember 2022-09-30 0000875729 us-gaap:RetainedEarningsMember 2022-09-30 0000875729 us-gaap:NoncontrollingInterestMember 2022-09-30 0000875729 2022-09-30 0000875729 bnet:SeriesAPreferredStocksMember 2023-09-30 0000875729 bnet:SeriesCPreferredStocksMember 2023-09-30 0000875729 us-gaap:CommonStockMember 2023-09-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000875729 bnet:SubscriptionsReceivableMember 2023-09-30 0000875729 us-gaap:RetainedEarningsMember 2023-09-30 0000875729 us-gaap:NoncontrollingInterestMember 2023-09-30 0000875729 2023-09-30 0000875729 bnet:SeriesAPreferredStocksMember 2022-06-30 0000875729 bnet:SeriesCPreferredStocksMember 2022-06-30 0000875729 us-gaap:CommonStockMember 2022-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000875729 bnet:SubscriptionsReceivableMember 2022-06-30 0000875729 us-gaap:RetainedEarningsMember 2022-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2022-06-30 0000875729 2022-06-30 0000875729 bnet:SeriesAPreferredStocksMember 2023-06-30 0000875729 bnet:SeriesCPreferredStocksMember 2023-06-30 0000875729 us-gaap:CommonStockMember 2023-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000875729 bnet:SubscriptionsReceivableMember 2023-06-30 0000875729 us-gaap:RetainedEarningsMember 2023-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2023-06-30 0000875729 bnet:SeriesAPreferredStocksMember 2022-10-01 2022-12-31 0000875729 bnet:SeriesCPreferredStocksMember 2022-10-01 2022-12-31 0000875729 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0000875729 bnet:SubscriptionsReceivableMember 2022-10-01 2022-12-31 0000875729 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2022-10-01 2022-12-31 0000875729 bnet:SeriesAPreferredStocksMember 2023-10-01 2023-12-31 0000875729 bnet:SeriesCPreferredStocksMember 2023-10-01 2023-12-31 0000875729 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0000875729 bnet:SubscriptionsReceivableMember 2023-10-01 2023-12-31 0000875729 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2023-10-01 2023-12-31 0000875729 bnet:SeriesAPreferredStocksMember 2022-07-01 2022-12-31 0000875729 bnet:SeriesCPreferredStocksMember 2022-07-01 2022-12-31 0000875729 us-gaap:CommonStockMember 2022-07-01 2022-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-12-31 0000875729 bnet:SubscriptionsReceivableMember 2022-07-01 2022-12-31 0000875729 us-gaap:RetainedEarningsMember 2022-07-01 2022-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-12-31 0000875729 bnet:SeriesAPreferredStocksMember 2023-07-01 2023-12-31 0000875729 bnet:SeriesCPreferredStocksMember 2023-07-01 2023-12-31 0000875729 us-gaap:CommonStockMember 2023-07-01 2023-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-12-31 0000875729 bnet:SubscriptionsReceivableMember 2023-07-01 2023-12-31 0000875729 us-gaap:RetainedEarningsMember 2023-07-01 2023-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-12-31 0000875729 bnet:SeriesAPreferredStocksMember 2022-12-31 0000875729 bnet:SeriesCPreferredStocksMember 2022-12-31 0000875729 us-gaap:CommonStockMember 2022-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000875729 bnet:SubscriptionsReceivableMember 2022-12-31 0000875729 us-gaap:RetainedEarningsMember 2022-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2022-12-31 0000875729 2022-12-31 0000875729 bnet:SeriesAPreferredStocksMember 2023-12-31 0000875729 bnet:SeriesCPreferredStocksMember 2023-12-31 0000875729 us-gaap:CommonStockMember 2023-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000875729 bnet:SubscriptionsReceivableMember 2023-12-31 0000875729 us-gaap:RetainedEarningsMember 2023-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2023-12-31 0000875729 bnet:SEBFarmsLLCMember 2023-09-28 0000875729 bnet:BridgeLoanAgreementsMember 2023-09-28 0000875729 bnet:BridgeLoanAgreementsMember 2023-10-31 0000875729 2023-10-03 2023-10-05 0000875729 bnet:Gen3TechMember 2023-07-01 2023-12-31 0000875729 2022-01-27 2022-01-28 0000875729 2022-06-01 2022-06-30 0000875729 2023-01-16 2023-01-17 0000875729 2023-04-23 2023-04-24 0000875729 2023-05-01 2023-05-02 0000875729 2023-07-25 2023-07-26 0000875729 2021-07-01 2022-06-30 0000875729 2022-07-01 2023-06-30 0000875729 2023-11-01 2023-11-30 0000875729 2017-07-01 2018-06-30 0000875729 srt:MinimumMember 2023-12-31 0000875729 srt:MaximumMember 2023-12-31 0000875729 us-gaap:WarrantMember 2023-07-01 2023-12-31 0000875729 us-gaap:WarrantMember 2022-07-01 2022-12-31 0000875729 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-12-31 0000875729 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-12-31 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2023-07-01 2023-12-31 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2022-07-01 2022-12-31 0000875729 us-gaap:ComputerEquipmentMember 2023-12-31 0000875729 us-gaap:ComputerEquipmentMember 2023-06-30 0000875729 us-gaap:ConstructionInProgressMember 2023-12-31 0000875729 us-gaap:ConstructionInProgressMember 2023-06-30 0000875729 bnet:PropertyPlantAndEquipmentOfPA1Member 2023-07-01 2023-12-31 0000875729 bnet:WilliamONeillMember 2023-12-31 0000875729 srt:ChiefExecutiveOfficerMember 2023-12-31 0000875729 srt:ChiefOperatingOfficerMember 2023-12-31 0000875729 bnet:BassaniMember 2022-12-31 0000875729 bnet:SmithMember 2022-12-31 0000875729 bnet:ConsultantsMember 2023-12-31 0000875729 bnet:ConsultantsMember 2022-12-31 0000875729 srt:ChiefExecutiveOfficerMember 2023-07-01 2023-12-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2023-10-01 2023-12-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2022-10-01 2022-12-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2023-07-01 2023-12-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2022-07-01 2022-12-31 0000875729 bnet:PennvestLoanMember 2023-12-31 0000875729 2021-09-30 0000875729 2021-12-29 0000875729 bnet:YearsOneThroughFiveMember bnet:PennvestLoanMember 2023-07-01 2023-12-31 0000875729 bnet:YearsSixThroughMaturityMember bnet:PennvestLoanMember 2023-07-01 2023-12-31 0000875729 bnet:PennvestLoanMember 2021-07-01 2022-06-30 0000875729 bnet:PennvestLoanMember 2020-07-01 2021-06-30 0000875729 2021-06-30 0000875729 bnet:PA1Member 2014-09-25 0000875729 bnet:PA1Member 2022-06-14 2022-06-15 0000875729 bnet:MarkASmithMember 2023-12-31 0000875729 bnet:DominicBassaniMember 2023-12-31 0000875729 bnet:EdSchaferMember 2023-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember bnet:SmithMember 2023-02-02 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember bnet:BassaniFamilyTrustsMember 2023-02-02 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember bnet:SchaferMember 2023-02-02 0000875729 bnet:BassaniMember srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember 2023-02-02 0000875729 bnet:EdSchaferMember srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember 2023-02-02 0000875729 bnet:BassaniMember bnet:The2020ConvertibleObligationsMember 2023-12-31 0000875729 bnet:SmithMember bnet:The2020ConvertibleObligationsMember 2023-12-31 0000875729 bnet:EdwardSchaferMember bnet:The2020ConvertibleObligationsMember 2023-12-31 0000875729 bnet:BassaniMember bnet:The2020ConvertibleObligationsMember 2023-06-30 0000875729 bnet:SmithMember bnet:The2020ConvertibleObligationsMember 2023-06-30 0000875729 bnet:EdwardSchaferMember bnet:The2020ConvertibleObligationsMember 2023-06-30 0000875729 bnet:BassaniMember bnet:September2015ConvertibleNotesMember 2023-12-31 0000875729 bnet:EdwardSchaferMember bnet:September2015ConvertibleNotesMember 2023-12-31 0000875729 bnet:BassaniMember bnet:September2015ConvertibleNotesMember 2023-06-30 0000875729 bnet:EdwardSchaferMember bnet:September2015ConvertibleNotesMember 2023-06-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-01-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-12-31 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-12-31 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-12-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-12-31 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member 2023-07-01 2023-12-31 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member 2023-12-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-07-01 2023-12-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-07-01 2022-12-31 0000875729 2023-02-02 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2023-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniMember 2023-12-31 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember bnet:SchaferMember 2023-12-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember bnet:ShareholderMember 2023-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniMember 2022-12-31 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember bnet:SchaferMember 2022-12-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember bnet:ShareholderMember 2022-12-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2023-07-01 2023-12-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2022-07-01 2022-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniFamilyTrustsMember 2023-12-31 0000875729 bnet:ConvertibleBridgeLoanDefaultMember 2023-09-28 0000875729 bnet:ConvertibleBridgeLoanDefaultMember 2023-10-31 0000875729 bnet:ConvertibleBridgeLoanDefaultMember us-gaap:ConvertibleDebtMember 2023-07-01 2023-12-31 0000875729 bnet:September2015ConvertibleNotesMember bnet:RestrictedCommonSharesMember 2023-12-31 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-01 0000875729 us-gaap:SeriesBPreferredStockMember 2014-06-30 2014-07-01 0000875729 us-gaap:SeriesBPreferredStockMember 2023-07-01 2023-12-31 0000875729 us-gaap:SeriesBPreferredStockMember 2023-12-31 0000875729 us-gaap:SeriesBPreferredStockMember 2022-07-01 2023-06-30 0000875729 us-gaap:SeriesBPreferredStockMember 2021-07-01 2022-06-30 0000875729 bnet:RestrictedCommonStockMember 2023-07-01 2023-12-31 0000875729 bnet:RestrictedCommonStockMember 2023-12-31 0000875729 bnet:RestrictedCommonStock1Member 2023-07-01 2023-12-31 0000875729 bnet:RestrictedCommonStock1Member 2023-12-31 0000875729 bnet:RestrictedCommonStock2Member 2023-07-01 2023-12-31 0000875729 bnet:RestrictedCommonStock2Member 2023-12-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember bnet:PrincipalMember 2023-07-01 2023-12-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2023-07-01 2023-12-31 0000875729 bnet:ConsultantServiceMember 2023-07-01 2023-12-31 0000875729 bnet:ConsultantServiceMember 2023-12-31 0000875729 bnet:ConsultantService1Member 2023-07-01 2023-12-31 0000875729 bnet:ConsultantService1Member 2023-12-31 0000875729 bnet:ConsultantService2Member 2023-07-01 2023-12-31 0000875729 bnet:ConsultantService2Member 2023-12-31 0000875729 bnet:ConsultantService3Member 2023-07-01 2023-12-31 0000875729 bnet:ConsultantService3Member 2023-12-31 0000875729 bnet:ConsultantService4Member 2023-07-01 2023-12-31 0000875729 bnet:ConsultantService4Member 2023-12-31 0000875729 bnet:WarrantsMember 2023-12-31 0000875729 bnet:WarrantsMember 2023-07-01 2023-12-31 0000875729 bnet:The2020ConvertibleObligationsMember bnet:PrincipalMember us-gaap:WarrantMember 2023-07-01 2023-12-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2023-07-01 2023-12-31 0000875729 us-gaap:ConvertibleDebtMember bnet:The2020ConvertibleObligationsMember us-gaap:WarrantMember 2023-12-31 0000875729 us-gaap:WarrantMember bnet:RestrictedCommonStockMember 2023-07-01 2023-12-31 0000875729 us-gaap:WarrantMember bnet:RestrictedCommonStockMember 2023-12-31 0000875729 2023-09-25 2023-09-26 0000875729 2023-09-26 0000875729 us-gaap:WarrantMember 2023-07-01 2023-12-31 0000875729 bnet:ConsultantService4Member us-gaap:WarrantMember 2023-07-01 2023-12-31 0000875729 bnet:ConsultantService1Member us-gaap:WarrantMember 2023-07-01 2023-12-31 0000875729 srt:ChiefExecutiveOfficerMember 2022-05-01 0000875729 bnet:ConsultantsMember us-gaap:WarrantMember 2023-12-31 0000875729 bnet:ConsultantsMember us-gaap:WarrantMember 2023-07-01 2023-12-31 0000875729 us-gaap:EmployeeStockOptionMember bnet:EquityIncentivePlanMember 2022-04-07 0000875729 us-gaap:EmployeeStockOptionMember 2023-12-31 0000875729 bnet:Plan2006Member 2023-03-14 2023-03-15 0000875729 bnet:Plan2006Member 2023-05-08 2023-05-09 0000875729 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-12-31 0000875729 bnet:BassaniMember bnet:SecuredPromissoryNoteMember 2023-12-31 0000875729 bnet:SecuredPromissoryNoteMember 2023-12-31 0000875729 srt:PresidentMember bnet:SecuredPromissoryNoteMember 2023-12-31 0000875729 srt:PresidentMember bnet:WarrantsIssuedSubscriptionReceivableMember 2023-12-31 0000875729 bnet:SmithsMember bnet:SecuredPromissoryNoteMember 2023-12-31 0000875729 bnet:FormerEmployeeMember bnet:SecuredPromissoryNoteMember 2023-12-31 0000875729 bnet:FormerEmployeeMember bnet:WarrantsIssuedSubscriptionReceivableMember 2023-12-31 0000875729 srt:PresidentMember 2016-10-09 2016-10-10 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2023-03-31 0000875729 srt:PresidentMember bnet:WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember 2023-03-31 0000875729 2022-04-27 2022-05-02 0000875729 bnet:SmithMember 2023-10-01 2023-12-31 0000875729 bnet:SmithMember 2022-10-01 2022-12-31 0000875729 bnet:SmithMember 2023-07-01 2023-12-31 0000875729 bnet:SmithMember 2022-07-01 2022-12-31 0000875729 srt:ChiefExecutiveOfficerMember 2015-02-03 2015-02-10 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2016-10-31 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2017-04-27 0000875729 bnet:BassaniMember 2018-02-28 0000875729 bnet:BassaniMember 2018-07-28 2018-08-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsExpiringOnDecember312025Member 2018-08-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2023-10-01 2023-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2022-10-01 2022-12-31 0000875729 srt:ChiefExecutiveOfficerMember 2023-10-01 2023-12-31 0000875729 bnet:WilliamONeillMember 2022-04-27 2022-05-02 0000875729 srt:ChiefExecutiveOfficerMember 2022-10-01 2022-12-31 0000875729 2022-03-01 2022-03-31 0000875729 2023-05-02 0000875729 2022-04-29 2022-04-30 0000875729 2022-03-22 2022-03-23 0000875729 2023-06-22 2023-06-23 0000875729 bnet:SEBFarmsLLCMember 2023-09-29 0000875729 bnet:BridgeLoanAgreementsMember 2023-09-29 0000875729 2023-12-29 2024-01-02 0000875729 us-gaap:SubsequentEventMember 2024-01-01 2024-01-02 0000875729 us-gaap:SubsequentEventMember 2024-01-02 0000875729 us-gaap:SubsequentEventMember 2024-01-17 2024-01-18 0000875729 us-gaap:SubsequentEventMember 2024-01-18 0000875729 us-gaap:SubsequentEventMember 2024-02-13 0000875729 us-gaap:SubsequentEventMember bnet:SmithMember 2024-02-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure bnet:Decimal

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended December 31, 2023

 

   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______ to _________

 

Commission File No. 000-19333

 

Bion Environmental Technologies, Inc.

(Name of registrant in its charter)

 

Colorado   84-1176672
(State or other jurisdiction of incorporation or formation)   (I.R.S. employer identification number)

 

9 East Park Court

Old Bethpage, New York 11804

(Address of principal executive offices)

 

516-586-5643

(Registrant’s telephone number, including area code) 

 

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Securities Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock BNET OTCQB

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

    Large accelerated filer     Accelerated filer    
    Non-accelerated filer     Smaller reporting company    
    Emerging growth company         

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 

 

 
 

 

 

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS: Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Not applicable.

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

On February 1, 2024, there were 56,906,124 Common Shares issued and 56,201,815 Common Shares outstanding.

 

 

 

 
 
 

 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC.

 

FORM 10-Q

 

TABLE OF CONTENTS

 

PART I.  FINANCIAL INFORMATION   Page
       
Item 1. Condensed Consolidated Financial Statements    1
    Balance sheets   1
    Statements of operations   2
    Statement of changes in equity (deficit)   3
    Statements of cash flows   4
    Notes to unaudited condensed consolidated financial statements   5
       
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations   41
       
Item 3. Quantitative and Qualitative Disclosures about Market Risk   53
       
Item 4. Controls and Procedures   53
       
PART II.  OTHER INFORMATION    
       
Item 1. Legal Proceedings   54
       
Item 1A. Risk Factors   56
       
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   56
       
Item 3. Defaults Upon Senior Securities   56
       
Item 4. Mine Safety Disclosures   56
       
Item 5. Other Information   56
       
Item 6. Exhibits   57
       
  Signatures   58

 

 

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements, within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that involve substantial risks and uncertainties. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expect," "intend," "estimate," "anticipate," "project," "predict," "plan," "believe" or "continue" or the negative thereof or variations thereon or similar terminology. The expectations reflected in forward-looking statements may prove to be incorrect.

 

 ii
 
 

 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

         
   December 31,   June 30, 
   2023   2023 
   (unaudited)     
         
ASSETS
         
 Current assets:          
 Cash  $384,735   $625,964 
 Prepaid expenses   3,394    16,785 
 Deposits and other assets   6,000    6,000 
           
 Total current assets   394,129    648,749 
           
 Operating lease right-of-use asset   66,090    93,875 
 Property and equipment, net (Note 3)   9,110,640    6,851,009 
           
 Total assets  $9,570,859   $7,593,633 
           
 LIABILITIES AND EQUITY (DEFICIT)          
           
 Current liabilities:          
 Accounts payable and accrued expenses  $2,648,005   $677,136 
 Deferred compensation (Note 4)   1,225,226    864,781 
 Convertible Bridge Note Payable (Note 6)   255,407       
 Operating lease liability, current (Note 9)   71,091    75,000 
           
 Total current liabilities   4,199,729    1,616,917 
           
 Operating lease liability, long term (Note 9)         29,068 
 Convertible notes payable - affiliates (Note 6)   1,740,083    1,715,970 
           
 Total liabilities   5,939,812    3,361,955 
           
           
 Equity (deficit):          

Common stock, no par value, 250,000,000 shares authorized,

50,611,962  and 48,044,790 shares issued, respectively;

49,907,653 and 47,340,480 shares outstanding, respectively

          
Additional paid-in capital   132,798,923    131,935,418 
Subscription receivable - affiliates (Note 8)   (504,650)   (504,650)
Accumulated deficit   (128,700,799)   (127,236,663)
           
Total Bion's stockholders’ equity (deficit)   3,593,474    4,194,105 
           
Noncontrolling interest   37,573    37,573 
           
Total equity (deficit)   3,631,047    4,231,678 
           
Total liabilities and deficit  $9,570,859   $7,593,633 

  

 

See notes to condensed consolidated financial statements

 

 

 

1 
 

 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
SIX MONTHS ENDED DECEMBER 31, 2023 AND 2022
(UNAUDITED)

                 
   Three months ended   Six months ended 
   December 31,   December 31, 
   2023   2022   2023   2022 
                 
Revenue  $     $     $     $   
                     
Operating expenses:                    
General and administrative (including stock-based compensation)   636,017    630,542    1,302,272    1,497,036 
Depreciation   460    394    921    724 
Research and development (including stock-based compensation)   7,431    15,148    15,730    43,591 
                     
Total operating expenses   643,908    646,084    1,318,923    1,541,351 
                     
Loss from operations   (643,908)   (646,084)   (1,318,923)   (1,541,351)
                     
Other (income) expense:                    
Interest income   (109)   (1,375)   (504)   (3,310)
Interest expense   74,790    85,285    145,717    111,380 
                     
Total other expense   74,681    83,910    145,213    108,070 
                     
Net income (loss)   (718,589)   (729,994)   (1,464,136)   (1,649,421)
                     
Net loss attributable to the noncontrolling interest                        
                     
Net income (loss) applicable to Bion's common stockholders  $(718,589)  $(729,994)  $(1,464,136)  $(1,649,421)
                     
Net income (loss) applicable to Bion's common stockholders                    
per basic and diluted common share  $(0.01)  $(0.02)  $(0.03)  $(0.04)
                     
Weighted-average number of common shares outstanding:                    
Basic and diluted   48,748,554    43,620,051    49,321,180    43,533,789 

 

   

 

See notes to condensed consolidated financial statements

 

2 
 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)
THREE AND SIX MONTHS ENDED DECEMBER 31, 2023 AND 2022
(UNAUDITED)

 

                                                        
Three months ended December 31, 2023 and 2022         
Bion's Stockholders'         
   Series A Preferred Stock   Series C Preferred Stock   Common Stock  

Additional

paid-in

   Subscription Receivables   Accumulated   Noncontrolling   Total 
   Shares   Amount   Shares   Amount   Shares   Amount   capital   for Shares   deficit   interest   equity/(deficit) 
                                             
Balances, October 1, 2022        $           $      44,303,654   $      124,300,604   $(504,650)  $(124,966,975)  $37,573   $(1,133,448)
Sale of units   —            —            226,230          226,230                      226,230 
Issuance of warrants for services   —            —            —            32,250                      32,250 
Modification of warrants   —            —            —            68,088                      68,088 
Net loss   —            —            —                        (729,994)         (729,994)
Balances, December 31, 2022        $           $      44,529,884   $     $124,627,172   $(504,650)  $(125,696,969)  $37,573   $(1,536,874)
                                                        
Balances, October 1, 2023        $           $      49,485,556   $      132,197,829   $(504,650)  $(127,982,210)  $37,573   $3,748,542 
Sale of units   —            —            375,000          375,000                      375,000 
Warrants exercised under cashless exercise   —            —            265,639                                     
Issuance of units for services   —            —            36,506          48,334                      48,334 
Issuance of warrants for services                       —            5,000                   5,000 
Vesting of options for employees and services   —            —            —            52,378                      52,378 
Vesting of warrants for employees and services   —            —            —            3,281                      3,281 
Debt Modification   —            —            —            (8,430)                     (8,430)
Conversion of debt and liabilities   —            —            449,261          42,500                      42,500 
Modification of warrants   —            —            —            89,031                      89,031 
Commission on sale of units   —            —            —            (6,000)                     (6,000)
Net loss   —            —            —                      (718,589)         (718,589)
Balances, December 31, 2023        $           $      50,611,962   $     $132,798,923   $(504,650)   (128,700,799)  $37,573   $3,631,047 

  

 

 

 

3 
 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)
THREE AND SIX MONTHS ENDED DECEMBER 31, 2023 AND 2022
(UNAUDITED) CONTINUED

   

Six months ended December 31, 2023 and 2022        
Bion's Stockholders'         
   Series A Preferred Stock   Series C Preferred Stock   Common Stock   Additional paid-in   Subscription Receivables   Accumulated   Noncontrolling   Total 
   Shares   Amount   Shares   Amount   Shares   Amount   capital   for Shares   deficit   interest   equity/(deficit) 
                                             
Balances, July 1, 2022        $           $      43,758,820   $      123,620,046   $(504,650)  $(124,047,548)  $37,573   $(894,579)
Sale of units   —            —            546,230          546,230                      546,230 
Warrants exercised for common shares   —            —            74,834          88,375                      88,375 
Issuance of units for services   —            —            50,000          80,000                      80,000 
Issuance of warrants for services   —            —            —            15,000                      15,000 
Conversion of debt and liabilities   —            —            100,000          50,000                      50,000 
Modification of warrants   —            —            —            227,521                      227,521 
Net loss   —            —            —                        (1,649,421)         (1,649,421)
Balances, December 31, 2022        $           $      44,529,884   $     $124,627,172   $(504,650)  $(125,696,969)  $37,573   $(1,536,874)
                                                        
Balances, July 1, 2023        $           $      48,880,237   $      131,935,418   $(504,650)  $(127,236,663)  $37,573   $4,231,678 
Sale of units   —            —            403,589          420,742                      420,742 
Warrants exercised for common shares   —            —            38,000          28,500                      28,500 
Warrants exercised under cashless exercise   —            —            265,639                                     
Issuance of units for services   —            —            56,759          76,320                      76,320 
Issuance of warrants for services   —            —            —            5,000                      5,000 
Vesting of options for employees and services   —            —            —            107,487                      107,487 
Vesting of warrants for employees and services   —            —            —            6,563                      6,563 
Debt Modification   —            —            —            (16,861)                     (16,861)
Conversion of debt and liabilities   —            —            967,738          91,548                      91,548 
Modification of warrants   —            —            —            150,206                      150,206 
Commission on sale of units   —            —            —            (6,000)                     (6,000)
Net loss   —            —            —                        (1,464,136)         (1,464,136)
Balances, December 31, 2023        $           $      50,611,962   $     $132,798,923   $(504,650)  $(128,700,799)  $37,573   $3,631,047 

 

 

  

 

See notes to condensed consolidated financial statements

 

  

4 
 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
SIX MONTHS ENDED DECEMBER 31, 2023 AND 2022

 

           
   2023   2022 
CASH FLOWS FROM OPERATING ACTIVITIES          
Net income (loss)  $(1,464,136)  $(1,649,421)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation expense   921    724 
Accrued interest on loans payable, deferred compensation and other   145,717    43,292 
Stock- based compensation   129,048    223,021 
Stock-based compensation for services   81,321    127,250 
Decrease in prepaid expenses   13,391    80,062 
Decrease in accounts payable and accrued expenses   220,699    (949,097)
Decrease (increase) in operating lease assets and liabilities   (5,192)   32,308 
Increase in deferred compensation   427,583    170,000 
           
Net cash used in operating activities   (450,648)   (1,921,861)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Purchase of property and equipment   (483,823)   (739,486)
           
Net cash used in investing activities   (483,823)   (739,486)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Proceeds from sale of units   420,742    546,230 
Commission on the sale of units   (6,000)      
Proceeds from convertible bridge loan   250,000       
Proceeds from exercise of warrants   28,500    56,125 
           
Net cash provided by financing activities   693,242    602,355 
           
Net decrease in cash   (241,229)   (2,058,992)
           
Cash at beginning of year   625,964    3,160,442 
           
Cash at end of year  $384,735   $1,101,450 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest  $     $   
           
Non-cash investing and financing transactions:          
Conversion of debt and liabilities into common units  $49,048   $50,000 
Conversion of debt and liabilities into notes payable  $     $23,943 
Conversion of deferred compensation to notes payable  $80,767   $60,000 
Conversion of notes payable into shares  $91,548       
Purchase of property and equipment for accounts payable  $1,750,170   $135,673 

 

 

See notes to condensed consolidated financial statements

5 
 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SIX MONTHS ENDED DECEMBER 31, 2023 AND 2022

 

 

1.       ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS:

 

Organization and nature of business:

 

DUE TO THE RECENT DEATH (FOLLOWING EXTENDED ILLNESS) OF DOMINIC BASSANI (WHO MOST RECENTLY SERVED AS OUR COO (FROM MAY 2022) AFTER SERVING AS OUR CEO FOR THE PRIOR DECADE) AND DIFFICULTIES IN RAISING NEEDED FUNDS (WHICH RE-EMERGED DURING THE 2023 FISCAL YEAR AND HAVE CONTINUED THROUGH THE CURRENT QUARTER TO DATE), THE COMPANY IS FACING INCREASED CAPITAL NEEDS AND THE NEED TO TRANSITION TO A YOUNGER MANAGEMENT TEAM (MARK A. SMITH, THE COMPANY’S PRESIDENT AND GENERAL COUNSEL, PROVIDED NOTICE DURING EARLY 2023 OF HIS INTENT TO PHASE OUT HIS MANAGEMENT ROLES EARLY THIS CALENDAR YEAR). THESE ITEMS HAVE BEEN PREVIOUSLY DISCLOSED BUT THE COMPANY BELIEVES IT IS IMPORTANT TO FEATURE THEM ‘UPFRONT’ AT THIS POINT. PLEASE NOTE:

 

A: The Company is not generating any significant revenues. Further, the Company’s anticipated revenues, if any, from existing Projects, JVs and proposed Projects will not be sufficient to meet the Company’s anticipated operational and capital expenditure needs for many years. See “Going Concern and Management’s Plans” below. Current liabilities were approximately $4.2 million at December 31, 2023. There was an increase of approximately $2.6 million from a year earlier (which was largely due to an increase in ‘accounts payable and accrued expenses’ totaling approximately $2.0 million and an increase in ‘deferred compensation’ of approximately $.35 million) as a result of the Company’s limited success in raising new financing (equity and/or debt) during the recent period in combination with continued expenses (including those related to the Initial Project); and

B: On September 28, 2023 the Company entered into an agreement for a $1,500,000 bridge loan and executed documents including a convertible promissory note (“Note”) and a binding subscription agreement (“Subscription”) (collectively the Note and the Subscription are the “Bridge Loan Agreements”) with SEB LLC, a non-affiliated party (“Lender”). The Bridge Loan Agreements require the Lender to loan the Company $1,500,000 in six monthly tranches of $250,000 commencing October 2023. All sums advanced under the Bridge Loan Agreements (and accrued interest thereon) would due and payable (with interest accrued at 9% per annum) on October 1, 2024 if not previously converted into securities of the Company. The Note is convertible at $1.00 per unit, at the sole election of the Lender, into units consisting of one share of the Company’s common stock and a warrant to purchase one half share. The initial $250,000 tranche was received by the Company on October 5, 2023. However, no further funds were received by the Company from the Lender. During early November 2023 the Lender informed the Company verbally that it did not intend to fulfill its obligations pursuant to the Bridge Loan Agreements and since such time the Lender has been in default (“Default”). The Default (which is continuing) has exacerbated the Company’s exiting problems and materially damaged the Company and rendered the Company unable to meet its creditor obligations on a timely basis. The Company is currently evaluating its rights regarding the Default by the Lender. See Notes re Bridge Loan/Default. This situation has contributed to the substantial increase in the Company’s ‘Current Liabilities’ including ‘accounts payable’ over recent periods. See Consolidated Financial Statements and ‘Management’s Discussion and Analysis’. The Company is in discussion/negotiation with its larger creditors (including its largest creditor--- the primary contractor on the Initial Project) and anticipates reaching agreements re payments during the current quarter (or soon thereafter).

 

 

6 
 

 

 

Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to make livestock production more sustainable, profitable and transparent. We intend to accomplish this by deploying our Gen3Tech platform/business model (discussed below) in ventures focused on the ‘feeder’ space of the livestock production/value chain to provide the consumer with verifiably sustainable premium meat products (together with environmentally friendly, sustainable and/or organic co-products from the production process).  Bion believes this approach can create extraordinary value for our shareholders and employees (all of whom own securities in the Company) and for livestock/agriculture industry ‘partners’ who join us in our ventures. We anticipate pursuing the opportunity created by our third generation technology (“Gen3Tech”) and business/technology platform in conjunction with other industry practices (“Gen3Tech Platform” or “Platform”) utilizing a joint venture/strategic partner model. We believe our approach will improve the well-being of farmers, ranchers, feeders, etc. that we work with and create value for our shareholders while improving the environment.  

 

Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our Gen3Tech” can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These waste ‘assets’ – nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate surface groundwater, and exacerbate climate change.

 

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms) (“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). To accomplish Bion’s goals, we anticipate the we will ‘partner’ with other technology companies who provide solutions for different links of the beef (and other livestock) value chain and with strategic partners up and down the supply chain. We anticipate this will result in substantial long-term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent one of the largest enhanced revenue contributors provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

Bion’s Gen3Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the animal raising and waste treatment process will be third-party verified, providing the basis for additional revenues, including carbon and/or renewable energy-related credits and, eventually, payment for a range of ecosystem services, including nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.

 

During the first half of calendar 2022 Bion began pre-marketing our sustainable beef opportunity to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During our 2023 fiscal year, Bion entered into three (3) letters of intent (“LOIs”): a) July 2022 letter of intent to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch (“Ribbonwire LOI”), in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”), (b) January 2023 letter of intent to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Olson Feeders and TD Angus (“Olson LOI”), near North Platte, Nebraska (with a provision to expand to 45,000 head or more) (“Olson Project”) and c)April 2023 letter of intent to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with Dakota Valley Growers (“DVG LOI”) near Bathgate, North Dakota (“DVG Project”). The Company is in discussions with additional parties regarding potential further LOIs. Based on our experience to date, we believe we will not have difficulty in securing participation in our Projects from additional feeders/cattlemen. The Olson, Dalhart and DVG Projects (and subsequent Projects) will be developed to produce blockchain-verified, sustainable beef in customized covered barns (resulting in reduced stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) with ongoing manure transfer (through slatted floors) to anaerobic digesters (AD) to capture nitrogen from the manure stream before loss to the atmosphere and generate renewable natural gas (RNG) for sale while remediating the environmental/carbon impacts usually associated with cattle feedlots and CAFOs. Bion’s patented Gen3Tech platform will refine the waste stream into valuable coproducts that include clean water, RNG, photovoltaic solar electricity and fertilizer (‘climate smart’ and/or organic) products. We anticipate converting tone or more of these LOIs into definitive JV agreements and creating related distribution agreements with key retailers and food service distributors during the current calendar year.

 

 

7 
 

 

Our business plan is focused on executing multiple agreements and letters of intent related to additional sustainable beef JV projects over the next twenty-four (24) months while continuing our work at the Initial Project (see below) and commencing development of one or more of the Dalhart/Olson/DVG Projects (“LOI Projects”)(and/or other Gen3Tech beef JV projects) while pursuing other opportunities in the livestock industry enabled by our Gen3Tech business model.  The LOI announcements have generated significant interest within the livestock industry (among ranchers, feedlot operators, farmers and other AG industry parties) and has led to and assisted our discussions with many major of the larger agriculture/livestock industry companies (including those involved with distribution and/or sales of meat products) in the country which are ongoing at this date. We believe that this interest, combined with consumer interest in ‘sustainable products’ and growing enthusiasm among some livestock industry parties for environmental/sustainable/regenerative practices, may provide Bion (and its partners/venturers) with an opportunity to move forward with a truly sustainable solution in this industry segment at a rapid pace. 

 

During the 2023 calendar year, the Company has constructed (construction is largely completed) our 3GTech Ammonia Recovery System (‘ARS’) located near Fair Oaks, Indiana and begun operations of phase 1 of our Initial Project (our commercial scale demonstration facility) located near Fair Oaks, Indiana. The Initial Project has been deemed ‘placed in service’ effective January 1, 2024. Operating results to date at Fair Oaks indicate ARS performance will exceed initial expectations for ammonia recovery and related economics. The Company recently announced that we have achieved key objectives in the optimization of its ARS and will now begin the final design process for full-scale systems based on results to date (and testing over the remainder of this fiscal year) at the Initial Project. The ARS has achieved and maintained controlled steady-state operations under a variety of conditions. When operated at steady state, the system produces an ammonium distillate (solution), the base of Bion’s nitrogen fertilizer products. Bion has begun optimizing the ARS’s operating parameters with the goal of meeting and/or exceeding the results needed for Bion’s economic models for large-scale commercial projects. The Company expects the current optimization phase will continue during the next quarter (or longer) and provide data required to support final design/engineering for commercial project modules. We believe this data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, distributors, retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below). Final economic and energy efficiency models will be validated during the final design process. The Company intends to engage a third party engineering firm during the next quarter to prepare a third-party evaluation of the ARS while also moving forward on final commercial design process.

 

The patented ARS is the core of Bion’s Gen3Tech platform. It recovers and upcycles problem ammonia contained in the effluent from anaerobic digestion (where methane is captured and more ammonia is released) of the livestock manure waste stream. The ARS captures the ammonia, minimizing its environmental impacts and creating low-carbon and/or organic nitrogen fertilizer products with it. During the last three (3) months,, the Company has produced ammonium distillate and ammonium bicarbonate solutions at the Initial Project in several concentrations and plans to initiate the application process for organic certification for each concentration of liquid fertilizer product. Multiple applications to OMRI (Organic Materials Review Institute) and CDFA (California Department of Food and Agriculture) are being prepared for listing/certification of new organic products. Bion received an OMRI-Listing in 2020 for its initial product. Bion will continue producing liquid and crystal fertilizers at the Initial Project to support testing and life-cycle analysis, product trials, and ongoing organic initiatives. Bion will produce a solid/granular nitrogen fertilizer product at the Initial Project (when the crystalizer module is ready for operation) which we believe will be both ‘Climate-Smart’ and ‘Water-Smart’ – a pure nitrogen fertilizer with a low carbon footprint, that is water soluble and readily available to plants. Samples of the granular product will also be utilized to support organic certification applications. See Fertilizer---Organic and ‘ClimateSmart’ below.

 

 Bion expects the Initial Project data will document the effectiveness of our Gen3Tech in a commercial-scale setting during the current fiscal year and support development of one or more of the LOI Projects (and/or other Gen3Tech beef JV projects) commencing later this fiscal year.  We do not presently know the order in which the JV Projects will be developed as that decision will be made based on many factors not yet in place. We believe the Initial Project data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, food distributors and retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below).

 

Note that Bion recently announced its intention to establish strategic partnerships to market the ARS as a stand-alone addition to anaerobic digestion (“AD”) nitrogen control solution in two sectors:

A)     INDUSTRIAL AND MUNICIPAL WASTEWATER. AD is now used at 1,269 water resource recovery facilities in the U.S., with another 102 stand-alone systems that digest food waste. The American Biogas Council estimates an additional 8,600 sites with development potential. Germany, by comparison, has almost 10,000 operating AD sites. In the U.S., wastewater and AD digestate from industrial and municipal sources is already regulated for ammonia and nitrates. The EPA recently proposed tougher standards for slaughter facilities. Bion believes ARS ammonia treatment costs will be competitive in these markets and that its unique premium fertilizer byproducts will create an advantage, especially with waste streams that are still considered ‘organic’, like slaughter and food waste.

 

 

8 
 

 

B)     ANIMAL WASTE. According to the American Biogas Council here are 473 animal waste digesters operating in the U.S. today, most on dairy operations. The American Biogas Council and USDA’s AgSTAR program estimate more than 8,000 additional sites with development potential. The ARS was designed specifically for this purpose: control ammonia from livestock waste and produce the highest value byproducts with it. Digestate from animal waste AD has enjoyed the same reduced regulatory requirements as land applying raw manure. Recent trends in Michigan and California indicate they will treat animal waste digestate as any industrial source, subject to groundwater permitting requirements. Bion believes its proven technology and value-added fertilizers will give it a significant competitive advantage in this evolving market.

Bion is now focused primarily on: i) operation and further testing at the Initial Project, our initial commercial-scale Gen3Tech installation, for support of design/feasibility studies/reports related to our initial JV Projects (and further optimization of its operational parameters), ii) pre-development planning of the LOI Projects (and/or other Gen3Tech beef JV projects) including steps toward distribution agreements, iii) developing applications and markets for its low carbon ‘ClimateSmart’ and organic fertilizer products (including listings/certifications of multiple liquid and solid products) and its sustainable (conventional and organic) animal protein products, and iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed herein) (and related Projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), (v) exploring JVs re stand-alone ARS markets, while (vi) continuing to pursue business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&D activities.

 

HISTORY, BACKGROUND AND CURRENT ACTIVITIES

 

Since the Company’s inception, Bion has designed and developed advanced waste treatment systems for livestock. The first and second generations of Bion’s technology platform were biological systems, primarily focused on nutrient control. Over 30 of these systems were deployed at New York dairies, Florida food processing facilities and dairies, North Carolina hog farms, a Texas dairy and a Pennsylvania dairy (“Kreider 1 Project”). The systems were highly effective at their intended purpose: capturing nitrogen and phosphorus. They produced BionSoil as a byproduct, which was a remarkably effective soil amendment/ fertilizer product, but whose value was not enough to support a viable business model. As such, these early technology iterations were entirely dependent on either implementation of new regulations requiring waste treatment, or subsidy/ incentive programs that would provide ‘payment for ecosystem services’. By the mid-2010’s, it became apparent that neither of these options were imminent or even assured, so the Company initiated the steps to reimagine and redesign its technology.

 

From 2016 to 2021 fiscal years, the Company focused most of its activities and resources on developing, testing and demonstrating the third generation of its technology and technology platform (“Gen3Tech”) that was developed with an emphasis producing more valuable co-products from the waste treatment process, including renewable natural gas and ammonium bicarbonate, a low-carbon, organic ’pure’ nitrogen fertilizer product, while raising sustainable livestock.

 

The $175 billion U.S. livestock industry is under intense scrutiny for its environmental and public health impacts – its ‘environmental sustainability’-- at the same time it is struggling with declining revenues and margins (derived in part from clinging to its historic practices and resulting limitations and impacts) which threaten its ‘economic sustainability’. Its failure to adequately respond to consumer concerns including food safety, environmental impacts, and inhumane treatment of animals have provided impetus for plant-based alternatives such as Beyond Meat and Impossible Burger (and many others) being marketed as “sustainable” alternatives for this growing consumer segment of the market (despite the lack of verifiably sustainable attributes).

 

The Company believes that its Gen3Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of i) verifiably sustainable-branded conventional livestock products and ii) verifiably sustainable organic-branded livestock products, both of which will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a production/marketing opportunity for Bion (but the former is far larger). Our Gen3Tech will also produce (as co-products) biogas, solar photovoltaic electricity in appropriate locations, and valuable low carbon/organic fertilizer products, which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects) and/or marketed to the growing organic fertilizer market.

 

During 2022-23, the Company entered into 3 LOIs setting forth the parties’ intention to negotiate joint venture agreement (“JVA”) and enter into joint ventures (“JV”) to develop and operate 15,000 head integrated, sustainable beef facilities (with future expansion under consideration) including:

 

  a) innovative cattle barns (with slatted floors to facilitate movement of manure to the anaerobic digester and potentially solar PV generation on the rooftops which barns will improve the living conditions of the animals while increasing feeding/weight gain efficiency,

 

  b) ‘customized’ anaerobic digestion systems (including pretreatment to increase renewable natural gas (‘RNG’) production and an RNG cleaning system (which will include capture/recycling of the CO2) to allow pipeline sales and monetization of related environmental credits,

 

  c) a Bion Gen3Tech module (which will utilize the recycled CO2 to increase ammonia nitrogen/ammonium bicarbonate recovery) for the production of ammonia nitrogen fertilizer for use in organic and/or ‘ClimateSmart’ low carbon crop production (plus residual organic solids and clean water),

 

  d) which will produce verifiably sustainable beef products with USDA certified branding.

 

9 
 

 

The opportunity presented by the LOIs to commercialize the Company’s Gen3Tech and business model matured more quickly than anticipated (reflecting strong industry and public momentum in favor of verifiably sustainable food ventures). As a result, we have shifted our plans to focus resources and make our initial 15,000 head operation a reality as soon as possible.

To place the LOI Projects in the context of Company’s business plan (and our prior public disclosure), if the contemplated ventures move forward on the timelines currently contemplated, active development of the initial LOI Project will commence during 2024.

 

As a pre-cursor to such activity, the Company has constructed and commenced operations of the initial phase of our previously discussed Gen3Tech demonstration project near Fair Oaks, Indiana (“Initial Project”): i) to validate our existing data and modeling at commercial scale and ii) to optimize the Bion Gen3Tech module for finalization of design parameters and fabrication details of our planned 15,000 head commercial facilities (including the LOI Projects). For the purposes of this initial phase, the Company, in order to accelerate the data acquisition phase, is utilizing anaerobic digester effluent from the nearby/contiguous Fair Oaks dairy. Thereafter, the Company will evaluate what, if any, additional facilities and testing will take place at that location.

 

The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.

 

During late September 2021, Bion entered into a lease for the development site of the Initial Project, our initial commercial scale Gen3Tech project, which Initial Project will be located on approximately four (4) acres of leased land near Fair Oaks, Indiana, and a related agreement regarding disposal of certain manure effluent with the Curtis Creek Dairy unit of Fair Oaks Farms (“FOF”). Design and pre-development work commenced during August 2021 and preliminary surveying, site engineering and other work is now underway along with site-specific engineering and design work. The Initial Project was initially planned to be an environmentally sustainable beef cattle feeding facility, equipped with state-of-the-art housing and Bion’s 3G-Tech platform to provide waste treatment and resource recovery. Bion has designed the project to house and feed approximately 300 head of beef cattle. If all phases of the Initial Project are constructed, the facility will include Bion’s Gen3Tech platform including: i) covered barns (possibly including roof top solar photovoltaic generation), ii) anaerobic digestion for renewable energy recovery, iii) livestock waste treatment and resource recovery technology, iv) Bion’s ammonium bicarbonate recovery and crystallization technology and iv) data collection software to document system efficiencies and environmental benefits (with the Bion Gen3Tech facilities capable of treating the waste from approximately 1,500 head). The facility is large enough to demonstrate engineering capabilities of Bion’s Gen3Tech at commercial scale, but small enough that it can be constructed and commissioned relatively quickly. Originally, construction and onsite assembly operations were targeted to commence sometime late in 2022, however, supply chain backlogs (many pandemic-associated) delayed delivery dates for core modules of the Bion system to the site until during January 2023. Construction has been substantially completed related to Phase 1 of the Initial Project, shakedown operations undertaken and the operation is now focused on optimization of operation parameters. See Note 3 “Property and Equipment” and Note 12 “Subsequent Events” (for activities since the start of the first quarter of the 2024 fiscal year).

 

The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.

 

 

10 
 

 

Specifically, the Initial Project was designed/developed to provide and/or accomplish the following:

 

i.   Proof of Gen3Tech platform scalability

 

  - Document system efficiency and environmental benefits and enable final engineering modifications to optimize each unit process within the Bion Gen3Technology platform.

 

  - Environmental benefits will include (without limitation) renewable energy production (natural gas recovery from AD and solar electric from integrated roof top photovoltaic generation); nutrient recovery and conversion to stable organic fertilizer; pathogen destruction; water recovery and reuse; air emission reductions.

 

ii.   Use Bion’s data collection system to support 3rd party verified system efficiency requirement to qualify for USDA Process-Verified-Program (PVP): certification of sustainable branded beef (and potentially pork) product metrics.

 

iii.   Produce sufficient ammonium bicarbonate nitrogen fertilizer (“AD Nitrogen”) in liquid and solid forms for commercial testing by potential joint venture partners and/or purchasers, for university growth trials and to provide samples (and related documentation) to support applications for organic and/or ‘ClimateSmart’ certifications.

 

iv.   Produce sustainable beef products for initial test marketing efforts.

 

On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $2,665,500 (and made the initial 25% payment ($666,375) for the core of the ‘Bion System’ portion (without the crystallization modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. The Company received progress billing in March 2022 and June 2022 for the second and third 25% installments, both of which have been paid as of the filing date. On January 17, 2023 the Company received an invoice from Buflovak for $533,100 which was paid on March 1, 2023 and on April 24, 2023 the Company received an invoice from Buflovak for $83,275 which was paid on May 2, 2023 bringing the aggregate payments to $2,615,500 as of the date of this filing. There remains $50,000 open on the Purchase Order has been billed on July 26, 2023. In addition to the Purchase Order, through December 31, 2023 the Company has incurred additional costs of $6,442,812 on the Initial Project for capitalized interest and costs, non-cash compensation, equipment and consulting fees. $6,983954 has been paid and $1,750,170 has been billed and not yet paid.

 

Buflovak has worked with the Company on design and testing of its 3G Tech over several years. The basic design for the Initial Project’s Bion System is complete, fabrication and delivery of equipment from Buflovak from the Purchase Order Agreement has been largely completed and assembly/construction is in process.  3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, utilities, etc.) for work related to the Initial Project. The Company has incurred costs of $8,177,452 on the Initial Project, not including capitalized labor and interest.

 

The Initial Project will be carried out in stages with phase one focused largely on portions of items i. and iii. set forth above.

 

Upon completing the primary goals of phase 1 of the Initial Project (coupled with obtaining organic certifications(s) for our liquid and/or solid ammonium bicarbonate fertilizer product lines), Bion expects to be ready to move forward with its plans for development of much larger facilities including the LOI Projects, including final design of its Gen3Tech modules. The Company anticipates that discussions and negotiations it has begun (together with additional opportunities that will be generated over the next 12-24 months) regarding potential JVs with strategic partners in the financial, livestock and food distribution industries to develop large scale projects will continue during the optimization operations of the Initial Project with a 2024 goal of establishing multiple JV’s for large scale projects that will produce sustainable and/or sustainable-organic corn-fed beef. These products will be supported by a USDA PVP-certified sustainable brand that will, initially, highlight reductions in carbon and nutrient footprint, as well as pathogen reductions associated with foodborne illness and antibiotic resistance, along with the organic designation where appropriate. Bion has successfully navigated the USDA PVP application process previously, having received conditional approval of its 2G Tech platform (pending resubmission and final site audits), and is confident it will be successful in qualifying its Gen3Tech platform.

 

 

11 
 

 

After the basic technology start-up milestones of the Initial Project (primarily optimization and steady-state operations of the core modules of our Gen3Tech platform) have been met, the Company will determine whether to complete the entire Initial Project as originally designed at that location or the relocate the core modules to an alternative permanent location. The Company has engaged in discussion with the University of Nebraska-Lincoln to jointly develop an integrated beef facility based on Bion’s Gen3Tech and business model at its Klosterman Feedyard Innovation Center (“KFIC”) (or other mutually agreed upon location) which facility would include innovative barns, an anaerobic digester and a Bion Gen3Tech system to conduct ongoing research and development related thereto and the KFIC is a possible site for the long-term re-location of the core modules. This venture, if it moves forward, is anticipated to include joint preparation of applications for grants and other funding from the USDA (‘climate smart’ program, rural development, etc.) and other sources. The Company will also evaluate re-locating the core module of the Initial Project to Dalhart, Texas, where it might be integrated into the first phases of the Dalhart Project and/or other locations. 

 

The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020. Applications for our first solid ammonium bicarbonate product line have been filed with OMRI and the California Department of Food & Agriculture (“CDFA”) without success to date , in part due to the novel nature of our Gen3Tech in the context of organic certifications). The Company anticipates filing multiple new applications with OMRI and CDFA (and possible others) for higher concentration liquid products and solid products based on production from the Initial Project over the next several months. See “Fertilizer– Organic and ‘ClimateSmart’” below.

 

Additionally, the Company believes there will also be opportunities to proceed with selected ‘retrofit projects’ of existing facilities (see ‘Gen3Tech Kreider 2 Poultry Project’ below as an example) in the swine, dairy and poultry industries utilizing our Gen3Tech.

 

Bion believes that substantial unmet demand currently exists– potentially very large – for ‘real’ meat/dairy/egg products that offer the verifiable/believable sustainability consumers seek, but with the taste and texture they have come to expect from American beef and pork, dairy and poultry. Numerous studies demonstrate the U.S. consumers’ preferences for sustainability. For example, 2019 NYU Stern’s Center for Sustainable Business study found that ‘products marketed as sustainable grew 5.6 times faster than those that were not…’ and that ‘…in more than 90 percent of consumer-packaged-goods (CPG) categories, sustainability-marketed products grew faster than their conventional counterparts.’ Sales growth of plant-based alternatives, including both dairy and more recently ground meat (Beyond Meat, Impossible Foods, etc.) have shown that a large, but apparently limited, segment of consumers is choosing seemingly sustainable offering, and are also willing to pay a premium for it. Tyson Foods, in the context of launching its Brazen beef initiative, recently said, “consumers would be willing to pay at least 24 percent more for environmentally friendly, sustainable options at retail.” Numerous studies also support the consumers’ ‘willingness-to-pay’ (WTP) for sustainable choices, including a recent meta-analysis of 80 worldwide studies with results that calculate the overall WTP premium for sustainability is 29.5 percent on average.

 

As one of the largest contributors to some of the greatest air and water quality problems in America, it is clear that livestock waste cleanup, at scale, represents one of the greatest opportunities we have to reduce negative environmental impacts of the food supply chain on air and water quality. Bion’s Gen3Tech platform, along with its business model, will enable the cleanup of one of the ‘dirtiest’ parts of the food supply chain: animal protein production and creates the opportunity to produce and market verifiably sustainable organic and conventional ‘real meat’ products that can participate in the growth and premium pricing that appears to be readily available for the ‘right’ products.

 

 

12 
 

 

Bion believes that at least a premium segment of the U.S. beef industry (and potentially other livestock industry groups) is at the doorstep of a transformative opportunity to address the growing demand for sustainable food product offerings, while pushing back against today’s anti-meat messaging. At $66 billion/year (2021 wholesale/farmgate value), the beef industry is a fragmented, commodity industry whose practices date back decades. In 1935 inflation-adjusted terms, beef was 63% more expensive in 2021, while pork and chicken, which are now primarily raised in covered barns at CAFOs with highly integrated supply chains, were 12% and 62% cheaper, respectively. In recent years, the beef industry has come under increasing fire from advocacy groups, regulatory agencies, institutional investors, and ultimately, their own consumers, over concerns that include climate change, water pollution, food safety, and the treatment of animals and workers.

 

Advocacy groups targeting livestock and the beef industry have recently been joined by competitors that produce animal protein alternatives in seeking to exploit the industry’s environmental and economic weaknesses. Their global anti-meat messaging has had a substantial chilling effect on the relationships the beef industry has with its institutional investors; retail distributors, such as fast-food restaurants; and mostly, its consumers. Led by the United Nations Food and Agriculture Organization, a coordinated anti-meat messaging campaign has targeted consumers worldwide, primarily focused on the industry’s impacts on climate change. A 2018 NielsenIQ Homescan survey last year found that 39% of Americans are actively trying to eat more plant-based foods. Some of the recent growth in plant-based proteins results from increasing lactose intolerance and other health concerns; however, most of that growth is attributed to consumers’ growing concerns for the environmental impacts of real meat and dairy. Several large US companies that have traditionally focused on livestock production, including Cargill, ADM, Perdue Foods, and Tyson, have also recently entered the plant protein space. While meat alternatives, especially plant-based protein producers like Beyond Meat and Impossible Foods, have been heavily promoted (by themselves and the media) and enjoyed remarkable initial sales growth, recently, sales have flattened and/or declined over the past 18 months. It should be noted that these plant-based protein producers are primarily expected to be able to serve the ground/ processed meat market, which represents only about 10 percent of the overall animal protein market. Further, there has recently been pushback to these plant-based products, focusing on their highly processed nature and unproven health benefits, scalability/ pricing, and their uncertain carbon footprint---and market growth rates have substantially slowed and may have already plateaued and/or peaked. There have also been several companies recently enter the cellular and 3D-printed meat arena. While facing myriad challenges and further out on the development timeline, some people believe cellular agriculture (aka cultured, clean, lab-grown, cultivated) meat may have the potential to service a much larger percentage of the market than plant-based protein, including cuts like steaks, chops and roasts, but the likely cost remains very uncertain at this point.

 

In terms of changing customer preferences, ‘saving the planet’ has proven to be a more compelling argument than the traditional animal activism/ welfare pitch. To date, the primary beef ‘industry response’ to this has been grass-fed beef, which is regarded as a generally more sustainable offering than grain-fed (largely without empirical evidence). However grass-fed beef has had only limited acceptance in U.S. markets, because it is less flavorful and tougher than the traditional corn-fed beef consumers have grown to enjoy. Sustainability initiatives have been launched by large US livestock producers (including Tyson’s very recent ‘Brazen’ program), but it is not yet possible to determine the extent the attributes of such products will be substantive and verifiable rather than completely ‘modeled’ and largely public relations ‘greenwashing’.

 

Each of these items supports Bion’s belief that there is a potentially very large opportunity to supply premium sustainable beef products that satisfy consumer concerns. We believe that the real meat/beef products that can be cost-effectively produced today using our Gen3Tech platform, both sustainable and/or organic, can provide an affordable product that satisfies the consumer’s desire for sustainability, but with the superior taste and texture those consumers have grown to prefer.

 

Sustainable Beef

 

Bion’s goal is to be one of the ‘first to market’ with meaningfully verified sustainable beef products that can be produced at sufficient scale to service national market demand. The cattle produced at Bion facilities will have a substantially lower carbon footprint, dramatically reduced nutrient impacts to water, and an almost total pathogen kill in the waste stream. Further, the economics of producing these cattle (including the cost of the facility/technology upgrade) will be greatly enhanced by the revenue realized from the recovery of valuable resources, including renewable energy, high-value fertilizer products, and clean water.

 

 

13 
 

 

A Bion sustainable beef facility will be comprised of covered barns with slotted floors (allowing the waste to pass through) which will reduce ammonia and greenhouse gas volatilization and loss, as well as odors, thereby improving animal health and human working conditions while preventing air/soil pollution. The manure will be collected and moved directly to anaerobic digestion facilities which will produce renewable natural gas (and re-cycle CO2 from the gas cleaning process). Covered barns will reduce weather impacts on the livestock and have been demonstrated to promote improved general health and weight gain in the cattle housed in them. The barns’ very large roof surface area will be utilized (in geographical locations with adequate sunshine and appropriate ‘tariffs’) for the installation of photovoltaic solar generation systems to produce electricity for the facility, as well as export to the grid. The barn roofs will also be configured to capture rainwater, which, coupled with the water recovered from the treatment process, will reduce the projects’ reliance on current water supplies.

  

Waste treatment and resource recovery will be provided by Bion’s advanced Gen3Tech platform, which Bion believes offers the most comprehensive solution for livestock waste available today. In addition to direct environmental benefits, every pound of nitrogen that is captured, upcycled, and returned to the agricultural nitrogen cycle as high-quality fertilizer (vs lost to contaminate downstream waters), is also a pound of nitrogen that will not have to be produced as synthetic urea or anhydrous ammonia, with their tremendous carbon cost. System performance and environmental benefits will be monitored and verified through third parties, with USDA PVP certification of the sustainable brand that Bion also believes will be the most comprehensive available in the market.

 

Recently there have been efforts to establish sustainable brands (including USDA PVP certification) for a number of small-scale livestock producers (largely in the grass-fed beef category). To date, the reach and extent of such efforts is limited and it is difficult to determine their effectiveness. Additionally, there have been public announcements of initiatives related to beef sustainability (largely focused on the ‘cow-calf’ segment of the livestock chain) in procurement by major beef processing companies (including Tyson’s very recent ‘Brazen’ program), but a closer look finds that many have consisted largely of ‘green washing’ public proclamations in the wake of environmental and social criticism that re-package prior initiatives and lack any significant new substance.

 

Sustainable Organic Beef

 

Bion also believes it may also have a unique opportunity to produce, at scale, affordable corn-fed organic beef that is also certified as sustainable. In addition to the sustainable practices described above, organic-sourced beef cows would be finished on organic corn, which would be produced using the ammonium bicarbonate fertilizer captured by the Gen3Tech platform. Bion believes its meat products will meet consumer demands with respect to sustainability and safety (organic) and provide the tenderness and taste American consumers have come to expect from premium conventional American beef. Such products are largely unavailable in the market today. We believe Bion’s unique ability to produce the fertilizer needed to grow a supply of relatively low-cost organic corn, and the resulting opportunity to produce organic beef, will dramatically differentiate us from potential competitors. This organic opportunity is dependent on successfully establishing Bion’s fertilizer products as acceptable for use in organic grain production.

 

Today, organic beef demand is limited and mostly supplied with grass-fed cattle. While organic ground/ chopped meat has enjoyed success in U.S. markets, grass-fed steaks have seen limited acceptance, mostly resulting from consumer issues with taste and texture. In other words, it’s tough. Regardless, such steaks sell for a significant premium over conventional beef. A grain-finished organic beef product is largely unavailable in the marketplace today due to the higher costs of producing organic corn and grain. The exception is offerings that are very expensive from small ‘boutique’ beef producers. Like all plants, corn requires nitrogen to grow. Corn is especially sensitive to a late-season application of readily available nitrogen – the key to maximizing yields. With non-organic field corn, this nitrogen is supplied by an application of a low-cost synthetic fertilizer, such as urea or anhydrous ammonia. However, the cost for suitable nitrogen fertilizer that can be applied late-season in organic corn production is so high that the late-season application becomes uneconomical, resulting in substantially lower yields – a widely recognized phenomena known as the ‘yield gap’ in organic production. The yield gap results in higher costs for organic corn that, in turn, make it uneconomical to feed that corn to livestock. As is the case for sustainable but not organic beef, Bion believes there is a potentially large unmet demand for affordable beef products that are both sustainable AND organic, but with the taste and texture consumers have come to expect from American beef. Bion’s ability to produce the low-cost nitrogen fertilizer that can close the organic yield (and affordability) gap puts the Company in a unique, if not exclusive at this time, position to participate in JV’s that will benefit from this opportunity starting next year.

 

 

14 
 

 

The demonstrated willingness of consumers to purchase sustainable products (along with numerous research and marketing studies confirming consumers are seeking, and are willing to pay a premium for, sustainable products)---in combination with the threat to the livestock industry market (primarily beef and pork) posed by plant-based alternatives (heightened by pandemic conditions)--- has succeeded in focusing the large scale livestock industry on how to meet the plant-based market challenge by addressing the consumer sustainability issues. The consumer demand for sustainability appears to be a real and lasting trend, but consumers remain skeptical of generalized claims of ‘sustainability’. To date, a large portion of the industry responses to this trend have been at a superficial level or consist of ‘green washing’, a deceptive marketing practice where companies promote non-substantive initiatives. Real sustainability for the livestock industry will require implementation of advanced waste treatment technology at or near the CAFOs – where most of the negative environmental impacts take place.

 

Fertilizer: Organic and ‘Climate Smart’

 

The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“Gen3Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of low carbon and/or organically certified soluble nitrogen fertilizer products. The Company’s low concentration ammonium bicarbonate liquid product successfully completed its Organic Materials Review Institute (“OMRI”) application and review process with listing approval during May 2020. During the next 2 months the Company intends to file applications with OMRI and the California Department of Food & Agriculture (“CDFA”) for a line of higher concentration liquid ammonium nitrogen products (ranging from 4% up to 16% (or higher)) based on production of liquid samples during operation of the Initial Project. The Company anticipates applying for and obtaining one or more listings/certifications for higher concentration products in our liquid ammonium nitrogen fertilizer line well prior to operational dates for the Company’s initial large-scale JV Gen3Tech Sustainable Beef Projects.

 

Additionally, the Company intends to explore the market potential for its fertilizer (in liquid and/or solid forms) to be a verifiably ‘ClimateSmart’ product (potentially a much larger market than the organic market) with focus on higher value specialty crops. This will require working with industry and academic entities to develop appropriate metrics and producing a ‘life cycle assessment’ (LCA) for Bion’s ammonium nitrogen fertilizer product which can be compared to conventional nitrogen fertilizer products. Bion’s processes will capture and utilize CO2 in the waste stream (including CO2 produced with the renewable natural gas (RNG) by anaerobic digestion that is usually vented to the atmosphere) as stabilizing agent thereby potentially creating carbon offsets compared to natural gas utilized as feedstock in chemical ammonia production which reduction will be reflected in the LCA. This LCA will assess environmental impacts associated with fertilizer production in support of the beef cattle supply chain for both the existing conventional approach (primarily fossil fuel-based Haber-Bosch production methods) and the largely decarbonized Bion production approach. We believe a series of coincident yet significant LCA benefits accrue from Bion’s patented fertilizer production approach including the reduced loss of ammonia to the environment via air (volatilized) and water (nitrate in groundwater) pathways, recycled/reused water, elimination of pathogens, the production of renewable natural gas, the production solar energy from photovoltaic panels on barn roofs, enhanced animal welfare practices and reduced animal husbandry risks from extreme weather events. Bion believes that current evaluations of the carbon impact from feedlot operations materially underestimate the negative impacts because existing models do not properly include significant ‘downstream’ carbon impacts of required energy intensive waste water treatment for re-deposited ammonia nitrogen. If the Company determines there is a significant ‘ClimateSmart’ opportunity for our fertilizer products, such an LCA can be completed (based in part on data from the Initial Project) and support marketing efforts well prior to operational dates for the Company’s initial large scale JV Gen3Tech projects.

 

Ammonium bicarbonate, manufactured using thermal and mechanical processes, has a long history of use as a fertilizer. In addition to liquid ammonium nitrogen fertilizer, Bion’s Gen3Tech is capable of recovering nitrogen in the form of solid ammonium bicarbonate products containing up to 18%-22% (or higher) nitrogen in a crystalline form that is easily transported (while producing liquids with various percentages of ammonium bicarbonate nitrogen during interim stages of the process). This solid product is water soluble and provides a readily available nitrogen source for crops. It will contain virtually none of the other salt, iron and mineral constituents of the livestock waste stream that often accompany other organic fertilizers. This product is being developed to fertilizer industry standards so that it that can be precision-applied to crops using existing equipment. Bion believes that this product will potentially have broad applications in the production of organic and/or ClimateSmart grains for livestock feed, row crops, horticulture, greenhouse and hydroponic production, and potentially retail lawn and garden products.

 

 

15 
 

 

The ammonium bicarbonate products (liquid and solid) produced by Bion’s Gen3Tech platform will enjoy a dramatically lower carbon footprint than synthetic nitrogen fertilizers. Much of the reactive nitrogen captured and upcycled into our fertilizer products was going to be lost through volatilization and runoff, and that loss would generally need to be offset with a synthetic nitrogen fertilizer, such as anhydrous ammonia or urea. These synthetic nitrogen products are produced through the Haber-Bosch (and other) synthetic processes, which converts hydrogen and atmospheric nitrogen to ammonia, with methane from fossil fuels as the energy source. It is an extremely energy-intensive process with a carbon footprint that, while not yet fully understood, is widely accepted to by very large. While a complete Life Cycle Assessment (LCA) of carbon impacts from synthetic fertilizer production is not yet available, according to the Institute for Industrial Productivity, its production alone is responsible for approximately 1 percent of total global CO2 emissions. To the extent that Bion can capture and repurpose the nitrogen traditionally lost from livestock waste, that carbon cost will no longer need to be paid by the environment/climate.

 

Applications for our first solid form of concentrated ammonia, soluble nitrogen fertilizer product line were filed with OMRI (filed during May 2021) and CDFA (filed during May 2022) without success to date. After an extended review processes (which was largely opaque), the OMRI application proceeded through multiple stages without receiving a positive result. We have initiated an informal dialogue with CDFA regarding the basis for and re-consideration of its initial determination and have submitted additional supplemental supporting materials to CDFA. The Company’s solid product line is novel (in the context of organic certification) in part due to the fact that no formal listing category currently in the organic space for a solid form of concentrated ammonia, soluble nitrogen fertilizers and there is no clear guidance at present from internal policy manuals on how to categorize this product and the process that produces it. There is also no clear guidance at present from either the NOP or the National Organic Standards Board (“NOSB”) (which is currently involved in a related review and recommendations process regarding ‘high nitrogen liquid fertilizers’ derived from ammonia from manure). The Company and its representatives, along with a number of other organic fertilizer stakeholders, are involved in discussions regarding resolution of these matters at all three levels. The Company intends to continue efforts to obtain listing/certification for its solid nitrogen fertilizer line over the course of this fiscal year.

 

Gen3Tech Kreider 2 Poultry Project

 

Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) (‘Kreider Renewable Energy Facility’ or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). Now that development of the Company’s Gen3Tech is being deployed, the Company has commenced discussions with KF regarding updating and amending the JV agreement and anticipates executing an amended joint venture agreement during 2023. During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA). Note that this Project may also be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). The Company anticipates if and when PA2 re-commences work on the Kreider 2 Project, it will submit a new application based on our Gen3Tech. Site specific design and engineering work for this facility have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during the following calendar year. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its proposed use of Bion’s Gen3Tech for increased recovery of marketable by-products and sustainable branding, are based in material part the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. However, liquidity in the Pennsylvania nutrient credit market has not yet developed significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.

 

 

16 
 

 

Note that while Bion believes that the Kreider 2 Project and/or subsequent Bion Projects in PA and the Chesapeake Bay Watershed will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees/premiums related to a ‘sustainable brand’, the Covid-19 pandemic has delayed legislative efforts needed to commence its development. However, the Company is currently engaged in dialogue with the regional EPA office and the Chesapeake Bay Program Office regarding the potential of the Company’s Gen3Tech Kreider2 Project (and other potential projects) to enable Pennsylvania to move forward toward meeting its Chesapeake Bay clean-up goals. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.

 

Technology Deployment: Bion Gen3Tech

 

In the absence of firm regulatory mandates, widespread deployment of waste treatment technology, and the sustainability it enables, is largely dependent upon generating sufficient additional revenues to offset the capital and operating costs associated with technology adoption. Bion’s Gen3Tech business platform has been developed to create opportunities for such augmented revenue streams, while providing third party verification of sustainability claims. The Gen3Tech platform has been designed to maximize the value of co-products produced during the waste treatment/recovery processes, including pipeline-quality renewable natural gas (biogas) and commercial fertilizer products approved for organic production and/or certified as ‘ClimateSmart’. All processes will be verifiable by third parties (including regulatory authorities and certifying boards) to comply with environmental regulations and trading programs and meet the requirements for: a) renewable energy and carbon credits, b) organic certification of the fertilizer coproducts and c) USDA PVP certification of an ‘Environmentally Sustainable’ brand (see discussion above and below), and d) payment for verified ecosystem services. The Company’s first patent on its Gen3Tech was issued during 2018. In August 2020, the Company received a Notice of Allowance on its third patent which significantly expands the breadth and depth of the Company’s Gen3Tech coverage. The Company has additional applications pending and/or planned. 

 

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

In parallel with technology development, Bion has worked (which work continues) to implement market-driven strategies designed to stimulate private-sector participation in the overall U.S. nutrient and carbon reduction strategy. These market-driven strategies can generate “payment for ecosystem services”, in which farmers or landowners are rewarded for managing their land and operations to provide environmental benefits that will generate additional revenues. Existing renewable energy credits for the production and use of biogas are an example of payment for ecosystem services. Another such strategy is nutrient trading (or water quality trading), which will potentially create markets (in Pennsylvania and other states) that will utilize taxpayer funding for the purchase of verified pollution reductions from agriculture (“nutrient credits”) by the state (or others) through competitively-bid procurement programs. Such credits can then be used as a ‘qualified offset’ by an individual state (or municipality) to meet its federal clean water mandates at significantly lower cost to the taxpayer. Market-driven strategies, including competitive procurement of verified credits, is supported by U.S. EPA, the Chesapeake Bay Commission, national livestock interests, and other key stakeholders. Legislation in Pennsylvania to establish the first such state competitive procurement program passed the Pennsylvania Senate by a bi-partisan majority during March 2019 but has not yet crossed the hurdles required for actual adoption. The Covid-19 pandemic and related financial/budgetary crises have slowed progress for this and other policy initiatives and, as a result, it is not currently possible to project the timeline for completion (or meaningful progress) of this and other similar initiatives (see discussion below).

 

 

17 
 

 

The livestock industry and its markets are already changing. With our commercial-ready technology and business model, Bion believes it has a ‘first-mover advantage’ over others that will seek to exploit the opportunities that will arise from the industry’s inevitable transformation. Bion anticipates moving forward with the development process of its initial commercial installations utilizing its Gen3Tech, during the current 2024 fiscal year. We believe that Bion’s Gen3Tech platform and business model can provide a pathway to true economic and environmental sustainability with ‘win-win’ benefits for at least a premium sector of the livestock industry, the environment, and the consumer, an opportunity which the Company intends to pursue.

 

The Livestock Problem

 

The livestock industry is under tremendous pressure from regulatory agencies, a wide range of advocacy groups, institutional investors and the industry’s own consumers, to adopt sustainable practices. Environmental cleanup is inevitable and has already begun — and policies have already begun to change, as well. Bion’s Gen3Tech was developed for implementation on large scale livestock production facilities, where scale drives both lower treatment costs and efficient co-products production, as well as dramatic environmental improvements. We believe that scale, coupled with Bion’s verifiable treatment technology platform, will create a transformational opportunity to integrate clean production practices at (or close to) the point of production—the primary source of the industry’s environmental impacts. Bion intends to assist the forward-looking segment of the livestock industry to bring animal protein production in line with 21st Century consumer demands for meaningful sustainability.

 

In the U.S. (according to the USDA’s 2017 agricultural census) there are over 9 million dairy cows, 90 million beef cattle, 60 million swine and more than 2 billion poultry which provides an indication of both the scope of the problem addressed by Bion’s technology, as well as the size of Bion’s opportunity. Environmental impacts from livestock production include surface and groundwater pollution, greenhouse gas emissions, ammonia, and other air pollution, excess water use, and pathogens related to foodborne illnesses and antibiotic resistance. While the most visible and immediate problems are related to nutrient runoff and its effects on water quality, the industry has recently been targeted by various stakeholder groups for its impacts on climate change.

 

Estimates of total annual U.S. livestock manure waste vary widely, but start around a billion tons, between 100 and 130 times greater than human waste. However, while human waste is generally treated by septic or municipal wastewater plants, livestock waste – raw manure – is spread on our nation’s croplands for its fertilizer value. Large portions of U.S. feed crop production (and most organic crop production) are fertilized, in part, in this manner. Under current manure management practices, 80% or more of total nitrogen from manure, much of it in the form of ammonia, escapes during storage, transportation, and during and after soil application, representing both substantial lost value and environmental costs.

 

More than half of the nitrogen impacts from livestock waste come from airborne ammonia emissions, which are extremely volatile, reactive and mobile. Airborne ammonia nitrogen eventually settles back to the ground through atmospheric deposition — it ‘rains’ everywhere. While some of this nitrogen is captured and used by plants, most of it runs off and enters surface waters or percolates down to groundwater. It is now well-established that most of the voluntary conservation practices, such as vegetated buffers that ‘filter’ runoff (often referred to as “BMPs” or “Best Management Practices” that have traditionally been implemented to attempt to mitigate nutrient runoff), are considerably less effective than was previously believed to be the case. This is especially true with regard to addressing the volatile and mobile nitrogen from ammonia emissions, because BMPs are primarily focused on surface water runoff, directly from farm fields in current production, versus the re-deposition that takes place everywhere or groundwater flow.

 

Runoff from livestock waste has been identified in most of our major watersheds as a primary source of excess nutrients that fuel algae blooms in both fresh and saltwater. Over the last several years, algae blooms have become increasingly toxic to both humans and animals, such as the Red Tides on the Florida and California coasts, and the Lake Erie algae bloom that cut off the water supply to Toledo, Ohio, residents in 2014. When the nutrient runoff subsides, it leaves the algae blooms with no more ‘food’ and the blooms die. The algae’s decomposition takes oxygen from the water, leading to ‘dead zones’ in local ponds, lakes, and ultimately, the Great Lakes, as well as the Chesapeake Bay, Gulf of Mexico, and other estuary waters. Both the toxic algae blooms and the low/no-oxygen dead zones devastate marine life, from shrimp and fish to higher mammals, including dolphins and manatees. U.S. EPA already considers excess nutrients “one of America’s most widespread, costly and challenging environmental problems”. Nutrient runoff is expected to worsen dramatically in the coming decades due to rising temperatures and increasing rainstorm intensity as a result of climate change.

 

18 
 

 

Nitrate-contaminated groundwater is of growing concern in agricultural regions nationwide, where it has been directly correlated with nutrient runoff from upstream agricultural operations using raw manure as fertilizer. Pennsylvania, Wisconsin, California and Washington, and others, now have regions where groundwater nitrate levels exceed EPA standards for safe drinking water. High levels of nitrate can cause blue baby syndrome (methemoglobinemia) in infants and affect women who are or may become pregnant, and it has been linked to thyroid disease and colon cancer. EPA has set an enforceable standard called a maximum contaminant level (MCL) in water for nitrates at 10 parts per million (ppm) (10 mg/L) and for nitrites at 1 ppm (1 mg/L). Federal regulations require expensive pretreatment for community water sources that exceed the MCL; however, private drinking water wells are not regulated, and it is the owners’ responsibility to test and treat their wells. Additionally, groundwater flows also transport this volatile nitrogen downstream where, along its way, it intermixes with surface water, further exacerbating the runoff problem. Like atmospheric deposition, the current conservation practices we rely on to reduce agricultural runoff are largely bypassed by this subsurface flow.

 

Additionally, in arid climates, such as California, airborne ammonia emissions from livestock manure contribute to air pollution as a precursor to PM2.5 formation, small inhalable particulate matter that is a regulated air pollutant with significant public health risks. Whether airborne or dissolved in water, ammonia can only be cost-effectively controlled and treated at the source—before it has a chance to escape into the environment where it becomes extremely expensive to ‘chase’, capture, and treat.

 

High phosphorus concentrations in soils fertilized with raw manure are another growing problem. The ratio of nitrogen to phosphorus in livestock waste is fixed, and because manure application rates are calculated based on nitrogen requirements, often phosphorus is overapplied as an unintended consequence. Phosphorus accumulation in agricultural soils reduces its productivity, increases the risk of phosphorus runoff, and represents a waste of a finite resource. Decoupling the nitrogen from the phosphorus would allow them to be precision-applied, independently of each other, when and where needed.

 

The livestock industry has recently come under heavy fire for its impacts on climate change, which has become a rallying cry for the anti-meat campaign discussed above. Estimates of the magnitude of those impacts vary widely, but the general consensus is that globally, livestock account for 14.5 percent of greenhouse emissions. In the U.S. however, that number drops to 4.2 percent, due to the increased efficiencies of American beef production. The greatest impacts come from direct emissions of methane from enteric fermentation (belches), methane and nitrous oxide emissions from the manure, with arguably the largest being the massive carbon footprint of the synthetic nitrogen fertilizers used to grow the grains to feed the livestock.

 

For decades the livestock industry has overlooked and/or socialized its environmental problems and costs. Today, the impacts of livestock production on public health and the environment can no longer be ignored and are coming under increasing scrutiny from environmental groups and health organizations, regulatory agencies and the courts, the media, consumers, and activist institutional investors. The result has been a significant and alarming loss of market share to plant-based protein and other alternative products. Bion’s Gen3Tech platform was designed to resolve these environmental issues and bring the industry in line with twenty-first century consumer expectations.

 

 

19 
 

Going Concern and Management’s Plans:

 

The Company’s condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company incurred a net loss of $1,464,000 and $1,649,000 for the six months ended December 31, 2023 and 2022, respectively. At December 31, 2023, the Company has a working deficit and a stockholders’ equity of approximately $3,806,000 and $3,593,000, respectively. The Company has not generated significant revenues (even though it earned a net income of $8,291,000 for the year ended June 30, 2022) and incurred a net loss of approximately ($3,189,000) during the year ended June 30, 2023. The net income for the year ended June 30, 2022 was largely due to a one-time, non-cash event of the dissolution of Bion PA-1, LLC (“PA-1”) resulting in a gain of approximately $10,235,000 as well as a one-time gain of $902,000 from the sale of the Company’s ‘biontech.com’ domain pursuant to a purchase agreement during the period. During the year ended June 30, 2023 the Company had debt modifications that resulted in a reduction of debt of $3,516,000 and an increase in equity. The Company’s lack of revenue and/or operating profits, together with the low likelihood of generating positive cash flow and/or net income during the next 12-24 months, raise substantial doubt about the Company’s ability to continue as a going concern. The Company is not currently generating any significant revenues. Further, the Company’s anticipated revenues, if any, from existing projects, JVs and proposed projects will not be sufficient to meet the Company’s anticipated operational and capital expenditure needs for many years. As previously noted, the Company is currently not generating significant revenue and accordingly has not generated cash flows from operations. The Company does not anticipate generating sufficient revenues to offset operating and capital costs (for Projects) for a minimum of two to five years. While there are no assurances that the Company will be successful in its efforts to develop and construct its Projects and market its Systems, it is certain that the Company will require substantial funding from external sources. Given the unsettled state of the current credit and capital markets for companies such as Bion, there is no assurance the Company will be able to raise the funds it needs on reasonable terms. The aggregate effect of these factors raises substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. The following paragraphs describe management’s plans with regard to these conditions.

 

Current liabilities were approximately $4.2 million and $1.6 million at December 31, 2023 and 2022, respectively. There was an increase of approximately $2.6 million (which was largely due to an increase in ‘accounts payable and accrued expenses’ totaling approximately $2.0 million and an increase in ‘deferred compensation’ of approximately $.35 million) as a result of the Company’s limited success in raising new financing (equity and/or debt) during the recent period combined with continued expenses (including those related to the Initial Project).

 

The Company continues to explore sources of additional financing to satisfy its current operating requirements as it is not currently generating any significant revenues. During fiscal years 2023 and 2022 (as a whole), the Company faced less difficulty in raising equity funding (but was subject to substantial equity dilution from the larger amounts of equity financing during the periods) than was experienced in the prior 3 years. However, this positive trend did not continue during the last quarter of the 2023 fiscal year and first and second quarters of the current fiscal year (and the third quarter through the date of this report). The Company raised only raised very limited equity funds during such periods to meet its some of its immediate needs, and therefore, the Company needs to raise substantial additional funds in the upcoming periods. The Company has faced substantial increases in demand for capital and operating expenditures for the fiscal year 2024 to date (and we anticipate such increased demands will continue during the remainder of the 2024 fiscal year and periods thereafter) as it moves toward commercial implementation of its 3G Tech and development of JVs (including costs associated with additions of personnel to carry out the business activities of the Company) and, therefore, is likely to continue to face, significant cash flow management issues due to limited capital resources and working capital constraints which had only recently begun to be alleviated. As a result, the Company has faced, and continues to face, significant cash flow management challenges due to material working capital constraints. To partially mitigate these working capital constraints, the Company's core senior management and some key employees and consultants have been deferring most of their cash compensation and/or are accepting compensation in the form of securities of the Company and members of the Company's senior management have from time-to-time made loans to the Company in the past and may do so in future periods. The Company continues to explore sources of additional financing (including potential agreements with strategic partners – both financial and ag-industry) to satisfy its current and future operating and capital expenditure requirements as it is not currently generating any significant revenues.

 

During the years ended June 30, 2023 and 2022, the Company received gross proceeds of approximately $4,038,000 and $1,737,000, respectively, from the sale of its debt and equity securities. The Company paid commissions on the exercise of warrants in the amount of $86,000 and $19,000 in 2023 and 2022, respectively.

 

During the six months ended December 31, 2023 and 2022 the Company received total proceeds of approximately $443,000 and $602,000, respectively, from the sale of its debt and equity securities. During the six months ended December 31, 2023 the Company received proceeds of $250,000 from a convertible bridge loan but the provider of the bridge loan breached its contractual obligation/binding subscription agreement to fund an additional $1,250,000 to the Company during November 2023 (and on an ongoing basis since such time), which breach (combined with management stresses related to the final illness and passing of Dominic Bassani, Bion’s COO and former CEO, and required management transitions) has created a substantial cash flow difficulties for the Company which are ongoing. See Note 6 and Note 9, E4) Bridge Loan/Default below.

 

 

20 
 

 

The Company anticipates substantial increases in demand for capital and operating expenditures for the balance of fiscal year 2024 (and we anticipate such increased demands will continue during the 2025 fiscal year and periods thereafter) as it moves toward commercial implementation of its 3G Tech and development of JVs (including costs associated with additions of personnel to carry out the business activities of the Company) and, therefore, is likely to continue to face, significant cash flow management issues due to limited capital resources and working capital constraints which had only recently begun to be alleviated during the 2023 fiscal year. As a result, the Company has faced, and continues to face, significant cash flow management challenges due to material working capital constraints. To partially mitigate these working capital constraints, the Company's core senior management and some key employees and consultants have been deferring most of their cash compensation and/or are accepting compensation in the form of securities of the Company and members of the Company's senior management have from time-to-time made loans to the year ended June 30, 2018, senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $2,404,000. Additionally, the Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again during the year ended June 30, 2018. As set forth in detail elsewhere herein, during the year ended June 30, 2023 senior management (and family members) who held convertible obligations of the Company adjusted the terms of their outstanding notes and agreed to debt modifications that reduced of the Company’s debt by $3,516,000 and increased shareholders equity by the same amount.

 

The constraints on available resources have had, and continue to have, negative effects on the pace and scope of the Company’s efforts to operate and develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and/or curtailment of ongoing activities including research and development activities. The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including the Initial Project, JV Projects (including the Dalhart, Olson and DVG Projects), and the Kreider 2 facility) and CAFO Retrofit waste remediation systems. The Company anticipates that it will seek to raise from $20,000,000 to $80,000,000 or more debt and/or equity through joint ventures, strategic partnerships and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) and/or through other means during the next twelve months. However, as discussed above, there is no assurance, especially in light of the difficulties the Company has experienced in many recent years and the extremely unsettled capital markets that presently exist for small companies like us, that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and Projects.

 

There is no realistic likelihood that funds required during the next twelve months (or in the periods immediately thereafter) for the Company’s basic operations, the Initial Project and/or proposed JVs and/or Projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company’s existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for small companies like Bion.

 

Covid-19 pandemic related matters:

 

 The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

 

21 
 

 

 

2.       SIGNIFICANT ACCOUNTING POLICIES

 

Principles of consolidation:

 

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.

 

The accompanying condensed consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at December 31, 2023, the results of operations and cash flows of the Company for the three and six months ended December 31, 2023 and 2022. Operating results for the three and six months ended December 31, 2023 are not necessarily indicative of the results that may be expected for the year ending June 30, 2024.

 

Cash and cash equivalents:

 

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of December 31, 2023 and June 30, 2023 there are no cash equivalents.

 

Property and equipment:

 

Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects such as consulting fees, internal salaries and benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.

 

Patents:

 

The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s condensed consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.

 

 

22 
 

 

Stock-based compensation:

 

The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.

 

Derivative Financial Instruments:

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

 

Options:

 

The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

 

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

Concentrations of credit risk:

 

The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.

 

Noncontrolling interests:

 

In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the condensed consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the condensed consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.

 

Fair value measurements:

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.

 

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

 

 

23 
 

 

Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

 

Level 3 – assets and liabilities whose significant value drivers are unobservable.

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.

 

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the condensed consolidated statements of operations over the lease term.

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

 

Revenue Recognition:

 

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.

 

Income (Loss) per share:

 

Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise, or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the three and six months ended December 31, 2023 and 2022, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.

 

 

 

24 
 

The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:

        
   December 31,
2023
   December 31,
2022
 
Warrants   23,905,539    20,660,031 
Options   12,006,600    11,201,600 
Convertible debt   9,754,772    11,010,012 

 

The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the three and six months ended December 31, 2023 and 2022.

                
  

Three months

ended

December 31,

2023

  

Three months

ended

December 31,

2022

  

Six months

ended

December 31,

2023

  

Six months

ended

December 31,

2022

 
Shares issued – beginning of period   49,485,556    44,303,654    48,880,237    43,758,820 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)   (704,309)   (704,309)
Shares outstanding – beginning of period   48,781,247    43,599,345    48,175,928    43,054,511 
Weighted average shares issued
    during the period
   98,186    20,706    572,626    479,278 
Diluted weighted average shares –
    end of period
   48,879,433    43,620,051    48,748,554    43,533,789 

 

 

Use of estimates:

 

In preparing the Company’s condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements:

 

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its condensed consolidated financial statements and assures that there are proper controls in place to ascertain that the Company’s condensed consolidated financial statements properly reflect the change.

 

 

25 
 

 

3.       PROPERTY AND EQUIPMENT:

 

Property and equipment consist of the following:

        
  

December 31,

2023

  

June 30,

2023

 
Computers and office equipment   15,156    15,156 
Initial Project: construction in process   9,108,312    6,847,760 
Property and equipment, gross   9,123,468    6,862,916 
Less accumulated depreciation   (12,828)   (11,907)
 Property and equipment, net  $9,110,640   $6,851,009 

 

The 3G1 project (“Initial Project”) began in July of 2021, with a lease signed on land October 1, 2021 (Note 9). Once the lease commenced the Company moved into construction phase. The balance for the Initial Project construction in process includes $238,540 and $98,104 for capitalized interest and $135,648 and $135,648 in non-cash compensation as of December 31, 2023 and 2022, respectively. On January 1, 2024 the Initial Project was deemed to have been ‘placed in service’ (Note 10).

 

Management has reviewed the remaining property and equipment for impairment as of December 31, 2023 and believes that no impairment exists.

 

Depreciation expense was $460 and $394 for the three months ended December 31, 2023 and 2022, respectively and $921 and $724 for the six months ended December 31, 2023 and 2022, respectively.

 

4.       DEFERRED COMPENSATION:

The Company owes deferred compensation to various employees, former employees and consultants totaling $1,225,226 and $714,222 as of December 31, 2023 and 2022, respectively. Included in the deferred compensation balances as of December 31, 2023, are $255,000, $652,252 and $70,450 owed William O’Neill (“O’Neill”), the Company’s CEO, Dominic Bassani (“Bassani”), the Company’s recently deceased Chief Operating Officer (who was Chief Executive Officer for a decade through April 30, 2022) (NOTE: Dominic Bassani passed away on October 11, 2023.), and Mark A. Smith (“Smith”), the Company’s President, respectively.

The sums owed to Bassani and Smith are owed pursuant to extension agreements effective January 1, 2015, whereby unpaid compensation earned after January 1, 2015, accrues interest at 4% per annum and can be converted into shares of the Company’s common stock at the election of the employee during the first five calendar days of any month. The conversion price shall be the average closing price of the Company’s common stock for the last 10 trading days of the immediately preceding month. The deferred compensation owed Bassani and Smith as of December 31, 2022 was $481,972.

O’Neill is owed balance of $255,000 and $80,000 at December 31, 2023 and 2022, respectively, pursuant to his 2021 employment agreement There is no interest accrual or conversion rights related to the deferred balance.

The Company also owes various consultants and an employee, pursuant to various agreements, for deferred compensation of $175,024 and $79,750 as of December 31, 2023 and 2022, respectively, with similar conversion terms as those described above for Bassani and Smith, with the exception that the interest accrues at 0% to 3% per annum. The Company also owes a former employee $72,500, which is not convertible and is non-interest bearing. Bassani and Smith have each been granted the right to convert up to $300,000 of deferred compensation balances at a price of $0.75 per share until June 30, 2024 into common shares (to be issued pursuant to the 2006 Plan). Smith also has the right to convert all or part of his deferred compensation balance into the Company’s securities (to be issued pursuant to the 2006 Plan) “at market” and/or on the same terms as the Company is selling or has sold its securities in its then current (or most recent if there is no current) private placement. Smith also received the right to transfer future deferred compensation to his 2020 Convertible Obligation at his election but such right is no longer in force.

The Company recorded interest expense of $7,201 ($6,875 with related parties) and $4,873 ($4,345 with related parties) for the three months ended December 31, 2023 and 2022, respectively and $13,629 ($12,511 with related parties) and $9,424 ($8,464 with related parties) for the six months ended December 31, 2023 and 2022, respectively.

 

26 
 

 

5.       LOANS PAYABLE:

 

Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s condensed consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s condensed consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436). The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s condensed consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

 

27 
 

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest described above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

6.       CONVERTIBLE NOTES PAYABLE:

 

Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes --- see below) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $3.47 million, in aggregate –See Note 7 below, ‘Debt Modification to Additional Paid in Capital’) while equitably maintaining existing conversion rights.  The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties.

 

Mark A. Smith (the Company’s President)(“Smith”), Dominic Bassani (the Company’s Chief Operating Officer) (“Bassani”) (NOTE: Dominic Bassani passed away on October 11, 2023.) and Ed Schafer (Director)(“Schafer”), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations and the adjusted portion of the September 2015 Convertible Notes were renamed Adjusted September 2015 Convertible Notes. The Adjusted 2020 Convertible Obligations of Smith, Bassani and Schafer are convertible into Units (consisting of 1 share and from one half (1/2) to one (1) warrant) at prices of $.0946, $.0953, and $.0953, respectively, and the Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.115 per share. The adjusted conversion prices slightly reduce the securities to be issued on conversion of each instrument from the amount receivable under the unadjusted instruments. The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). After the adjustment, the Company owed Smith, Bassani (and trust) and Schafer $262,154, $434,016 and $96,364, respectively, of Adjusted 2020 Convertible Obligations and Bassani and Schafer, respectively, $24,230 and $4,012 of Adjusted September 2015 Convertible Notes.

 

As of December 31, 2023, the Adjusted 2020 Convertible Obligation balances, including accrued interest, owed Bassani (and his donees), Smith and Edward Schafer were $450,361, $44,017 and $99,993, respectively. As of June 30 2023, the Adjusted 2020 Convertible Obligation balances, including accrued interest, owed Bassani (and his donees), Smith and Edward Schafer were $441,446, $130,180 and $98,014, respectively.

 

As of December 31, 2023 the Adjusted September 2015 Convertible Notes balances, including accrued interest, owed Bassani Family Trusts and Schafer were $25,143 and $4,163, respectively. As of June 30, 2023 the Adjusted September 2015 Convertible Notes balances, including accrued interest, owed Bassani Family Trusts and Schafer were $24,645 and $4,081, respectively.

 

  

28 
 

 

2020 Convertible Obligations

 

The 2020 Convertible Obligations (which combined/replaced prior convertible instruments dating to 2017 (or earlier), which accrue interest at either 4% per annum or 4% compounded quarterly and effective January 1, 2020 are due and payable on July 1, 2024. The 2020 Convertible Obligations (including accrued interest, plus all future deferred compensation added subsequently), are convertible, at the sole election of the holder, into Units consisting of one share of the Company’s common stock and one half to one warrant to purchase a share of the Company’s common stock, at a price of $0.50 per Unit until July 1, 2024. The original conversion price of $0.50 per Unit approximated the fair value of the Units at the date of the agreements; therefore, no beneficial conversion feature exists. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC 815-15 “Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are not “clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was not required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is not readily convertible to cash in accordance with ASC 815-10, “Derivatives and Hedging”. Effective February 1, 2023, a large portion of the 2020 Convertible Obligations were adjusted as set forth herein.

  

As of December 31, 2023, the remaining unadjusted portion of the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts (and his donees) and Smith, were $367,660 and $118,732, respectively.

As of December 31, 2022, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts, Smith and Schafer were $2,644,553, $1,388,421 and $508,352, respectively.

 

During the six months ended December, 2023, Smith elected to convert $91,548 of his Adjusted 2020 Convertible Obligation into 967,738 units at $0.0946 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until July 2026.

 

The Company recorded interest expense of $7,875 and $82,740 for the six months ended December 31, 2023 and 2022, respectively. The Company capitalized $26,559 and $66,104 related to the Initial Project for the six months ended December 31, 2023 and 2022, respectively.

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long-term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $3.47 million, in aggregate) while equitably maintaining existing conversion rights. Because the modifications where with affiliates that are related parties, the debt modification was treated as an equity transaction. The Company recorded a deemed dividend for the reductions.

 

Mark A. Smith (the Company’s President) (“Smith”), Dominic Bassani (the Company’s Chief Operating Officer) (“Bassani”) (NOTE: Dominic Bassani passed away on October 11, 2023. See Note 10) and Ed Schafer (Director) (“Schafer”), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations (see above and Note 7.). The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties.

 

 

29 
 

 

September 2015 Convertible Notes

 

During the year ended June 30, 2016, the Company entered into September 2015 Convertible Notes with Bassani, Schafer and a Shareholder which replaced previously issued promissory notes. The September 2015 Convertible Notes bear interest at 4% per annum, have maturity dates of July 1, 2024, and may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.60 per share. As the conversion price of $0.60 approximated the fair value of the common shares at the date of the September 2015 Convertible Notes, no beneficial conversion feature exists.

 

The balances of the September 2015 Convertible Notes as of December 31, 2023, including accrued interest owed Bassani, Schafer and Shareholder, are $186,725, $4,163 and $468,431, respectively. The balances of the September 2015 Convertible Notes as of December 31, 2022, including accrued interest, were $284,211, $21,173 and $453,314, respectively.

 

The Company recorded interest expense of $10,158 and $12,731 for the six months ended December 31, 2023 and 2022, respectively.

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including the September 2015 Convertible Notes owned by Bassani and Schafer) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $3.52 million, in aggregate) while equitably maintaining existing conversion rights.  Mark A. Smith (the Company’s President), Dominic Bassani (the Company’s Chief Operating Officer)(and a family Trust) and Ed Schafer (Director), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the Notes were renamed Adjusted September 2015 Convertible Notes. The Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.115 per share. As of December 31, 2023 the Adjusted September 2015 Convertible Notes balances, including accrued interest, owed Bassani Family Trusts and Schafer were $25,143 and $4,163, respectively. The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties. See above.

 

Convertible Bridge Loan/Default

 

On September 28, 2023 the Company entered into an agreement for a $1,500,000 Bridge Loan and executed documents including a convertible promissory note (“Note”) and a binding subscription agreement (“Subscription”) (collectively the Note and the Subscription are the “Bridge Loan Agreements”) with SEB LLC, a non-affiliated party (“Lender”). The Bridge Loan Agreements require the Lender to loan the Company $1,500,000 in six monthly tranches of $250,000 commencing October 2023. All sums advanced under the Bridge Loan Agreements (and accrued interest thereon) would due and payable (with interest accrued at 9% per annum) on October 1, 2024 if not previously converted into securities of the Company. The Note is convertible at $1.00 per unit, at the sole election of the Lender, into units consisting of one share of the Company’s Common Stock and a warrant to purchase one-half share. The initial $250,000 tranche was received by the Company on October 5, 2023. However, no further funds were received by the Company from the Lender. During early November 2023 the Lender informed the Company verbally that it did not intend to fulfill its obligations pursuant to the Bridge Loan Agreements and since such time the Lender has been in default (“Default”). The Default (which is continuing) has created substantial problems for and materially damaged the Company and rendered the Company unable to meet its current creditor obligations on a timely basis. The Company is currently evaluating its rights regarding the Default by the Lender. See Note 10.

  

The Company recorded interest expense of $5,407 and nil for the six months ended December 31, 2023 and 2022, respectively.

 

 

30 
 

 

7.       STOCKHOLDERS’ EQUITY:

 

Debt Modification to Additional paid in capital

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes --- see below) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $3.47 million, in aggregatewhile equitably maintaining existing conversion rights. Because the modifications where with affiliates that are related parties, the debt modification was treated as an equity transaction. The Company recorded a deemed dividend for the reductions.

 

Mark A. Smith (the Company’s President)(“Smith”), Dominic Bassani (then the Company’s Chief Operating Officer)(“Bassani”) (NOTE: Dominic Bassani passed away on October 11, 2023.) and Ed Schafer (Director)(“Schafer”), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations and the adjusted portion of the September 2015 Convertible Notes were renamed Adjusted September 2015 Convertible Notes. The Adjusted 2020 Convertible Obligations of Smith, Bassani and Schafer are convertible into Units at prices of $.0946, $.0953, and $.0953, respectively, and the Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.115 per share. The adjusted conversion prices slightly reduce the securities to be issued on conversion of each instrument from the amount receivable under the unadjusted instruments. The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). After the adjustment, the Company owed Smith, Bassani (and trust) and Schafer $262,154, $434,016 and $96,364, respectively, of Adjusted 2020 Convertible Obligations and Bassani and Schafer, respectively, $24,230 and $4,012 of Adjusted September 2015 Convertible Notes. The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties.

 

The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). The Company treated this as an equity transaction and recorded the reduction of debt through additional paid in capital at the net present value of the modified debt agreements. This resulted in an increase to Additional Paid in Capital of $3,522,000 at the modification date and a reduction of additional paid in capital of $14,051 for the year ended June 30, 2023 and $16,861 for the six months ended December 31, 2023 for the adjustment to the net present value of the modified debt agreements.

 

Series B Preferred stock:

 

Since July 1, 2014, the Company had 200 shares of Series B redeemable convertible Preferred stock outstanding with a par value of $0.01 per share, convertible at the option of the holder at $2.00 per share, with dividends accrued and payable at 2.5% per quarter. The Series B Preferred stock is mandatorily redeemable at $100 per share by the Company three years after issuance and accordingly was classified as a liability. The 200 shares had reached their redemption date and the Company approved the redemption of the Series B preferred stock during the year ended June 30, 2022. The 200 shares of Series B redeemable convertible Preferred stock were redeemed for $41,000, which included the $21,000 in accrued dividend payable.

 

During the years ended June 30, 2023, and 2022, the Company declared dividends of nil and $1,000 respectively. The dividends are classified as a component of operations as the Series B Preferred stock is presented as a liability in these financial statements. There is no liability at December 31, 2023.

 

Common stock:

 

Holders of common stock are entitled to one vote per share on all matters to be voted on by common stockholders. In the event of liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to share in all assets remaining after liabilities have been paid in full or set aside and the rights of any outstanding preferred stock have been satisfied. Common stock has no preemptive, redemption or conversion rights. The rights of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of any outstanding series of preferred stock or any series of preferred stock the Company may designate in the future.

 

Centerpoint holds 704,309 shares of the Company’s common stock. These shares of the Company’s common stock held by Centerpoint are for the benefit of its shareholders without any beneficial interest.

 

 

31 
 

 

During the six months ended December 31, 2023, the Company entered into subscription agreements to sell 28,589 units at a price of $1.60, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $2.40 per share with an expiry date of June 30, 2024, and pursuant thereto, the Company issued 28,589 units for total proceeds of $45,742. See ‘Warrants’ below.

 

During the six months ended December 31, 2023, the Company entered into subscription agreements to sell 75,000 units at a price of $1.00, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $1.25 per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued 75,000 units for total proceeds of $75,000. See ‘Warrants’ below.

 

During the six months ended December 31, 2023, the Company entered into subscription agreements to sell 300,000 units at a price of $1.00, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $1.25 per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued 300,000 units for total proceeds of $300,000. See ‘Warrants’ below.

 

During the six months ended December 31, 2023, 38,000 warrants were exercised to purchase 38,000 shares of the Company’s common stock at $0.75 per share for total proceeds of $28,500.

 

During the six months ended December 31,2023, Smith elected to converted $91,548 of principal from his Adjusted 2020 Convertible note into 967,738 Units; each unit consisting of one share and one warrant with the exercise price of $.75 until July 21, 2026. Each of these warrants carry an exercise bonus of 75%.

 

During the six months ended December 31, 2023, the Company issued 7,500 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.20 per share for a total value of $9,000.

 

During the six months ended December 31, 2023, the Company issued 10,753 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.55 per share for a total value of $16,667.

 

During the six months ended December 31, 2023, the Company issued 2,000 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.16 per share for a total value of $2,320.

 

During the six months ended December 31, 2023, the Company issued 15,000 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.00 per share for a total value of $15,000.

 

During the six months ended December 31, 2023, the Company issued 21,506 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.55 per share for a total value of $33,334.

 

During the six months ended December 31, 2023, the Company issued 265,639 shares of the Company’s common stock upon cashless exercise of ____ outstanding warrants held by non-affiliates of the Company.

 

Warrants:

 

As of December 31, 2023, the Company had approximately 24 million warrants outstanding, with exercise prices from $0.60 to $2.40 and expiring on various dates through November 9, 2026.

 

The weighted-average exercise price for the outstanding warrants is $0.64, and the weighted-average remaining contractual life as of December 31, 2023 is 1 years.

 

During the six months ended December 31, 2023, Smith elected to converted $91,548 of principal from his Adjusted 2020 Convertible note into 967,738 Units; each unit consisting of one share and one warrant with the exercise price of $.75 until July 21, 2026. Each of these warrants carry an exercise bonus of 75%.

 

 

32 
 

 

During the six months ended December 31, 2023, the Company entered into subscription agreements to sell 28,589 units at a price of $1.60, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $2.40 per share with an expiry date of June 30, 2024, and pursuant thereto, the Company issued 28,589 units for total proceeds of $45,742. On September 26, the Company’s Board of Directors, due to a misunderstanding related to a private placement (memorandum of March 2023) and the securities sold thereunder, adjusted the units sold in the offering by substituting 1,003,590 warrants with an exercise price of $1.25 per share for 501,795 previously issued warrants effective October 1, 2023.

 

During the six months ended December 31, 2023, the Company approved the modification of existing warrants held by brokers, which extended certain expiration dates. The modifications resulted in interest  expenses of $135,207 and non-cash compensation of $15,000.

During the six months ended December 31, 2023, 38,000 warrants were exercised to purchase 38,000 shares of the Company’s common stock at $0.75 per share for total proceeds of $28,500.

During the six months ended December 31, 2023, the Company issued 50,000 warrants to a consultant for services. The warrants were issued for a total value of $5,000.

 

During the six months ended December 31, 2023, the Company issued 265,639 shares of the Company’s common stock upon cashless exercise of outstanding warrants held by non-affiliates of the Company.

 

Effective May 1, 2022, an entity affiliated with William O’Neill (“O’Neill”) was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise price adjustment provision if the terms set forth therein are met. 700,000 of the warrants are vesting through May 1, 2023  and 2024. The vesting resulted in non-cash compensation of $6,563 for the six months ended December 31, 2023.

 

Stock options:

 

On April 7, 2022 the Company’s shareholders approved the Bion Environmental Technologies, Inc. 2021 Equity Incentive Award Plan (the “Equity Plan”). The Equity Plan provides for the issuance of options (and/or other securities) to purchase up to 30,000,000 shares of the Company’s common stock. The Equity Plan was adopted and ratified by Board of Directors on April 8, 2022. Terms of exercise and expiration of options/securities granted under the Equity Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. No grants have been made pursuant to the Equity Plan as of the date of this report.

 

The Company’s 2006 Consolidated Incentive Plan, as amended during the year ended June 30, 2021 (the “2006 Plan”), provides for the issuance of options (and/or other securities) to purchase up to 36,000,000 shares of the Company’s common stock. Terms of exercise and expiration of options/securities granted under the 2006 Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. The 2006 Plan will be maintained to service grants already made thereunder (together with new grants, if any, to employees and consultants who already has received grants pursuant to its terms).

 

On March 15, 2023, the Company granted 30,000 options under the 2006 Plan to two consultants. The options vested equally in thirds on March 20, 2023, June 20, 2023 and September 30, 2023.

 

On May 9, 2023, the Company granted 500,000 options under the 2006 Plan to Bill O’Neill. 250,000 of these options vest on June 1, 2024 and 250,000 options vest on June 1, 2025; all options expire on June 30, 2026.

 

The Company recorded compensation expense related to employee stock options of $107,487 and nil for the six months ended December 31, 2023 and 2022, respectively. The Company granted nil and nil options for the six months ended December 31, 2023 and 2022, respectively.

  

 

33 
 

 

A summary of option activity under the 2006 Plan for six months ended December 31, 2023 is as follows:

                 
    Options   Weighted-
Average
Exercise
Price
   Weighted-
Average
Remaining
Contractual
Life
   Aggregate
Intrinsic
Value
 
 Outstanding at July 1, 2023    12,006,600   $0.85    1.83   $5,085,659 
   Granted                       
   Exercised                       
   Forfeited                       
   Expired                       
 Outstanding at December 31, 2023    12,006,600   $0.85    1.32   $1,778,547 

 

The total fair value of stock options that vested during the six months ended December 31, 2023 and 2022 was nil and nil, respectively. As of December 31, 2023, the Company had no unrecognized compensation cost related to stock options.

 

8.       SUBSCRIPTION RECEIVABLE - AFFILIATES:

 

As of December 31, 2023, the Company has three interest bearing, secured promissory notes with an aggregate principal amount of $428,250 ($526,142, including interest) from Bassani which were received as consideration for purchases of warrants to purchase 5,565,000 shares, in aggregate, of the Company’s restricted common stock, which warrants have an exercise price of $0.75 (with a 75% exercise price adjustment provision) and have expiry dates ranging from December 31, 2024 to December 31, 2025 (subject to extension rights) secured by portions of Bassani Family Trust’s 2020 Convertible Obligation and Bassani Family Trust’s September 2015 Convertible Notes. The secured promissory notes are payable July 1, 2024.

 

 As of December 31, 2023, the Company has an interest bearing, secured promissory note for $30,000 ($36,487 including interest) from Smith as consideration to purchase warrants to purchase 300,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 (with a 75% exercise price adjustment provision) and have expiry dates of December 31, 2024 (subject to extension rights) The promissory note bears interest at 4% per annum, and is secured by $30,000 original principal ($37,157 including interest) of Smith’s 2020 Convertible Obligations. The secured promissory note is payable on July 1, 2024.

 

As of December 31, 2023, the Company has two interest bearing, secured promissory notes with an aggregate principal amount of $46,400 ($57,790 including interest) from two employee/consultants as consideration to acquire warrants to purchase 928,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.75 (with a 90% exercise price adjustment provision) and have expiry dates of December 31, 2024. (The promissory notes bear interest at 4% per annum, are secured by a perfected security interest in the warrants, and are payable on July 1, 2024.

 

These secured promissory notes are recorded as “Subscription receivable—affiliates” on the Company’s balance sheet pending payment.

9.       COMMITMENTS AND CONTINGENCIES:

 

A: Employment and consulting agreements:

 

Smith has held the positions of Director, Executive Chairman, President and General Counsel of Company and its subsidiaries under various agreements (and extensions) and terms since March 2003. On October 10, 2016, the Company approved a month-to-month contract extension with Smith which included provisions for i) a monthly salary of $18,000 ( deferred until the Board of Directors re-instated cash payments to all employees and consultants who are deferring compensation), ii) the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, until December 31, 2024, and iii) the right to convert his deferred compensation in whole or in part, at his sole election, at any time in any amount at “market” or into securities sold in the Company’s current/most recent private offering at the price of such offering to third parties. Smith agreed effective July 29, 2018 to continue to serve the Company under the same basic terms on a month-to-month basis. On May 1, 2022 Smith’s compensation was increased to $25,000 per month of which $5,000 per month is deferred. Currently Smith is deferring all of his monthly compensation to help the Company conserve cash. For the three months ended December 31, 2023 and 2022, Smith was paid $5,000 and $60,000, respectively, of cash compensation. For the six months ended December 31, 2023 and 2022, Smith was paid $20,000 and $100,000, respectively, of cash compensation.

 

  

34 
 

Since March 31, 2005, the Company has had various agreements with Dominic Bassani (and/or Brightcap which provided his services during some of the years) (NOTE: Dominic Bassani passed away on October 11, 2023.) who was serving as the Company’s Chief Operating Officer (‘COO’) at the time of his passing and formerly served as the Company’s Chief Executive Officer (‘CEO’) for the prior decade (any reference to Brightcap or Bassani for all purposes are referring to the same individual). The Board appointed Bassani as the Company's CEO effective May 13, 2011. On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017 (with the Company having an option to extend the term an additional six months.) Pursuant to the Extension Agreement, Bassani continued to defer his cash compensation ($31,000 per month) until the Board of Directors re-instated cash payments to all employees and consultants who were deferring their compensation. During October 2016 Bassani was granted the right to convert up to $125,000 of his deferred compensation, at his sole election, at $0.75 per share, until March 15, 2018 (which was expanded on April 27, 2017 to the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, until June 30, 2024 (including extensions). During February 2018, the Company agreed to the material terms for a binding two-year extension agreement for Bassani’s services as CEO. Bassani’s salary remained $31,000 per month, which will continue to be accrued in part during periods when the Board determines there is not adequate cash available. Additionally, the Company agreed to pay or accrue $2,000 per month to be applied to life insurance premiums (which sums have been accrued as liabilities). On August 1, 2018, in the context of extending his agreement to provide services to the Company on a full-time basis through December 31, 2022) plus 2 years after that on a part-time basis, the Company received an interest bearing secured promissory note for $300,000 from Bassani as consideration to purchase warrants to purchase 3,000,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of June 30, 2025. The promissory note is secured by a portion of Bassani’s 2020 Convertible Obligations and as of June 30, 2023, the principal and accrued interest was $364,490. For the three months ended December 31, 2023 and 2022, Brightcap was paid $5,000 and $75,500, respectively, of cash compensation.

 

William O’Neill (“O’Neill”) was hired as the Company’s Chief Executive Officer (“CEO”) effective May 1, 2022.  O’Neill had previously been working with the Company as a consultant and had been employed by the Company as its CEO during 2010-2011. (Upon the hiring of O’Neill, Bassani, CEO of the Company since 2011, assumed the position of COO while retaining existing operational management responsibilities and working with O’Neill on ‘commercialization’ of the Company’s technology and work related to JVs (and other transactions) based on the Company’s Gen3 Technology and related matters until his recent death. Bassani’s compensation arrangements with the Company were not altered in the context of the change of positions.) The Company and O’Neill entered into a thirty-seven (37) month employment agreement with compensation of $25,000 cash and $10,000 deferred compensation per month. The cash payment is paid $12,500 to O’Neill and $12,500 to an entity affiliated with O’Neill. An entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share (a 75% exercise price adjustment provision if the terms set forth therein are met) until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. Currently O’Neill is deferring all of his monthly compensation to help the Company conserve cash. For the three months ended December 31, 2023 and 2022, O’Neill and the entity affiliated with O’Neill were paid $42,500 and $75,000, respectively, of cash compensation.

 

B: Exercise Price Adjustments/Extension Rights:

 

As part of agreements the Company entered into with Bassani and Smith effective May 15, 2013, they were each granted the following: a) a 50% execution/exercise price adjustment provision (exercise bonus in the context of options) which shall be applied upon the effective date of the notice of intent to exercise (for options and warrants) or issuance event, as applicable, of any currently outstanding and/or subsequently acquired options, warrants and/or contingent stock bonuses owned by each (and/or their donees) as follows: i) in the case of exercise by payment of cash, the bonus shall take the form of reduction of the exercise price; ii) in the case of cashless exercise, the adjustment shall be applied to reduce the exercise price prior to the cashless exercise calculations; and iii) with regard to contingent stock adjustments, issuance shall be triggered upon the Company’s common stock reaching a closing price equal to 50% of currently specified price; and b) the right to extend the exercise period of all or part of the applicable options and warrants for up to five years (one year at a time) by annual payments of $.05 per option or warrant to the Company on or before a date during the three months prior to expiration of the exercise period at least three business days before the end of the expiration period. Effective January 1, 2016 such annual payments to extend warrant exercise periods were reduced to $.01 per option or warrant. These exercise adjustments were subsequently increased to 75%.

 

 

35 
 

During the year ended June 30, 2021, the Company added a 75% exercise price adjustment to the terms of 3,000,000 warrants held by a trust owned by Bassani.

 

As of December 31, 2023, exercise price adjustment provisions ranging from 50-90% were applicable to 11,771,600 of the Company’s outstanding options and 20,415,408 of the Company’s outstanding warrants.

 

Effective May 1, 2022, an entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants were cancellable if O’Neill was not renewed at 13 months (renewal has happened) and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise price adjustments if the terms set forth therein are met.

 

C: Initial Project:

 

On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $2,665,500 (and made the initial 25% payment ($666,375) for the core of the ‘Bion System’ portion (without the crystallization modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. The Company received progress billing in March 2022 and June 2022 for the second and third 25% installments, both of which have been paid as of the filing date. On January 17, 2023 the Company received an invoice from Buflovak for $533,100 which was paid on March 1, 2023 and on April 24, 2023 the Company received an invoice from Buflovak for $83,275 which was paid on May 2, 2023 bringing the aggregate payments to $2,615,500 as of the date of this filing. There remains $50,000 open on the Purchase Order has been billed on July 26, 2023. In addition to the Purchase Order, through December 31, 2023 the Company has incurred additional costs of 6,442,812 on the Initial Project for capitalized interest and costs, non-cash compensation, equipment and consulting fees. $6,983,954 has been paid and $1,750,170 has been billed and not yet paid.

 

Buflovak has worked with the Company on design and testing of its 3G Tech over several years. The basic design for the Initial Project’s Bion System is complete, fabrication and delivery of equipment from Buflovak from the Purchase Order Agreement has been largely completed and assembly/construction is in process.  3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, utilities, etc.) for work related to the Initial Project. The Company has incurred costs of $8,177,452 on the Initial Project, not including capitalized labor and interest.

 

The Initial Project was deemed to have been ‘placed in service’ on January 1, 2024 (Note 10).

 

D: Lease:

 

The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.

 

The future minimum lease payment under noncancelable operating lease with terms greater than one year as of December 31, 2023:

    
From January 2024 to December 2024  75,000 
Undiscounted cash flow  75,000 
Less imputed interest  (3,909)
Total  71,091 

  

The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of December 31, 2023 were 1 years and 10%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.

  

 

36 
 

E: Litigation (and related matters):

 

1)  Website: Domain Sale/Resolved Litigation/Hacking/Theft

 

On March 23, 2022 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name <biontech.com> no longer represented a core asset of the Company.

 

As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the <biontech.com> domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.

 

On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name <biontech.com> ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name <biontech.com> to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).

 

No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations were subjected to disruption and expenses were incurred related to the matter including legal fees.

 

The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.

 

2)  Pennvest Loan and Dissolution of Bion PA1, LLC (“PA1”)

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s consolidated balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

 

37 
 

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.

 

 

38 
 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

 PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest set forth above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception, and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

3)  Bank Account Hacking

 

On June 23, 2023, an officer of the Company with personal accounts with Signature Bank was hacked and $75,000 was transferred from the Company’s accounts at Signature Bank to the officer’s personal accounts. The bank was notified and all Company accounts were placed on hold. Subsequently, the funds were released and transferred back to the Company prior to June 30, 2023, the end of the fiscal year, and there were no losses incurred.  The Company has reviewed the authorized individuals on all accounts and further limited access after the hacking incident.  

 

The Company currently is not involved in any other material litigation or similar events.

 

4)  Bridge Loan/Default

 

On September 29, 2023 the Company entered into an agreement for a $1,500,000 Bridge Loan and executed documents including a convertible promissory note (“Note”) and a binding subscription agreement (“Subscription”) (collectively the Note and the Subscription are the “Bridge Loan Agreements”) with SEB LLC, a non-affiliated party (“Lender”). The Bridge Loan Agreements require the Lender to loan the Company $1,500,000 in six monthly tranches of $250,000 commencing October 2023. All sums advanced under the Bridge Loan Agreements (and accrued interest thereon) would due and payable (with interest accrued at 8% per annum) on October 1, 2024 if not previously converted into securities of the Company. The Note is convertible at $1.00 per unit, at the sole election of the Lender, into units consisting of one share of the Company’s Common Stock and a warrant to purchase one-half share. The initial $250,000 tranche was received by the Company on October 5, 2023. However, no further funds were received by the Company from the Lender. During early November 2023 the Lender informed the Company verbally that it did not intend to fulfill its obligations pursuant to the Bridge Loan Agreements and since such time the lender has been in default (“Default”). The Default (which is continuing) has created substantial problems for and materially damaged the Company and rendered the Company unable to meet its current creditor obligations on a timely basis. The Company is currently evaluating its rights regarding the Default by the Lender.

 

10.       SUBSEQUENT EVENTS:

 

The Company is in discussion/negotiation with its largest creditor--the primary contractor on the Initial Project-- and anticipates reaching agreement regarding payment of its accrued obligations during the current quarter. The Company is also involved in discussions and negotiations with other creditors.   

On January 1, 2024 the Initial Project was ‘placed into service’ with a total capitalized cost of $9,108,312. During the current quarter the Company will commence depreciation of this asset.

 

On January 1, 2024, Smith elected to convert the $49,403 remaining balance of his Adjusted 2020 Convertible note into 522,231 units (each unit consisting of one share and one warrant with the exercise price of $.75 until July 21, 2026). Smith made gifts/donations of 122,231 units and 200,000 to his spouse. 

On January 18, 2024, the Company entered into a subscription agreement to sell 10,000 units at a price of $1.00, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $1.25 per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued 10,000 units for total proceeds of $10,000.

 

From January 1, 2024 to February 13, 2024, the Company issued 3,307,516 shares of the Company’s common stock upon cashless exercise of outstanding warrants held by non-affiliates of the Company.

 

From January 1, 2024 to February 13, 2024, the Company issued 2,439,428 shares of the Company’s common stock upon cashless exercise of outstanding warrants held by Mark Smith (which includes 700,062 by his wife.)

 

 

 

   

39 
 

 

  

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

 

Statements made in this Form 10-Q that are not historical or current facts, which represent the Company's expectations or beliefs including, but not limited to, statements concerning the Company's operations, performance, financial condition, business strategies, and other information, involve substantial risks and uncertainties. The Company's actual results of operations, most of which are beyond the Company's control, could differ materially. These statements often can be identified by the use of terms such as "may," "will," "expect," "believe," anticipate," "estimate," or "continue" or the negative thereof. We wish to caution readers not to place undue reliance on any such forward looking statements, which speak only as of the date made. Any forward-looking statements represent management's best judgment as to what may occur in the future. However, forward looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected.

 

These factors include adverse economic conditions, entry of new and stronger competitors, inadequate capital and limited ability to obtain financing, needed personnel and equipment, unexpected costs, failure (or delay) to gain product certifications and/or regulatory approvals in the United States (or particular states) or foreign countries, loss (permanently or for any extended period of time) of the services of members of the Company’s small core management team (many of whom are age 70 or older) and failure to capitalize upon access to new markets. Additional risks and uncertainties that may affect forward looking statements about Bion's business and prospects include: i) the possibility that markets for nutrient reduction credits (discussed below) and/or other ways to monetize nutrient reductions and other environmental benefits will be slow to develop (or not develop at all), ii) PA1’s dissolution and its effect on how the Company is viewed, (if any), iii) the possibility that competitors will develop more comprehensive and/or less expensive environmental solutions, iv) delays in market awareness of Bion and our Systems, v) uncertainties and costs increases related to research and development efforts to update and improve Bion’s technologies and applications thereof, and/or vi) delays and/or costs exceeding expectations relating to Bion's development of the Initial Project, JVs and/or Projects and vii) failure of marketing strategies, each of which could have both immediate and long term material adverse effects by placing us behind our competitors and requiring expenditures of our limited resources.

 

THESE RISKS, UNCERTAINTIES AND FACTORS BEYOND OUR CONTROL ARE MAGNIFIED DURING THE CURRENT UNCERTAIN PERIOD RELATED TO THE COVID-19 PANDEMIC AND THE UNIQUE ECONOMIC, FINANCIAL, GOVERNMENTAL AND HEALTH-RELATED CONDITIONS IN WHICH THE COMPANY, THE ENTIRE COUNTRY AND THE ENTIRE WORLD NOW RESIDE.  TO DATE THE COMPANY HAS EXPERIENCED DIRECT IMPACTS  IN VARIOUS AREAS INCLUDING WITHOUT LIMITATION: I) GOVERNMENT-ORDERED  SHUTDOWNS WHICH HAVE SLOWED THE COMPANY’S RESEARCH AND DEVELOPMENT PROJECTS AND OTHER INITIATIVES, II) SHIFTED FOCUS OF STATE AND FEDERAL GOVERNMENT WHICH IS LIKELY TO NEGATIVELY IMPACT THE COMPANY’S LEGISLATIVE INITIATIVES IN PENNSYLVANIA AND WASHINGTON DC, III) STRAINS AND UNCERTAINTIES IN BOTH THE EQUITY AND DEBT MARKETS HAVE MADE DISCUSSION AND PLANNING OF FUNDING OF THE COMPANY AND ITS INITIATIVES AND PROJECTS WITH INVESTMENT BANKERS, BANKS AND POTENTIAL STRATEGIC PARTNERS MORE TENUOUS, IV) STRAINS AND UNCERTAINTIES IN THE AGRICULTURAL SECTOR AND MARKETS HAVE MADE DISCUSSION AND PLANNING OF FUNDING OF THE COMPANY AND ITS INITIATIVES AND PROJECTS MORE DIFFICULT AS FUTURE INDUSTRY CONDITIONS ARE NOW MORE DIFFICULT TO ASSESS/PREDICT, V) CONSTRAINTS DUE TO PROBLEMS EXPERIENCED IN THE GLOBAL INDUSTRIAL SUPPLY CHAIN WHICH HAVE INCREASED ANTICIPATED PROJECT DEVELOPMENT COSTS, VI) DUE TO THE AGE AND HEALTH OF OUR CORE MANAGEMENT TEAM, MOST OF WHOM ARE AGE 70 OR OLDER AND HAVE HAD ONE OR MORE EXISTING HEALTH ISSUES, THE COVID-19 PANDEMIC PLACES THE COMPANY AT GREATER RISK THAN WAS PREVIOUSLY THE CASE (TO A HIGHER DEGREE THAN WOULD BE THE CASE IF THE COMPANY HAD A LARGER, DEEPER AND/OR YOUNGER CORE MANAGEMENT TEAM), AND VII) THERE ALMOST CERTAINLY WILL BE OTHER UNANTICIPATED CONSEQUENCES FOR THE COMPANY AS A RESULT OF THE CURRENT PANDEMIC EMERGENCY AND ITS AFTERMATH.

 

Bion disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

 

The following discussion and analysis should be read in conjunction with the Condensed Consolidated Financial Statements and Notes to Condensed Consolidated Financial Statements filed with this Report. 

 

  

40 
 

BUSINESS OVERVIEW AND PLAN

 

THE COMPANY HAS BEEN UNDER SUBSTANTIAL FINANCIAL AND MANAGEMENT STRESS OF THE PAST SIX MONTHS (AND THE CURRENT QUARTER TO DATE) DUE TO THE RECENT DEATH (FOLLOWING EXTENDED ILLNESS) OF DOMINIC BASSANI (WHO MOST RECENTLY SERVED AS OUR COO (FROM MAY 2022) AFTER SERVING AS OUR CEO FOR THE PRIOR DECADE) AND DIFFICULTIES IN RAISING NEEDED FUNDS (WHICH RE-EMERGED LATE IN THE 2023 FISCAL YEAR AND HAS CONTINUED). THE COMPANY IS FACING INCREASED CAPITAL NEEDS AND THE NEED TO TRANSITION TO A YOUNGER MANAGEMENT TEAM (MARK A. SMITH, THE COMPANY’S PRESIDENT AND GENERAL COUNSEL PROVIDED NOTICE DURING EARLY 2023 OF HIS INTENT TO PHASE OUT HIS MANAGEMENT ROLES EARLY THIS CALENDAR YEAR). THESE ITEMS HAVE BEEN PREVIOUSLY DISCLOSED BUT THE COMPANY BELIEVES IT IS IMPORTANT TO FEATURE THEM ‘UPFRONT’ AT THIS POINT.

 

PLEASE NOTE:

 

A: The Company is not currently generating any significant revenues. Further, the Company’s anticipated revenues, if any, from existing Projects, JVs and proposed Projects will not be sufficient to meet the Company’s anticipated operational and capital expenditure needs for many years. Current liabilities were approximately $4.2 million and $1.6 million at December 31, 2023 and 2022, respectively. There was an increase of approximately $2.6 million (which was largely due to an increase in ‘accounts payable and accrued expenses’ totaling approximately $2.0 million and an increase in ‘deferred compensation’ of approximately $.35 million as a result of the Company’s limited success in raising new financing (equity and/or debt) during the recent period combined with continued expenses (including those related to the Initial Project). See NOTE 1, “Going Concern and Management’s Plans” above and “Plan of Operations and Outlook below.

 

B: On September 28, 2023 the Company entered into an agreement for a $1,500,000 bridge loan and executed documents including a convertible promissory note (“Note”) and a binding subscription agreement (“Subscription”) (collectively the Note and the Subscription are the “Bridge Loan Agreements”) with SEB LLC, a non-affiliated party (“Lender”). The Bridge Loan Agreements require the Lender to loan the Company $1,500,000 in six monthly tranches of $250,000 commencing October 2023. All sums advanced under the Bridge Loan Agreements (and accrued interest thereon) would due and payable (with interest accrued at 8% per annum) on October 1, 2024 if not previously converted into securities of the Company. The Note is convertible at $1.00 per unit, at the sole election of the Lender, into units consisting of one share of the Company’s common stock and a warrant to purchase one half share. The initial $250,000 tranche was received by the Company on October 5, 2023. However, no further funds were received by the Company from the Lender. During early November 2023 the Lender informed the Company verbally that it did not intend to fulfill its obligations pursuant to the Bridge Loan Agreements and since such time the Lender has been in default (“Default”). The Default (which is continuing) has created substantial problems for and materially damaged the Company and rendered the Company unable to meet its current creditor obligations on a timely basis. The Company is currently evaluating its rights regarding the Default by the Lender. This situation has contributed to the substantial increase in the Company’s ‘Current Liabilities’ including ‘accounts payable’ over recent periods. See Consolidated Financial Statements (above) and ‘Management’s Discussion and Analysis’ (below). The Company is in discussion/negotiation with its larger creditors (including its largest creditor--- the primary contractor on the Initial Project) and anticipates reaching agreements re payments during the current quarter (or soon thereafter).

  

Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to make livestock production more sustainable, profitable and transparent. We intend to accomplish this by deploying our Gen3Tech platform/business model (discussed below) in ventures focused on the ‘feeder’ space of the livestock production/value chain to provide the consumer with verifiably sustainable premium meat products (together with environmentally friendly, sustainable and/or organic co-products from the production process).  Bion believes this approach can create extraordinary value for our shareholders and employees (all of whom own securities in the Company) and for livestock/agriculture industry ‘partners’ who join us in our ventures. We anticipate pursuing the opportunity created by our third generation technology (“Gen3Tech”) and business/technology platform in conjunction with other industry practices (“Gen3Tech Platform” or “Platform”).

 

 

41 
 

Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our Gen3Tech can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These waste ‘assets’ – nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate surface groundwater, and exacerbate climate change.

 

We anticipate this will result in substantial long-term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent one of the largest enhanced revenue contributors provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

Bion’s Gen3Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the animal raising and waste treatment process will be third-party verified, providing the basis for additional revenues, including carbon and/or renewable energy-related credits and, eventually, payment for a range of ecosystem services, including nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.

 

During the first half of calendar 2022 Bion began pre-marketing our sustainable beef opportunity to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During our 2023 fiscal year, Bion entered into three (3) letters of intent (“LOIs”): a) July 2022 letter of intent to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch (“Ribbonwire LOI”), in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”), (b) January 2023 letter of intent to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Olson Feeders and TD Angus (“Olson LOI”), near North Platte, Nebraska (with a provision to expand to 45,000 head or more) (“Olson Project”) and c)April 2023 letter of intent to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with Dakota Valley Growers (“DVG LOI”) near Bathgate, North Dakota (“DVG Project”). The Company is in discussions with additional parties regarding potential further LOIs. Based on our experience to date, we believe we will not have difficulty in securing participation in our Projects from additional feeders/cattlemen. The Olson, Dalhart and DVG Projects (and subsequent Projects) will be developed to produce blockchain-verified, sustainable beef in customized covered barns (resulting in reduced stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) with ongoing manure transfer (through slatted floors) to anaerobic digesters (AD) to capture nitrogen from the manure stream before loss to the atmosphere and generate renewable natural gas (RNG) for sale while remediating the environmental/carbon impacts usually associated with cattle feedlots and CAFOs. Bion’s patented Gen3Tech platform will refine the waste stream into valuable coproducts that include clean water, RNG, photovoltaic solar electricity and fertilizer (‘climate smart’ and/or organic) products. We anticipate converting tone or more of these LOIs into definitive JV agreements and creating related distribution agreements with key retailers and food service distributors during the current calendar year.

 

During the 2023 calendar year, the Company has constructed (construction is largely completed) our 3GTech Ammonia Recovery System (‘ARS’) located near Fair Oaks, Indiana and begun operations of phase 1 of our Initial Project (our commercial scale demonstration facility) located near Fair Oaks, Indiana. The Initial Project has been deemed ‘placed in service’ effective January 1, 2024. Operating results to date at Fair Oaks indicate ARS performance will exceed initial expectations for ammonia recovery and related economics. The Company recently announced that we have achieved key objectives in the optimization of its ARS and will now begin the final design process for full-scale systems based on results to date (and testing over the remainder of this fiscal year) at the Initial Project. The ARS has achieved and maintained controlled steady-state operations under a variety of conditions. When operated at steady state, the system produces an ammonium distillate (solution), the base of Bion’s nitrogen fertilizer products. Bion has begun optimizing the ARS’s operating parameters with the goal of meeting and/or exceeding the results needed for Bion’s economic models for large-scale commercial projects. The Company expects the current optimization phase will continue during the next quarter (or longer) and provide data required to support final design/engineering for commercial project modules. We believe this data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, distributors, retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below). Final economic and energy efficiency models will be validated during the final design process. The Company intends to engage a third party engineering firm during the next quarter to prepare a third-party evaluation of the ARS while also moving forward on final commercial design process.

 

42 
 

The patented ARS is the core of Bion’s Gen3Tech platform. It recovers and upcycles problem ammonia contained in the effluent from anaerobic digestion (where methane is captured and more ammonia is released) of the livestock manure waste stream. The ARS captures the ammonia, minimizing its environmental impacts and creating low-carbon and/or organic nitrogen fertilizer products with it. During the last three (3) months,, the Company has produced ammonium distillate and ammonium bicarbonate solutions at the Initial Project in several concentrations and plans to initiate the application process for organic certification for each concentration of liquid fertilizer product. Multiple applications to OMRI (Organic Materials Review Institute) and CDFA (California Department of Food and Agriculture) are being prepared for listing/certification of new organic products. Bion received an OMRI-Listing in 2020 for its initial product. Bion will continue producing liquid and crystal fertilizers at the Initial Project to support testing and life-cycle analysis, product trials, and ongoing organic initiatives. Bion will produce a solid/granular nitrogen fertilizer product at the Initial Project (when the crystalizer module is ready for operation) which we believe will be both ‘Climate-Smart’ and ‘Water-Smart’ – a pure nitrogen fertilizer with a low carbon footprint, that is water soluble and readily available to plants. Samples of the granular product will also be utilized to support organic certification applications. See Fertilizer---Organic and ‘ClimateSmart’ below.

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long-term value for Bion. To accomplish Bion’s goals, we anticipate the we will ‘partner’ with other technology companies who provide solutions for different links of the beef (and other livestock) value chain and with strategic partners up and down the supply chain. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent one of the single largest enhanced revenue contributor provided by Bion to the JVs (and, in some cases, Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

Bion expects the Initial Project data will document the effectiveness of our Gen3Tech in a commercial-scale setting during the current fiscal year and support development of one or more of the LOI Projects (and/or other Gen3Tech beef JV projects) commencing later this fiscal year.  We do not presently know the order in which the JV Projects will be developed as that decision will be made based on many factors not yet in place. We believe the Initial Project data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, food distributors and retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below).

 

Note that Bion recently announced its intention to establish strategic partnerships to market the ARS as a stand-alone addition to anaerobic digestion (“AD”) nitrogen control solution in two sectors:

A)INDUSTRIAL AND MUNICIPAL WASTEWATER. AD is now used at 1,269 water resource recovery facilities in the U.S., with another 102 stand-alone systems that digest food waste. The American Biogas Council estimates an additional 8,600 sites with development potential. Germany, by comparison, has almost 10,000 operating AD sites. In the U.S., wastewater and AD digestate from industrial and municipal sources is already regulated for ammonia and nitrates. The EPA recently proposed tougher standards for slaughter facilities. Bion believes ARS ammonia treatment costs will be competitive in these markets and that its unique premium fertilizer byproducts will create an advantage, especially with waste streams that are still considered ‘organic’, like slaughter and food waste.

 

B)ANIMAL WASTE. According to the American Biogas Council here are 473 animal waste digesters operating in the U.S. today, most on dairy operations. The American Biogas Council and USDA’s AgSTAR program estimate more than 8,000 additional sites with development potential. The ARS was designed specifically for this purpose: control ammonia from livestock waste and produce the highest value byproducts with it. Digestate from animal waste AD has enjoyed the same reduced regulatory requirements as land applying raw manure. Recent trends in Michigan and California indicate they will treat animal waste digestate as any industrial source, subject to groundwater permitting requirements. Bion believes its proven technology and value-added fertilizers will give it a significant competitive advantage in this evolving market.

 

 

43 
 

Bion is now focused primarily on: i) operation and further testing at the Initial Project, our initial commercial-scale Gen3Tech installation, for support of design/feasibility studies/reports related to our initial JV Projects (and further optimization of its operational parameters), ii) pre-development planning of the LOI Projects (and/or other Gen3Tech beef JV projects) including steps toward distribution agreements, iii) developing applications and markets for its low carbon ‘ClimateSmart’ and organic fertilizer products (including listings/certifications of multiple liquid and solid products) and its sustainable (conventional and organic) animal protein products, and iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed herein) (and related Projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), (v) exploring JVs re stand-alone ARS markets, while (vi) continuing to pursue business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&D activities.

 

At present, there is essentially no traceable and verifiable ‘sustainable beef’ available to the US market except for niche products. In response to consumer demand for transparency and sustainability, Bion expects the meat industry in general, and beef specifically, to evolve towards using new technologies to deliver these attributes in their products. While we anticipate a faster adoption of tracking, verification and sustainability technologies in other perishable food categories like produce and dairy due to their shorter product cycles (and related harvest and production techniques), meat industry leaders have also announced their willingness to move forward with initiatives in this area. Many companies have announced ‘sustainability’ initiatives but most appear to consist largely of ‘greenwashing’ marketing commitments rather than substantive undertakings at this date. Note, however, that Tyson’s Brazen beef initiative (which was announced during March 2023) may develop into a substantive competitive factor in the sustainable beef marketplace. Bion predicts that within approximately five-six years, consumers will be able to track and verify claims including sustainability on 25% (or more) of the products merchandised in the meat department. Bion believes that the retail market share of verifiably sustainable beef in the US will approach 7-10 % within three-four (3-4) years (end of 2028) and 25% in five-six (5-6) years (end of 2029-30) (approximately 6-7,000,000 cattle annually) (and more thereafter).

 

Based on these trends, Bion has set an aspirational target---which will require that Bion can successfully execute on its sustainable beef business plan (which is subject to many contingencies ---including raising extremely large amounts of project financing for its JVs and the acquisition of adequate senior and operating management personnel to implement the business plan---and is not assured). We believe that facilities utilizing Bion’s Gen3Tech platform will potentially supply one-third (1/3) or more of that of the premium market segment (and a higher portion of meat that is actually traceable and verifiably sustainable). Our goal is to have multiple sustainable beef projects under development (within 3-5 distinct JVs) by the end of 2025-6. Our first commercial project is likely to be one of our current LOI Projects (however, a different project might move to the foreground) with the target of commencing development of an initial sustainable beef project during the current calendar year. Our current target is to have at least three (3) facility modules (15,000 head per module)(“Modules”) in development and/or under construction during 2024-5 in three (3) different JVs with the initial barns being populated with livestock during 2025-6. Further expansion in the number of distinct JVs is projected through 2026-7 aiming at 5-10 JVs in process --- each of which JVs will be pursuing development of multiple Modules with targets of 12-15 populated Modules by the end of 2026-7 (approximately 2%-3% of the US beef market) and 30-45 Modules constructed and being populated by 2029-30 (approximately 6%-8% of the US beef market) with further expansion thereafter. Bion’s current goal is that its Gen3Tech platform will be utilized to produce 33% of the verifiable “sustainable beef” category at the end of the period (which will equal approximately 2 million cattle annually)(45 Modules).

 

During this 5-6 year period, the Company also anticipates having additional Gen3Tech projects underway in the pork/dairy/egg sectors of the US animal protein market.

 

There is no assurance that the Company will reach or approach the goals/targets set forth above. Reaching such goals/targets will require access to very large amounts of capital (equity and debt) as each module is projected to cost in excess of $50 million (debt/equity/grants) to construct and require mobilization of substantial personnel, technical resources and management skills. The Company does not possess either the financial or personnel resources required internally and will need to source such resources from outside itself.

 

For additional information regarding our ‘HISTORY, BACKGROUND AND CURRENT ACTIVITIES’, see discussion in Notes to the Financial Statements (particularly Notes 1, 3, 5 and 9) included in this report and Item 1 in our annual report on Form 10-K.

 

 

44 
 

COVID-19 PANDEMIC RELATED MATTERS:

 

The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

CRITICAL ACCOUNTING POLICIES

 

Revenue Recognition

 

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of Accounting Standards Codification (“ASC”) 606 “Revenue from Contracts with Customers”.

Stock-based compensation

 

The Company follows the provisions of ASC 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of income based upon their grant date fair values.

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. As of September 30, 2023 and 2022, there are no derivative financial instruments.

 

Options:

 

The Company has issued options to employees and consultants under its 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

 

 

45 
 

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease. 

THREE MONTHS ENDED DECEMBER 31, 2023 COMPARED TO THE THREE MONTHS ENDED DECEMBER 31, 2022

Revenue

Total revenues were nil for both the three months ended December 31, 2023 and 2022.

 

Current Liabilities

 

Current liabilities were approximately $4.2 million and $1.6 million at December 31, 2023 and 2022, respectively. There was an increase of approximately $2.6 million (which was largely due to an increase in ‘accounts payable and accrued expenses’ totaling approximately $2.0 million and an increase in ‘deferred compensation’ of approximately $.35 million) as a result of the Company’s limited success in raising new financing (equity and/or debt) during the recent period combined with continued expenses (including those related to the Initial Project).

General and Administrative

General and Administrative

Total general and administrative expenses were $636,000 and $631,000 for the three months ended December 31, 2023 and 2022, respectively.

 

Salaries and related payroll tax expenses were $161,000 and $176,000 for the three months ended December 31, 2023 and 2022, respectively. Consulting costs were $168,000 and $101,000 for the three months ended December 31, 2023 and 2022, respectively. The $67,000 increase in consulting costs is due an increase in activity with outside consultants during the second quarter. Investor relations expenses were $76,000 and $174,000 for the three months ended December 31, 2023 and 2022, respectively, and the $98,000 decrease was due to less investor related activity during the second quarter in order to conserve cash. Legal costs were $7,000 and $23,000 for the three months ended December 31, 2023 and 2022, respectively.

 

Stock-based compensation for the three months ended December 31, 2023 and 2022 were $67,000 and nil, respectively.

46 
 

Depreciation

Total depreciation expense was $461 and $394 for the three months ended December 31, 2023 and 2022, respectively.

Research and Development

Total research and development expenses were $7,000 and $15,000 for the three months ended December 31, 2023 and 2022, respectively, representing an $8,000 decrease was due to less consulting expense being allocated to research and development.

 

Salaries and related payroll tax expenses were $1,000 and $3,000 for the three months ended December 31, 2023 and 2022, respectively. Consulting costs were $1,000 and $10,000 for the three months ended December 31, 2023 and 2022, respectively. The decrease of $9,000 was due to a smaller portion of Brightcap’s consulting cost being allocated to research and development.

Loss from Operations

As a result of the factors described above, the loss from operations was $644,000 and $646,000 for the three months ended December 31, 2023 and 2022 respectively.

Other Expense

Other expense was $75,000 and $84,000 for the three months ended December 31, 2023 and 2022, respectively.

 

Interest expense related to deferred compensation, loan payable and convertible notes prior to capitalization was $91,000 and $121,000 for the three months ended December 31, 2023 and 2022, respectively. The decrease of $30,000 is due to debt modifications and reduction of principal balances.

Net Loss Attributable to the Noncontrolling Interest

The net loss attributable to the noncontrolling interest was nil and nil for the three months ended December 31, 2023 and 2022, respectively.

Net Loss Attributable to Bion’s Common Stockholders

As a result of the factors described above, the net loss attributable to Bion’s stockholders was $719,000 and $730,000 for the three months ended December 31, 2023 and 2022, respectively, and the net loss per basic common share was $.01 and $.02 for the three months ended December 31, 2023 and 2022, respectively.

 

SIX MONTHS ENDED DECEMBER 31, 2023 COMPARED TO THE SIX MONTHS ENDED DECEMBER 31, 2022

Revenue

Total revenues were nil for both the six months ended December 31, 2023 and 2022.

General and Administrative

Total general and administrative expenses were $1,302,000 and $1,497,000 for the six months ended December 31, 2023 and 2022, respectively.

 

Salaries and related payroll tax expenses were $327,000 and $347,000 for the six months ended December 31, 2023 and 2022, respectively. Consulting costs were $354,000 and $219,000 for the six months ended December 31, 2023 and 2022, respectively. The $135,000 increase in consulting costs is due an increase in activity with outside consultants during the first and second quarter. Investor relations expenses were $122,000 and $422,000 for the six months ended December 31, 2023 and 2022, respectively, and the $300,000 decrease was due to less investor related activity during the first and second quarters in order to conserve cash. Legal costs were $15,000 and $32,000 for the six months ended December 31, 2023 and 2022, respectively.

 

Stock-based compensation for the six months ended December 31, 2023 and 2022 were $129,000 and nil, respectively.

 

47 
 

Depreciation

Total depreciation expense was $921 and $724 for the six months ended December 31, 2023 and 2022, respectively.

Research and Development

Total research and development expenses were $16,000 and $44,000 for the six months ended December 31, 2023 and 2022, respectively, representing a $28,000 decrease was due to less consulting expense being allocated to research and development.

 

Salaries and related payroll tax expenses were $3,000 and $6,000 for the six months ended December 31, 2023 and 2022, respectively. Consulting costs were $4,000 and $26,000 for the six months ended December 31, 2023 and 2022, respectively. The decrease of $22,000 was due to a smaller portion of Brightcap’s consulting cost being allocated to research and development. Legal expenses were $7,000 and $5,000 for the six months ended December 31, 2023 and 2022, respectively.

Loss from Operations

As a result of the factors described above, the loss from operations was $1,319,000 and $1,541,000 for the six months ended December 31, 2023 and 2022 respectively.

Other Expense

Other expense was $145,000 and $108,000 for the six months ended December 31, 2023 and 2022, respectively. The increase of $37,000 was a result of a greater interest expense for warrant modifications.

 

Interest expense related to deferred compensation, loan payable and convertible notes prior to capitalization was $172,000 and $177,000 for the six months ended December 31, 2023 and 2022, respectively.

Net Loss Attributable to the Noncontrolling Interest

The net loss attributable to the noncontrolling interest was nil and nil for the six months ended December 31, 2023 and 2022, respectively.

Net Loss Attributable to Bion’s Common Stockholders

As a result of the factors described above, the net loss attributable to Bion’s stockholders was $1,464,000 and $1,649,000 for the six months ended December 31, 2023 and 2022, respectively, and the net loss per basic common share was $.03 and $.04 for the six months ended December 31, 2023 and 2022, respectively.

 

 

48 
 

LIQUIDITY AND CAPITAL RESOURCES

 

The Company's condensed consolidated financial statements for the six months ended December 31, 2023 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Report of our Independent Registered Public Accounting Firm on the Company's consolidated financial statements as of and for the year ended June 30, 2023 includes a "going concern" explanatory paragraph which means that the auditors stated that conditions exist that raise substantial doubt about the Company's ability to continue as a going concern.

 

Current Liabilities

 

Current liabilities were approximately $4.2 million and $1.6 million at December 31, 2023 and 2022, respectively. There was an increase of approximately $2.6 million (which was largely due to an increase in ‘accounts payable and accrued expenses’ totaling approximately $2.0 million and an increase in ‘deferred compensation’ of approximately $.35 million) largely as a result of the Company’s limited success in raising new financing (equity and/or debt) during the recent period combined with continued expenses (including those related to the Initial Project).

 

Operating Activities

 

As of December 31, 2023, the Company had cash of approximately $385,000. During the six months ended December 31, 2023, net cash used in operating activities was $451,000, primarily consisting of cash operating expenses related to salaries and benefits, and other general and administrative costs such as insurance, legal, accounting, consulting and investor relations expenses as well as the purchase of property and equipment. Cash expenditures were offset by proceeds from financing activities, primarily the exercise of warrants and sale of common shares. As previously noted, the Company is currently not generating significant revenue and accordingly has not generated cash flows from operations. The Company does not anticipate generating sufficient revenues to offset operating and capital costs for a minimum of two to five years. While there are no assurances that the Company will be successful in its efforts to develop and construct its Projects and market its Systems, it is certain that the Company will require substantial funding from external sources. Given the unsettled state of the current credit and capital markets for companies such as Bion, there is no assurance the Company will be able to raise the funds it needs on reasonable terms.

 

Investing Activities

 

During the six months ended December 31, 2023, the Company invested $484,000 in the purchase of property and equipment, primarily related to the Initial Project construction in process.

 

Financing Activities

During the six months ended December 31, 2023, the Company received gross cash proceeds of $415,000 from subscription agreements of $421,000 less commissions of $6,000.

During the six months ended December 31, 2023, the Company entered into subscription agreements to sell 28,589 units at a price of $1.60, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $2.40 per share with an expiry date of June 30, 2024, and pursuant thereto, the Company issued 28,589 units for total proceeds of $45,742.

 

During the six months ended December 31, 2023, the Company entered into subscription agreements to sell 75,000 units at a price of $1.00, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $1.25 per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued 75,000 units for total proceeds of $75,000.

 

During the six months ended December 31, 2023, the Company entered into subscription agreements to sell 300,000 units at a price of $1.00, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $1.25 per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued 300,000 units for total proceeds of $300,000.

During the six months ended December 31, 2023, the Company received gross cash proceeds of $28,500 from the exercise of 38,000 warrants to purchase 38,000 shares of the Company’s common stock at $0.75 per share.

 

During the six months ended December 31, 2023, the Company received gross cash proceeds of $250,000 from a convertible bridge loan.

 

As of December 31, 2023, the Company has debt obligations consisting of: a) deferred compensation of $1,225,000, b) convertible notes payable – affiliates of $1, 740,000, and c) current note payable including accrued interest of $255,000

 

49 
 

Plan of Operations and Outlook

 

As of December 31, 2023, the Company had cash of approximately $385,000.

 

The Company continues to explore sources of additional financing to satisfy its current operating requirements as it is not currently generating any significant revenues. During fiscal years 2023 and 2022 (as a whole), the Company faced less difficulty in raising equity funding (but was subject to substantial equity dilution from the larger amounts of equity financing during the periods) than was experienced in the prior 3 years. However, this positive trend did not continue during the last quarter of the 2023 fiscal year and first and second quarters of the current fiscal year (and the third quarter through the date of this report). The Company raised only raised very limited equity funds during such periods to meet its some of its immediate needs, therefore, the Company needs to raise substantial additional funds in the upcoming periods. The Company has faced substantial increases in demand for capital and operating expenditures for the fiscal year 2024 to date (and we anticipate such increased demands will continue during the remainder of the 2024 fiscal year and periods thereafter) as it moves toward commercial implementation of its 3G Tech and development of JVs (including costs associated with additions of personnel to carry out the business activities of the Company) and, therefore, is likely to continue to face, significant cash flow management issues due to limited capital resources and working capital constraints which had only recently begun to be alleviated. As a result, the Company has faced, and continues to face, significant cash flow management challenges due to material working capital constraints. To partially mitigate these working capital constraints, the Company's core senior management and some key employees and consultants have been deferring most of their cash compensation and/or are accepting compensation in the form of securities of the Company and members of the Company's senior management have from time-to-time made loans to the Company in the past and may do so in future periods. The Company continues to explore sources of additional financing (including potential agreements with strategic partners – both financial and ag-industry) to satisfy its current and future operating and capital expenditure requirements as it is not currently generating any significant revenues.

 

During the years ended June 30, 2023 and 2022, the Company received gross proceeds of approximately $4,038,000 and $1,737,000, respectively, from the sale of its debt and equity securities. The Company paid commissions on the exercise of warrants in the amount of $86,000 and $19,000 in 2023 and 2022, respectively.

 

During the six months ended December 31, 2023 and 2022 the Company received total proceeds of approximately $443,000 and $602,000, respectively, from the sale of its debt and equity securities. During the six months ended December 31, 2023 the Company received proceeds of $250,000 from a convertible bridge loan but the provider of the bridge loan during November 2023 (and on an ongoing basis since such time) breached its contractual obligation/binding subscription agreement to fund an additional $1,250,000 to the Company, which breach (combined with management stresses related to the final illness and passing of Dominic Bassani, Bion’s COO and former CEO, and required management transitions) has created substantial cash flow difficulties for the Company which are ongoing. See Notes 6 and 9 Bridge Loan/Default. During the current quarter, the Company has entered into discussions/negotiations with its largest creditor that have resulted in an agreement regarding repayment terms. Related discussions are taking place with other creditors. See Note 10 Subsequent Events.

 

The Company anticipates substantial increases in demand for capital and operating expenditures for the balance of fiscal year 2024 (and we anticipate such increased demands will continue during the 2025 fiscal year and periods thereafter) as it moves toward commercial implementation of its 3G Tech and development of JVs (including costs associated with additions of management and operating personnel to carry out the business activities of the Company) and, therefore, is likely to continue to face, significant cash flow management issues due to limited capital resources and working capital constraints which had only recently begun to be alleviated during the 2023 fiscal year. As a result, the Company has faced, and continues to face, significant cash flow management challenges due to material working capital constraints. To partially mitigate these working capital constraints, the Company's core senior management and some key employees and consultants have been deferring most of their cash compensation and/or are accepting compensation in the form of securities of the Company and members of the Company's senior management have from time-to-time made loans to the year ended June 30, 2018, senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $2,404,000. Additionally, the Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again during the year ended June 30, 2018. As set forth in detail elsewhere herein, during the year ended June 30, 2023 senior management (and family members) who held convertible obligations of the Company adjusted the terms of their outstanding notes and agreed to debt modifications that reduced of the Company’s debt by $3,516,000 and increased shareholders equity by the same amount. The constraints on available resources have had, and continue to have, negative effects on the pace and scope of the Company’s efforts to operate and develop its business.

 

The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and/or curtailment of ongoing activities including research and development activities. The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including the Initial Project, JV Projects (including the Dalhart, Olson and DVG Projects), and the Kreider 2 facility) and CAFO Retrofit waste remediation systems. The Company anticipates that it will seek to raise from $20,000,000 to $80,000,000 or more debt and/or equity through joint ventures, strategic partnerships and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) and/or through other means during the next twelve months. However, as discussed above, there is no assurance, especially in light of the difficulties the Company has experienced in many recent years and the extremely unsettled capital markets that presently exist for small companies like us, that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and Projects.

 

 

50 
 

There is no realistic likelihood that funds required during the next twelve months (or in the periods immediately thereafter) for the Company’s basic operations, the Initial Project and/or proposed JVs and/or Projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company’s existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for small companies like Bion.

 

Covid-19 pandemic related matters:

 

The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

CONTRACTUAL OBLIGATIONS

 

We have the following material contractual obligations (in addition to employment and consulting agreements with management and employees):

 

The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.

 

The future minimum lease payment under noncancelable operating lease with terms greater than one year as of December 31, 2023:

     
From January 2024 to December 2024  75,000 
Undiscounted cash flow  75,000 
Less imputed interest  (3,909)
Total  71,091 

 

The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of December 31, 2023 were 1 years and 10%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.

 

OFF-BALANCE SHEET ARRANGEMENTS

 

The Company does not have any off-balance sheet arrangements (as that term is defined in Item 303 of Regulation S-K) that are reasonably likely to have a current or future material effect on our financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

   

51 
 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable.

 

Item 4. Controls and Procedures.

 

(a) Evaluation of Disclosure Controls and Procedures.

 

The term "disclosure controls and procedures" is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). This term refers to the controls and procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files under the Exchange Act is recorded, processed, summarized, and reported within the required time periods. Our Chief Executive Officer and Principal Financial Officer has evaluated the effectiveness of the design and operations of our disclosure controls and procedures as of the end of the period covered by this quarterly report, and has concluded that, as of that date, our disclosure controls and procedures were not effective at ensuring that required information will be disclosed on a timely basis in our reports filed under the Exchange Act, as a result of the material weakness in internal control over financial reporting discussed in Item 9(A) of our Form 10-K for the year ended June 30, 2023.

 

(b) Changes in Internal Control over Financial Reporting.

 

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

 

52 
 

 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

The Company is not currently involved (and has not been involved in recent periods) in any litigation matters except:

 

A:Website: Domain Sale/Resolved Litigation/Hacking/Theft

 

On March 23, 2022 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name <biontech.com> no longer represented a core asset of the Company.

 

As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the <biontech.com> domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.

 

On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name <biontech.com> ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name <biontech.com> to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).

 

No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations were subject to short term disruption and expenses were incurred related to the matter including legal fees.

 

The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.

 

 

53 
 

 

 

 

B: Dissolution of Bion PA1, LLC (“PA1”)

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s condensed consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s condensed consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s condensed consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

 

54 
 

 

 

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who  arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest described above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1, since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

C: Bank Account Hacking

 

On June 23, 2023, an officer of the Company with personal accounts with Signature Bank was hacked and $75,000 was transferred from the Company’s accounts at Signature Bank to the officer’s personal accounts. The bank was notified and all Company accounts at Signature Bank were placed on hold. Subsequently, the funds were released and transferred back to the Company prior to June 30, 2023, the end of the fiscal year, and there were no losses incurred.  The Company has reviewed the authorized individuals on all accounts and further limited access after the hacking incident.

 

D: Convertible Bridge Loan/Default

On September 28, 2023 the Company entered into an agreement for a $1,500,000 bridge loan and executed documents including a convertible promissory note (“Note”) and a binding subscription agreement (“Subscription”) (collectively the Note and the Subscription are the “Bridge Loan Agreements”) with SEB LLC, a non-affiliated party (“Lender”). The Bridge Loan Agreements require the Lender to loan the Company $1,500,000 in six monthly tranches of $250,000 commencing October 2023. All sums advanced under the Bridge Loan Agreements (and accrued interest thereon) would due and payable (with interest accrued at 8% per annum) on October 1, 2024 if not previously converted into securities of the Company. The Note is convertible at $1.00 per unit, at the sole election of the Lender, into units consisting of one share of the Company’s common stock and a warrant to purchase one half share. The initial $250,000 tranche was received by the Company on October 5, 2023. However, no further funds were received by the Company from the Lender. During early November 2023 the Lender informed the Company verbally that it did not intend to fulfill its obligations pursuant to the Bridge Loan Agreements and since such time the Lender has been in default (“Default”). The Default (which is continuing) has created substantial problems for and materially damaged the Company and rendered the Company unable to meet its current creditor obligations on a timely basis. The Company is currently evaluating its rights regarding the Default by the Lender. See Notes re Bridge Loan/Default.

The Company currently is not involved in any other material litigation or similar events.

 

Item 1A.  Risk Factors.

Not applicable.

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds.

During the quarter ended December 31, 2023, the Company sold the following restricted securities: a) 375,000  units at $1.00 per unit consisting of one share of the Company’s restricted common stock and ½ warrant to purchase one share of the Company’s restricted common stock at $1.25 until December 31, 2024 and received gross proceeds of $375,000 and b) 449,261  shares were issued pursuant to our 2006 Consolidated Incentive Plan (“Plan”) upon the conversion of debt and c) 265,639 shares were issued when 321,554 warrants were exercised (using the “cashless exercise” provision of the warrants) and d) 36,506 shares were issued for consulting services.

Item 3.  Defaults Upon Senior Securities.

Not applicable.

Item 4.  Mine Safety Disclosures.

Not applicable.

Item 5.  Other Information.

Not applicable.

55 
 

 

 

Item 6.  Exhibits.

  (a) Exhibits required by Item 601 of Regulation S-K.

 

Exhibit       Incorporated by Reference   Filed/Furnished
No.   Description   Form     Exhibit   Filing Date   Herewith
31.1*   Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act                 X
31.2*   Certification of Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act                 X
32.1**   Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act                 X
32.2**   Certification of Principal Accounting Officer Pursuant to Section 906 of the Sarbanes-Oxley Act                 X
101.INS*   Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.                 X
101.SCH*   Inline XBRL Taxonomy Extension Schema Document                 X
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document                 X
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document                 X
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document                 X
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document                 X
104*   Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.                 X

  

 

* Filed herewith.
   
** Furnished herewith.

 

 

56 
 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

    BION ENVIRONMENTAL TECHNOLOGIES, INC.
     
     
Date: February 14, 2024 By: /s/ Mark A. Smith
    Mark A. Smith, President and Chief Financial Officer (Principal Financial and Accounting Officer)
     
     
     
Date:  February 14, 2024 By: /s/ William O’Neill
    William O’Neill, Chief Executive Officer
     
     

 

57 
 
EX-31.1 2 ex31x1.htm EXHIBIT 31.1

 Exhibit 31.1

 

 

SECTION 302 CERTIFICATION

 

I, William O’Neill, certify that:

 

1.   I have reviewed this quarterly report on Form 10-Q of Bion Environmental Technologies, Inc.;

 

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.   Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the of the registrant as of, and for, the periods presented in this report;

 

4.   The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)  Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.   The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 

Date: February 14, 2024

 

 

 

/s/ William O’Neill

William O’Neill

Chief Executive Officer

EX-31.2 3 ex31x2.htm EXHIBIT 31.2

Exhibit 31.2

 

SECTION 302 CERTIFICATION

 

I, Mark A. Smith, certify that:

 

1.   I have reviewed this quarterly report on Form 10-Q of Bion Environmental Technologies, Inc.;

 

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.   Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the of the registrant as of, and for, the periods presented in this report;

 

4.   The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)  Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.   The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date:  February 14, 2024

 

 

/s/ Mark A. Smith

Mark A. Smith

Executive Chairman, President and Chief Financial Officer

EX-32.1 4 ex32x1.htm EXHIBIT 32.1

Exhibit 32.1

 

 

CERTIFICATION OF CEO PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Form 10-Q of Bion Environmental Technologies, Inc., a company duly formed under the laws of Colorado (the "Company"), for the quarter ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), William O’Neill, Chief Executive Officer of the Company, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

February 14, 2024 /s/ William O’Neill  
 

William O’Neill

Chief Executive Officer

 

 

 This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by Section 906 has been provided to Bion Environmental Technologies, Inc. and will be retained by Bion Environmental Technologies, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

EX-32.2 5 ex32x2.htm EXHIBIT 32.2

Exhibit 32.2

 

 

CERTIFICATION OF CFO PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the Form 10-Q of Bion Environmental Technologies, Inc., a company duly formed under the laws of Colorado (the "Company"), for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Mark A. Smith, President (Executive Chairman) and Interim Chief Financial Officer (Principal Financial and  Accounting Officer) of the Company, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

       
Date: February 14, 2024   /s/ Mark A. Smith  
   

Mark A. Smith

Executive Chairman, President and

Interim Chief Financial Officer

 
       

 

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 

A signed original of this written statement required by Section 906 has been provided to Bion Environmental Technologies, Inc. and will be retained by Bion Environmental Technologies, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.SCH 6 bnet-20231231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS: link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - PROPERTY AND EQUIPMENT: link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - DEFERRED COMPENSATION: link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - LOANS PAYABLE: link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - CONVERTIBLE NOTES PAYABLE: link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - STOCKHOLDERS’ EQUITY: link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES: link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES: link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUBSEQUENT EVENTS: link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - PROPERTY AND EQUIPMENT: (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - STOCKHOLDERS’ EQUITY: (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - COMMITMENTS AND CONTINGENCIES: (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - PROPERTY AND EQUIPMENT: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - DEFERRED COMPENSATION: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - LOANS PAYABLE: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - CONVERTIBLE NOTES PAYABLE: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - STOCKHOLDERS’ EQUITY: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - SUBSEQUENT EVENTS: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 bnet-20231231_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 bnet-20231231_def.xml XBRL DEFINITION FILE EX-101.LAB 9 bnet-20231231_lab.xml XBRL LABEL FILE Equity Components [Axis] Series A Preferred Stock [Member] Series C Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Subscriptions Receivable [Member] Retained Earnings [Member] Noncontrolling Interest [Member] Title of Individual [Axis] S E B Farms L L C [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Bridge Loan Agreements [Member] Counterparty Name [Axis] Gen 3 Tech [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Antidilutive Securities [Axis] Warrant [Member] Share-Based Payment Arrangement, Option [Member] Convertible Debt Securities [Member] Long-Lived Tangible Asset [Axis] Computer Equipment [Member] Construction in Progress [Member] Property Plant and Equipment of PA1 [Member] William O Neill [Member] Chief Executive Officer [Member] Chief Operating Officer [Member] Bassani [Member] Smith [Member] Consultants [Member] Nature of Expense [Axis] Interest Expense On Deferred Compensation Obligation [Member] Debt Instrument [Axis] Pennvest Loan [Member] Scenario [Axis] Years One Through Five [Member] Years Six Through Maturity [Member] Legal Entity [Axis] P A 1 [Member] Mark A Smith [Member] Dominic Bassani [Member] Ed Schafer [Member] The 2020 Convertible Obligations [Member] Related Party Transaction [Axis] Bassani Family Trusts [Member] Schafer [Member] September 2015 Convertible Notes [Member] Edward Schafer [Member] Long-Term Debt, Type [Axis] Convertible Debt [Member] President [Member] Executive Vice Chairman [Member] Principal [Member] Convertible Obligations 2020 [Member] Shareholder [Member] Convertible Bridge Loan Default [Member] Award Type [Axis] Restricted Common Shares [Member] Class of Stock [Axis] Series B Preferred Stock [Member] Restricted Common Stock [Member] Restricted Common Stock 1 [Member] Restricted Common Stock 2 [Member] Consultant Service [Member] Consultant Service 1 [Member] Consultant Service 2 [Member] Consultant Service 3 [Member] Consultant Service 4 [Member] Warrants [Member] Plan Name [Axis] Equity Incentive Plan [Member] Plan 2006 [Member] Receivable Type [Axis] Secured Promissory Note [Member] Class of Warrant or Right [Axis] Warrants Issued Subscription Receivable [Member] Smiths [Member] Former Employee [Member] Warrants Issused Subscription Receivable [Member] Warrants Issued In Connection With Sale Of Units In Exchange For Salary [Member] Extension Bonus [Member] Fy 2016 Extension Agreement [Member] Warrants Expiring On December 312025 [Member] Secured Promissory Note Consideration For Warrants Expiring On December 312025 [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS  Current assets:  Cash  Prepaid expenses  Deposits and other assets  Total current assets  Operating lease right-of-use asset  Property and equipment, net (Note 3)  Total assets  LIABILITIES AND EQUITY (DEFICIT)  Current liabilities:  Accounts payable and accrued expenses  Deferred compensation (Note 4)  Convertible Bridge Note Payable (Note 6)  Operating lease liability, current (Note 9)  Total current liabilities  Operating lease liability, long term (Note 9)  Convertible notes payable - affiliates (Note 6)  Total liabilities  Equity (deficit): Common stock, no par value, 250,000,000 shares authorized, 50,611,962  and 48,044,790 shares issued, respectively; 49,907,653 and 47,340,480 shares outstanding, respectively Additional paid-in capital Subscription receivable - affiliates (Note 8) Accumulated deficit Total Bion's stockholders’ equity (deficit) Noncontrolling interest Total equity (deficit) Total liabilities and deficit Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Operating expenses: General and administrative (including stock-based compensation) Depreciation Research and development (including stock-based compensation) Total operating expenses Loss from operations Other (income) expense: Interest income Interest expense Total other expense Net income (loss) Net loss attributable to the noncontrolling interest Net income (loss) applicable to Bion's common stockholders Net income (loss) applicable to Bion's common stockholders per basic Net income (loss) applicable to Bion's common stockholders per diluted Weighted-average number of common shares outstanding, Basic Weighted-average number of common shares outstanding, Diluted Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares Sale of units Sale of units, shares Warrants exercised for common shares Warrants exercised for common shares , shares Warrants exercised under cashless exercise Warrants exercised under cashless exercise , shares Issuance of units for services Issuance of units for services, shares Issuance of warrants for services Vesting of options for employees and services Vesting of warrants for employees and services Debt Modification Conversion of debt and liabilities Conversion of debt and liabilities, shares Modification of warrants Commission on sale of units Net loss Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net income (loss) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense Accrued interest on loans payable, deferred compensation and other Stock- based compensation Stock-based compensation for services Decrease in prepaid expenses Decrease in accounts payable and accrued expenses Decrease (increase) in operating lease assets and liabilities Increase in deferred compensation Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from sale of units Commission on the sale of units Proceeds from convertible bridge loan Proceeds from exercise of warrants Net cash provided by financing activities Net decrease in cash Cash at beginning of year Cash at end of year Supplemental disclosure of cash flow information: Cash paid for interest Non-cash investing and financing transactions: Conversion of debt and liabilities into common units Conversion of debt and liabilities into notes payable Conversion of deferred compensation to notes payable Conversion of notes payable into shares Purchase of property and equipment for accounts payable Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS: Accounting Policies [Abstract] SIGNIFICANT ACCOUNTING POLICIES Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT: Share-Based Payment Arrangement [Abstract] DEFERRED COMPENSATION: Debt Disclosure [Abstract] LOANS PAYABLE: Convertible Notes Payable CONVERTIBLE NOTES PAYABLE: Equity [Abstract] STOCKHOLDERS’ EQUITY: Subscription Receivable - Affiliates SUBSCRIPTION RECEIVABLE - AFFILIATES: Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES: Subsequent Events [Abstract] SUBSEQUENT EVENTS: Principles of consolidation: Cash and cash equivalents: Property and equipment: Patents: Stock-based compensation: Derivative Financial Instruments: Options: Warrants: Concentrations of credit risk: Noncontrolling interests: Fair value measurements: Lease Accounting: Revenue Recognition: Income (Loss) per share: Use of estimates: Recent Accounting Pronouncements: Schedule of warrants and option and convertible securities Schedule of basic and diluted income (loss) per share Schedule of property and equipment Schedule of option activity Schedule of future minimum lease payment Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Current liabilities Increase in current liabilities Bridge loan Interest accrued percentage Convertible price Initial tranche Tech wastage Debt instrument paid amount Percentage of initial amount Principal, interest Aggregate payment Purchase order Additional incurred additional costs Capitalized labour and interest costs paid Capitalized labour and interest costs yet to pay Incurred costs Percentage of sustainable Description of kreider 2 poultry project Net loss Working capital deficit Gain in non-cash event Gain on sale of domain Increased shareholders equity Gross proceeds Payments to exercise of warrants Gross convertible loan Total of aggregate amount Capital required for capital adequacy Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities Shares issued – beginning of period Shares held by subsidiaries (Note 7) Shares outstanding – beginning of period Weighted average shares issued     during the period Diluted weighted average shares –     end of period Cash equivalents Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property and equipment, gross Less accumulated depreciation  Property and equipment, net Capitalized interest Non cash compensation Impairment of long lived assets Depreciation expense Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Deferred compensation liability Interest rate on deferred compensation Deferred compensation consecutive trading days Deferred compensation Deferred compensation balance Deferred compensation, Price per share Interest expense Interest expense related party Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Construction loan Accrued interest and late charges payable Total assets Total liabilities Accounts payable and accrued liabilities Accounts payable Accrued liabilities, current Gain on legal dissolution of subsidiary Repayments of loans Debt instrument interest rate Principal payment Long term debt maturity year two Long term debt maturity year three Long term debt maturity year four Interest expense, debt Loans as a liability Debt instrument debt default amount Realized from the asset sale Principal amount Conversion price per unit Convertible notes payable Convertible notes payable, noncurrent Debt instrument interest rate Debt instrument interest rate quarterly Debt conversion value Debt conversion shares Capitalized amount Convertible note Options outstanding, beginning Options outstanding, beginning weighted-average exercise price Outstanding, weighted-average remaining contractual life (Year) Outstanding, aggregate intrinsic value beginning Granted, options Granted, weighted-average exercise price Exercised, options Exercised, weighted-average exercise price Forfeited, options Forfeited, weighted-average exercise price Expired, options Expired, weighted-average exercise price Options outstanding, ending Options outstanding, ending weighted-average exercise price Outstanding, aggregate intrinsic value ending Schedule of Stock by Class [Table] Class of Stock [Line Items] Increase to additional paid in capital Reduction of additional paid in capital Debt modified Preferred stock, shares outstanding Preferred stock, par value Preferred stock, convertible option per share Preferred stock dividend rate percentage Preferred stock, redemption price per share Redemption of convertible preferred stock Dividends payable Dividends, preferred stock Liability Shares Held by Subsidiaries Sale of stock, shares Sale of units Sell units Number of shares issued Number of shares issued, value Class of warrant or right, exercised Common Stock Shares Issued upon Exercise of Warrants Warrants exercisable per share Total proceeds Exercise bonus Shares issued for consultant services Share price Shares issued for consultant services, value Shares issued for cashless exercise Warrant outstanding Weighted average exercise price Remaining contractual life Conversion price per share Sale of warrants Warrant exercise price per share Number of shares issued Effective period Interest expenses Non-cash compensation Warrant Exercised for Common Stock Cancellation of warrants Exercise price Vesting period Non cash compensation Stock options, authorized Number of shares granted Compensation expense Aggregate principal amount Notes receivable interest Purchases of warrants Exercise price Financing receivable interest rate stated percentage From January 2024 to December 2024 Undiscounted cash flow Less imputed interest Total Loss Contingencies [Table] Loss Contingencies [Line Items] Monthly officers cash compensation Warrants purchase Compensation increased Cash compensation paid Deferred Compensation, Maximum Convertible Amount Deferred compensation, price per share Salaries and wages Additional paid amount Interest bearing secured promissory note Principal and accrued interest Repayments of compensation Payment for cash Warrants held by trust owned Warrants and rights outstanding Debt instrument, interest rate Paid invoice amount Capitalized labour and interest costs Interests costs incurred capitalized Sale of domain, description Accrued interest Gain on legal dissolution of subsidiary Line of credit facility, maximum borrowing capacity Long-Term debt, maturity, year two Long-Term debt, maturity, year three Long-Term debt, maturity, year four Principal amount Bank account hacked amount Subsequent Event [Table] Subsequent Event [Line Items] Capitalized cost Sale of units Sale of units, price per unit Sale of units, price per share Expiry date Proceeds from sale of units Number of warrants or rights outstanding Assets, Current Common Stock, Share Subscribed but Unissued, Subscriptions Receivable Equity, Attributable to Parent Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Income, Operating Other Nonoperating Income (Expense) Net Income (Loss) Attributable to Noncontrolling Interest Net Income (Loss) Available to Common Stockholders, Basic Shares, Outstanding Increase (Decrease) in Prepaid Expense Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities CommissionOnSaleOfUnit Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Net Income (Loss) Available to Common Stockholders, Diluted Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Interest Expense Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value SaleOfUnitPricePerUnit Shares, Issued Share-Based Payment Arrangement, Expense Extinguishment of Debt, Gain (Loss), Net of Tax Sale of Stock, Consideration Received Per Transaction EX-101.PRE 10 bnet-20231231_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover - shares
6 Months Ended
Dec. 31, 2023
Feb. 01, 2024
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Dec. 31, 2023  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2024  
Current Fiscal Year End Date --06-30  
Entity File Number 000-19333  
Entity Registrant Name Bion Environmental Technologies, Inc.  
Entity Central Index Key 0000875729  
Entity Tax Identification Number 84-1176672  
Entity Incorporation, State or Country Code CO  
Entity Address, Address Line One 9 East Park Court  
Entity Address, City or Town Old Bethpage  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 11804  
City Area Code 516  
Local Phone Number 586-5643  
Title of 12(b) Security Common Stock  
Trading Symbol BNET  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   56,201,815
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2023
Jun. 30, 2023
 Current assets:    
 Cash $ 384,735 $ 625,964
 Prepaid expenses 3,394 16,785
 Deposits and other assets 6,000 6,000
 Total current assets 394,129 648,749
 Operating lease right-of-use asset 66,090 93,875
 Property and equipment, net (Note 3) 9,110,640 6,851,009
 Total assets 9,570,859 7,593,633
 Current liabilities:    
 Accounts payable and accrued expenses 2,648,005 677,136
 Deferred compensation (Note 4) 1,225,226 864,781
 Convertible Bridge Note Payable (Note 6) 255,407
 Operating lease liability, current (Note 9) 71,091 75,000
 Total current liabilities 4,199,729 1,616,917
 Operating lease liability, long term (Note 9) 29,068
 Convertible notes payable - affiliates (Note 6) 1,740,083 1,715,970
 Total liabilities 5,939,812 3,361,955
 Equity (deficit):    
Common stock, no par value, 250,000,000 shares authorized, 50,611,962  and 48,044,790 shares issued, respectively; 49,907,653 and 47,340,480 shares outstanding, respectively
Additional paid-in capital 132,798,923 131,935,418
Subscription receivable - affiliates (Note 8) (504,650) (504,650)
Accumulated deficit (128,700,799) (127,236,663)
Total Bion's stockholders’ equity (deficit) 3,593,474 4,194,105
Noncontrolling interest 37,573 37,573
Total equity (deficit) 3,631,047 4,231,678
Total liabilities and deficit $ 9,570,859 $ 7,593,633
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Dec. 31, 2023
Jun. 30, 2023
Statement of Financial Position [Abstract]    
Common stock, par value $ 0 $ 0
Common stock, shares authorized 250,000,000 250,000,000
Common stock, shares issued 50,611,962 48,044,790
Common stock, shares outstanding 49,907,653 47,340,480
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]        
Revenue
Operating expenses:        
General and administrative (including stock-based compensation) 636,017 630,542 1,302,272 1,497,036
Depreciation 460 394 921 724
Research and development (including stock-based compensation) 7,431 15,148 15,730 43,591
Total operating expenses 643,908 646,084 1,318,923 1,541,351
Loss from operations (643,908) (646,084) (1,318,923) (1,541,351)
Other (income) expense:        
Interest income (109) (1,375) (504) (3,310)
Interest expense 74,790 85,285 145,717 111,380
Total other expense 74,681 83,910 145,213 108,070
Net income (loss) (718,589) (729,994) (1,464,136) (1,649,421)
Net loss attributable to the noncontrolling interest
Net income (loss) applicable to Bion's common stockholders $ (718,589) $ (729,994) $ (1,464,136) $ (1,649,421)
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical) - $ / shares
3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]        
Net income (loss) applicable to Bion's common stockholders per basic $ (0.01) $ (0.02) $ (0.03) $ (0.04)
Net income (loss) applicable to Bion's common stockholders per diluted $ (0.01) $ (0.02) $ (0.03) $ (0.04)
Weighted-average number of common shares outstanding, Basic 48,748,554 43,620,051 49,321,180 43,533,789
Weighted-average number of common shares outstanding, Diluted 48,748,554 43,620,051 49,321,180 43,533,789
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) - USD ($)
Series A Preferred Stock [Member]
Series C Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Subscriptions Receivable [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
Beginning balance, value at Jun. 30, 2022 $ 123,620,046 $ (504,650) $ (124,047,548) $ 37,573 $ (894,579)
Beginning balance, shares at Jun. 30, 2022 43,758,820          
Sale of units 546,230 546,230
Sale of units, shares     546,230          
Warrants exercised for common shares 88,375 88,375
Warrants exercised for common shares , shares     74,834          
Issuance of units for services 80,000 80,000
Issuance of units for services, shares     50,000          
Issuance of warrants for services 15,000 15,000
Conversion of debt and liabilities 50,000 50,000
Conversion of debt and liabilities, shares     100,000          
Modification of warrants 227,521 227,521
Net loss (1,649,421) (1,649,421)
Ending balance, value at Dec. 31, 2022 124,627,172 (504,650) (125,696,969) 37,573 (1,536,874)
Ending balance, shares at Dec. 31, 2022 44,529,884          
Beginning balance, value at Sep. 30, 2022 124,300,604 (504,650) (124,966,975) 37,573 (1,133,448)
Beginning balance, shares at Sep. 30, 2022 44,303,654          
Sale of units 226,230 226,230
Sale of units, shares     226,230          
Issuance of warrants for services 32,250 32,250
Modification of warrants 68,088 68,088
Net loss (729,994) (729,994)
Ending balance, value at Dec. 31, 2022 124,627,172 (504,650) (125,696,969) 37,573 (1,536,874)
Ending balance, shares at Dec. 31, 2022 44,529,884          
Beginning balance, value at Jun. 30, 2023 131,935,418 (504,650) (127,236,663) 37,573 4,231,678
Beginning balance, shares at Jun. 30, 2023 48,880,237          
Sale of units 420,742 420,742
Sale of units, shares     403,589          
Warrants exercised for common shares 28,500 28,500
Warrants exercised for common shares , shares     38,000          
Warrants exercised under cashless exercise
Warrants exercised under cashless exercise , shares     265,639          
Issuance of units for services 76,320 76,320
Issuance of units for services, shares     56,759          
Issuance of warrants for services 5,000 5,000
Vesting of options for employees and services 107,487 107,487
Vesting of warrants for employees and services 6,563 6,563
Debt Modification (16,861) (16,861)
Conversion of debt and liabilities 91,548 91,548
Conversion of debt and liabilities, shares     967,738          
Modification of warrants 150,206 150,206
Commission on sale of units (6,000) (6,000)
Net loss (1,464,136) (1,464,136)
Ending balance, value at Dec. 31, 2023 132,798,923 (504,650) (128,700,799) 37,573 3,631,047
Ending balance, shares at Dec. 31, 2023 50,611,962          
Beginning balance, value at Sep. 30, 2023 132,197,829 (504,650) (127,982,210) 37,573 3,748,542
Beginning balance, shares at Sep. 30, 2023 49,485,556          
Sale of units 375,000 375,000
Sale of units, shares     375,000          
Warrants exercised under cashless exercise
Warrants exercised under cashless exercise , shares     265,639          
Issuance of units for services 48,334 48,334
Issuance of units for services, shares     36,506          
Issuance of warrants for services     5,000       5,000
Vesting of options for employees and services 52,378 52,378
Vesting of warrants for employees and services 3,281 3,281
Debt Modification (8,430) (8,430)
Conversion of debt and liabilities 42,500 42,500
Conversion of debt and liabilities, shares     449,261          
Modification of warrants 89,031 89,031
Commission on sale of units (6,000) (6,000)
Net loss     (718,589) (718,589)
Ending balance, value at Dec. 31, 2023 $ 132,798,923 $ (504,650) $ (128,700,799) $ 37,573 $ 3,631,047
Ending balance, shares at Dec. 31, 2023 50,611,962          
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES    
Net income (loss) $ (1,464,136) $ (1,649,421)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation expense 921 724
Accrued interest on loans payable, deferred compensation and other 145,717 43,292
Stock- based compensation 129,048 223,021
Stock-based compensation for services 81,321 127,250
Decrease in prepaid expenses 13,391 80,062
Decrease in accounts payable and accrued expenses 220,699 (949,097)
Decrease (increase) in operating lease assets and liabilities (5,192) 32,308
Increase in deferred compensation 427,583 170,000
Net cash used in operating activities (450,648) (1,921,861)
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchase of property and equipment (483,823) (739,486)
Net cash used in investing activities (483,823) (739,486)
CASH FLOWS FROM FINANCING ACTIVITIES    
Proceeds from sale of units 420,742 546,230
Commission on the sale of units (6,000)
Proceeds from convertible bridge loan 250,000
Proceeds from exercise of warrants 28,500 56,125
Net cash provided by financing activities 693,242 602,355
Net decrease in cash (241,229) (2,058,992)
Cash at beginning of year 625,964 3,160,442
Cash at end of year 384,735 1,101,450
Supplemental disclosure of cash flow information:    
Cash paid for interest
Non-cash investing and financing transactions:    
Conversion of debt and liabilities into common units 49,048 50,000
Conversion of debt and liabilities into notes payable 23,943
Conversion of deferred compensation to notes payable 80,767 60,000
Conversion of notes payable into shares 91,548
Purchase of property and equipment for accounts payable $ 1,750,170 $ 135,673
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS:
6 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS:

1.       ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS:

 

Organization and nature of business:

 

DUE TO THE RECENT DEATH (FOLLOWING EXTENDED ILLNESS) OF DOMINIC BASSANI (WHO MOST RECENTLY SERVED AS OUR COO (FROM MAY 2022) AFTER SERVING AS OUR CEO FOR THE PRIOR DECADE) AND DIFFICULTIES IN RAISING NEEDED FUNDS (WHICH RE-EMERGED DURING THE 2023 FISCAL YEAR AND HAVE CONTINUED THROUGH THE CURRENT QUARTER TO DATE), THE COMPANY IS FACING INCREASED CAPITAL NEEDS AND THE NEED TO TRANSITION TO A YOUNGER MANAGEMENT TEAM (MARK A. SMITH, THE COMPANY’S PRESIDENT AND GENERAL COUNSEL, PROVIDED NOTICE DURING EARLY 2023 OF HIS INTENT TO PHASE OUT HIS MANAGEMENT ROLES EARLY THIS CALENDAR YEAR). THESE ITEMS HAVE BEEN PREVIOUSLY DISCLOSED BUT THE COMPANY BELIEVES IT IS IMPORTANT TO FEATURE THEM ‘UPFRONT’ AT THIS POINT. PLEASE NOTE:

 

A: The Company is not generating any significant revenues. Further, the Company’s anticipated revenues, if any, from existing Projects, JVs and proposed Projects will not be sufficient to meet the Company’s anticipated operational and capital expenditure needs for many years. See “Going Concern and Management’s Plans” below. Current liabilities were approximately $4.2 million at December 31, 2023. There was an increase of approximately $2.6 million from a year earlier (which was largely due to an increase in ‘accounts payable and accrued expenses’ totaling approximately $2.0 million and an increase in ‘deferred compensation’ of approximately $.35 million) as a result of the Company’s limited success in raising new financing (equity and/or debt) during the recent period in combination with continued expenses (including those related to the Initial Project); and

B: On September 28, 2023 the Company entered into an agreement for a $1,500,000 bridge loan and executed documents including a convertible promissory note (“Note”) and a binding subscription agreement (“Subscription”) (collectively the Note and the Subscription are the “Bridge Loan Agreements”) with SEB LLC, a non-affiliated party (“Lender”). The Bridge Loan Agreements require the Lender to loan the Company $1,500,000 in six monthly tranches of $250,000 commencing October 2023. All sums advanced under the Bridge Loan Agreements (and accrued interest thereon) would due and payable (with interest accrued at 9% per annum) on October 1, 2024 if not previously converted into securities of the Company. The Note is convertible at $1.00 per unit, at the sole election of the Lender, into units consisting of one share of the Company’s common stock and a warrant to purchase one half share. The initial $250,000 tranche was received by the Company on October 5, 2023. However, no further funds were received by the Company from the Lender. During early November 2023 the Lender informed the Company verbally that it did not intend to fulfill its obligations pursuant to the Bridge Loan Agreements and since such time the Lender has been in default (“Default”). The Default (which is continuing) has exacerbated the Company’s exiting problems and materially damaged the Company and rendered the Company unable to meet its creditor obligations on a timely basis. The Company is currently evaluating its rights regarding the Default by the Lender. See Notes re Bridge Loan/Default. This situation has contributed to the substantial increase in the Company’s ‘Current Liabilities’ including ‘accounts payable’ over recent periods. See Consolidated Financial Statements and ‘Management’s Discussion and Analysis’. The Company is in discussion/negotiation with its larger creditors (including its largest creditor--- the primary contractor on the Initial Project) and anticipates reaching agreements re payments during the current quarter (or soon thereafter).

Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to make livestock production more sustainable, profitable and transparent. We intend to accomplish this by deploying our Gen3Tech platform/business model (discussed below) in ventures focused on the ‘feeder’ space of the livestock production/value chain to provide the consumer with verifiably sustainable premium meat products (together with environmentally friendly, sustainable and/or organic co-products from the production process).  Bion believes this approach can create extraordinary value for our shareholders and employees (all of whom own securities in the Company) and for livestock/agriculture industry ‘partners’ who join us in our ventures. We anticipate pursuing the opportunity created by our third generation technology (“Gen3Tech”) and business/technology platform in conjunction with other industry practices (“Gen3Tech Platform” or “Platform”) utilizing a joint venture/strategic partner model. We believe our approach will improve the well-being of farmers, ranchers, feeders, etc. that we work with and create value for our shareholders while improving the environment.  

 

Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our Gen3Tech” can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These waste ‘assets’ – nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate surface groundwater, and exacerbate climate change.

 

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms) (“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). To accomplish Bion’s goals, we anticipate the we will ‘partner’ with other technology companies who provide solutions for different links of the beef (and other livestock) value chain and with strategic partners up and down the supply chain. We anticipate this will result in substantial long-term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent one of the largest enhanced revenue contributors provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

Bion’s Gen3Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the animal raising and waste treatment process will be third-party verified, providing the basis for additional revenues, including carbon and/or renewable energy-related credits and, eventually, payment for a range of ecosystem services, including nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.

 

During the first half of calendar 2022 Bion began pre-marketing our sustainable beef opportunity to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During our 2023 fiscal year, Bion entered into three (3) letters of intent (“LOIs”): a) July 2022 letter of intent to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch (“Ribbonwire LOI”), in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”), (b) January 2023 letter of intent to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Olson Feeders and TD Angus (“Olson LOI”), near North Platte, Nebraska (with a provision to expand to 45,000 head or more) (“Olson Project”) and c)April 2023 letter of intent to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with Dakota Valley Growers (“DVG LOI”) near Bathgate, North Dakota (“DVG Project”). The Company is in discussions with additional parties regarding potential further LOIs. Based on our experience to date, we believe we will not have difficulty in securing participation in our Projects from additional feeders/cattlemen. The Olson, Dalhart and DVG Projects (and subsequent Projects) will be developed to produce blockchain-verified, sustainable beef in customized covered barns (resulting in reduced stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) with ongoing manure transfer (through slatted floors) to anaerobic digesters (AD) to capture nitrogen from the manure stream before loss to the atmosphere and generate renewable natural gas (RNG) for sale while remediating the environmental/carbon impacts usually associated with cattle feedlots and CAFOs. Bion’s patented Gen3Tech platform will refine the waste stream into valuable coproducts that include clean water, RNG, photovoltaic solar electricity and fertilizer (‘climate smart’ and/or organic) products. We anticipate converting tone or more of these LOIs into definitive JV agreements and creating related distribution agreements with key retailers and food service distributors during the current calendar year.

 

Our business plan is focused on executing multiple agreements and letters of intent related to additional sustainable beef JV projects over the next twenty-four (24) months while continuing our work at the Initial Project (see below) and commencing development of one or more of the Dalhart/Olson/DVG Projects (“LOI Projects”)(and/or other Gen3Tech beef JV projects) while pursuing other opportunities in the livestock industry enabled by our Gen3Tech business model.  The LOI announcements have generated significant interest within the livestock industry (among ranchers, feedlot operators, farmers and other AG industry parties) and has led to and assisted our discussions with many major of the larger agriculture/livestock industry companies (including those involved with distribution and/or sales of meat products) in the country which are ongoing at this date. We believe that this interest, combined with consumer interest in ‘sustainable products’ and growing enthusiasm among some livestock industry parties for environmental/sustainable/regenerative practices, may provide Bion (and its partners/venturers) with an opportunity to move forward with a truly sustainable solution in this industry segment at a rapid pace. 

 

During the 2023 calendar year, the Company has constructed (construction is largely completed) our 3GTech Ammonia Recovery System (‘ARS’) located near Fair Oaks, Indiana and begun operations of phase 1 of our Initial Project (our commercial scale demonstration facility) located near Fair Oaks, Indiana. The Initial Project has been deemed ‘placed in service’ effective January 1, 2024. Operating results to date at Fair Oaks indicate ARS performance will exceed initial expectations for ammonia recovery and related economics. The Company recently announced that we have achieved key objectives in the optimization of its ARS and will now begin the final design process for full-scale systems based on results to date (and testing over the remainder of this fiscal year) at the Initial Project. The ARS has achieved and maintained controlled steady-state operations under a variety of conditions. When operated at steady state, the system produces an ammonium distillate (solution), the base of Bion’s nitrogen fertilizer products. Bion has begun optimizing the ARS’s operating parameters with the goal of meeting and/or exceeding the results needed for Bion’s economic models for large-scale commercial projects. The Company expects the current optimization phase will continue during the next quarter (or longer) and provide data required to support final design/engineering for commercial project modules. We believe this data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, distributors, retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below). Final economic and energy efficiency models will be validated during the final design process. The Company intends to engage a third party engineering firm during the next quarter to prepare a third-party evaluation of the ARS while also moving forward on final commercial design process.

 

The patented ARS is the core of Bion’s Gen3Tech platform. It recovers and upcycles problem ammonia contained in the effluent from anaerobic digestion (where methane is captured and more ammonia is released) of the livestock manure waste stream. The ARS captures the ammonia, minimizing its environmental impacts and creating low-carbon and/or organic nitrogen fertilizer products with it. During the last three (3) months,, the Company has produced ammonium distillate and ammonium bicarbonate solutions at the Initial Project in several concentrations and plans to initiate the application process for organic certification for each concentration of liquid fertilizer product. Multiple applications to OMRI (Organic Materials Review Institute) and CDFA (California Department of Food and Agriculture) are being prepared for listing/certification of new organic products. Bion received an OMRI-Listing in 2020 for its initial product. Bion will continue producing liquid and crystal fertilizers at the Initial Project to support testing and life-cycle analysis, product trials, and ongoing organic initiatives. Bion will produce a solid/granular nitrogen fertilizer product at the Initial Project (when the crystalizer module is ready for operation) which we believe will be both ‘Climate-Smart’ and ‘Water-Smart’ – a pure nitrogen fertilizer with a low carbon footprint, that is water soluble and readily available to plants. Samples of the granular product will also be utilized to support organic certification applications. See Fertilizer---Organic and ‘ClimateSmart’ below.

 

 Bion expects the Initial Project data will document the effectiveness of our Gen3Tech in a commercial-scale setting during the current fiscal year and support development of one or more of the LOI Projects (and/or other Gen3Tech beef JV projects) commencing later this fiscal year.  We do not presently know the order in which the JV Projects will be developed as that decision will be made based on many factors not yet in place. We believe the Initial Project data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, food distributors and retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below).

 

Note that Bion recently announced its intention to establish strategic partnerships to market the ARS as a stand-alone addition to anaerobic digestion (“AD”) nitrogen control solution in two sectors:

A)     INDUSTRIAL AND MUNICIPAL WASTEWATER. AD is now used at 1,269 water resource recovery facilities in the U.S., with another 102 stand-alone systems that digest food waste. The American Biogas Council estimates an additional 8,600 sites with development potential. Germany, by comparison, has almost 10,000 operating AD sites. In the U.S., wastewater and AD digestate from industrial and municipal sources is already regulated for ammonia and nitrates. The EPA recently proposed tougher standards for slaughter facilities. Bion believes ARS ammonia treatment costs will be competitive in these markets and that its unique premium fertilizer byproducts will create an advantage, especially with waste streams that are still considered ‘organic’, like slaughter and food waste.

B)     ANIMAL WASTE. According to the American Biogas Council here are 473 animal waste digesters operating in the U.S. today, most on dairy operations. The American Biogas Council and USDA’s AgSTAR program estimate more than 8,000 additional sites with development potential. The ARS was designed specifically for this purpose: control ammonia from livestock waste and produce the highest value byproducts with it. Digestate from animal waste AD has enjoyed the same reduced regulatory requirements as land applying raw manure. Recent trends in Michigan and California indicate they will treat animal waste digestate as any industrial source, subject to groundwater permitting requirements. Bion believes its proven technology and value-added fertilizers will give it a significant competitive advantage in this evolving market.

Bion is now focused primarily on: i) operation and further testing at the Initial Project, our initial commercial-scale Gen3Tech installation, for support of design/feasibility studies/reports related to our initial JV Projects (and further optimization of its operational parameters), ii) pre-development planning of the LOI Projects (and/or other Gen3Tech beef JV projects) including steps toward distribution agreements, iii) developing applications and markets for its low carbon ‘ClimateSmart’ and organic fertilizer products (including listings/certifications of multiple liquid and solid products) and its sustainable (conventional and organic) animal protein products, and iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed herein) (and related Projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), (v) exploring JVs re stand-alone ARS markets, while (vi) continuing to pursue business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&D activities.

 

HISTORY, BACKGROUND AND CURRENT ACTIVITIES

 

Since the Company’s inception, Bion has designed and developed advanced waste treatment systems for livestock. The first and second generations of Bion’s technology platform were biological systems, primarily focused on nutrient control. Over 30 of these systems were deployed at New York dairies, Florida food processing facilities and dairies, North Carolina hog farms, a Texas dairy and a Pennsylvania dairy (“Kreider 1 Project”). The systems were highly effective at their intended purpose: capturing nitrogen and phosphorus. They produced BionSoil as a byproduct, which was a remarkably effective soil amendment/ fertilizer product, but whose value was not enough to support a viable business model. As such, these early technology iterations were entirely dependent on either implementation of new regulations requiring waste treatment, or subsidy/ incentive programs that would provide ‘payment for ecosystem services’. By the mid-2010’s, it became apparent that neither of these options were imminent or even assured, so the Company initiated the steps to reimagine and redesign its technology.

 

From 2016 to 2021 fiscal years, the Company focused most of its activities and resources on developing, testing and demonstrating the third generation of its technology and technology platform (“Gen3Tech”) that was developed with an emphasis producing more valuable co-products from the waste treatment process, including renewable natural gas and ammonium bicarbonate, a low-carbon, organic ’pure’ nitrogen fertilizer product, while raising sustainable livestock.

 

The $175 billion U.S. livestock industry is under intense scrutiny for its environmental and public health impacts – its ‘environmental sustainability’-- at the same time it is struggling with declining revenues and margins (derived in part from clinging to its historic practices and resulting limitations and impacts) which threaten its ‘economic sustainability’. Its failure to adequately respond to consumer concerns including food safety, environmental impacts, and inhumane treatment of animals have provided impetus for plant-based alternatives such as Beyond Meat and Impossible Burger (and many others) being marketed as “sustainable” alternatives for this growing consumer segment of the market (despite the lack of verifiably sustainable attributes).

 

The Company believes that its Gen3Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of i) verifiably sustainable-branded conventional livestock products and ii) verifiably sustainable organic-branded livestock products, both of which will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a production/marketing opportunity for Bion (but the former is far larger). Our Gen3Tech will also produce (as co-products) biogas, solar photovoltaic electricity in appropriate locations, and valuable low carbon/organic fertilizer products, which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects) and/or marketed to the growing organic fertilizer market.

 

During 2022-23, the Company entered into 3 LOIs setting forth the parties’ intention to negotiate joint venture agreement (“JVA”) and enter into joint ventures (“JV”) to develop and operate 15,000 head integrated, sustainable beef facilities (with future expansion under consideration) including:

 

  a) innovative cattle barns (with slatted floors to facilitate movement of manure to the anaerobic digester and potentially solar PV generation on the rooftops which barns will improve the living conditions of the animals while increasing feeding/weight gain efficiency,

 

  b) ‘customized’ anaerobic digestion systems (including pretreatment to increase renewable natural gas (‘RNG’) production and an RNG cleaning system (which will include capture/recycling of the CO2) to allow pipeline sales and monetization of related environmental credits,

 

  c) a Bion Gen3Tech module (which will utilize the recycled CO2 to increase ammonia nitrogen/ammonium bicarbonate recovery) for the production of ammonia nitrogen fertilizer for use in organic and/or ‘ClimateSmart’ low carbon crop production (plus residual organic solids and clean water),

 

  d) which will produce verifiably sustainable beef products with USDA certified branding.

 

The opportunity presented by the LOIs to commercialize the Company’s Gen3Tech and business model matured more quickly than anticipated (reflecting strong industry and public momentum in favor of verifiably sustainable food ventures). As a result, we have shifted our plans to focus resources and make our initial 15,000 head operation a reality as soon as possible.

To place the LOI Projects in the context of Company’s business plan (and our prior public disclosure), if the contemplated ventures move forward on the timelines currently contemplated, active development of the initial LOI Project will commence during 2024.

 

As a pre-cursor to such activity, the Company has constructed and commenced operations of the initial phase of our previously discussed Gen3Tech demonstration project near Fair Oaks, Indiana (“Initial Project”): i) to validate our existing data and modeling at commercial scale and ii) to optimize the Bion Gen3Tech module for finalization of design parameters and fabrication details of our planned 15,000 head commercial facilities (including the LOI Projects). For the purposes of this initial phase, the Company, in order to accelerate the data acquisition phase, is utilizing anaerobic digester effluent from the nearby/contiguous Fair Oaks dairy. Thereafter, the Company will evaluate what, if any, additional facilities and testing will take place at that location.

 

The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.

 

During late September 2021, Bion entered into a lease for the development site of the Initial Project, our initial commercial scale Gen3Tech project, which Initial Project will be located on approximately four (4) acres of leased land near Fair Oaks, Indiana, and a related agreement regarding disposal of certain manure effluent with the Curtis Creek Dairy unit of Fair Oaks Farms (“FOF”). Design and pre-development work commenced during August 2021 and preliminary surveying, site engineering and other work is now underway along with site-specific engineering and design work. The Initial Project was initially planned to be an environmentally sustainable beef cattle feeding facility, equipped with state-of-the-art housing and Bion’s 3G-Tech platform to provide waste treatment and resource recovery. Bion has designed the project to house and feed approximately 300 head of beef cattle. If all phases of the Initial Project are constructed, the facility will include Bion’s Gen3Tech platform including: i) covered barns (possibly including roof top solar photovoltaic generation), ii) anaerobic digestion for renewable energy recovery, iii) livestock waste treatment and resource recovery technology, iv) Bion’s ammonium bicarbonate recovery and crystallization technology and iv) data collection software to document system efficiencies and environmental benefits (with the Bion Gen3Tech facilities capable of treating the waste from approximately 1,500 head). The facility is large enough to demonstrate engineering capabilities of Bion’s Gen3Tech at commercial scale, but small enough that it can be constructed and commissioned relatively quickly. Originally, construction and onsite assembly operations were targeted to commence sometime late in 2022, however, supply chain backlogs (many pandemic-associated) delayed delivery dates for core modules of the Bion system to the site until during January 2023. Construction has been substantially completed related to Phase 1 of the Initial Project, shakedown operations undertaken and the operation is now focused on optimization of operation parameters. See Note 3 “Property and Equipment” and Note 12 “Subsequent Events” (for activities since the start of the first quarter of the 2024 fiscal year).

 

The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.

 

Specifically, the Initial Project was designed/developed to provide and/or accomplish the following:

 

i.   Proof of Gen3Tech platform scalability

 

  - Document system efficiency and environmental benefits and enable final engineering modifications to optimize each unit process within the Bion Gen3Technology platform.

 

  - Environmental benefits will include (without limitation) renewable energy production (natural gas recovery from AD and solar electric from integrated roof top photovoltaic generation); nutrient recovery and conversion to stable organic fertilizer; pathogen destruction; water recovery and reuse; air emission reductions.

 

ii.   Use Bion’s data collection system to support 3rd party verified system efficiency requirement to qualify for USDA Process-Verified-Program (PVP): certification of sustainable branded beef (and potentially pork) product metrics.

 

iii.   Produce sufficient ammonium bicarbonate nitrogen fertilizer (“AD Nitrogen”) in liquid and solid forms for commercial testing by potential joint venture partners and/or purchasers, for university growth trials and to provide samples (and related documentation) to support applications for organic and/or ‘ClimateSmart’ certifications.

 

iv.   Produce sustainable beef products for initial test marketing efforts.

 

On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $2,665,500 (and made the initial 25% payment ($666,375) for the core of the ‘Bion System’ portion (without the crystallization modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. The Company received progress billing in March 2022 and June 2022 for the second and third 25% installments, both of which have been paid as of the filing date. On January 17, 2023 the Company received an invoice from Buflovak for $533,100 which was paid on March 1, 2023 and on April 24, 2023 the Company received an invoice from Buflovak for $83,275 which was paid on May 2, 2023 bringing the aggregate payments to $2,615,500 as of the date of this filing. There remains $50,000 open on the Purchase Order has been billed on July 26, 2023. In addition to the Purchase Order, through December 31, 2023 the Company has incurred additional costs of $6,442,812 on the Initial Project for capitalized interest and costs, non-cash compensation, equipment and consulting fees. $6,983954 has been paid and $1,750,170 has been billed and not yet paid.

 

Buflovak has worked with the Company on design and testing of its 3G Tech over several years. The basic design for the Initial Project’s Bion System is complete, fabrication and delivery of equipment from Buflovak from the Purchase Order Agreement has been largely completed and assembly/construction is in process.  3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, utilities, etc.) for work related to the Initial Project. The Company has incurred costs of $8,177,452 on the Initial Project, not including capitalized labor and interest.

 

The Initial Project will be carried out in stages with phase one focused largely on portions of items i. and iii. set forth above.

 

Upon completing the primary goals of phase 1 of the Initial Project (coupled with obtaining organic certifications(s) for our liquid and/or solid ammonium bicarbonate fertilizer product lines), Bion expects to be ready to move forward with its plans for development of much larger facilities including the LOI Projects, including final design of its Gen3Tech modules. The Company anticipates that discussions and negotiations it has begun (together with additional opportunities that will be generated over the next 12-24 months) regarding potential JVs with strategic partners in the financial, livestock and food distribution industries to develop large scale projects will continue during the optimization operations of the Initial Project with a 2024 goal of establishing multiple JV’s for large scale projects that will produce sustainable and/or sustainable-organic corn-fed beef. These products will be supported by a USDA PVP-certified sustainable brand that will, initially, highlight reductions in carbon and nutrient footprint, as well as pathogen reductions associated with foodborne illness and antibiotic resistance, along with the organic designation where appropriate. Bion has successfully navigated the USDA PVP application process previously, having received conditional approval of its 2G Tech platform (pending resubmission and final site audits), and is confident it will be successful in qualifying its Gen3Tech platform.

 

After the basic technology start-up milestones of the Initial Project (primarily optimization and steady-state operations of the core modules of our Gen3Tech platform) have been met, the Company will determine whether to complete the entire Initial Project as originally designed at that location or the relocate the core modules to an alternative permanent location. The Company has engaged in discussion with the University of Nebraska-Lincoln to jointly develop an integrated beef facility based on Bion’s Gen3Tech and business model at its Klosterman Feedyard Innovation Center (“KFIC”) (or other mutually agreed upon location) which facility would include innovative barns, an anaerobic digester and a Bion Gen3Tech system to conduct ongoing research and development related thereto and the KFIC is a possible site for the long-term re-location of the core modules. This venture, if it moves forward, is anticipated to include joint preparation of applications for grants and other funding from the USDA (‘climate smart’ program, rural development, etc.) and other sources. The Company will also evaluate re-locating the core module of the Initial Project to Dalhart, Texas, where it might be integrated into the first phases of the Dalhart Project and/or other locations. 

 

The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020. Applications for our first solid ammonium bicarbonate product line have been filed with OMRI and the California Department of Food & Agriculture (“CDFA”) without success to date , in part due to the novel nature of our Gen3Tech in the context of organic certifications). The Company anticipates filing multiple new applications with OMRI and CDFA (and possible others) for higher concentration liquid products and solid products based on production from the Initial Project over the next several months. See “Fertilizer– Organic and ‘ClimateSmart’” below.

 

Additionally, the Company believes there will also be opportunities to proceed with selected ‘retrofit projects’ of existing facilities (see ‘Gen3Tech Kreider 2 Poultry Project’ below as an example) in the swine, dairy and poultry industries utilizing our Gen3Tech.

 

Bion believes that substantial unmet demand currently exists– potentially very large – for ‘real’ meat/dairy/egg products that offer the verifiable/believable sustainability consumers seek, but with the taste and texture they have come to expect from American beef and pork, dairy and poultry. Numerous studies demonstrate the U.S. consumers’ preferences for sustainability. For example, 2019 NYU Stern’s Center for Sustainable Business study found that ‘products marketed as sustainable grew 5.6 times faster than those that were not…’ and that ‘…in more than 90 percent of consumer-packaged-goods (CPG) categories, sustainability-marketed products grew faster than their conventional counterparts.’ Sales growth of plant-based alternatives, including both dairy and more recently ground meat (Beyond Meat, Impossible Foods, etc.) have shown that a large, but apparently limited, segment of consumers is choosing seemingly sustainable offering, and are also willing to pay a premium for it. Tyson Foods, in the context of launching its Brazen beef initiative, recently said, “consumers would be willing to pay at least 24 percent more for environmentally friendly, sustainable options at retail.” Numerous studies also support the consumers’ ‘willingness-to-pay’ (WTP) for sustainable choices, including a recent meta-analysis of 80 worldwide studies with results that calculate the overall WTP premium for sustainability is 29.5 percent on average.

 

As one of the largest contributors to some of the greatest air and water quality problems in America, it is clear that livestock waste cleanup, at scale, represents one of the greatest opportunities we have to reduce negative environmental impacts of the food supply chain on air and water quality. Bion’s Gen3Tech platform, along with its business model, will enable the cleanup of one of the ‘dirtiest’ parts of the food supply chain: animal protein production and creates the opportunity to produce and market verifiably sustainable organic and conventional ‘real meat’ products that can participate in the growth and premium pricing that appears to be readily available for the ‘right’ products.

 

Bion believes that at least a premium segment of the U.S. beef industry (and potentially other livestock industry groups) is at the doorstep of a transformative opportunity to address the growing demand for sustainable food product offerings, while pushing back against today’s anti-meat messaging. At $66 billion/year (2021 wholesale/farmgate value), the beef industry is a fragmented, commodity industry whose practices date back decades. In 1935 inflation-adjusted terms, beef was 63% more expensive in 2021, while pork and chicken, which are now primarily raised in covered barns at CAFOs with highly integrated supply chains, were 12% and 62% cheaper, respectively. In recent years, the beef industry has come under increasing fire from advocacy groups, regulatory agencies, institutional investors, and ultimately, their own consumers, over concerns that include climate change, water pollution, food safety, and the treatment of animals and workers.

 

Advocacy groups targeting livestock and the beef industry have recently been joined by competitors that produce animal protein alternatives in seeking to exploit the industry’s environmental and economic weaknesses. Their global anti-meat messaging has had a substantial chilling effect on the relationships the beef industry has with its institutional investors; retail distributors, such as fast-food restaurants; and mostly, its consumers. Led by the United Nations Food and Agriculture Organization, a coordinated anti-meat messaging campaign has targeted consumers worldwide, primarily focused on the industry’s impacts on climate change. A 2018 NielsenIQ Homescan survey last year found that 39% of Americans are actively trying to eat more plant-based foods. Some of the recent growth in plant-based proteins results from increasing lactose intolerance and other health concerns; however, most of that growth is attributed to consumers’ growing concerns for the environmental impacts of real meat and dairy. Several large US companies that have traditionally focused on livestock production, including Cargill, ADM, Perdue Foods, and Tyson, have also recently entered the plant protein space. While meat alternatives, especially plant-based protein producers like Beyond Meat and Impossible Foods, have been heavily promoted (by themselves and the media) and enjoyed remarkable initial sales growth, recently, sales have flattened and/or declined over the past 18 months. It should be noted that these plant-based protein producers are primarily expected to be able to serve the ground/ processed meat market, which represents only about 10 percent of the overall animal protein market. Further, there has recently been pushback to these plant-based products, focusing on their highly processed nature and unproven health benefits, scalability/ pricing, and their uncertain carbon footprint---and market growth rates have substantially slowed and may have already plateaued and/or peaked. There have also been several companies recently enter the cellular and 3D-printed meat arena. While facing myriad challenges and further out on the development timeline, some people believe cellular agriculture (aka cultured, clean, lab-grown, cultivated) meat may have the potential to service a much larger percentage of the market than plant-based protein, including cuts like steaks, chops and roasts, but the likely cost remains very uncertain at this point.

 

In terms of changing customer preferences, ‘saving the planet’ has proven to be a more compelling argument than the traditional animal activism/ welfare pitch. To date, the primary beef ‘industry response’ to this has been grass-fed beef, which is regarded as a generally more sustainable offering than grain-fed (largely without empirical evidence). However grass-fed beef has had only limited acceptance in U.S. markets, because it is less flavorful and tougher than the traditional corn-fed beef consumers have grown to enjoy. Sustainability initiatives have been launched by large US livestock producers (including Tyson’s very recent ‘Brazen’ program), but it is not yet possible to determine the extent the attributes of such products will be substantive and verifiable rather than completely ‘modeled’ and largely public relations ‘greenwashing’.

 

Each of these items supports Bion’s belief that there is a potentially very large opportunity to supply premium sustainable beef products that satisfy consumer concerns. We believe that the real meat/beef products that can be cost-effectively produced today using our Gen3Tech platform, both sustainable and/or organic, can provide an affordable product that satisfies the consumer’s desire for sustainability, but with the superior taste and texture those consumers have grown to prefer.

 

Sustainable Beef

 

Bion’s goal is to be one of the ‘first to market’ with meaningfully verified sustainable beef products that can be produced at sufficient scale to service national market demand. The cattle produced at Bion facilities will have a substantially lower carbon footprint, dramatically reduced nutrient impacts to water, and an almost total pathogen kill in the waste stream. Further, the economics of producing these cattle (including the cost of the facility/technology upgrade) will be greatly enhanced by the revenue realized from the recovery of valuable resources, including renewable energy, high-value fertilizer products, and clean water.

 

A Bion sustainable beef facility will be comprised of covered barns with slotted floors (allowing the waste to pass through) which will reduce ammonia and greenhouse gas volatilization and loss, as well as odors, thereby improving animal health and human working conditions while preventing air/soil pollution. The manure will be collected and moved directly to anaerobic digestion facilities which will produce renewable natural gas (and re-cycle CO2 from the gas cleaning process). Covered barns will reduce weather impacts on the livestock and have been demonstrated to promote improved general health and weight gain in the cattle housed in them. The barns’ very large roof surface area will be utilized (in geographical locations with adequate sunshine and appropriate ‘tariffs’) for the installation of photovoltaic solar generation systems to produce electricity for the facility, as well as export to the grid. The barn roofs will also be configured to capture rainwater, which, coupled with the water recovered from the treatment process, will reduce the projects’ reliance on current water supplies.

  

Waste treatment and resource recovery will be provided by Bion’s advanced Gen3Tech platform, which Bion believes offers the most comprehensive solution for livestock waste available today. In addition to direct environmental benefits, every pound of nitrogen that is captured, upcycled, and returned to the agricultural nitrogen cycle as high-quality fertilizer (vs lost to contaminate downstream waters), is also a pound of nitrogen that will not have to be produced as synthetic urea or anhydrous ammonia, with their tremendous carbon cost. System performance and environmental benefits will be monitored and verified through third parties, with USDA PVP certification of the sustainable brand that Bion also believes will be the most comprehensive available in the market.

 

Recently there have been efforts to establish sustainable brands (including USDA PVP certification) for a number of small-scale livestock producers (largely in the grass-fed beef category). To date, the reach and extent of such efforts is limited and it is difficult to determine their effectiveness. Additionally, there have been public announcements of initiatives related to beef sustainability (largely focused on the ‘cow-calf’ segment of the livestock chain) in procurement by major beef processing companies (including Tyson’s very recent ‘Brazen’ program), but a closer look finds that many have consisted largely of ‘green washing’ public proclamations in the wake of environmental and social criticism that re-package prior initiatives and lack any significant new substance.

 

Sustainable Organic Beef

 

Bion also believes it may also have a unique opportunity to produce, at scale, affordable corn-fed organic beef that is also certified as sustainable. In addition to the sustainable practices described above, organic-sourced beef cows would be finished on organic corn, which would be produced using the ammonium bicarbonate fertilizer captured by the Gen3Tech platform. Bion believes its meat products will meet consumer demands with respect to sustainability and safety (organic) and provide the tenderness and taste American consumers have come to expect from premium conventional American beef. Such products are largely unavailable in the market today. We believe Bion’s unique ability to produce the fertilizer needed to grow a supply of relatively low-cost organic corn, and the resulting opportunity to produce organic beef, will dramatically differentiate us from potential competitors. This organic opportunity is dependent on successfully establishing Bion’s fertilizer products as acceptable for use in organic grain production.

 

Today, organic beef demand is limited and mostly supplied with grass-fed cattle. While organic ground/ chopped meat has enjoyed success in U.S. markets, grass-fed steaks have seen limited acceptance, mostly resulting from consumer issues with taste and texture. In other words, it’s tough. Regardless, such steaks sell for a significant premium over conventional beef. A grain-finished organic beef product is largely unavailable in the marketplace today due to the higher costs of producing organic corn and grain. The exception is offerings that are very expensive from small ‘boutique’ beef producers. Like all plants, corn requires nitrogen to grow. Corn is especially sensitive to a late-season application of readily available nitrogen – the key to maximizing yields. With non-organic field corn, this nitrogen is supplied by an application of a low-cost synthetic fertilizer, such as urea or anhydrous ammonia. However, the cost for suitable nitrogen fertilizer that can be applied late-season in organic corn production is so high that the late-season application becomes uneconomical, resulting in substantially lower yields – a widely recognized phenomena known as the ‘yield gap’ in organic production. The yield gap results in higher costs for organic corn that, in turn, make it uneconomical to feed that corn to livestock. As is the case for sustainable but not organic beef, Bion believes there is a potentially large unmet demand for affordable beef products that are both sustainable AND organic, but with the taste and texture consumers have come to expect from American beef. Bion’s ability to produce the low-cost nitrogen fertilizer that can close the organic yield (and affordability) gap puts the Company in a unique, if not exclusive at this time, position to participate in JV’s that will benefit from this opportunity starting next year.

 

The demonstrated willingness of consumers to purchase sustainable products (along with numerous research and marketing studies confirming consumers are seeking, and are willing to pay a premium for, sustainable products)---in combination with the threat to the livestock industry market (primarily beef and pork) posed by plant-based alternatives (heightened by pandemic conditions)--- has succeeded in focusing the large scale livestock industry on how to meet the plant-based market challenge by addressing the consumer sustainability issues. The consumer demand for sustainability appears to be a real and lasting trend, but consumers remain skeptical of generalized claims of ‘sustainability’. To date, a large portion of the industry responses to this trend have been at a superficial level or consist of ‘green washing’, a deceptive marketing practice where companies promote non-substantive initiatives. Real sustainability for the livestock industry will require implementation of advanced waste treatment technology at or near the CAFOs – where most of the negative environmental impacts take place.

 

Fertilizer: Organic and ‘Climate Smart’

 

The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“Gen3Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of low carbon and/or organically certified soluble nitrogen fertilizer products. The Company’s low concentration ammonium bicarbonate liquid product successfully completed its Organic Materials Review Institute (“OMRI”) application and review process with listing approval during May 2020. During the next 2 months the Company intends to file applications with OMRI and the California Department of Food & Agriculture (“CDFA”) for a line of higher concentration liquid ammonium nitrogen products (ranging from 4% up to 16% (or higher)) based on production of liquid samples during operation of the Initial Project. The Company anticipates applying for and obtaining one or more listings/certifications for higher concentration products in our liquid ammonium nitrogen fertilizer line well prior to operational dates for the Company’s initial large-scale JV Gen3Tech Sustainable Beef Projects.

 

Additionally, the Company intends to explore the market potential for its fertilizer (in liquid and/or solid forms) to be a verifiably ‘ClimateSmart’ product (potentially a much larger market than the organic market) with focus on higher value specialty crops. This will require working with industry and academic entities to develop appropriate metrics and producing a ‘life cycle assessment’ (LCA) for Bion’s ammonium nitrogen fertilizer product which can be compared to conventional nitrogen fertilizer products. Bion’s processes will capture and utilize CO2 in the waste stream (including CO2 produced with the renewable natural gas (RNG) by anaerobic digestion that is usually vented to the atmosphere) as stabilizing agent thereby potentially creating carbon offsets compared to natural gas utilized as feedstock in chemical ammonia production which reduction will be reflected in the LCA. This LCA will assess environmental impacts associated with fertilizer production in support of the beef cattle supply chain for both the existing conventional approach (primarily fossil fuel-based Haber-Bosch production methods) and the largely decarbonized Bion production approach. We believe a series of coincident yet significant LCA benefits accrue from Bion’s patented fertilizer production approach including the reduced loss of ammonia to the environment via air (volatilized) and water (nitrate in groundwater) pathways, recycled/reused water, elimination of pathogens, the production of renewable natural gas, the production solar energy from photovoltaic panels on barn roofs, enhanced animal welfare practices and reduced animal husbandry risks from extreme weather events. Bion believes that current evaluations of the carbon impact from feedlot operations materially underestimate the negative impacts because existing models do not properly include significant ‘downstream’ carbon impacts of required energy intensive waste water treatment for re-deposited ammonia nitrogen. If the Company determines there is a significant ‘ClimateSmart’ opportunity for our fertilizer products, such an LCA can be completed (based in part on data from the Initial Project) and support marketing efforts well prior to operational dates for the Company’s initial large scale JV Gen3Tech projects.

 

Ammonium bicarbonate, manufactured using thermal and mechanical processes, has a long history of use as a fertilizer. In addition to liquid ammonium nitrogen fertilizer, Bion’s Gen3Tech is capable of recovering nitrogen in the form of solid ammonium bicarbonate products containing up to 18%-22% (or higher) nitrogen in a crystalline form that is easily transported (while producing liquids with various percentages of ammonium bicarbonate nitrogen during interim stages of the process). This solid product is water soluble and provides a readily available nitrogen source for crops. It will contain virtually none of the other salt, iron and mineral constituents of the livestock waste stream that often accompany other organic fertilizers. This product is being developed to fertilizer industry standards so that it that can be precision-applied to crops using existing equipment. Bion believes that this product will potentially have broad applications in the production of organic and/or ClimateSmart grains for livestock feed, row crops, horticulture, greenhouse and hydroponic production, and potentially retail lawn and garden products.

 

The ammonium bicarbonate products (liquid and solid) produced by Bion’s Gen3Tech platform will enjoy a dramatically lower carbon footprint than synthetic nitrogen fertilizers. Much of the reactive nitrogen captured and upcycled into our fertilizer products was going to be lost through volatilization and runoff, and that loss would generally need to be offset with a synthetic nitrogen fertilizer, such as anhydrous ammonia or urea. These synthetic nitrogen products are produced through the Haber-Bosch (and other) synthetic processes, which converts hydrogen and atmospheric nitrogen to ammonia, with methane from fossil fuels as the energy source. It is an extremely energy-intensive process with a carbon footprint that, while not yet fully understood, is widely accepted to by very large. While a complete Life Cycle Assessment (LCA) of carbon impacts from synthetic fertilizer production is not yet available, according to the Institute for Industrial Productivity, its production alone is responsible for approximately 1 percent of total global CO2 emissions. To the extent that Bion can capture and repurpose the nitrogen traditionally lost from livestock waste, that carbon cost will no longer need to be paid by the environment/climate.

 

Applications for our first solid form of concentrated ammonia, soluble nitrogen fertilizer product line were filed with OMRI (filed during May 2021) and CDFA (filed during May 2022) without success to date. After an extended review processes (which was largely opaque), the OMRI application proceeded through multiple stages without receiving a positive result. We have initiated an informal dialogue with CDFA regarding the basis for and re-consideration of its initial determination and have submitted additional supplemental supporting materials to CDFA. The Company’s solid product line is novel (in the context of organic certification) in part due to the fact that no formal listing category currently in the organic space for a solid form of concentrated ammonia, soluble nitrogen fertilizers and there is no clear guidance at present from internal policy manuals on how to categorize this product and the process that produces it. There is also no clear guidance at present from either the NOP or the National Organic Standards Board (“NOSB”) (which is currently involved in a related review and recommendations process regarding ‘high nitrogen liquid fertilizers’ derived from ammonia from manure). The Company and its representatives, along with a number of other organic fertilizer stakeholders, are involved in discussions regarding resolution of these matters at all three levels. The Company intends to continue efforts to obtain listing/certification for its solid nitrogen fertilizer line over the course of this fiscal year.

 

Gen3Tech Kreider 2 Poultry Project

 

Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) (‘Kreider Renewable Energy Facility’ or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). Now that development of the Company’s Gen3Tech is being deployed, the Company has commenced discussions with KF regarding updating and amending the JV agreement and anticipates executing an amended joint venture agreement during 2023. During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA). Note that this Project may also be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). The Company anticipates if and when PA2 re-commences work on the Kreider 2 Project, it will submit a new application based on our Gen3Tech. Site specific design and engineering work for this facility have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during the following calendar year. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its proposed use of Bion’s Gen3Tech for increased recovery of marketable by-products and sustainable branding, are based in material part the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. However, liquidity in the Pennsylvania nutrient credit market has not yet developed significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.

 

Note that while Bion believes that the Kreider 2 Project and/or subsequent Bion Projects in PA and the Chesapeake Bay Watershed will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees/premiums related to a ‘sustainable brand’, the Covid-19 pandemic has delayed legislative efforts needed to commence its development. However, the Company is currently engaged in dialogue with the regional EPA office and the Chesapeake Bay Program Office regarding the potential of the Company’s Gen3Tech Kreider2 Project (and other potential projects) to enable Pennsylvania to move forward toward meeting its Chesapeake Bay clean-up goals. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.

 

Technology Deployment: Bion Gen3Tech

 

In the absence of firm regulatory mandates, widespread deployment of waste treatment technology, and the sustainability it enables, is largely dependent upon generating sufficient additional revenues to offset the capital and operating costs associated with technology adoption. Bion’s Gen3Tech business platform has been developed to create opportunities for such augmented revenue streams, while providing third party verification of sustainability claims. The Gen3Tech platform has been designed to maximize the value of co-products produced during the waste treatment/recovery processes, including pipeline-quality renewable natural gas (biogas) and commercial fertilizer products approved for organic production and/or certified as ‘ClimateSmart’. All processes will be verifiable by third parties (including regulatory authorities and certifying boards) to comply with environmental regulations and trading programs and meet the requirements for: a) renewable energy and carbon credits, b) organic certification of the fertilizer coproducts and c) USDA PVP certification of an ‘Environmentally Sustainable’ brand (see discussion above and below), and d) payment for verified ecosystem services. The Company’s first patent on its Gen3Tech was issued during 2018. In August 2020, the Company received a Notice of Allowance on its third patent which significantly expands the breadth and depth of the Company’s Gen3Tech coverage. The Company has additional applications pending and/or planned. 

 

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

In parallel with technology development, Bion has worked (which work continues) to implement market-driven strategies designed to stimulate private-sector participation in the overall U.S. nutrient and carbon reduction strategy. These market-driven strategies can generate “payment for ecosystem services”, in which farmers or landowners are rewarded for managing their land and operations to provide environmental benefits that will generate additional revenues. Existing renewable energy credits for the production and use of biogas are an example of payment for ecosystem services. Another such strategy is nutrient trading (or water quality trading), which will potentially create markets (in Pennsylvania and other states) that will utilize taxpayer funding for the purchase of verified pollution reductions from agriculture (“nutrient credits”) by the state (or others) through competitively-bid procurement programs. Such credits can then be used as a ‘qualified offset’ by an individual state (or municipality) to meet its federal clean water mandates at significantly lower cost to the taxpayer. Market-driven strategies, including competitive procurement of verified credits, is supported by U.S. EPA, the Chesapeake Bay Commission, national livestock interests, and other key stakeholders. Legislation in Pennsylvania to establish the first such state competitive procurement program passed the Pennsylvania Senate by a bi-partisan majority during March 2019 but has not yet crossed the hurdles required for actual adoption. The Covid-19 pandemic and related financial/budgetary crises have slowed progress for this and other policy initiatives and, as a result, it is not currently possible to project the timeline for completion (or meaningful progress) of this and other similar initiatives (see discussion below).

 

The livestock industry and its markets are already changing. With our commercial-ready technology and business model, Bion believes it has a ‘first-mover advantage’ over others that will seek to exploit the opportunities that will arise from the industry’s inevitable transformation. Bion anticipates moving forward with the development process of its initial commercial installations utilizing its Gen3Tech, during the current 2024 fiscal year. We believe that Bion’s Gen3Tech platform and business model can provide a pathway to true economic and environmental sustainability with ‘win-win’ benefits for at least a premium sector of the livestock industry, the environment, and the consumer, an opportunity which the Company intends to pursue.

 

The Livestock Problem

 

The livestock industry is under tremendous pressure from regulatory agencies, a wide range of advocacy groups, institutional investors and the industry’s own consumers, to adopt sustainable practices. Environmental cleanup is inevitable and has already begun — and policies have already begun to change, as well. Bion’s Gen3Tech was developed for implementation on large scale livestock production facilities, where scale drives both lower treatment costs and efficient co-products production, as well as dramatic environmental improvements. We believe that scale, coupled with Bion’s verifiable treatment technology platform, will create a transformational opportunity to integrate clean production practices at (or close to) the point of production—the primary source of the industry’s environmental impacts. Bion intends to assist the forward-looking segment of the livestock industry to bring animal protein production in line with 21st Century consumer demands for meaningful sustainability.

 

In the U.S. (according to the USDA’s 2017 agricultural census) there are over 9 million dairy cows, 90 million beef cattle, 60 million swine and more than 2 billion poultry which provides an indication of both the scope of the problem addressed by Bion’s technology, as well as the size of Bion’s opportunity. Environmental impacts from livestock production include surface and groundwater pollution, greenhouse gas emissions, ammonia, and other air pollution, excess water use, and pathogens related to foodborne illnesses and antibiotic resistance. While the most visible and immediate problems are related to nutrient runoff and its effects on water quality, the industry has recently been targeted by various stakeholder groups for its impacts on climate change.

 

Estimates of total annual U.S. livestock manure waste vary widely, but start around a billion tons, between 100 and 130 times greater than human waste. However, while human waste is generally treated by septic or municipal wastewater plants, livestock waste – raw manure – is spread on our nation’s croplands for its fertilizer value. Large portions of U.S. feed crop production (and most organic crop production) are fertilized, in part, in this manner. Under current manure management practices, 80% or more of total nitrogen from manure, much of it in the form of ammonia, escapes during storage, transportation, and during and after soil application, representing both substantial lost value and environmental costs.

 

More than half of the nitrogen impacts from livestock waste come from airborne ammonia emissions, which are extremely volatile, reactive and mobile. Airborne ammonia nitrogen eventually settles back to the ground through atmospheric deposition — it ‘rains’ everywhere. While some of this nitrogen is captured and used by plants, most of it runs off and enters surface waters or percolates down to groundwater. It is now well-established that most of the voluntary conservation practices, such as vegetated buffers that ‘filter’ runoff (often referred to as “BMPs” or “Best Management Practices” that have traditionally been implemented to attempt to mitigate nutrient runoff), are considerably less effective than was previously believed to be the case. This is especially true with regard to addressing the volatile and mobile nitrogen from ammonia emissions, because BMPs are primarily focused on surface water runoff, directly from farm fields in current production, versus the re-deposition that takes place everywhere or groundwater flow.

 

Runoff from livestock waste has been identified in most of our major watersheds as a primary source of excess nutrients that fuel algae blooms in both fresh and saltwater. Over the last several years, algae blooms have become increasingly toxic to both humans and animals, such as the Red Tides on the Florida and California coasts, and the Lake Erie algae bloom that cut off the water supply to Toledo, Ohio, residents in 2014. When the nutrient runoff subsides, it leaves the algae blooms with no more ‘food’ and the blooms die. The algae’s decomposition takes oxygen from the water, leading to ‘dead zones’ in local ponds, lakes, and ultimately, the Great Lakes, as well as the Chesapeake Bay, Gulf of Mexico, and other estuary waters. Both the toxic algae blooms and the low/no-oxygen dead zones devastate marine life, from shrimp and fish to higher mammals, including dolphins and manatees. U.S. EPA already considers excess nutrients “one of America’s most widespread, costly and challenging environmental problems”. Nutrient runoff is expected to worsen dramatically in the coming decades due to rising temperatures and increasing rainstorm intensity as a result of climate change.

 

Nitrate-contaminated groundwater is of growing concern in agricultural regions nationwide, where it has been directly correlated with nutrient runoff from upstream agricultural operations using raw manure as fertilizer. Pennsylvania, Wisconsin, California and Washington, and others, now have regions where groundwater nitrate levels exceed EPA standards for safe drinking water. High levels of nitrate can cause blue baby syndrome (methemoglobinemia) in infants and affect women who are or may become pregnant, and it has been linked to thyroid disease and colon cancer. EPA has set an enforceable standard called a maximum contaminant level (MCL) in water for nitrates at 10 parts per million (ppm) (10 mg/L) and for nitrites at 1 ppm (1 mg/L). Federal regulations require expensive pretreatment for community water sources that exceed the MCL; however, private drinking water wells are not regulated, and it is the owners’ responsibility to test and treat their wells. Additionally, groundwater flows also transport this volatile nitrogen downstream where, along its way, it intermixes with surface water, further exacerbating the runoff problem. Like atmospheric deposition, the current conservation practices we rely on to reduce agricultural runoff are largely bypassed by this subsurface flow.

 

Additionally, in arid climates, such as California, airborne ammonia emissions from livestock manure contribute to air pollution as a precursor to PM2.5 formation, small inhalable particulate matter that is a regulated air pollutant with significant public health risks. Whether airborne or dissolved in water, ammonia can only be cost-effectively controlled and treated at the source—before it has a chance to escape into the environment where it becomes extremely expensive to ‘chase’, capture, and treat.

 

High phosphorus concentrations in soils fertilized with raw manure are another growing problem. The ratio of nitrogen to phosphorus in livestock waste is fixed, and because manure application rates are calculated based on nitrogen requirements, often phosphorus is overapplied as an unintended consequence. Phosphorus accumulation in agricultural soils reduces its productivity, increases the risk of phosphorus runoff, and represents a waste of a finite resource. Decoupling the nitrogen from the phosphorus would allow them to be precision-applied, independently of each other, when and where needed.

 

The livestock industry has recently come under heavy fire for its impacts on climate change, which has become a rallying cry for the anti-meat campaign discussed above. Estimates of the magnitude of those impacts vary widely, but the general consensus is that globally, livestock account for 14.5 percent of greenhouse emissions. In the U.S. however, that number drops to 4.2 percent, due to the increased efficiencies of American beef production. The greatest impacts come from direct emissions of methane from enteric fermentation (belches), methane and nitrous oxide emissions from the manure, with arguably the largest being the massive carbon footprint of the synthetic nitrogen fertilizers used to grow the grains to feed the livestock.

 

For decades the livestock industry has overlooked and/or socialized its environmental problems and costs. Today, the impacts of livestock production on public health and the environment can no longer be ignored and are coming under increasing scrutiny from environmental groups and health organizations, regulatory agencies and the courts, the media, consumers, and activist institutional investors. The result has been a significant and alarming loss of market share to plant-based protein and other alternative products. Bion’s Gen3Tech platform was designed to resolve these environmental issues and bring the industry in line with twenty-first century consumer expectations.

 

Going Concern and Management’s Plans:

 

The Company’s condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company incurred a net loss of $1,464,000 and $1,649,000 for the six months ended December 31, 2023 and 2022, respectively. At December 31, 2023, the Company has a working deficit and a stockholders’ equity of approximately $3,806,000 and $3,593,000, respectively. The Company has not generated significant revenues (even though it earned a net income of $8,291,000 for the year ended June 30, 2022) and incurred a net loss of approximately ($3,189,000) during the year ended June 30, 2023. The net income for the year ended June 30, 2022 was largely due to a one-time, non-cash event of the dissolution of Bion PA-1, LLC (“PA-1”) resulting in a gain of approximately $10,235,000 as well as a one-time gain of $902,000 from the sale of the Company’s ‘biontech.com’ domain pursuant to a purchase agreement during the period. During the year ended June 30, 2023 the Company had debt modifications that resulted in a reduction of debt of $3,516,000 and an increase in equity. The Company’s lack of revenue and/or operating profits, together with the low likelihood of generating positive cash flow and/or net income during the next 12-24 months, raise substantial doubt about the Company’s ability to continue as a going concern. The Company is not currently generating any significant revenues. Further, the Company’s anticipated revenues, if any, from existing projects, JVs and proposed projects will not be sufficient to meet the Company’s anticipated operational and capital expenditure needs for many years. As previously noted, the Company is currently not generating significant revenue and accordingly has not generated cash flows from operations. The Company does not anticipate generating sufficient revenues to offset operating and capital costs (for Projects) for a minimum of two to five years. While there are no assurances that the Company will be successful in its efforts to develop and construct its Projects and market its Systems, it is certain that the Company will require substantial funding from external sources. Given the unsettled state of the current credit and capital markets for companies such as Bion, there is no assurance the Company will be able to raise the funds it needs on reasonable terms. The aggregate effect of these factors raises substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. The following paragraphs describe management’s plans with regard to these conditions.

 

Current liabilities were approximately $4.2 million and $1.6 million at December 31, 2023 and 2022, respectively. There was an increase of approximately $2.6 million (which was largely due to an increase in ‘accounts payable and accrued expenses’ totaling approximately $2.0 million and an increase in ‘deferred compensation’ of approximately $.35 million) as a result of the Company’s limited success in raising new financing (equity and/or debt) during the recent period combined with continued expenses (including those related to the Initial Project).

 

The Company continues to explore sources of additional financing to satisfy its current operating requirements as it is not currently generating any significant revenues. During fiscal years 2023 and 2022 (as a whole), the Company faced less difficulty in raising equity funding (but was subject to substantial equity dilution from the larger amounts of equity financing during the periods) than was experienced in the prior 3 years. However, this positive trend did not continue during the last quarter of the 2023 fiscal year and first and second quarters of the current fiscal year (and the third quarter through the date of this report). The Company raised only raised very limited equity funds during such periods to meet its some of its immediate needs, and therefore, the Company needs to raise substantial additional funds in the upcoming periods. The Company has faced substantial increases in demand for capital and operating expenditures for the fiscal year 2024 to date (and we anticipate such increased demands will continue during the remainder of the 2024 fiscal year and periods thereafter) as it moves toward commercial implementation of its 3G Tech and development of JVs (including costs associated with additions of personnel to carry out the business activities of the Company) and, therefore, is likely to continue to face, significant cash flow management issues due to limited capital resources and working capital constraints which had only recently begun to be alleviated. As a result, the Company has faced, and continues to face, significant cash flow management challenges due to material working capital constraints. To partially mitigate these working capital constraints, the Company's core senior management and some key employees and consultants have been deferring most of their cash compensation and/or are accepting compensation in the form of securities of the Company and members of the Company's senior management have from time-to-time made loans to the Company in the past and may do so in future periods. The Company continues to explore sources of additional financing (including potential agreements with strategic partners – both financial and ag-industry) to satisfy its current and future operating and capital expenditure requirements as it is not currently generating any significant revenues.

 

During the years ended June 30, 2023 and 2022, the Company received gross proceeds of approximately $4,038,000 and $1,737,000, respectively, from the sale of its debt and equity securities. The Company paid commissions on the exercise of warrants in the amount of $86,000 and $19,000 in 2023 and 2022, respectively.

 

During the six months ended December 31, 2023 and 2022 the Company received total proceeds of approximately $443,000 and $602,000, respectively, from the sale of its debt and equity securities. During the six months ended December 31, 2023 the Company received proceeds of $250,000 from a convertible bridge loan but the provider of the bridge loan breached its contractual obligation/binding subscription agreement to fund an additional $1,250,000 to the Company during November 2023 (and on an ongoing basis since such time), which breach (combined with management stresses related to the final illness and passing of Dominic Bassani, Bion’s COO and former CEO, and required management transitions) has created a substantial cash flow difficulties for the Company which are ongoing. See Note 6 and Note 9, E4) Bridge Loan/Default below.

 

The Company anticipates substantial increases in demand for capital and operating expenditures for the balance of fiscal year 2024 (and we anticipate such increased demands will continue during the 2025 fiscal year and periods thereafter) as it moves toward commercial implementation of its 3G Tech and development of JVs (including costs associated with additions of personnel to carry out the business activities of the Company) and, therefore, is likely to continue to face, significant cash flow management issues due to limited capital resources and working capital constraints which had only recently begun to be alleviated during the 2023 fiscal year. As a result, the Company has faced, and continues to face, significant cash flow management challenges due to material working capital constraints. To partially mitigate these working capital constraints, the Company's core senior management and some key employees and consultants have been deferring most of their cash compensation and/or are accepting compensation in the form of securities of the Company and members of the Company's senior management have from time-to-time made loans to the year ended June 30, 2018, senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $2,404,000. Additionally, the Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again during the year ended June 30, 2018. As set forth in detail elsewhere herein, during the year ended June 30, 2023 senior management (and family members) who held convertible obligations of the Company adjusted the terms of their outstanding notes and agreed to debt modifications that reduced of the Company’s debt by $3,516,000 and increased shareholders equity by the same amount.

 

The constraints on available resources have had, and continue to have, negative effects on the pace and scope of the Company’s efforts to operate and develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and/or curtailment of ongoing activities including research and development activities. The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including the Initial Project, JV Projects (including the Dalhart, Olson and DVG Projects), and the Kreider 2 facility) and CAFO Retrofit waste remediation systems. The Company anticipates that it will seek to raise from $20,000,000 to $80,000,000 or more debt and/or equity through joint ventures, strategic partnerships and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) and/or through other means during the next twelve months. However, as discussed above, there is no assurance, especially in light of the difficulties the Company has experienced in many recent years and the extremely unsettled capital markets that presently exist for small companies like us, that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and Projects.

 

There is no realistic likelihood that funds required during the next twelve months (or in the periods immediately thereafter) for the Company’s basic operations, the Initial Project and/or proposed JVs and/or Projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company’s existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for small companies like Bion.

 

Covid-19 pandemic related matters:

 

 The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES

2.       SIGNIFICANT ACCOUNTING POLICIES

 

Principles of consolidation:

 

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.

 

The accompanying condensed consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at December 31, 2023, the results of operations and cash flows of the Company for the three and six months ended December 31, 2023 and 2022. Operating results for the three and six months ended December 31, 2023 are not necessarily indicative of the results that may be expected for the year ending June 30, 2024.

 

Cash and cash equivalents:

 

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of December 31, 2023 and June 30, 2023 there are no cash equivalents.

 

Property and equipment:

 

Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects such as consulting fees, internal salaries and benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.

 

Patents:

 

The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s condensed consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.

 

Stock-based compensation:

 

The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.

 

Derivative Financial Instruments:

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

 

Options:

 

The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

 

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

Concentrations of credit risk:

 

The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.

 

Noncontrolling interests:

 

In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the condensed consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the condensed consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.

 

Fair value measurements:

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.

 

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

 

Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

 

Level 3 – assets and liabilities whose significant value drivers are unobservable.

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.

 

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the condensed consolidated statements of operations over the lease term.

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

 

Revenue Recognition:

 

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.

 

Income (Loss) per share:

 

Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise, or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the three and six months ended December 31, 2023 and 2022, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.

 

The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:

        
   December 31,
2023
   December 31,
2022
 
Warrants   23,905,539    20,660,031 
Options   12,006,600    11,201,600 
Convertible debt   9,754,772    11,010,012 

 

The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the three and six months ended December 31, 2023 and 2022.

                
  

Three months

ended

December 31,

2023

  

Three months

ended

December 31,

2022

  

Six months

ended

December 31,

2023

  

Six months

ended

December 31,

2022

 
Shares issued – beginning of period   49,485,556    44,303,654    48,880,237    43,758,820 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)   (704,309)   (704,309)
Shares outstanding – beginning of period   48,781,247    43,599,345    48,175,928    43,054,511 
Weighted average shares issued
    during the period
   98,186    20,706    572,626    479,278 
Diluted weighted average shares –
    end of period
   48,879,433    43,620,051    48,748,554    43,533,789 

 

 

Use of estimates:

 

In preparing the Company’s condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements:

 

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its condensed consolidated financial statements and assures that there are proper controls in place to ascertain that the Company’s condensed consolidated financial statements properly reflect the change.

 

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY AND EQUIPMENT:
6 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT:

3.       PROPERTY AND EQUIPMENT:

 

Property and equipment consist of the following:

        
  

December 31,

2023

  

June 30,

2023

 
Computers and office equipment   15,156    15,156 
Initial Project: construction in process   9,108,312    6,847,760 
Property and equipment, gross   9,123,468    6,862,916 
Less accumulated depreciation   (12,828)   (11,907)
 Property and equipment, net  $9,110,640   $6,851,009 

 

The 3G1 project (“Initial Project”) began in July of 2021, with a lease signed on land October 1, 2021 (Note 9). Once the lease commenced the Company moved into construction phase. The balance for the Initial Project construction in process includes $238,540 and $98,104 for capitalized interest and $135,648 and $135,648 in non-cash compensation as of December 31, 2023 and 2022, respectively. On January 1, 2024 the Initial Project was deemed to have been ‘placed in service’ (Note 10).

 

Management has reviewed the remaining property and equipment for impairment as of December 31, 2023 and believes that no impairment exists.

 

Depreciation expense was $460 and $394 for the three months ended December 31, 2023 and 2022, respectively and $921 and $724 for the six months ended December 31, 2023 and 2022, respectively.

 

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEFERRED COMPENSATION:
6 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
DEFERRED COMPENSATION:

4.       DEFERRED COMPENSATION:

The Company owes deferred compensation to various employees, former employees and consultants totaling $1,225,226 and $714,222 as of December 31, 2023 and 2022, respectively. Included in the deferred compensation balances as of December 31, 2023, are $255,000, $652,252 and $70,450 owed William O’Neill (“O’Neill”), the Company’s CEO, Dominic Bassani (“Bassani”), the Company’s recently deceased Chief Operating Officer (who was Chief Executive Officer for a decade through April 30, 2022) (NOTE: Dominic Bassani passed away on October 11, 2023.), and Mark A. Smith (“Smith”), the Company’s President, respectively.

The sums owed to Bassani and Smith are owed pursuant to extension agreements effective January 1, 2015, whereby unpaid compensation earned after January 1, 2015, accrues interest at 4% per annum and can be converted into shares of the Company’s common stock at the election of the employee during the first five calendar days of any month. The conversion price shall be the average closing price of the Company’s common stock for the last 10 trading days of the immediately preceding month. The deferred compensation owed Bassani and Smith as of December 31, 2022 was $481,972.

O’Neill is owed balance of $255,000 and $80,000 at December 31, 2023 and 2022, respectively, pursuant to his 2021 employment agreement There is no interest accrual or conversion rights related to the deferred balance.

The Company also owes various consultants and an employee, pursuant to various agreements, for deferred compensation of $175,024 and $79,750 as of December 31, 2023 and 2022, respectively, with similar conversion terms as those described above for Bassani and Smith, with the exception that the interest accrues at 0% to 3% per annum. The Company also owes a former employee $72,500, which is not convertible and is non-interest bearing. Bassani and Smith have each been granted the right to convert up to $300,000 of deferred compensation balances at a price of $0.75 per share until June 30, 2024 into common shares (to be issued pursuant to the 2006 Plan). Smith also has the right to convert all or part of his deferred compensation balance into the Company’s securities (to be issued pursuant to the 2006 Plan) “at market” and/or on the same terms as the Company is selling or has sold its securities in its then current (or most recent if there is no current) private placement. Smith also received the right to transfer future deferred compensation to his 2020 Convertible Obligation at his election but such right is no longer in force.

The Company recorded interest expense of $7,201 ($6,875 with related parties) and $4,873 ($4,345 with related parties) for the three months ended December 31, 2023 and 2022, respectively and $13,629 ($12,511 with related parties) and $9,424 ($8,464 with related parties) for the six months ended December 31, 2023 and 2022, respectively.

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
LOANS PAYABLE:
6 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
LOANS PAYABLE:

5.       LOANS PAYABLE:

 

Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s condensed consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s condensed consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436). The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s condensed consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest described above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONVERTIBLE NOTES PAYABLE:
6 Months Ended
Dec. 31, 2023
Convertible Notes Payable  
CONVERTIBLE NOTES PAYABLE:

6.       CONVERTIBLE NOTES PAYABLE:

 

Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes --- see below) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $3.47 million, in aggregate –See Note 7 below, ‘Debt Modification to Additional Paid in Capital’) while equitably maintaining existing conversion rights.  The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties.

 

Mark A. Smith (the Company’s President)(“Smith”), Dominic Bassani (the Company’s Chief Operating Officer) (“Bassani”) (NOTE: Dominic Bassani passed away on October 11, 2023.) and Ed Schafer (Director)(“Schafer”), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations and the adjusted portion of the September 2015 Convertible Notes were renamed Adjusted September 2015 Convertible Notes. The Adjusted 2020 Convertible Obligations of Smith, Bassani and Schafer are convertible into Units (consisting of 1 share and from one half (1/2) to one (1) warrant) at prices of $.0946, $.0953, and $.0953, respectively, and the Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.115 per share. The adjusted conversion prices slightly reduce the securities to be issued on conversion of each instrument from the amount receivable under the unadjusted instruments. The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). After the adjustment, the Company owed Smith, Bassani (and trust) and Schafer $262,154, $434,016 and $96,364, respectively, of Adjusted 2020 Convertible Obligations and Bassani and Schafer, respectively, $24,230 and $4,012 of Adjusted September 2015 Convertible Notes.

 

As of December 31, 2023, the Adjusted 2020 Convertible Obligation balances, including accrued interest, owed Bassani (and his donees), Smith and Edward Schafer were $450,361, $44,017 and $99,993, respectively. As of June 30 2023, the Adjusted 2020 Convertible Obligation balances, including accrued interest, owed Bassani (and his donees), Smith and Edward Schafer were $441,446, $130,180 and $98,014, respectively.

 

As of December 31, 2023 the Adjusted September 2015 Convertible Notes balances, including accrued interest, owed Bassani Family Trusts and Schafer were $25,143 and $4,163, respectively. As of June 30, 2023 the Adjusted September 2015 Convertible Notes balances, including accrued interest, owed Bassani Family Trusts and Schafer were $24,645 and $4,081, respectively.

 

2020 Convertible Obligations

 

The 2020 Convertible Obligations (which combined/replaced prior convertible instruments dating to 2017 (or earlier), which accrue interest at either 4% per annum or 4% compounded quarterly and effective January 1, 2020 are due and payable on July 1, 2024. The 2020 Convertible Obligations (including accrued interest, plus all future deferred compensation added subsequently), are convertible, at the sole election of the holder, into Units consisting of one share of the Company’s common stock and one half to one warrant to purchase a share of the Company’s common stock, at a price of $0.50 per Unit until July 1, 2024. The original conversion price of $0.50 per Unit approximated the fair value of the Units at the date of the agreements; therefore, no beneficial conversion feature exists. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC 815-15 “Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are not “clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was not required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is not readily convertible to cash in accordance with ASC 815-10, “Derivatives and Hedging”. Effective February 1, 2023, a large portion of the 2020 Convertible Obligations were adjusted as set forth herein.

  

As of December 31, 2023, the remaining unadjusted portion of the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts (and his donees) and Smith, were $367,660 and $118,732, respectively.

As of December 31, 2022, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts, Smith and Schafer were $2,644,553, $1,388,421 and $508,352, respectively.

 

During the six months ended December, 2023, Smith elected to convert $91,548 of his Adjusted 2020 Convertible Obligation into 967,738 units at $0.0946 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until July 2026.

 

The Company recorded interest expense of $7,875 and $82,740 for the six months ended December 31, 2023 and 2022, respectively. The Company capitalized $26,559 and $66,104 related to the Initial Project for the six months ended December 31, 2023 and 2022, respectively.

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long-term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $3.47 million, in aggregate) while equitably maintaining existing conversion rights. Because the modifications where with affiliates that are related parties, the debt modification was treated as an equity transaction. The Company recorded a deemed dividend for the reductions.

 

Mark A. Smith (the Company’s President) (“Smith”), Dominic Bassani (the Company’s Chief Operating Officer) (“Bassani”) (NOTE: Dominic Bassani passed away on October 11, 2023. See Note 10) and Ed Schafer (Director) (“Schafer”), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations (see above and Note 7.). The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties.

 

September 2015 Convertible Notes

 

During the year ended June 30, 2016, the Company entered into September 2015 Convertible Notes with Bassani, Schafer and a Shareholder which replaced previously issued promissory notes. The September 2015 Convertible Notes bear interest at 4% per annum, have maturity dates of July 1, 2024, and may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.60 per share. As the conversion price of $0.60 approximated the fair value of the common shares at the date of the September 2015 Convertible Notes, no beneficial conversion feature exists.

 

The balances of the September 2015 Convertible Notes as of December 31, 2023, including accrued interest owed Bassani, Schafer and Shareholder, are $186,725, $4,163 and $468,431, respectively. The balances of the September 2015 Convertible Notes as of December 31, 2022, including accrued interest, were $284,211, $21,173 and $453,314, respectively.

 

The Company recorded interest expense of $10,158 and $12,731 for the six months ended December 31, 2023 and 2022, respectively.

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including the September 2015 Convertible Notes owned by Bassani and Schafer) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $3.52 million, in aggregate) while equitably maintaining existing conversion rights.  Mark A. Smith (the Company’s President), Dominic Bassani (the Company’s Chief Operating Officer)(and a family Trust) and Ed Schafer (Director), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the Notes were renamed Adjusted September 2015 Convertible Notes. The Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.115 per share. As of December 31, 2023 the Adjusted September 2015 Convertible Notes balances, including accrued interest, owed Bassani Family Trusts and Schafer were $25,143 and $4,163, respectively. The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties. See above.

 

Convertible Bridge Loan/Default

 

On September 28, 2023 the Company entered into an agreement for a $1,500,000 Bridge Loan and executed documents including a convertible promissory note (“Note”) and a binding subscription agreement (“Subscription”) (collectively the Note and the Subscription are the “Bridge Loan Agreements”) with SEB LLC, a non-affiliated party (“Lender”). The Bridge Loan Agreements require the Lender to loan the Company $1,500,000 in six monthly tranches of $250,000 commencing October 2023. All sums advanced under the Bridge Loan Agreements (and accrued interest thereon) would due and payable (with interest accrued at 9% per annum) on October 1, 2024 if not previously converted into securities of the Company. The Note is convertible at $1.00 per unit, at the sole election of the Lender, into units consisting of one share of the Company’s Common Stock and a warrant to purchase one-half share. The initial $250,000 tranche was received by the Company on October 5, 2023. However, no further funds were received by the Company from the Lender. During early November 2023 the Lender informed the Company verbally that it did not intend to fulfill its obligations pursuant to the Bridge Loan Agreements and since such time the Lender has been in default (“Default”). The Default (which is continuing) has created substantial problems for and materially damaged the Company and rendered the Company unable to meet its current creditor obligations on a timely basis. The Company is currently evaluating its rights regarding the Default by the Lender. See Note 10.

  

The Company recorded interest expense of $5,407 and nil for the six months ended December 31, 2023 and 2022, respectively.

 

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS’ EQUITY:
6 Months Ended
Dec. 31, 2023
Equity [Abstract]  
STOCKHOLDERS’ EQUITY:

7.       STOCKHOLDERS’ EQUITY:

 

Debt Modification to Additional paid in capital

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes --- see below) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $3.47 million, in aggregatewhile equitably maintaining existing conversion rights. Because the modifications where with affiliates that are related parties, the debt modification was treated as an equity transaction. The Company recorded a deemed dividend for the reductions.

 

Mark A. Smith (the Company’s President)(“Smith”), Dominic Bassani (then the Company’s Chief Operating Officer)(“Bassani”) (NOTE: Dominic Bassani passed away on October 11, 2023.) and Ed Schafer (Director)(“Schafer”), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations and the adjusted portion of the September 2015 Convertible Notes were renamed Adjusted September 2015 Convertible Notes. The Adjusted 2020 Convertible Obligations of Smith, Bassani and Schafer are convertible into Units at prices of $.0946, $.0953, and $.0953, respectively, and the Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.115 per share. The adjusted conversion prices slightly reduce the securities to be issued on conversion of each instrument from the amount receivable under the unadjusted instruments. The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). After the adjustment, the Company owed Smith, Bassani (and trust) and Schafer $262,154, $434,016 and $96,364, respectively, of Adjusted 2020 Convertible Obligations and Bassani and Schafer, respectively, $24,230 and $4,012 of Adjusted September 2015 Convertible Notes. The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties.

 

The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). The Company treated this as an equity transaction and recorded the reduction of debt through additional paid in capital at the net present value of the modified debt agreements. This resulted in an increase to Additional Paid in Capital of $3,522,000 at the modification date and a reduction of additional paid in capital of $14,051 for the year ended June 30, 2023 and $16,861 for the six months ended December 31, 2023 for the adjustment to the net present value of the modified debt agreements.

 

Series B Preferred stock:

 

Since July 1, 2014, the Company had 200 shares of Series B redeemable convertible Preferred stock outstanding with a par value of $0.01 per share, convertible at the option of the holder at $2.00 per share, with dividends accrued and payable at 2.5% per quarter. The Series B Preferred stock is mandatorily redeemable at $100 per share by the Company three years after issuance and accordingly was classified as a liability. The 200 shares had reached their redemption date and the Company approved the redemption of the Series B preferred stock during the year ended June 30, 2022. The 200 shares of Series B redeemable convertible Preferred stock were redeemed for $41,000, which included the $21,000 in accrued dividend payable.

 

During the years ended June 30, 2023, and 2022, the Company declared dividends of nil and $1,000 respectively. The dividends are classified as a component of operations as the Series B Preferred stock is presented as a liability in these financial statements. There is no liability at December 31, 2023.

 

Common stock:

 

Holders of common stock are entitled to one vote per share on all matters to be voted on by common stockholders. In the event of liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to share in all assets remaining after liabilities have been paid in full or set aside and the rights of any outstanding preferred stock have been satisfied. Common stock has no preemptive, redemption or conversion rights. The rights of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of any outstanding series of preferred stock or any series of preferred stock the Company may designate in the future.

 

Centerpoint holds 704,309 shares of the Company’s common stock. These shares of the Company’s common stock held by Centerpoint are for the benefit of its shareholders without any beneficial interest.

 

During the six months ended December 31, 2023, the Company entered into subscription agreements to sell 28,589 units at a price of $1.60, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $2.40 per share with an expiry date of June 30, 2024, and pursuant thereto, the Company issued 28,589 units for total proceeds of $45,742. See ‘Warrants’ below.

 

During the six months ended December 31, 2023, the Company entered into subscription agreements to sell 75,000 units at a price of $1.00, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $1.25 per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued 75,000 units for total proceeds of $75,000. See ‘Warrants’ below.

 

During the six months ended December 31, 2023, the Company entered into subscription agreements to sell 300,000 units at a price of $1.00, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $1.25 per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued 300,000 units for total proceeds of $300,000. See ‘Warrants’ below.

 

During the six months ended December 31, 2023, 38,000 warrants were exercised to purchase 38,000 shares of the Company’s common stock at $0.75 per share for total proceeds of $28,500.

 

During the six months ended December 31,2023, Smith elected to converted $91,548 of principal from his Adjusted 2020 Convertible note into 967,738 Units; each unit consisting of one share and one warrant with the exercise price of $.75 until July 21, 2026. Each of these warrants carry an exercise bonus of 75%.

 

During the six months ended December 31, 2023, the Company issued 7,500 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.20 per share for a total value of $9,000.

 

During the six months ended December 31, 2023, the Company issued 10,753 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.55 per share for a total value of $16,667.

 

During the six months ended December 31, 2023, the Company issued 2,000 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.16 per share for a total value of $2,320.

 

During the six months ended December 31, 2023, the Company issued 15,000 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.00 per share for a total value of $15,000.

 

During the six months ended December 31, 2023, the Company issued 21,506 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.55 per share for a total value of $33,334.

 

During the six months ended December 31, 2023, the Company issued 265,639 shares of the Company’s common stock upon cashless exercise of ____ outstanding warrants held by non-affiliates of the Company.

 

Warrants:

 

As of December 31, 2023, the Company had approximately 24 million warrants outstanding, with exercise prices from $0.60 to $2.40 and expiring on various dates through November 9, 2026.

 

The weighted-average exercise price for the outstanding warrants is $0.64, and the weighted-average remaining contractual life as of December 31, 2023 is 1 years.

 

During the six months ended December 31, 2023, Smith elected to converted $91,548 of principal from his Adjusted 2020 Convertible note into 967,738 Units; each unit consisting of one share and one warrant with the exercise price of $.75 until July 21, 2026. Each of these warrants carry an exercise bonus of 75%.

 

During the six months ended December 31, 2023, the Company entered into subscription agreements to sell 28,589 units at a price of $1.60, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $2.40 per share with an expiry date of June 30, 2024, and pursuant thereto, the Company issued 28,589 units for total proceeds of $45,742. On September 26, the Company’s Board of Directors, due to a misunderstanding related to a private placement (memorandum of March 2023) and the securities sold thereunder, adjusted the units sold in the offering by substituting 1,003,590 warrants with an exercise price of $1.25 per share for 501,795 previously issued warrants effective October 1, 2023.

 

During the six months ended December 31, 2023, the Company approved the modification of existing warrants held by brokers, which extended certain expiration dates. The modifications resulted in interest  expenses of $135,207 and non-cash compensation of $15,000.

During the six months ended December 31, 2023, 38,000 warrants were exercised to purchase 38,000 shares of the Company’s common stock at $0.75 per share for total proceeds of $28,500.

During the six months ended December 31, 2023, the Company issued 50,000 warrants to a consultant for services. The warrants were issued for a total value of $5,000.

 

During the six months ended December 31, 2023, the Company issued 265,639 shares of the Company’s common stock upon cashless exercise of outstanding warrants held by non-affiliates of the Company.

 

Effective May 1, 2022, an entity affiliated with William O’Neill (“O’Neill”) was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise price adjustment provision if the terms set forth therein are met. 700,000 of the warrants are vesting through May 1, 2023  and 2024. The vesting resulted in non-cash compensation of $6,563 for the six months ended December 31, 2023.

 

Stock options:

 

On April 7, 2022 the Company’s shareholders approved the Bion Environmental Technologies, Inc. 2021 Equity Incentive Award Plan (the “Equity Plan”). The Equity Plan provides for the issuance of options (and/or other securities) to purchase up to 30,000,000 shares of the Company’s common stock. The Equity Plan was adopted and ratified by Board of Directors on April 8, 2022. Terms of exercise and expiration of options/securities granted under the Equity Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. No grants have been made pursuant to the Equity Plan as of the date of this report.

 

The Company’s 2006 Consolidated Incentive Plan, as amended during the year ended June 30, 2021 (the “2006 Plan”), provides for the issuance of options (and/or other securities) to purchase up to 36,000,000 shares of the Company’s common stock. Terms of exercise and expiration of options/securities granted under the 2006 Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. The 2006 Plan will be maintained to service grants already made thereunder (together with new grants, if any, to employees and consultants who already has received grants pursuant to its terms).

 

On March 15, 2023, the Company granted 30,000 options under the 2006 Plan to two consultants. The options vested equally in thirds on March 20, 2023, June 20, 2023 and September 30, 2023.

 

On May 9, 2023, the Company granted 500,000 options under the 2006 Plan to Bill O’Neill. 250,000 of these options vest on June 1, 2024 and 250,000 options vest on June 1, 2025; all options expire on June 30, 2026.

 

The Company recorded compensation expense related to employee stock options of $107,487 and nil for the six months ended December 31, 2023 and 2022, respectively. The Company granted nil and nil options for the six months ended December 31, 2023 and 2022, respectively.

  

A summary of option activity under the 2006 Plan for six months ended December 31, 2023 is as follows:

                 
    Options   Weighted-
Average
Exercise
Price
   Weighted-
Average
Remaining
Contractual
Life
   Aggregate
Intrinsic
Value
 
 Outstanding at July 1, 2023    12,006,600   $0.85    1.83   $5,085,659 
   Granted                       
   Exercised                       
   Forfeited                       
   Expired                       
 Outstanding at December 31, 2023    12,006,600   $0.85    1.32   $1,778,547 

 

The total fair value of stock options that vested during the six months ended December 31, 2023 and 2022 was nil and nil, respectively. As of December 31, 2023, the Company had no unrecognized compensation cost related to stock options.

 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUBSCRIPTION RECEIVABLE - AFFILIATES:
6 Months Ended
Dec. 31, 2023
Subscription Receivable - Affiliates  
SUBSCRIPTION RECEIVABLE - AFFILIATES:

8.       SUBSCRIPTION RECEIVABLE - AFFILIATES:

 

As of December 31, 2023, the Company has three interest bearing, secured promissory notes with an aggregate principal amount of $428,250 ($526,142, including interest) from Bassani which were received as consideration for purchases of warrants to purchase 5,565,000 shares, in aggregate, of the Company’s restricted common stock, which warrants have an exercise price of $0.75 (with a 75% exercise price adjustment provision) and have expiry dates ranging from December 31, 2024 to December 31, 2025 (subject to extension rights) secured by portions of Bassani Family Trust’s 2020 Convertible Obligation and Bassani Family Trust’s September 2015 Convertible Notes. The secured promissory notes are payable July 1, 2024.

 

 As of December 31, 2023, the Company has an interest bearing, secured promissory note for $30,000 ($36,487 including interest) from Smith as consideration to purchase warrants to purchase 300,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 (with a 75% exercise price adjustment provision) and have expiry dates of December 31, 2024 (subject to extension rights) The promissory note bears interest at 4% per annum, and is secured by $30,000 original principal ($37,157 including interest) of Smith’s 2020 Convertible Obligations. The secured promissory note is payable on July 1, 2024.

 

As of December 31, 2023, the Company has two interest bearing, secured promissory notes with an aggregate principal amount of $46,400 ($57,790 including interest) from two employee/consultants as consideration to acquire warrants to purchase 928,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.75 (with a 90% exercise price adjustment provision) and have expiry dates of December 31, 2024. (The promissory notes bear interest at 4% per annum, are secured by a perfected security interest in the warrants, and are payable on July 1, 2024.

 

These secured promissory notes are recorded as “Subscription receivable—affiliates” on the Company’s balance sheet pending payment.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENCIES:
6 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES:

9.       COMMITMENTS AND CONTINGENCIES:

 

A: Employment and consulting agreements:

 

Smith has held the positions of Director, Executive Chairman, President and General Counsel of Company and its subsidiaries under various agreements (and extensions) and terms since March 2003. On October 10, 2016, the Company approved a month-to-month contract extension with Smith which included provisions for i) a monthly salary of $18,000 ( deferred until the Board of Directors re-instated cash payments to all employees and consultants who are deferring compensation), ii) the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, until December 31, 2024, and iii) the right to convert his deferred compensation in whole or in part, at his sole election, at any time in any amount at “market” or into securities sold in the Company’s current/most recent private offering at the price of such offering to third parties. Smith agreed effective July 29, 2018 to continue to serve the Company under the same basic terms on a month-to-month basis. On May 1, 2022 Smith’s compensation was increased to $25,000 per month of which $5,000 per month is deferred. Currently Smith is deferring all of his monthly compensation to help the Company conserve cash. For the three months ended December 31, 2023 and 2022, Smith was paid $5,000 and $60,000, respectively, of cash compensation. For the six months ended December 31, 2023 and 2022, Smith was paid $20,000 and $100,000, respectively, of cash compensation.

 

Since March 31, 2005, the Company has had various agreements with Dominic Bassani (and/or Brightcap which provided his services during some of the years) (NOTE: Dominic Bassani passed away on October 11, 2023.) who was serving as the Company’s Chief Operating Officer (‘COO’) at the time of his passing and formerly served as the Company’s Chief Executive Officer (‘CEO’) for the prior decade (any reference to Brightcap or Bassani for all purposes are referring to the same individual). The Board appointed Bassani as the Company's CEO effective May 13, 2011. On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017 (with the Company having an option to extend the term an additional six months.) Pursuant to the Extension Agreement, Bassani continued to defer his cash compensation ($31,000 per month) until the Board of Directors re-instated cash payments to all employees and consultants who were deferring their compensation. During October 2016 Bassani was granted the right to convert up to $125,000 of his deferred compensation, at his sole election, at $0.75 per share, until March 15, 2018 (which was expanded on April 27, 2017 to the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, until June 30, 2024 (including extensions). During February 2018, the Company agreed to the material terms for a binding two-year extension agreement for Bassani’s services as CEO. Bassani’s salary remained $31,000 per month, which will continue to be accrued in part during periods when the Board determines there is not adequate cash available. Additionally, the Company agreed to pay or accrue $2,000 per month to be applied to life insurance premiums (which sums have been accrued as liabilities). On August 1, 2018, in the context of extending his agreement to provide services to the Company on a full-time basis through December 31, 2022) plus 2 years after that on a part-time basis, the Company received an interest bearing secured promissory note for $300,000 from Bassani as consideration to purchase warrants to purchase 3,000,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of June 30, 2025. The promissory note is secured by a portion of Bassani’s 2020 Convertible Obligations and as of June 30, 2023, the principal and accrued interest was $364,490. For the three months ended December 31, 2023 and 2022, Brightcap was paid $5,000 and $75,500, respectively, of cash compensation.

 

William O’Neill (“O’Neill”) was hired as the Company’s Chief Executive Officer (“CEO”) effective May 1, 2022.  O’Neill had previously been working with the Company as a consultant and had been employed by the Company as its CEO during 2010-2011. (Upon the hiring of O’Neill, Bassani, CEO of the Company since 2011, assumed the position of COO while retaining existing operational management responsibilities and working with O’Neill on ‘commercialization’ of the Company’s technology and work related to JVs (and other transactions) based on the Company’s Gen3 Technology and related matters until his recent death. Bassani’s compensation arrangements with the Company were not altered in the context of the change of positions.) The Company and O’Neill entered into a thirty-seven (37) month employment agreement with compensation of $25,000 cash and $10,000 deferred compensation per month. The cash payment is paid $12,500 to O’Neill and $12,500 to an entity affiliated with O’Neill. An entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share (a 75% exercise price adjustment provision if the terms set forth therein are met) until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. Currently O’Neill is deferring all of his monthly compensation to help the Company conserve cash. For the three months ended December 31, 2023 and 2022, O’Neill and the entity affiliated with O’Neill were paid $42,500 and $75,000, respectively, of cash compensation.

 

B: Exercise Price Adjustments/Extension Rights:

 

As part of agreements the Company entered into with Bassani and Smith effective May 15, 2013, they were each granted the following: a) a 50% execution/exercise price adjustment provision (exercise bonus in the context of options) which shall be applied upon the effective date of the notice of intent to exercise (for options and warrants) or issuance event, as applicable, of any currently outstanding and/or subsequently acquired options, warrants and/or contingent stock bonuses owned by each (and/or their donees) as follows: i) in the case of exercise by payment of cash, the bonus shall take the form of reduction of the exercise price; ii) in the case of cashless exercise, the adjustment shall be applied to reduce the exercise price prior to the cashless exercise calculations; and iii) with regard to contingent stock adjustments, issuance shall be triggered upon the Company’s common stock reaching a closing price equal to 50% of currently specified price; and b) the right to extend the exercise period of all or part of the applicable options and warrants for up to five years (one year at a time) by annual payments of $.05 per option or warrant to the Company on or before a date during the three months prior to expiration of the exercise period at least three business days before the end of the expiration period. Effective January 1, 2016 such annual payments to extend warrant exercise periods were reduced to $.01 per option or warrant. These exercise adjustments were subsequently increased to 75%.

 

During the year ended June 30, 2021, the Company added a 75% exercise price adjustment to the terms of 3,000,000 warrants held by a trust owned by Bassani.

 

As of December 31, 2023, exercise price adjustment provisions ranging from 50-90% were applicable to 11,771,600 of the Company’s outstanding options and 20,415,408 of the Company’s outstanding warrants.

 

Effective May 1, 2022, an entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants were cancellable if O’Neill was not renewed at 13 months (renewal has happened) and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise price adjustments if the terms set forth therein are met.

 

C: Initial Project:

 

On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $2,665,500 (and made the initial 25% payment ($666,375) for the core of the ‘Bion System’ portion (without the crystallization modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. The Company received progress billing in March 2022 and June 2022 for the second and third 25% installments, both of which have been paid as of the filing date. On January 17, 2023 the Company received an invoice from Buflovak for $533,100 which was paid on March 1, 2023 and on April 24, 2023 the Company received an invoice from Buflovak for $83,275 which was paid on May 2, 2023 bringing the aggregate payments to $2,615,500 as of the date of this filing. There remains $50,000 open on the Purchase Order has been billed on July 26, 2023. In addition to the Purchase Order, through December 31, 2023 the Company has incurred additional costs of 6,442,812 on the Initial Project for capitalized interest and costs, non-cash compensation, equipment and consulting fees. $6,983,954 has been paid and $1,750,170 has been billed and not yet paid.

 

Buflovak has worked with the Company on design and testing of its 3G Tech over several years. The basic design for the Initial Project’s Bion System is complete, fabrication and delivery of equipment from Buflovak from the Purchase Order Agreement has been largely completed and assembly/construction is in process.  3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, utilities, etc.) for work related to the Initial Project. The Company has incurred costs of $8,177,452 on the Initial Project, not including capitalized labor and interest.

 

The Initial Project was deemed to have been ‘placed in service’ on January 1, 2024 (Note 10).

 

D: Lease:

 

The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.

 

The future minimum lease payment under noncancelable operating lease with terms greater than one year as of December 31, 2023:

    
From January 2024 to December 2024  75,000 
Undiscounted cash flow  75,000 
Less imputed interest  (3,909)
Total  71,091 

  

The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of December 31, 2023 were 1 years and 10%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.

  

E: Litigation (and related matters):

 

1)  Website: Domain Sale/Resolved Litigation/Hacking/Theft

 

On March 23, 2022 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name <biontech.com> no longer represented a core asset of the Company.

 

As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the <biontech.com> domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.

 

On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name <biontech.com> ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name <biontech.com> to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).

 

No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations were subjected to disruption and expenses were incurred related to the matter including legal fees.

 

The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.

 

2)  Pennvest Loan and Dissolution of Bion PA1, LLC (“PA1”)

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s consolidated balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

 PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest set forth above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception, and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

3)  Bank Account Hacking

 

On June 23, 2023, an officer of the Company with personal accounts with Signature Bank was hacked and $75,000 was transferred from the Company’s accounts at Signature Bank to the officer’s personal accounts. The bank was notified and all Company accounts were placed on hold. Subsequently, the funds were released and transferred back to the Company prior to June 30, 2023, the end of the fiscal year, and there were no losses incurred.  The Company has reviewed the authorized individuals on all accounts and further limited access after the hacking incident.  

 

The Company currently is not involved in any other material litigation or similar events.

 

4)  Bridge Loan/Default

 

On September 29, 2023 the Company entered into an agreement for a $1,500,000 Bridge Loan and executed documents including a convertible promissory note (“Note”) and a binding subscription agreement (“Subscription”) (collectively the Note and the Subscription are the “Bridge Loan Agreements”) with SEB LLC, a non-affiliated party (“Lender”). The Bridge Loan Agreements require the Lender to loan the Company $1,500,000 in six monthly tranches of $250,000 commencing October 2023. All sums advanced under the Bridge Loan Agreements (and accrued interest thereon) would due and payable (with interest accrued at 8% per annum) on October 1, 2024 if not previously converted into securities of the Company. The Note is convertible at $1.00 per unit, at the sole election of the Lender, into units consisting of one share of the Company’s Common Stock and a warrant to purchase one-half share. The initial $250,000 tranche was received by the Company on October 5, 2023. However, no further funds were received by the Company from the Lender. During early November 2023 the Lender informed the Company verbally that it did not intend to fulfill its obligations pursuant to the Bridge Loan Agreements and since such time the lender has been in default (“Default”). The Default (which is continuing) has created substantial problems for and materially damaged the Company and rendered the Company unable to meet its current creditor obligations on a timely basis. The Company is currently evaluating its rights regarding the Default by the Lender.

 

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUBSEQUENT EVENTS:
6 Months Ended
Dec. 31, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS:

10.       SUBSEQUENT EVENTS:

 

The Company is in discussion/negotiation with its largest creditor--the primary contractor on the Initial Project-- and anticipates reaching agreement regarding payment of its accrued obligations during the current quarter. The Company is also involved in discussions and negotiations with other creditors.   

On January 1, 2024 the Initial Project was ‘placed into service’ with a total capitalized cost of $9,108,312. During the current quarter the Company will commence depreciation of this asset.

 

On January 1, 2024, Smith elected to convert the $49,403 remaining balance of his Adjusted 2020 Convertible note into 522,231 units (each unit consisting of one share and one warrant with the exercise price of $.75 until July 21, 2026). Smith made gifts/donations of 122,231 units and 200,000 to his spouse. 

On January 18, 2024, the Company entered into a subscription agreement to sell 10,000 units at a price of $1.00, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $1.25 per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued 10,000 units for total proceeds of $10,000.

 

From January 1, 2024 to February 13, 2024, the Company issued 3,307,516 shares of the Company’s common stock upon cashless exercise of outstanding warrants held by non-affiliates of the Company.

 

From January 1, 2024 to February 13, 2024, the Company issued 2,439,428 shares of the Company’s common stock upon cashless exercise of outstanding warrants held by Mark Smith (which includes 700,062 by his wife.)

 

 

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Principles of consolidation:

Principles of consolidation:

 

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.

 

The accompanying condensed consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at December 31, 2023, the results of operations and cash flows of the Company for the three and six months ended December 31, 2023 and 2022. Operating results for the three and six months ended December 31, 2023 are not necessarily indicative of the results that may be expected for the year ending June 30, 2024.

 

Cash and cash equivalents:

Cash and cash equivalents:

 

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of December 31, 2023 and June 30, 2023 there are no cash equivalents.

 

Property and equipment:

Property and equipment:

 

Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects such as consulting fees, internal salaries and benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.

 

Patents:

Patents:

 

The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s condensed consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.

 

Stock-based compensation:

Stock-based compensation:

 

The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.

 

Derivative Financial Instruments:

Derivative Financial Instruments:

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

 

Options:

Options:

 

The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

 

Warrants:

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

Concentrations of credit risk:

Concentrations of credit risk:

 

The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.

 

Noncontrolling interests:

Noncontrolling interests:

 

In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the condensed consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the condensed consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.

 

Fair value measurements:

Fair value measurements:

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.

 

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

 

Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

 

Level 3 – assets and liabilities whose significant value drivers are unobservable.

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.

 

Lease Accounting:

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the condensed consolidated statements of operations over the lease term.

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

 

Revenue Recognition:

Revenue Recognition:

 

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.

 

Income (Loss) per share:

Income (Loss) per share:

 

Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise, or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the three and six months ended December 31, 2023 and 2022, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.

 

The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:

        
   December 31,
2023
   December 31,
2022
 
Warrants   23,905,539    20,660,031 
Options   12,006,600    11,201,600 
Convertible debt   9,754,772    11,010,012 

 

The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the three and six months ended December 31, 2023 and 2022.

                
  

Three months

ended

December 31,

2023

  

Three months

ended

December 31,

2022

  

Six months

ended

December 31,

2023

  

Six months

ended

December 31,

2022

 
Shares issued – beginning of period   49,485,556    44,303,654    48,880,237    43,758,820 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)   (704,309)   (704,309)
Shares outstanding – beginning of period   48,781,247    43,599,345    48,175,928    43,054,511 
Weighted average shares issued
    during the period
   98,186    20,706    572,626    479,278 
Diluted weighted average shares –
    end of period
   48,879,433    43,620,051    48,748,554    43,533,789 

 

 

Use of estimates:

Use of estimates:

 

In preparing the Company’s condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements:

Recent Accounting Pronouncements:

 

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its condensed consolidated financial statements and assures that there are proper controls in place to ascertain that the Company’s condensed consolidated financial statements properly reflect the change.

 

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACCOUNTING POLICIES (Tables)
6 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Schedule of warrants and option and convertible securities
        
   December 31,
2023
   December 31,
2022
 
Warrants   23,905,539    20,660,031 
Options   12,006,600    11,201,600 
Convertible debt   9,754,772    11,010,012 
Schedule of basic and diluted income (loss) per share
                
  

Three months

ended

December 31,

2023

  

Three months

ended

December 31,

2022

  

Six months

ended

December 31,

2023

  

Six months

ended

December 31,

2022

 
Shares issued – beginning of period   49,485,556    44,303,654    48,880,237    43,758,820 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)   (704,309)   (704,309)
Shares outstanding – beginning of period   48,781,247    43,599,345    48,175,928    43,054,511 
Weighted average shares issued
    during the period
   98,186    20,706    572,626    479,278 
Diluted weighted average shares –
    end of period
   48,879,433    43,620,051    48,748,554    43,533,789 

 

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY AND EQUIPMENT: (Tables)
6 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Schedule of property and equipment
        
  

December 31,

2023

  

June 30,

2023

 
Computers and office equipment   15,156    15,156 
Initial Project: construction in process   9,108,312    6,847,760 
Property and equipment, gross   9,123,468    6,862,916 
Less accumulated depreciation   (12,828)   (11,907)
 Property and equipment, net  $9,110,640   $6,851,009 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS’ EQUITY: (Tables)
6 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Schedule of option activity
                 
    Options   Weighted-
Average
Exercise
Price
   Weighted-
Average
Remaining
Contractual
Life
   Aggregate
Intrinsic
Value
 
 Outstanding at July 1, 2023    12,006,600   $0.85    1.83   $5,085,659 
   Granted                       
   Exercised                       
   Forfeited                       
   Expired                       
 Outstanding at December 31, 2023    12,006,600   $0.85    1.32   $1,778,547 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENCIES: (Tables)
6 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Schedule of future minimum lease payment
    
From January 2024 to December 2024  75,000 
Undiscounted cash flow  75,000 
Less imputed interest  (3,909)
Total  71,091 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS: (Details Narrative)
1 Months Ended 6 Months Ended 12 Months Ended
Oct. 05, 2023
USD ($)
Jul. 26, 2023
USD ($)
May 02, 2023
USD ($)
Apr. 24, 2023
USD ($)
Jan. 17, 2023
USD ($)
Apr. 30, 2022
USD ($)
Jan. 28, 2022
USD ($)
Nov. 30, 2023
USD ($)
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2023
USD ($)
Decimal
$ / shares
Dec. 31, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2018
USD ($)
Oct. 31, 2023
USD ($)
Sep. 29, 2023
USD ($)
$ / shares
Sep. 28, 2023
USD ($)
$ / shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Current liabilities                     $ 4,199,729 $ 1,600,000 $ 1,616,917          
Increase in current liabilities                     $ 2,600,000              
Convertible price | $ / shares                     $ 0.50              
Initial tranche $ 250,000                                  
Tech wastage | Decimal                     1,500              
Debt instrument paid amount             $ 2,665,500                      
Percentage of initial amount             25.00%   25.00% 25.00%                
Principal, interest       $ 83,275 $ 533,100   $ 666,375                      
Aggregate payment     $ 2,615,500                              
Purchase order   $ 50,000       $ 50,000                        
Additional incurred additional costs                     $ 6,442,812              
Capitalized labour and interest costs paid                     6,983,954              
Capitalized labour and interest costs yet to pay                     1,750,170              
Incurred costs                     $ 8,177,452              
Percentage of sustainable                     29.50%              
Description of kreider 2 poultry project                     Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) (‘Kreider Renewable Energy Facility’ or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). Now that development of the Company’s Gen3Tech is being deployed, the Company has commenced discussions with KF regarding updating and amending the JV agreement and anticipates executing an amended joint venture agreement during 2023. During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA).              
Net loss                     $ 1,464,000 1,649,000 3,189,000 $ 8,291,000        
Working capital deficit                     3,806,000              
Gain in non-cash event                           10,235,000        
Gain on sale of domain                           902,000        
Increased shareholders equity                     3,516,000   3,516,000          
Gross proceeds                     443,000 602,000 $ 4,038,000 $ 1,737,000        
Payments to exercise of warrants                     86,000 19,000            
Gross convertible loan                     250,000            
Total of aggregate amount               $ 1,250,000             $ 2,404,000      
Minimum [Member]                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Capital required for capital adequacy                     20,000,000              
Maximum [Member]                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Capital required for capital adequacy                     $ 80,000,000              
Gen 3 Tech [Member]                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Tech wastage | Decimal                     15,000              
Bridge Loan Agreements [Member]                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Bridge loan                               $ 250,000 $ 1,500,000 $ 1,500,000
Interest accrued percentage                                 8.00% 9.00%
Convertible price | $ / shares                                 $ 1.00 $ 1.00
S E B Farms L L C [Member]                                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                    
Bridge loan                                 $ 1,500,000 $ 1,500,000
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) - shares
6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities 23,905,539 20,660,031
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities 12,006,600 11,201,600
Convertible Debt Securities [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities 9,754,772 11,010,012
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) - shares
3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Accounting Policies [Abstract]        
Shares issued – beginning of period 49,485,556 44,303,654 48,880,237 43,758,820
Shares held by subsidiaries (Note 7) (704,309) (704,309) (704,309) (704,309)
Shares outstanding – beginning of period 48,781,247 43,599,345 48,175,928 43,054,511
Weighted average shares issued     during the period 98,186 20,706 572,626 479,278
Diluted weighted average shares –     end of period 48,879,433 43,620,051 48,748,554 43,533,789
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
Dec. 31, 2023
Jun. 30, 2023
Accounting Policies [Abstract]    
Cash equivalents $ 0 $ 0
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY AND EQUIPMENT - Property and Equipment (Details) - USD ($)
Dec. 31, 2023
Jun. 30, 2023
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 9,123,468 $ 6,862,916
Less accumulated depreciation (12,828) (11,907)
 Property and equipment, net 9,110,640 6,851,009
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 15,156 15,156
Construction in Progress [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 9,108,312 $ 6,847,760
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
PROPERTY AND EQUIPMENT: (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]        
Capitalized interest     $ 238,540 $ 98,104
Non cash compensation     135,648 135,648
Depreciation expense $ 460 $ 394 921 $ 724
Property Plant and Equipment of PA1 [Member]        
Property, Plant and Equipment [Line Items]        
Impairment of long lived assets     $ 0  
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEFERRED COMPENSATION: (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2023
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Deferred compensation liability $ 1,225,226 $ 714,222 $ 1,225,226 $ 714,222 $ 864,781
Interest rate on deferred compensation 4.00%   4.00%    
Deferred compensation consecutive trading days     10 days    
Deferred compensation $ 255,000 80,000 $ 255,000 80,000  
Interest Expense On Deferred Compensation Obligation [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Interest expense 7,201 4,873 13,629 9,424  
Interest expense related party 6,875 4,345 12,511 8,464  
Bassani [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Deferred compensation liability   481,972   481,972  
Smith [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Deferred compensation liability   481,972   481,972  
William O Neill [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Deferred compensation liability 255,000   255,000    
Chief Executive Officer [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Deferred compensation liability $ 652,252   652,252    
Deferred compensation balance     $ 300,000    
Deferred compensation, Price per share $ 0.75   $ 0.75    
Chief Operating Officer [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Deferred compensation liability $ 70,450   $ 70,450    
Consultants [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Deferred compensation liability $ 175,024 $ 79,750 $ 175,024 $ 79,750  
Interest rate on deferred compensation 0.00% 3.00% 0.00% 3.00%  
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
LOANS PAYABLE: (Details Narrative) - USD ($)
1 Months Ended 6 Months Ended 12 Months Ended
Jun. 15, 2022
Jan. 28, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2023
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2023
Dec. 29, 2021
Sep. 30, 2021
Sep. 25, 2014
Short-Term Debt [Line Items]                      
Total assets         $ 9,570,859     $ 7,593,633   $ 297  
Total liabilities         5,939,812     3,361,955 $ 10,234,501 10,154,334  
Accounts payable and accrued liabilities         2,648,005     $ 677,136 10,009,802 9,939,148  
Accounts payable                 212,263 214,235  
Accrued liabilities, current                 $ 12,436 $ 950  
Gain on legal dissolution of subsidiary         10,234,501            
Debt instrument interest rate   25.00% 25.00% 25.00%              
Loans as a liability             $ 9,868,495        
P A 1 [Member]                      
Short-Term Debt [Line Items]                      
Debt instrument debt default amount                     $ 8,137,117
Realized from the asset sale $ 104,725                    
Pennvest Loan [Member]                      
Short-Term Debt [Line Items]                      
Construction loan         10,010,000            
Accrued interest and late charges payable         2,255,802            
Repayments of loans         7,754,000            
Principal payment         5,886,000            
Long term debt maturity year two         846,000            
Long term debt maturity year three         873,000            
Long term debt maturity year four         $ 149,000            
Interest expense, debt           $ 123,444 $ 246,887        
Pennvest Loan [Member] | Years One Through Five [Member]                      
Short-Term Debt [Line Items]                      
Debt instrument interest rate         2.547%            
Pennvest Loan [Member] | Years Six Through Maturity [Member]                      
Short-Term Debt [Line Items]                      
Debt instrument interest rate         3.184%            
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONVERTIBLE NOTES PAYABLE: (Details Narrative) - USD ($)
6 Months Ended
Oct. 05, 2023
Jan. 28, 2022
Dec. 31, 2023
Dec. 31, 2022
Oct. 31, 2023
Sep. 29, 2023
Sep. 28, 2023
Jun. 30, 2023
Feb. 02, 2023
Jan. 01, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible notes payable, noncurrent     $ 1,740,083         $ 1,715,970    
Convertible price     $ 0.50              
Debt conversion value   $ 2,665,500                
Capitalized amount     $ 26,559 $ 66,104            
Convertible note     255,407         $ 3,470,000  
Initial tranche $ 250,000                  
Convertible Bridge Loan Default [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible price             $ 1.00      
Bridge loan         $ 250,000   $ 1,500,000      
Interest accrued percentage             9.00%      
The 2020 Convertible Obligations [Member] | Convertible Debt [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Conversion price per unit                   $ 0.50
Debt instrument interest rate                   4.00%
Debt instrument interest rate quarterly                   4.00%
Interest expense     $ 7,875 82,740            
September 2015 Convertible Notes [Member] | Convertible Debt [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Conversion price per unit     $ 0.60              
Interest expense     $ 10,158 12,731            
Principal [Member] | Convertible Obligations 2020 [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible price     $ 0.0946              
Debt conversion value     $ 91,548              
Debt conversion shares     967,738              
Convertible Bridge Loan Default [Member] | Convertible Debt [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Interest expense     $ 5,407              
Chief Executive Officer [Member] | The 2020 Convertible Obligations [Member] | Convertible Debt [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible notes payable, noncurrent     367,660 2,644,553            
Chief Executive Officer [Member] | The 2020 Convertible Obligations [Member] | Smith [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible notes payable                 262,154  
Chief Executive Officer [Member] | The 2020 Convertible Obligations [Member] | Bassani Family Trusts [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible notes payable                 434,016  
Chief Executive Officer [Member] | The 2020 Convertible Obligations [Member] | Schafer [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible notes payable                 96,364  
Chief Executive Officer [Member] | September 2015 Convertible Notes [Member] | Bassani Family Trusts [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible notes payable     25,143              
Chief Executive Officer [Member] | September 2015 Convertible Notes [Member] | Bassani [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible notes payable     186,725 284,211            
President [Member] | The 2020 Convertible Obligations [Member] | Convertible Debt [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible notes payable, noncurrent     118,732 1,388,421            
Executive Vice Chairman [Member] | The 2020 Convertible Obligations [Member] | Convertible Debt [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible notes payable, noncurrent       508,352            
Executive Vice Chairman [Member] | September 2015 Convertible Notes [Member] | Shareholder [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible notes payable     468,431 453,314            
Consultants [Member] | September 2015 Convertible Notes [Member] | Schafer [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible notes payable     4,163 $ 21,173            
S E B Farms L L C [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Bridge loan           $ 1,500,000 $ 1,500,000      
Mark A Smith [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Principal amount     $ 1,109,649              
Conversion price per unit     $ 0.0946              
Dominic Bassani [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Principal amount     $ 1,939,670              
Conversion price per unit     $ 0.0953              
Ed Schafer [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Principal amount     $ 424,873              
Conversion price per unit     $ 0.0953              
Ed Schafer [Member] | Chief Executive Officer [Member] | September 2015 Convertible Notes [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible notes payable                 4,012  
Bassani [Member] | The 2020 Convertible Obligations [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible notes payable, noncurrent     $ 450,361         441,446    
Bassani [Member] | September 2015 Convertible Notes [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible notes payable, noncurrent     25,143         24,645    
Bassani [Member] | Chief Executive Officer [Member] | September 2015 Convertible Notes [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible notes payable                 $ 24,230  
Smith [Member] | The 2020 Convertible Obligations [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible notes payable, noncurrent     44,017         130,180    
Edward Schafer [Member] | The 2020 Convertible Obligations [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible notes payable, noncurrent     99,993         98,014    
Edward Schafer [Member] | September 2015 Convertible Notes [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Convertible notes payable, noncurrent     $ 4,163         $ 4,081    
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS' EQUITY (Details) - USD ($)
6 Months Ended 12 Months Ended
Dec. 31, 2023
Jun. 30, 2022
Equity [Abstract]    
Options outstanding, beginning 12,006,600  
Options outstanding, beginning weighted-average exercise price $ 0.85  
Outstanding, weighted-average remaining contractual life (Year) 1 year 3 months 25 days 1 year 9 months 29 days
Outstanding, aggregate intrinsic value beginning $ 5,085,659  
Granted, options  
Granted, weighted-average exercise price  
Exercised, options  
Exercised, weighted-average exercise price  
Forfeited, options  
Forfeited, weighted-average exercise price  
Expired, options  
Expired, weighted-average exercise price  
Options outstanding, ending 12,006,600  
Options outstanding, ending weighted-average exercise price $ 0.85  
Outstanding, aggregate intrinsic value ending $ 1,778,547  
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS’ EQUITY: (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Sep. 26, 2023
May 09, 2023
Mar. 15, 2023
Jan. 28, 2022
Jul. 01, 2014
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Feb. 02, 2023
May 01, 2022
Apr. 07, 2022
Jun. 30, 2021
Jan. 01, 2020
Class of Stock [Line Items]                                
Convertible note           $ 255,407   $ 255,407     $ 3,470,000        
Increase to additional paid in capital                   3,522,000            
Reduction of additional paid in capital                   14,051            
Debt modified               16,861                
Liability           $ 4,199,729 $ 1,600,000 $ 4,199,729 $ 1,600,000 $ 1,616,917            
Shares Held by Subsidiaries           704,309 704,309 704,309 704,309              
Class of warrant or right, exercised               38,000                
Common Stock Shares Issued upon Exercise of Warrants               38,000                
Total proceeds               $ 28,500                
Debt conversion value       $ 2,665,500                        
Exercise bonus           75.00%   75.00%             75.00%  
Shares issued for consultant services, value           $ 48,334   $ 76,320 $ 80,000              
Shares issued for cashless exercise                              
Warrant outstanding           24,000,000   24,000,000                
Weighted average exercise price           $ 0.85   $ 0.85   $ 0.85            
Conversion price per share           0.50   $ 0.50                
Sale of warrants 1,003,590                              
Warrant exercise price per share $ 1.25                              
Number of shares issued 501,795                              
Effective period Oct. 01, 2023                              
Non-cash compensation               $ 129,048 $ 223,021              
Warrant Exercised for Common Stock               $ 28,500                
Number of shares granted                              
Plan 2006 [Member]                                
Class of Stock [Line Items]                                
Number of shares granted   500,000 30,000                          
Maximum [Member]                                
Class of Stock [Line Items]                                
Warrants exercisable per share           $ 2.40   $ 2.40                
Exercise bonus           90.00%   90.00%                
Consultant Service [Member]                                
Class of Stock [Line Items]                                
Shares issued for consultant services               7,500                
Share price           $ 1.20   $ 1.20                
Shares issued for consultant services, value               $ 9,000                
Shares issued for cashless exercise               265,639                
Consultant Service 1 [Member]                                
Class of Stock [Line Items]                                
Shares issued for consultant services               10,753                
Share price           1.55   $ 1.55                
Shares issued for consultant services, value               $ 16,667                
Consultant Service 2 [Member]                                
Class of Stock [Line Items]                                
Shares issued for consultant services               2,000                
Share price           1.16   $ 1.16                
Shares issued for consultant services, value               $ 2,320                
Consultant Service 3 [Member]                                
Class of Stock [Line Items]                                
Shares issued for consultant services               15,000                
Share price           1.00   $ 1.00                
Shares issued for consultant services, value               $ 15,000                
Consultant Service 4 [Member]                                
Class of Stock [Line Items]                                
Shares issued for consultant services               21,506                
Share price           $ 1.55   $ 1.55                
Shares issued for consultant services, value               $ 33,334                
Chief Executive Officer [Member]                                
Class of Stock [Line Items]                                
Warrants exercisable per share                         $ 1.00      
Exercise bonus                         75.00%      
Number of shares issued                         1,000,000      
Non-cash compensation           $ 42,500 $ 75,000                  
Cancellation of warrants                         700,000      
Exercise price                         75.00%      
Common Stock [Member]                                
Class of Stock [Line Items]                                
Warrants exercisable per share           $ 0.75   $ 0.75                
Shares issued for consultant services           36,506   56,759 50,000              
Shares issued for consultant services, value                          
Warrant [Member]                                
Class of Stock [Line Items]                                
Interest expenses               135,207                
Non-cash compensation               $ 15,000                
Warrant [Member] | Consultants [Member]                                
Class of Stock [Line Items]                                
Number of shares issued           700,000   700,000                
Vesting period               May 01, 2023                
Non cash compensation               $ 6,563                
Series B Preferred Stock [Member]                                
Class of Stock [Line Items]                                
Preferred stock, shares outstanding         200                      
Preferred stock, par value         $ 0.01                      
Preferred stock, convertible option per share         $ 2.00                      
Preferred stock dividend rate percentage         2.50%                      
Preferred stock, redemption price per share         $ 100                      
Redemption of convertible preferred stock               41,000                
Dividends payable           $ 21,000   21,000                
Dividends, preferred stock                   $ 1,000 $ 1,000          
Liability           $ 0   $ 0                
Restricted Common Stock [Member]                                
Class of Stock [Line Items]                                
Sale of stock, shares               28,589                
Sale of units           $ 1.60   $ 1.60                
Sell units           2.40   $ 2.40                
Number of shares issued               28,589                
Number of shares issued, value               $ 45,742                
Restricted Common Stock [Member] | Warrant [Member]                                
Class of Stock [Line Items]                                
Sale of stock, shares               28,589                
Sale of units           1.60   $ 1.60                
Sell units           2.40   $ 2.40                
Number of shares issued               28,589                
Number of shares issued, value               $ 45,742                
Restricted Common Stock 1 [Member]                                
Class of Stock [Line Items]                                
Sale of stock, shares               75,000                
Sale of units           1.00   $ 1.00                
Sell units           1.25   $ 1.25                
Number of shares issued               75,000                
Number of shares issued, value               $ 75,000                
Restricted Common Stock 2 [Member]                                
Class of Stock [Line Items]                                
Sale of stock, shares               300,000                
Sale of units           1.00   $ 1.00                
Sell units           1.25   $ 1.25                
Number of shares issued               300,000                
Number of shares issued, value               $ 300,000                
Warrants [Member]                                
Class of Stock [Line Items]                                
Weighted average exercise price           $ 0.64   $ 0.64                
Remaining contractual life               1 year                
Warrant [Member] | Consultant Service 1 [Member]                                
Class of Stock [Line Items]                                
Shares issued for consultant services, value               $ 5,000                
Warrant [Member] | Consultant Service 4 [Member]                                
Class of Stock [Line Items]                                
Shares issued for consultant services               50,000                
Shares issued for cashless exercise               265,639                
Share-Based Payment Arrangement, Option [Member]                                
Class of Stock [Line Items]                                
Stock options, authorized           36,000,000   36,000,000                
Compensation expense               $ 107,487                
Share-Based Payment Arrangement, Option [Member] | Equity Incentive Plan [Member]                                
Class of Stock [Line Items]                                
Stock options, authorized                           30,000,000    
September 2015 Convertible Notes [Member] | Convertible Debt [Member]                                
Class of Stock [Line Items]                                
Conversion price per unit           $ 0.60   $ 0.60                
September 2015 Convertible Notes [Member] | Restricted Common Shares [Member]                                
Class of Stock [Line Items]                                
Conversion price per unit           $ 0.115   $ 0.115                
The 2020 Convertible Obligations [Member] | Convertible Debt [Member]                                
Class of Stock [Line Items]                                
Conversion price per unit                               $ 0.50
The 2020 Convertible Obligations [Member] | Convertible Debt [Member] | Principal [Member]                                
Class of Stock [Line Items]                                
Debt conversion value               $ 91,548                
The 2020 Convertible Obligations [Member] | Common Stock [Member] | Convertible Debt [Member]                                
Class of Stock [Line Items]                                
Debt conversion shares               967,738                
The 2020 Convertible Obligations [Member] | Warrant [Member] | Principal [Member]                                
Class of Stock [Line Items]                                
Debt conversion value               $ 91,548                
The 2020 Convertible Obligations [Member] | Warrant [Member] | Convertible Debt [Member]                                
Class of Stock [Line Items]                                
Debt conversion shares               967,738                
Exercise bonus           75.00%   75.00%                
Conversion price per share           $ 0.75   $ 0.75                
Mark A Smith [Member]                                
Class of Stock [Line Items]                                
Principal amount           $ 1,109,649   $ 1,109,649                
Conversion price per unit           $ 0.0946   $ 0.0946                
Dominic Bassani [Member]                                
Class of Stock [Line Items]                                
Principal amount           $ 1,939,670   $ 1,939,670                
Conversion price per unit           $ 0.0953   $ 0.0953                
Ed Schafer [Member]                                
Class of Stock [Line Items]                                
Principal amount           $ 424,873   $ 424,873                
Conversion price per unit           $ 0.0953   $ 0.0953                
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUBSCRIPTION RECEIVABLE - AFFILIATES: (Details Narrative)
Dec. 31, 2023
USD ($)
$ / shares
shares
President [Member] | Warrants Issued Subscription Receivable [Member]  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Exercise price | $ / shares $ 0.60
Former Employee [Member] | Warrants Issued Subscription Receivable [Member]  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Purchases of warrants | shares 928,000
Exercise price | $ / shares $ 0.75
Secured Promissory Note [Member]  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Purchases of warrants | shares 5,565,000
Exercise price | $ / shares $ 0.75
Secured Promissory Note [Member] | President [Member]  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Aggregate principal amount $ 30,000
Notes receivable interest $ 36,487
Financing receivable interest rate stated percentage 4.00%
Secured Promissory Note [Member] | Smiths [Member]  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Aggregate principal amount $ 30,000
Notes receivable interest 37,157
Secured Promissory Note [Member] | Former Employee [Member]  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Aggregate principal amount 46,400
Notes receivable interest $ 57,790
Financing receivable interest rate stated percentage 4.00%
Bassani [Member] | Secured Promissory Note [Member]  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Aggregate principal amount $ 428,250
Notes receivable interest $ 526,142
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENCIES (Details)
Dec. 31, 2023
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
From January 2024 to December 2024 $ 75,000
Undiscounted cash flow 75,000
Less imputed interest (3,909)
Total $ 71,091
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENCIES: (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Oct. 05, 2023
Jul. 26, 2023
Jun. 23, 2023
May 02, 2023
Apr. 24, 2023
Jan. 17, 2023
May 02, 2022
Apr. 30, 2022
Mar. 23, 2022
Jan. 28, 2022
Aug. 01, 2018
Oct. 10, 2016
Feb. 10, 2015
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2022
Jun. 30, 2021
Oct. 31, 2023
Sep. 29, 2023
Sep. 28, 2023
Sep. 26, 2023
Jun. 30, 2023
Mar. 31, 2023
May 01, 2022
Dec. 29, 2021
Sep. 30, 2021
Feb. 28, 2018
Apr. 27, 2017
Oct. 31, 2016
Sep. 25, 2014
Loss Contingencies [Line Items]                                                                    
Compensation increased             $ 25,000                                                      
Cash compensation paid                                   $ 129,048 $ 223,021                              
Exercise bonus                               75.00%   75.00%     75.00%                          
Warrants held by trust owned                                         3,000,000                          
Warrants and rights outstanding                               20,415,408   20,415,408                                
Number of shares issued                                                 501,795                  
Debt instrument paid amount                   $ 2,665,500                                                
Debt instrument, interest rate                   25.00%       25.00% 25.00%                                      
Principal, interest         $ 83,275 $ 533,100       $ 666,375                                                
Paid invoice amount       $ 83,275                                                            
Aggregate payment       $ 2,615,500                                                            
Purchase order   $ 50,000           $ 50,000                                                    
Capitalized labour and interest costs                                   $ 6,442,812                                
Capitalized labour and interest costs paid                                   6,983,954                                
Capitalized labour and interest costs yet to pay                                   1,750,170                                
Interests costs incurred capitalized                                   8,177,452                                
Sale of domain, description                 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490.                                                  
Accrued interest                                                         $ 2,255,802          
Total assets                               $ 9,570,859   9,570,859               $ 7,593,633       $ 297        
Total liabilities                               5,939,812   5,939,812               3,361,955     10,234,501 10,154,334        
Accounts payable and accrued liabilities                               $ 2,648,005   2,648,005               677,136     10,009,802 9,939,148        
Accounts payable                                                         212,263 214,235        
Accrued liabilities, current                                                         $ 12,436 $ 950        
Gain on legal dissolution of subsidiary                                   $ 10,234,501                                
Loans as a liability                                         $ 9,868,495                          
Bank account hacked amount     $ 75,000                                                              
Convertible price                               $ 0.50   $ 0.50                                
Initial tranche $ 250,000                                                                  
Bridge Loan Agreements [Member]                                                                    
Loss Contingencies [Line Items]                                                                    
Bridge loan                                           $ 250,000 $ 1,500,000 $ 1,500,000                    
Interest accrued percentage                                             8.00% 9.00%                    
Convertible price                                             $ 1.00 $ 1.00                    
P A 1 [Member]                                                                    
Loss Contingencies [Line Items]                                                                    
Principal amount                                                                   $ 8,137,117
Pennvest Loan [Member]                                                                    
Loss Contingencies [Line Items]                                                                    
Line of credit facility, maximum borrowing capacity                               $ 7,754,000   $ 7,754,000                                
Principal payment                               5,886,000   5,886,000                                
Long-Term debt, maturity, year two                               846,000   846,000                                
Long-Term debt, maturity, year three                               873,000   873,000                                
Long-Term debt, maturity, year four                               $ 149,000   $ 149,000                                
Interest expense, debt                                       $ 123,444 $ 246,887                          
Pennvest Loan [Member] | Years One Through Five [Member]                                                                    
Loss Contingencies [Line Items]                                                                    
Debt instrument, interest rate                                   2.547%                                
Pennvest Loan [Member] | Years Six Through Maturity [Member]                                                                    
Loss Contingencies [Line Items]                                                                    
Debt instrument, interest rate                                   3.184%                                
Minimum [Member]                                                                    
Loss Contingencies [Line Items]                                                                    
Exercise bonus                               50.00%   50.00%                                
Maximum [Member]                                                                    
Loss Contingencies [Line Items]                                                                    
Warrants exercisable per share                               $ 2.40   $ 2.40                                
Exercise bonus                               90.00%   90.00%                                
Smith [Member]                                                                    
Loss Contingencies [Line Items]                                                                    
Cash compensation paid                               $ 5,000 $ 60,000 $ 20,000 $ 100,000                              
William O Neill [Member]                                                                    
Loss Contingencies [Line Items]                                                                    
Payment for cash             $ 12,500                                                      
President [Member]                                                                    
Loss Contingencies [Line Items]                                                                    
Monthly officers cash compensation                       $ 18,000                                            
President [Member] | Extension Bonus [Member] | Fy 2016 Extension Agreement [Member]                                                                    
Loss Contingencies [Line Items]                                                                    
Deferred Compensation, Maximum Convertible Amount                                                               $ 300,000 $ 125,000  
Deferred compensation, price per share                                                               $ 0.75 $ 0.75  
President [Member] | Warrants Issused Subscription Receivable [Member]                                                                    
Loss Contingencies [Line Items]                                                                    
Warrants purchase                                                     300,000              
President [Member] | Warrants Issued In Connection With Sale Of Units In Exchange For Salary [Member]                                                                    
Loss Contingencies [Line Items]                                                                    
Warrants exercisable per share                                                     $ 0.75              
Chief Executive Officer [Member]                                                                    
Loss Contingencies [Line Items]                                                                    
Monthly officers cash compensation                         $ 31,000     25,000                                    
Warrants exercisable per share                                                       $ 1.00            
Cash compensation paid                               42,500 75,000                                  
Deferred Compensation, Maximum Convertible Amount                               10,000   $ 10,000                                
Exercise bonus                                                       75.00%            
Number of shares issued                                                       1,000,000            
Cancellation of warrants                                                       700,000            
Chief Executive Officer [Member] | Secured Promissory Note Consideration For Warrants Expiring On December 312025 [Member]                                                                    
Loss Contingencies [Line Items]                                                                    
Principal and accrued interest                                                   $ 364,490                
Repayments of compensation                               $ 5,000 $ 75,500                                  
Chief Executive Officer [Member] | Warrants Expiring On December 312025 [Member]                                                                    
Loss Contingencies [Line Items]                                                                    
Warrants purchase                     3,000,000                                              
Bassani [Member]                                                                    
Loss Contingencies [Line Items]                                                                    
Salaries and wages                                                             $ 31,000      
Additional paid amount                                                             $ 2,000      
Interest bearing secured promissory note                     $ 300,000                                              
S E B Farms L L C [Member]                                                                    
Loss Contingencies [Line Items]                                                                    
Bridge loan                                             $ 1,500,000 $ 1,500,000                    
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUBSEQUENT EVENTS: (Details Narrative) - USD ($)
Jan. 18, 2024
Jan. 02, 2024
Jan. 02, 2024
Jan. 28, 2022
Feb. 13, 2024
Dec. 31, 2023
Subsequent Event [Line Items]            
Capitalized cost   $ 9,108,312        
Debt conversion value       $ 2,665,500    
Number of warrants or rights outstanding           24,000,000
Subsequent Event [Member]            
Subsequent Event [Line Items]            
Debt conversion value     $ 49,403      
Debt conversion shares     522,231      
Exercise price   $ 0.75 $ 0.75      
Sale of units 10,000          
Sale of units, price per unit $ 1.00          
Sale of units, price per share $ 1.25          
Expiry date Dec. 31, 2024          
Proceeds from sale of units $ 10,000          
Number of warrants or rights outstanding         3,307,516  
Subsequent Event [Member] | Smith [Member]            
Subsequent Event [Line Items]            
Number of warrants or rights outstanding         2,439,428  
EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

  •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end XML 50 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 259 288 1 false 77 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://biontech.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://biontech.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://biontech.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical) Sheet http://biontech.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) Sheet http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) Statements 6 false false R7.htm 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 00000008 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS: Sheet http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS: Notes 8 false false R9.htm 00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://biontech.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 00000010 - Disclosure - PROPERTY AND EQUIPMENT: Sheet http://biontech.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT: Notes 10 false false R11.htm 00000011 - Disclosure - DEFERRED COMPENSATION: Sheet http://biontech.com/role/DeferredCompensation DEFERRED COMPENSATION: Notes 11 false false R12.htm 00000012 - Disclosure - LOANS PAYABLE: Sheet http://biontech.com/role/LoansPayable LOANS PAYABLE: Notes 12 false false R13.htm 00000013 - Disclosure - CONVERTIBLE NOTES PAYABLE: Notes http://biontech.com/role/ConvertibleNotesPayable CONVERTIBLE NOTES PAYABLE: Notes 13 false false R14.htm 00000014 - Disclosure - STOCKHOLDERS??? EQUITY: Sheet http://biontech.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY: Notes 14 false false R15.htm 00000015 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES: Sheet http://biontech.com/role/SubscriptionReceivable-Affiliates SUBSCRIPTION RECEIVABLE - AFFILIATES: Notes 15 false false R16.htm 00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES: Sheet http://biontech.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES: Notes 16 false false R17.htm 00000017 - Disclosure - SUBSEQUENT EVENTS: Sheet http://biontech.com/role/SubsequentEvents SUBSEQUENT EVENTS: Notes 17 false false R18.htm 00000018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://biontech.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 18 false false R19.htm 00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://biontech.com/role/SignificantAccountingPoliciesTables SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://biontech.com/role/SignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - PROPERTY AND EQUIPMENT: (Tables) Sheet http://biontech.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT: (Tables) Tables http://biontech.com/role/PropertyAndEquipment 20 false false R21.htm 00000021 - Disclosure - STOCKHOLDERS??? EQUITY: (Tables) Sheet http://biontech.com/role/StockholdersEquityTables STOCKHOLDERS??? EQUITY: (Tables) Tables http://biontech.com/role/StockholdersEquity 21 false false R22.htm 00000022 - Disclosure - COMMITMENTS AND CONTINGENCIES: (Tables) Sheet http://biontech.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES: (Tables) Tables http://biontech.com/role/CommitmentsAndContingencies 22 false false R23.htm 00000023 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS: (Details Narrative) Sheet http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS: (Details Narrative) Details http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans 23 false false R24.htm 00000024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) Sheet http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) Details 24 false false R25.htm 00000025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) Sheet http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) Details 25 false false R26.htm 00000026 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://biontech.com/role/SignificantAccountingPoliciesTables 26 false false R27.htm 00000027 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details) Sheet http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails PROPERTY AND EQUIPMENT - Property and Equipment (Details) Details 27 false false R28.htm 00000028 - Disclosure - PROPERTY AND EQUIPMENT: (Details Narrative) Sheet http://biontech.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT: (Details Narrative) Details http://biontech.com/role/PropertyAndEquipmentTables 28 false false R29.htm 00000029 - Disclosure - DEFERRED COMPENSATION: (Details Narrative) Sheet http://biontech.com/role/DeferredCompensationDetailsNarrative DEFERRED COMPENSATION: (Details Narrative) Details http://biontech.com/role/DeferredCompensation 29 false false R30.htm 00000030 - Disclosure - LOANS PAYABLE: (Details Narrative) Sheet http://biontech.com/role/LoansPayableDetailsNarrative LOANS PAYABLE: (Details Narrative) Details http://biontech.com/role/LoansPayable 30 false false R31.htm 00000031 - Disclosure - CONVERTIBLE NOTES PAYABLE: (Details Narrative) Notes http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative CONVERTIBLE NOTES PAYABLE: (Details Narrative) Details http://biontech.com/role/ConvertibleNotesPayable 31 false false R32.htm 00000032 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://biontech.com/role/StockholdersEquityDetails STOCKHOLDERS' EQUITY (Details) Details 32 false false R33.htm 00000033 - Disclosure - STOCKHOLDERS??? EQUITY: (Details Narrative) Sheet http://biontech.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY: (Details Narrative) Details http://biontech.com/role/StockholdersEquityTables 33 false false R34.htm 00000034 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES: (Details Narrative) Sheet http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative SUBSCRIPTION RECEIVABLE - AFFILIATES: (Details Narrative) Details http://biontech.com/role/SubscriptionReceivable-Affiliates 34 false false R35.htm 00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://biontech.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://biontech.com/role/CommitmentsAndContingenciesTables 35 false false R36.htm 00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES: (Details Narrative) Sheet http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES: (Details Narrative) Details http://biontech.com/role/CommitmentsAndContingenciesTables 36 false false R37.htm 00000037 - Disclosure - SUBSEQUENT EVENTS: (Details Narrative) Sheet http://biontech.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS: (Details Narrative) Details http://biontech.com/role/SubsequentEvents 37 false false All Reports Book All Reports bion_10q.htm bnet-20231231.xsd bnet-20231231_cal.xml bnet-20231231_def.xml bnet-20231231_lab.xml bnet-20231231_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 55 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bion_10q.htm": { "nsprefix": "bnet", "nsuri": "http://biontech.com/20231231", "dts": { "inline": { "local": [ "bion_10q.htm" ] }, "schema": { "local": [ "bnet-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "bnet-20231231_cal.xml" ] }, "definitionLink": { "local": [ "bnet-20231231_def.xml" ] }, "labelLink": { "local": [ "bnet-20231231_lab.xml" ] }, "presentationLink": { "local": [ "bnet-20231231_pre.xml" ] } }, "keyStandard": 206, "keyCustom": 82, "axisStandard": 19, "axisCustom": 0, "memberStandard": 17, "memberCustom": 51, "hidden": { "total": 272, "http://fasb.org/us-gaap/2023": 121, "http://biontech.com/20231231": 146, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 259, "entityCount": 1, "segmentCount": 77, "elementCount": 470, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 658, "http://xbrl.sec.gov/dei/2023": 28 }, "report": { "R1": { "role": "http://biontech.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "longName": "00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "unique": true } }, "R3": { "role": "http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations", "longName": "00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-10-012023-12-31", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-012023-12-31", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://biontech.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical", "longName": "00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "From2023-10-012023-12-31", "name": "us-gaap:EarningsPerShareBasic", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-012023-12-31", "name": "us-gaap:EarningsPerShareBasic", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R6": { "role": "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "longName": "00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows", "longName": "00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "unique": true } }, "R8": { "role": "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans", "longName": "00000008 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS:", "shortName": "ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS:", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://biontech.com/role/SignificantAccountingPolicies", "longName": "00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://biontech.com/role/PropertyAndEquipment", "longName": "00000010 - Disclosure - PROPERTY AND EQUIPMENT:", "shortName": "PROPERTY AND EQUIPMENT:", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://biontech.com/role/DeferredCompensation", "longName": "00000011 - Disclosure - DEFERRED COMPENSATION:", "shortName": "DEFERRED COMPENSATION:", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://biontech.com/role/LoansPayable", "longName": "00000012 - Disclosure - LOANS PAYABLE:", "shortName": "LOANS PAYABLE:", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://biontech.com/role/ConvertibleNotesPayable", "longName": "00000013 - Disclosure - CONVERTIBLE NOTES PAYABLE:", "shortName": "CONVERTIBLE NOTES PAYABLE:", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "bnet:ConvertibleDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "bnet:ConvertibleDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://biontech.com/role/StockholdersEquity", "longName": "00000014 - Disclosure - STOCKHOLDERS\u2019 EQUITY:", "shortName": "STOCKHOLDERS\u2019 EQUITY:", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://biontech.com/role/SubscriptionReceivable-Affiliates", "longName": "00000015 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES:", "shortName": "SUBSCRIPTION RECEIVABLE - AFFILIATES:", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "bnet:SubscriptionReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "bnet:SubscriptionReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://biontech.com/role/CommitmentsAndContingencies", "longName": "00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES:", "shortName": "COMMITMENTS AND CONTINGENCIES:", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://biontech.com/role/SubsequentEvents", "longName": "00000017 - Disclosure - SUBSEQUENT EVENTS:", "shortName": "SUBSEQUENT EVENTS:", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://biontech.com/role/SignificantAccountingPoliciesPolicies", "longName": "00000018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "18", "firstAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://biontech.com/role/SignificantAccountingPoliciesTables", "longName": "00000019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://biontech.com/role/PropertyAndEquipmentTables", "longName": "00000020 - Disclosure - PROPERTY AND EQUIPMENT: (Tables)", "shortName": "PROPERTY AND EQUIPMENT: (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://biontech.com/role/StockholdersEquityTables", "longName": "00000021 - Disclosure - STOCKHOLDERS\u2019 EQUITY: (Tables)", "shortName": "STOCKHOLDERS\u2019 EQUITY: (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://biontech.com/role/CommitmentsAndContingenciesTables", "longName": "00000022 - Disclosure - COMMITMENTS AND CONTINGENCIES: (Tables)", "shortName": "COMMITMENTS AND CONTINGENCIES: (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "bnet:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeaseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "bnet:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeaseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "longName": "00000023 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS: (Details Narrative)", "shortName": "ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS: (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:IncreaseDecreaseInOtherCurrentLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "unique": true } }, "R24": { "role": "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails", "longName": "00000024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "From2023-07-012023-12-31_us-gaap_WarrantMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-12-31_us-gaap_WarrantMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails", "longName": "00000025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "From2023-10-012023-12-31", "name": "bnet:SharesIssuedBeginningOfPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-012023-12-31", "name": "bnet:SharesIssuedBeginningOfPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative", "longName": "00000026 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails", "longName": "00000027 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)", "shortName": "PROPERTY AND EQUIPMENT - Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative", "longName": "00000028 - Disclosure - PROPERTY AND EQUIPMENT: (Details Narrative)", "shortName": "PROPERTY AND EQUIPMENT: (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:InterestCostsCapitalized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:InterestCostsCapitalized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://biontech.com/role/DeferredCompensationDetailsNarrative", "longName": "00000029 - Disclosure - DEFERRED COMPENSATION: (Details Narrative)", "shortName": "DEFERRED COMPENSATION: (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredCompensationLiabilityCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "bnet:DeferredCompensationConsecutiveTradingDays", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "unique": true } }, "R30": { "role": "http://biontech.com/role/LoansPayableDetailsNarrative", "longName": "00000030 - Disclosure - LOANS PAYABLE: (Details Narrative)", "shortName": "LOANS PAYABLE: (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Assets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:GainOrLossOnSaleOfStockInSubsidiary", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "unique": true } }, "R31": { "role": "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "longName": "00000031 - Disclosure - CONVERTIBLE NOTES PAYABLE: (Details Narrative)", "shortName": "CONVERTIBLE NOTES PAYABLE: (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ConvertibleLongTermNotesPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2023-12-31", "name": "us-gaap:CostsIncurredDevelopmentCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "bnet:ConvertibleDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "unique": true } }, "R32": { "role": "http://biontech.com/role/StockholdersEquityDetails", "longName": "00000032 - Disclosure - STOCKHOLDERS' EQUITY (Details)", "shortName": "STOCKHOLDERS' EQUITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://biontech.com/role/StockholdersEquityDetailsNarrative", "longName": "00000033 - Disclosure - STOCKHOLDERS\u2019 EQUITY: (Details Narrative)", "shortName": "STOCKHOLDERS\u2019 EQUITY: (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ConvertibleNotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-07-012023-06-30", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalOther", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "unique": true } }, "R34": { "role": "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative", "longName": "00000034 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES: (Details Narrative)", "shortName": "SUBSCRIPTION RECEIVABLE - AFFILIATES: (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2023-12-31_srt_PresidentMember_custom_WarrantsIssuedSubscriptionReceivableMember", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "bnet:SubscriptionReceivableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_srt_PresidentMember_custom_WarrantsIssuedSubscriptionReceivableMember", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "bnet:SubscriptionReceivableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://biontech.com/role/CommitmentsAndContingenciesDetails", "longName": "00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "bnet:OperatingLeasesFutureMinimumPaymentReceivableInTwoYears", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "bnet:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeaseTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "bnet:OperatingLeasesFutureMinimumPaymentReceivableInTwoYears", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "bnet:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeaseTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES: (Details Narrative)", "shortName": "COMMITMENTS AND CONTINGENCIES: (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "From2022-04-272022-05-02", "name": "bnet:CompensationIncreased", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-04-272022-05-02", "name": "bnet:CompensationIncreased", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://biontech.com/role/SubsequentEventsDetailsNarrative", "longName": "00000037 - Disclosure - SUBSEQUENT EVENTS: (Details Narrative)", "shortName": "SUBSEQUENT EVENTS: (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "From2023-12-292024-01-02", "name": "us-gaap:CapitalizedContractCostAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-12-292024-01-02", "name": "us-gaap:CapitalizedContractCostAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Receivable Type [Axis]", "documentation": "Information by type of receivable." } } }, "auth_ref": [ "r25" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "verboseLabel": "Accounts payable and accrued liabilities", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r17" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r14", "r533" ] }, "us-gaap_AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Salaries and wages", "documentation": "Amount of obligation to underwriters, promoters, and employees excluding salaries, wages and amount to related party, classified as current." } } }, "auth_ref": [ "r14" ] }, "bnet_AccruedInterestAndLateChargesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "AccruedInterestAndLateChargesPayable", "crdr": "credit", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued interest and late charges payable" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued liabilities, current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r19" ] }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued interest", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities." } } }, "auth_ref": [ "r75" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r42", "r145", "r399" ] }, "bnet_AdditionalInterestCostsIncurredCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "AdditionalInterestCostsIncurredCapitalized", "crdr": "debit", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional incurred additional costs" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r86", "r533", "r648" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r333", "r334", "r335", "r421", "r585", "r586", "r587", "r628", "r650" ] }, "bnet_AdjustmentToAdditionalPaidInCapitalModificationOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "AdjustmentToAdditionalPaidInCapitalModificationOfWarrants", "crdr": "credit", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Modification of warrants" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "crdr": "credit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Increase to additional paid in capital", "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "bnet_AggregatePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "AggregatePayment", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate payment" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Non cash compensation", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r329", "r340" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r562" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive securities", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r202" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r34" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r344" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r119", "r146", "r169", "r207", "r213", "r217", "r223", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r346", "r350", "r362", "r392", "r456", "r533", "r547", "r597", "r598", "r633" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r142", "r151", "r169", "r223", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r346", "r350", "r362", "r533", "r597", "r598", "r633" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r562" ] }, "us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesPurchasedOptionsPricePolicy", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Options:", "documentation": "Disclosure of accounting policy for premium paid to acquire option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r69" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r300", "r301", "r302", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r324", "r325", "r326", "r327", "r328" ] }, "bnet_BankAccountHackedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "BankAccountHackedAmount", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Bank account hacked amount" } } }, "auth_ref": [] }, "bnet_BassaniFamilyTrustsMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "BassaniFamilyTrustsMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Bassani Family Trusts [Member]" } } }, "auth_ref": [] }, "bnet_BassaniMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "BassaniMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Bassani [Member]" } } }, "auth_ref": [] }, "bnet_BridgeLoanAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "BridgeLoanAgreementsMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Bridge Loan Agreements [Member]" } } }, "auth_ref": [] }, "bnet_CancellationOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20231231", "localname": "CancellationOfWarrants", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cancellation of warrants" } } }, "auth_ref": [] }, "bnet_CapitalLeaseContingentRentalPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "CapitalLeaseContingentRentalPaymentsDue", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Total" } } }, "auth_ref": [] }, "us-gaap_CapitalRequiredForCapitalAdequacy": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalRequiredForCapitalAdequacy", "crdr": "credit", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Capital required for capital adequacy", "documentation": "Amount of minimum total risk-based capital required for capital adequacy as defined by regulatory framework." } } }, "auth_ref": [ "r390", "r391" ] }, "us-gaap_CapitalizedContractCostAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedContractCostAmortization", "crdr": "debit", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Capitalized cost", "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer." } } }, "auth_ref": [ "r229" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents:", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r31" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash", "periodStartLabel": "Cash at beginning of year", "periodEndLabel": "Cash at end of year", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r30", "r98", "r165" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r98" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash equivalents", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r572", "r646" ] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "auth_ref": [ "r591" ] }, "srt_ChiefOperatingOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefOperatingOfficerMember", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chief Operating Officer [Member]" } } }, "auth_ref": [ "r591", "r631" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r138", "r147", "r148", "r149", "r169", "r191", "r192", "r199", "r201", "r205", "r206", "r223", "r238", "r240", "r241", "r242", "r245", "r246", "r276", "r277", "r280", "r283", "r290", "r362", "r414", "r415", "r416", "r417", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r442", "r465", "r484", "r501", "r502", "r503", "r504", "r505", "r568", "r582", "r589" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r147", "r148", "r149", "r205", "r276", "r277", "r278", "r280", "r283", "r288", "r290", "r414", "r415", "r416", "r417", "r527", "r568", "r582" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r56" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants exercisable per share", "verboseLabel": "Exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r291" ] }, "bnet_ClassOfWarrantOrRightExercisedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20231231", "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of warrant or right, exercised" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Purchases of warrants", "verboseLabel": "Warrants purchase", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r291" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant outstanding", "verboseLabel": "Number of warrants or rights outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r344" ] }, "bnet_CommissionOnSaleOfUnit": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "CommissionOnSaleOfUnit", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Commission on the sale of units", "label": "CommissionOnSaleOfUnit" } } }, "auth_ref": [] }, "bnet_CommissionOnSaleOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "CommissionOnSaleOfUnits", "crdr": "credit", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Commission on sale of units" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://biontech.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES:", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r106", "r230", "r231", "r508", "r594" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r535", "r536", "r537", "r539", "r540", "r541", "r542", "r585", "r586", "r628", "r647", "r650" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r85" ] }, "us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockShareSubscribedButUnissuedSubscriptionsReceivable", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Subscription receivable - affiliates (Note 8)", "label": "Common Stock, Share Subscribed but Unissued, Subscriptions Receivable", "documentation": "Amount of subscription receivable from investors who have been allocated common stock." } } }, "auth_ref": [ "r85", "r450", "r489" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r85", "r442" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r85" ] }, "bnet_CommonStockSharesIssuedUponExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20231231", "localname": "CommonStockSharesIssuedUponExerciseOfWarrants", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock Shares Issued upon Exercise of Warrants" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r85", "r442", "r462", "r650", "r651" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, no par value, 250,000,000 shares authorized, 50,611,962\u00a0\u00a0and 48,044,790 shares issued, respectively; 49,907,653 and 47,340,480 shares outstanding, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r85", "r393", "r533" ] }, "bnet_CompensationIncreased": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "CompensationIncreased", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Compensation increased" } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentrations of credit risk:", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r77", "r129" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Principles of consolidation:", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r62", "r516" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_ConstructionLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionLoan", "crdr": "credit", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Construction loan", "documentation": "This element represents the carrying value of a short-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project, usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property. Note that there are separate concepts for the current and noncurrent portions of long-term construction loans." } } }, "auth_ref": [ "r81" ] }, "bnet_ConsultantService1Member": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "ConsultantService1Member", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consultant Service 1 [Member]" } } }, "auth_ref": [] }, "bnet_ConsultantService2Member": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "ConsultantService2Member", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consultant Service 2 [Member]" } } }, "auth_ref": [] }, "bnet_ConsultantService3Member": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "ConsultantService3Member", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consultant Service 3 [Member]" } } }, "auth_ref": [] }, "bnet_ConsultantService4Member": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "ConsultantService4Member", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consultant Service 4 [Member]" } } }, "auth_ref": [] }, "bnet_ConsultantServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "ConsultantServiceMember", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consultant Service [Member]" } } }, "auth_ref": [] }, "bnet_ConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "ConsultantsMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consultants [Member]" } } }, "auth_ref": [] }, "bnet_ConversionOfDebtAndLiabilitiesIntoCommonUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "ConversionOfDebtAndLiabilitiesIntoCommonUnits", "crdr": "credit", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of debt and liabilities into common units" } } }, "auth_ref": [] }, "bnet_ConversionOfDebtAndLiabilitiesIntoNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "ConversionOfDebtAndLiabilitiesIntoNotesPayable", "crdr": "credit", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of debt and liabilities into notes payable" } } }, "auth_ref": [] }, "bnet_ConversionOfDeferredCompensationToNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "ConversionOfDeferredCompensationToNotesPayable", "crdr": "credit", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of deferred compensation to notes payable" } } }, "auth_ref": [] }, "bnet_ConversionOfNotesPayableIntoShares": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "ConversionOfNotesPayableIntoShares", "crdr": "credit", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of notes payable into shares" } } }, "auth_ref": [] }, "bnet_ConversionPricePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://biontech.com/20231231", "localname": "ConversionPricePerUnit", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion price per unit" } } }, "auth_ref": [] }, "bnet_ConvertibleBridgeLoanDefaultMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "ConvertibleBridgeLoanDefaultMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Bridge Loan Default [Member]" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebt", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Bridge loan", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } }, "auth_ref": [ "r13", "r122", "r645" ] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r108", "r248", "r249", "r259", "r260", "r261", "r265", "r266", "r267", "r268", "r269", "r522", "r523", "r524", "r525", "r526" ] }, "us-gaap_ConvertibleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtSecuritiesMember", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Securities [Member]", "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder." } } }, "auth_ref": [ "r601" ] }, "bnet_ConvertibleDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biontech.com/20231231", "localname": "ConvertibleDebtTextBlock", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable" ], "lang": { "en-us": { "role": { "label": "CONVERTIBLE NOTES PAYABLE:" } } }, "auth_ref": [] }, "us-gaap_ConvertibleLongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleLongTermNotesPayable", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible notes payable - affiliates (Note 6)", "verboseLabel": "Convertible notes payable, noncurrent", "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayable", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible notes payable", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r13", "r122", "r645" ] }, "us-gaap_ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Bridge Note Payable (Note 6)", "verboseLabel": "Convertible note", "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r19" ] }, "bnet_ConvertibleObligations2020Member": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "ConvertibleObligations2020Member", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Obligations 2020 [Member]" } } }, "auth_ref": [] }, "us-gaap_CostsIncurredDevelopmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsIncurredDevelopmentCosts", "crdr": "debit", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Capitalized amount", "documentation": "Development costs incurred, including capitalized costs and costs charged to expense, in oil and gas activities." } } }, "auth_ref": [ "r74" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r170", "r171", "r251", "r278", "r379", "r513", "r515" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument paid amount", "verboseLabel": "Debt conversion value", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r32", "r33" ] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt conversion shares", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": [ "r32", "r33" ] }, "us-gaap_DebtDefaultLongtermDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDefaultLongtermDebtAmount", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument debt default amount", "verboseLabel": "Principal amount", "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured." } } }, "auth_ref": [ "r167" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://biontech.com/role/LoansPayable" ], "lang": { "en-us": { "role": { "label": "LOANS PAYABLE:", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r107", "r167", "r247", "r253", "r254", "r255", "r256", "r257", "r258", "r263", "r270", "r271", "r272" ] }, "us-gaap_DebtInstrumentAnnualPrincipalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAnnualPrincipalPayment", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principal payment", "documentation": "Amount of the total principal payments made during the annual reporting period." } } }, "auth_ref": [ "r13" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r13", "r81", "r82", "r120", "r122", "r173", "r248", "r249", "r250", "r251", "r252", "r254", "r259", "r260", "r261", "r262", "r264", "r265", "r266", "r267", "r268", "r269", "r372", "r522", "r523", "r524", "r525", "r526", "r583" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible price", "verboseLabel": "Conversion price per share", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r109", "r250" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principal amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r71", "r73", "r248", "r372", "r523", "r524" ] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of initial amount", "verboseLabel": "Debt instrument interest rate", "terseLabel": "Debt instrument, interest rate", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": [ "r21", "r71", "r266" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest accrued percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r21", "r71", "r273", "r372" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r21", "r249" ] }, "bnet_DebtInstrumentInterestRateStatedPercentageQuarterly": { "xbrltype": "percentItemType", "nsuri": "http://biontech.com/20231231", "localname": "DebtInstrumentInterestRateStatedPercentageQuarterly", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument interest rate quarterly" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r22", "r173", "r248", "r249", "r250", "r251", "r252", "r254", "r259", "r260", "r261", "r262", "r264", "r265", "r266", "r267", "r268", "r269", "r372", "r522", "r523", "r524", "r525", "r526", "r583" ] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principal, interest", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r22", "r76" ] }, "bnet_DebtModification": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "DebtModification", "crdr": "credit", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Debt Modification" } } }, "auth_ref": [] }, "bnet_DebtModifications": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "DebtModifications", "crdr": "credit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt modified" } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "bnet_DeferredCompensationConsecutiveTradingDays": { "xbrltype": "durationItemType", "nsuri": "http://biontech.com/20231231", "localname": "DeferredCompensationConsecutiveTradingDays", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred compensation consecutive trading days" } } }, "auth_ref": [] }, "bnet_DeferredCompensationConvertibleToCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "DeferredCompensationConvertibleToCommonStock", "crdr": "credit", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred compensation balance" } } }, "auth_ref": [] }, "bnet_DeferredCompensationConvertibleToCommonStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://biontech.com/20231231", "localname": "DeferredCompensationConvertibleToCommonStockPricePerShare", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred compensation, Price per share" } } }, "auth_ref": [] }, "bnet_DeferredCompensationLiabilityAmountCancelled": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "DeferredCompensationLiabilityAmountCancelled", "crdr": "debit", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total of aggregate amount" } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationLiabilityCurrent", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred compensation (Note 4)", "verboseLabel": "Deferred compensation liability", "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date." } } }, "auth_ref": [ "r55", "r114" ] }, "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred compensation", "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date." } } }, "auth_ref": [] }, "bnet_DeferredCompensationMaximumConvertibleAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "DeferredCompensationMaximumConvertibleAmount", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred Compensation, Maximum Convertible Amount" } } }, "auth_ref": [] }, "bnet_DeferredCompensationStockConversionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://biontech.com/20231231", "localname": "DeferredCompensationStockConversionPricePerShare", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred compensation, price per share" } } }, "auth_ref": [] }, "bnet_DeficitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biontech.com/20231231", "localname": "DeficitAbstract", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity (deficit):" } } }, "auth_ref": [] }, "us-gaap_DepositsAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositsAssetsCurrent", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deposits and other assets", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter." } } }, "auth_ref": [ "r575" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations", "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Depreciation", "verboseLabel": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r41" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation expense", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r5", "r41" ] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Derivative Financial Instruments:", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r10", "r65", "r66", "r67", "r68", "r172" ] }, "bnet_DescriptionOfKreider2PoultryProject": { "xbrltype": "stringItemType", "nsuri": "http://biontech.com/20231231", "localname": "DescriptionOfKreider2PoultryProject", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of kreider 2 poultry project" } } }, "auth_ref": [] }, "bnet_DisclosureConvertibleNotesPayableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biontech.com/20231231", "localname": "DisclosureConvertibleNotesPayableAbstract", "lang": { "en-us": { "role": { "label": "Convertible Notes Payable" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://biontech.com/role/DeferredCompensation" ], "lang": { "en-us": { "role": { "label": "DEFERRED COMPENSATION:", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r298", "r299", "r330", "r331", "r332", "r529" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "bnet_DisclosureSubscriptionReceivableAffiliatesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biontech.com/20231231", "localname": "DisclosureSubscriptionReceivableAffiliatesAbstract", "lang": { "en-us": { "role": { "label": "Subscription Receivable - Affiliates" } } }, "auth_ref": [] }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dividends payable", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding." } } }, "auth_ref": [ "r82", "r83", "r121", "r543", "r644" ] }, "us-gaap_DividendsPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPreferredStock", "crdr": "debit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dividends, preferred stock", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r2", "r113" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r561" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r559", "r561", "r562" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r560" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r548" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r561" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r561" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r563" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r551" ] }, "bnet_DominicBassaniMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "DominicBassaniMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dominic Bassani [Member]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" ], "lang": { "en-us": { "role": { "label": "Net income (loss) applicable to Bion's common stockholders per basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r158", "r179", "r180", "r181", "r182", "r183", "r188", "r191", "r199", "r200", "r201", "r203", "r360", "r361", "r387", "r404", "r518" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" ], "lang": { "en-us": { "role": { "label": "Net income (loss) applicable to Bion's common stockholders per diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r158", "r179", "r180", "r181", "r182", "r183", "r191", "r199", "r200", "r201", "r203", "r360", "r361", "r387", "r404", "r518" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income (Loss) per share:", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r34", "r35" ] }, "bnet_EdSchaferMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "EdSchaferMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Ed Schafer [Member]" } } }, "auth_ref": [] }, "bnet_EdwardSchaferMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "EdwardSchaferMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Edward Schafer [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeBenefitsAndShareBasedCompensation", "crdr": "debit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Compensation expense", "documentation": "Amount of expense for employee benefit and equity-based compensation." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r554" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r550" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r550" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r567" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r550" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r564" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r562" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r550" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r550" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r550" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r550" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r565" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r139", "r154", "r155", "r156", "r174", "r175", "r176", "r178", "r184", "r186", "r204", "r224", "r225", "r292", "r333", "r334", "r335", "r342", "r343", "r352", "r353", "r354", "r355", "r356", "r357", "r359", "r363", "r364", "r365", "r366", "r367", "r368", "r376", "r406", "r407", "r408", "r421", "r484" ] }, "bnet_EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "EquityIncentivePlanMember", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "bnet_EquityIssuancesWarrantsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biontech.com/20231231", "localname": "EquityIssuancesWarrantsPolicyPolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Warrants:" } } }, "auth_ref": [] }, "bnet_ExecutiveViceChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "ExecutiveViceChairmanMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Executive Vice Chairman [Member]" } } }, "auth_ref": [] }, "bnet_ExerciseBonus": { "xbrltype": "percentItemType", "nsuri": "http://biontech.com/20231231", "localname": "ExerciseBonus", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise bonus" } } }, "auth_ref": [] }, "bnet_ExercisePrice": { "xbrltype": "percentItemType", "nsuri": "http://biontech.com/20231231", "localname": "ExercisePrice", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise price" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "bnet_ExtensionBonusMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "ExtensionBonusMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Extension Bonus [Member]" } } }, "auth_ref": [] }, "us-gaap_ExtinguishmentOfDebtGainLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ExtinguishmentOfDebtGainLossNetOfTax", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Gain on legal dissolution of subsidiary", "label": "Extinguishment of Debt, Gain (Loss), Net of Tax", "documentation": "The difference between the reacquisition price and the net carrying amount of the extinguished debt recognized currently as a component of income in the period of extinguishment, net of tax." } } }, "auth_ref": [ "r44" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair value measurements:", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "bnet_FinancingReceivableInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://biontech.com/20231231", "localname": "FinancingReceivableInterestRateStatedPercentage", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Financing receivable interest rate stated percentage" } } }, "auth_ref": [] }, "bnet_FinancingReceivablePrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "FinancingReceivablePrincipalAmount", "crdr": "debit", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate principal amount" } } }, "auth_ref": [] }, "bnet_FormerEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "FormerEmployeeMember", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Former Employee [Member]" } } }, "auth_ref": [] }, "bnet_Fy2016ExtensionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "Fy2016ExtensionAgreementMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fy 2016 Extension Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_GainLossOnSecuritizationOfFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSecuritizationOfFinancialAssets", "crdr": "credit", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Realized from the asset sale", "documentation": "A gain (loss) realized on a transfer, accounted for as a sale, of all or a portion of financial assets in which the transferor surrenders control and receives consideration other than a beneficial interest in the assets transferred. Reflects the amount of sales proceeds in excess of, or deficient from, the sum of the carrying amounts of transferred financial assets plus transaction costs." } } }, "auth_ref": [ "r383", "r577", "r578", "r581", "r643" ] }, "bnet_GainOnSaleOfDomainAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "GainOnSaleOfDomainAmount", "crdr": "debit", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gain on sale of domain" } } }, "auth_ref": [] }, "us-gaap_GainOrLossOnSaleOfStockInSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainOrLossOnSaleOfStockInSubsidiary", "crdr": "credit", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gain on legal dissolution of subsidiary", "documentation": "Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries." } } }, "auth_ref": [ "r577", "r578", "r581", "r642" ] }, "bnet_Gen3TechMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "Gen3TechMember", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gen 3 Tech [Member]" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative (including stock-based compensation)", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r94", "r468" ] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Patents:", "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Impairment of long lived assets", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r5", "r40", "r105" ] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gain in non-cash event", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": [ "r61", "r93", "r100", "r179", "r180", "r181", "r182", "r197", "r201" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Decrease in accounts payable and accrued expenses", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredCompensation", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase in deferred compensation", "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Decrease (increase) in operating lease assets and liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r571", "r580" ] }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "crdr": "debit", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Increase in current liabilities", "documentation": "Amount of increase (decrease) in current liabilities classified as other." } } }, "auth_ref": [ "r580" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease in prepaid expenses", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r4" ] }, "bnet_InitialTranche": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "InitialTranche", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Initial tranche" } } }, "auth_ref": [] }, "bnet_InterestBearingSecuredPromissoryNote": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "InterestBearingSecuredPromissoryNote", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest bearing secured promissory note" } } }, "auth_ref": [] }, "us-gaap_InterestCostsCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestCostsCapitalized", "crdr": "debit", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Capitalized interest", "documentation": "Amount of interest capitalized during the period." } } }, "auth_ref": [ "r70" ] }, "us-gaap_InterestCostsCapitalizedAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestCostsCapitalizedAdjustment", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Capitalized labour and interest costs yet to pay", "documentation": "Amount of interest costs capitalized disclosed as an adjusting item to interest costs incurred." } } }, "auth_ref": [] }, "bnet_InterestCostsCapitalizedPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "InterestCostsCapitalizedPaid", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Capitalized labour and interest costs paid" } } }, "auth_ref": [] }, "us-gaap_InterestCostsIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestCostsIncurred", "crdr": "debit", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Incurred costs", "documentation": "Total interest costs incurred during the period and either capitalized or charged against earnings." } } }, "auth_ref": [ "r371" ] }, "us-gaap_InterestCostsIncurredCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestCostsIncurredCapitalized", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Capitalized labour and interest costs", "documentation": "Amount of interest capitalized, including amount of allowance for funds used during construction." } } }, "auth_ref": [ "r78" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r72", "r126", "r157", "r210", "r370", "r469", "r545", "r649" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest expense, debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r95", "r267", "r274", "r525", "r526" ] }, "bnet_InterestExpenseOnDeferredCompensationObligationMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "InterestExpenseOnDeferredCompensationObligationMember", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest Expense On Deferred Compensation Obligation [Member]" } } }, "auth_ref": [] }, "bnet_InterestExpenseRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "InterestExpenseRelatedParties", "crdr": "debit", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest expense related party" } } }, "auth_ref": [] }, "bnet_InterestExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "InterestExpenses", "crdr": "debit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest expenses" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeOperating", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest income", "label": "Interest Income, Operating", "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities." } } }, "auth_ref": [ "r92", "r466", "r499", "r500", "r544", "r545", "r652" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r160", "r163", "r164" ] }, "bnet_InterestRateOnDeferredCompensation": { "xbrltype": "percentItemType", "nsuri": "http://biontech.com/20231231", "localname": "InterestRateOnDeferredCompensation", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest rate on deferred compensation" } } }, "auth_ref": [] }, "bnet_InterestsCostsIncurredCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "InterestsCostsIncurredCapitalized", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interests costs incurred capitalized" } } }, "auth_ref": [] }, "bnet_InterestsExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "InterestsExpense", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest expense" } } }, "auth_ref": [] }, "us-gaap_InterimPeriodCostsNotAllocableDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterimPeriodCostsNotAllocableDomain", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred." } } }, "auth_ref": [ "r36" ] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation for services", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r5" ] }, "bnet_IssuanceOfWarrantsForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "IssuanceOfWarrantsForServices", "crdr": "debit", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of warrants for services" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "bnet_LessImputedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "LessImputedInterest", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Less imputed interest" } } }, "auth_ref": [] }, "us-gaap_LessorLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorLeasesPolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Lease Accounting:", "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor." } } }, "auth_ref": [ "r133", "r134", "r135", "r375" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Total liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r18", "r169", "r223", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r347", "r350", "r351", "r362", "r441", "r519", "r547", "r597", "r633", "r634" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and deficit", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r90", "r124", "r397", "r533", "r584", "r592", "r630" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND EQUITY (DEFICIT)" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Current liabilities", "verboseLabel": "Liability", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r20", "r143", "r169", "r223", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r347", "r350", "r351", "r362", "r533", "r597", "r633", "r634" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Repayments of loans", "verboseLabel": "Line of credit facility, maximum borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r15" ] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LinesOfCreditCurrent", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loans as a liability", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r81", "r120" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long term debt maturity year four", "verboseLabel": "Long-Term debt, maturity, year four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r173", "r265" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long term debt maturity year three", "verboseLabel": "Long-Term debt, maturity, year three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r173", "r265" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long term debt maturity year two", "verboseLabel": "Long-Term debt, maturity, year two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r173", "r265" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r22" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r22", "r43" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r232", "r233", "r234", "r237", "r595", "r596" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r232", "r233", "r234", "r237", "r595", "r596" ] }, "bnet_MarkASmithMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "MarkASmithMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Mark A Smith [Member]" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r233", "r234", "r235", "r236", "r296", "r385", "r405", "r433", "r434", "r490", "r492", "r495", "r496", "r497", "r509", "r510", "r521", "r527", "r528", "r534", "r599", "r635", "r636", "r637", "r638", "r639", "r640" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r233", "r234", "r235", "r236", "r296", "r385", "r405", "r433", "r434", "r490", "r492", "r495", "r496", "r497", "r509", "r510", "r521", "r527", "r528", "r534", "r599", "r635", "r636", "r637", "r638", "r639", "r640" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Noncontrolling interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r27", "r123", "r169", "r223", "r238", "r240", "r241", "r242", "r245", "r246", "r362", "r396", "r444" ] }, "bnet_MinorityInterestPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biontech.com/20231231", "localname": "MinorityInterestPolicyPolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Noncontrolling interests:" } } }, "auth_ref": [] }, "bnet_MonthlyOfficersCashCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "MonthlyOfficersCashCompensation", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Monthly officers cash compensation" } } }, "auth_ref": [] }, "us-gaap_NatureOfExpenseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfExpenseAxis", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Nature of Expense [Axis]", "documentation": "Information by type of cost or expense." } } }, "auth_ref": [ "r36" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r162" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r162" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r98", "r99", "r100" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 }, "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "label": "Net income (loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r91", "r100", "r125", "r141", "r152", "r153", "r156", "r169", "r177", "r179", "r180", "r181", "r182", "r185", "r186", "r197", "r207", "r212", "r216", "r218", "r223", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r361", "r362", "r403", "r464", "r482", "r483", "r520", "r545", "r597" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Net loss attributable to the noncontrolling interest", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r64", "r118", "r152", "r153", "r185", "r186", "r402", "r576" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) applicable to Bion's common stockholders", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r159", "r179", "r180", "r181", "r182", "r188", "r189", "r198", "r201", "r207", "r212", "r216", "r218", "r520" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r159", "r190", "r193", "r194", "r195", "r196", "r198", "r201" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements:", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "bnet_NonCashCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "NonCashCompensation", "crdr": "debit", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Non cash compensation" } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing transactions:" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r59", "r292", "r585", "r586", "r587", "r650" ] }, "us-gaap_NotesReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesReceivableNet", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Notes receivable interest", "verboseLabel": "Principal and accrued interest", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": [ "r222", "r226", "r451" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r207", "r212", "r216", "r218", "r520" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease liability, current (Note 9)", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r374" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease liability, long term (Note 9)", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r374" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r373" ] }, "bnet_OperatingLeasesFutureMinimumPaymentReceivableInTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "OperatingLeasesFutureMinimumPaymentReceivableInTwoYears", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "From January 2024 to December 2024" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans" ], "lang": { "en-us": { "role": { "label": "ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS:", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r80", "r117", "r411", "r412" ] }, "us-gaap_OtherAdditionalCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAdditionalCapital", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional paid amount", "documentation": "Amount of additional paid-in capital (APIC) classified as other." } } }, "auth_ref": [ "r26", "r394" ] }, "us-gaap_OtherNoncashExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashExpense", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accrued interest on loans payable, deferred compensation and other", "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other." } } }, "auth_ref": [ "r100" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total other expense", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r96" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other (income) expense:" } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r561" ] }, "bnet_PA1Member": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "PA1Member", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "P A 1 [Member]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForFees", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payment for cash", "documentation": "Amount of cash outflow for fees classified as other." } } }, "auth_ref": [ "r3" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r97" ] }, "bnet_PaymentsToWarrantExercisesCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "PaymentsToWarrantExercisesCommissions", "crdr": "debit", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payments to exercise of warrants" } } }, "auth_ref": [] }, "bnet_PennvestLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "PennvestLoanMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Pennvest Loan [Member]" } } }, "auth_ref": [] }, "bnet_PercentageOfSustainable": { "xbrltype": "percentItemType", "nsuri": "http://biontech.com/20231231", "localname": "PercentageOfSustainable", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of sustainable" } } }, "auth_ref": [] }, "bnet_Plan2006Member": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "Plan2006Member", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan 2006 [Member]" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r555" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r556" ] }, "bnet_PreferredStockConvertibleOptionPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://biontech.com/20231231", "localname": "PreferredStockConvertibleOptionPerShare", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, convertible option per share" } } }, "auth_ref": [] }, "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendRatePercentage", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock dividend rate percentage", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": [ "r277", "r491", "r493", "r494", "r498" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r84", "r276" ] }, "us-gaap_PreferredStockRedemptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockRedemptionPricePerShare", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, redemption price per share", "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer." } } }, "auth_ref": [ "r48", "r49", "r52" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r84", "r442", "r462", "r650", "r651" ] }, "us-gaap_PrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssets", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Paid invoice amount", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r150", "r227", "r228", "r512" ] }, "srt_PresidentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "PresidentMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "President [Member]" } } }, "auth_ref": [ "r591" ] }, "bnet_PrincipalMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "PrincipalMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principal [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from convertible bridge loan", "verboseLabel": "Gross convertible loan", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r28" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross proceeds", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r1", "r414" ] }, "bnet_ProceedsFromSaleOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "ProceedsFromSaleOfUnits", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of units" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of warrants", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r579" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r141", "r152", "r153", "r161", "r169", "r177", "r185", "r186", "r207", "r212", "r216", "r218", "r223", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r345", "r348", "r349", "r361", "r362", "r388", "r401", "r420", "r464", "r482", "r483", "r520", "r531", "r532", "r546", "r576", "r597" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails", "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://biontech.com/role/PropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "PROPERTY AND EQUIPMENT:", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r103", "r130", "r136", "r137" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r104", "r144", "r400" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails", "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net (Note 3)", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r389", "r400", "r533" ] }, "bnet_PropertyPlantAndEquipmentOfPA1Member": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "PropertyPlantAndEquipmentOfPA1Member", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property Plant and Equipment of PA1 [Member]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentOtherNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentOtherNet", "crdr": "debit", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property and equipment:", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r6", "r130", "r136", "r398" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Schedule of property and equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails", "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r104" ] }, "bnet_PurchaseOfPropertyAndEquipmentForAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "PurchaseOfPropertyAndEquipmentForAccountsPayable", "crdr": "credit", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Purchase of property and equipment for accounts payable" } } }, "auth_ref": [] }, "bnet_PurchaseOrder": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "PurchaseOrder", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Purchase order" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r233", "r234", "r235", "r236", "r295", "r296", "r325", "r326", "r327", "r384", "r385", "r405", "r433", "r434", "r490", "r492", "r495", "r496", "r497", "r509", "r510", "r521", "r527", "r528", "r534", "r537", "r593", "r599", "r636", "r637", "r638", "r639", "r640" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "auth_ref": [ "r233", "r234", "r235", "r236", "r295", "r296", "r325", "r326", "r327", "r384", "r385", "r405", "r433", "r434", "r490", "r492", "r495", "r496", "r497", "r509", "r510", "r521", "r527", "r528", "r534", "r537", "r593", "r599", "r636", "r637", "r638", "r639", "r640" ] }, "us-gaap_ReceivableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivableTypeDomain", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "auth_ref": [ "r25" ] }, "bnet_RedemptionOfConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "RedemptionOfConvertiblePreferredStock", "crdr": "debit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Redemption of convertible preferred stock" } } }, "auth_ref": [] }, "bnet_ReductionOfAdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "ReductionOfAdditionalPaidInCapital", "crdr": "debit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Reduction of additional paid in capital" } } }, "auth_ref": [] }, "bnet_ReductionOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "ReductionOfDebt", "crdr": "debit", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Increased shareholders equity" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r377", "r378", "r632" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Repayments of compensation", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r29", "r417" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "auth_ref": [ "r170", "r171", "r251", "r278", "r379", "r514", "r515" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development (including stock-based compensation)", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r79", "r341", "r641" ] }, "bnet_RestrictedCommonSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "RestrictedCommonSharesMember", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Common Shares [Member]" } } }, "auth_ref": [] }, "bnet_RestrictedCommonStock1Member": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "RestrictedCommonStock1Member", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Common Stock 1 [Member]" } } }, "auth_ref": [] }, "bnet_RestrictedCommonStock2Member": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "RestrictedCommonStock2Member", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Common Stock 2 [Member]" } } }, "auth_ref": [] }, "bnet_RestrictedCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "RestrictedCommonStockMember", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Common Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r87", "r113", "r395", "r409", "r410", "r418", "r443", "r533" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r139", "r174", "r175", "r176", "r178", "r184", "r186", "r224", "r225", "r333", "r334", "r335", "r342", "r343", "r352", "r354", "r355", "r357", "r359", "r406", "r408", "r421", "r650" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenue", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r208", "r209", "r211", "r214", "r215", "r219", "r220", "r221", "r293", "r294", "r386" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition:", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r467", "r511", "r517" ] }, "bnet_SEBFarmsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "SEBFarmsLLCMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "S E B Farms L L C [Member]" } } }, "auth_ref": [] }, "bnet_SaleOfDomainDescription": { "xbrltype": "stringItemType", "nsuri": "http://biontech.com/20231231", "localname": "SaleOfDomainDescription", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of domain, description" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedPerTransaction", "crdr": "debit", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from sale of units", "label": "Sale of Stock, Consideration Received Per Transaction", "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of stock, shares", "verboseLabel": "Sale of units", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of units, price per unit", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "bnet_SaleOfUnitPricePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://biontech.com/20231231", "localname": "SaleOfUnitPricePerUnit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Sale of units", "label": "SaleOfUnitPricePerUnit" } } }, "auth_ref": [] }, "bnet_SaleOfUnitsShares": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20231231", "localname": "SaleOfUnitsShares", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Sale of units, shares" } } }, "auth_ref": [] }, "bnet_SaleOfUnitsValue": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "SaleOfUnitsValue", "crdr": "credit", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Sale of units" } } }, "auth_ref": [] }, "bnet_SaleOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20231231", "localname": "SaleOfWarrants", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of warrants" } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "auth_ref": [ "r187", "r297", "r569", "r588" ] }, "bnet_SchaferMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "SchaferMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schafer [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of warrants and option and convertible securities", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r344" ] }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]", "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability." } } }, "auth_ref": [ "r54", "r115" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of basic and diluted income (loss) per share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r590" ] }, "bnet_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeaseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biontech.com/20231231", "localname": "ScheduleOfFutureMinimumLeasePaymentsForCapitalLeaseTableTextBlock", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of future minimum lease payment" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails", "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://biontech.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of option activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r11", "r12", "r58" ] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-Term Debt [Table]", "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r45", "r46", "r47", "r49", "r50", "r51", "r53", "r111", "r112", "r113", "r147", "r148", "r149", "r205", "r276", "r277", "r278", "r280", "r283", "r288", "r290", "r414", "r415", "r416", "r417", "r527", "r568", "r582" ] }, "bnet_SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Secured Promissory Note Consideration For Warrants Expiring On December 312025 [Member]" } } }, "auth_ref": [] }, "bnet_SecuredPromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "SecuredPromissoryNoteMember", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Secured Promissory Note [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r549" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r553" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r552" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r557" ] }, "bnet_September2015ConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "September2015ConvertibleNotesMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "September 2015 Convertible Notes [Member]" } } }, "auth_ref": [] }, "bnet_SeriesAPreferredStocksMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "SeriesAPreferredStocksMember", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesBPreferredStockMember", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": [ "r573", "r574", "r600" ] }, "bnet_SeriesCPreferredStocksMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "SeriesCPreferredStocksMember", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Series C Preferred Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock- based compensation", "verboseLabel": "Non-cash compensation", "terseLabel": "Cash compensation paid", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Remaining contractual life", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r116" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vesting period", "documentation": "Date the equity-based award expires, in YYYY-MM-DD format." } } }, "auth_ref": [ "r603" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock options, authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r530" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://biontech.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Expired, options", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r311" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://biontech.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Forfeited, options", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r310" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://biontech.com/role/StockholdersEquityDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Granted, options", "verboseLabel": "Number of shares granted", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r609" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, aggregate intrinsic value beginning", "periodEndLabel": "Outstanding, aggregate intrinsic value ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r57" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://biontech.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options outstanding, beginning", "periodEndLabel": "Options outstanding, ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r304", "r305" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://biontech.com/role/StockholdersEquityDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options outstanding, beginning weighted-average exercise price", "periodEndLabel": "Options outstanding, ending weighted-average exercise price", "label": "Weighted average exercise price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r304", "r305" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r300", "r301", "r302", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r324", "r325", "r326", "r327", "r328" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://biontech.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Exercised, weighted-average exercise price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r309" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://biontech.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Expired, weighted-average exercise price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r311" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://biontech.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Forfeited, weighted-average exercise price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r310" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://biontech.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Granted, weighted-average exercise price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r308" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation:", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r298", "r303", "r322", "r323", "r324", "r325", "r328", "r336", "r337", "r338", "r339" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sell units", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://biontech.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Outstanding, weighted-average remaining contractual life (Year)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r116" ] }, "bnet_ShareholderMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "ShareholderMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shareholder [Member]" } } }, "auth_ref": [] }, "bnet_SharesHeldBySubsidiaries": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20231231", "localname": "SharesHeldBySubsidiaries", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares held by subsidiaries (Note 7)", "negatedLabel": "Shares Held by Subsidiaries" } } }, "auth_ref": [] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssued", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of shares issued", "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r9" ] }, "bnet_SharesIssuedBeginningOfPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20231231", "localname": "SharesIssuedBeginningOfPeriod", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "lang": { "en-us": { "role": { "label": "Shares issued \u2013 beginning of period" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share price", "verboseLabel": "Sale of units, price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, shares", "periodEndLabel": "Ending balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "bnet_SharesOutstandingBeginningOfPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20231231", "localname": "SharesOutstandingBeginningOfPeriod", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "lang": { "en-us": { "role": { "label": "Shares outstanding \u2013 beginning of period" } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtLineItems", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r101", "r166" ] }, "bnet_SmithMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "SmithMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Smith [Member]" } } }, "auth_ref": [] }, "bnet_SmithsMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "SmithsMember", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Smiths [Member]" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r558" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r138", "r147", "r148", "r149", "r169", "r191", "r192", "r199", "r201", "r205", "r206", "r223", "r238", "r240", "r241", "r242", "r245", "r246", "r276", "r277", "r280", "r283", "r290", "r362", "r414", "r415", "r416", "r417", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r442", "r465", "r484", "r501", "r502", "r503", "r504", "r505", "r568", "r582", "r589" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r24", "r139", "r154", "r155", "r156", "r174", "r175", "r176", "r178", "r184", "r186", "r204", "r224", "r225", "r292", "r333", "r334", "r335", "r342", "r343", "r352", "r353", "r354", "r355", "r356", "r357", "r359", "r363", "r364", "r365", "r366", "r367", "r368", "r376", "r406", "r407", "r408", "r421", "r484" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r174", "r175", "r176", "r204", "r386", "r413", "r432", "r435", "r436", "r437", "r438", "r439", "r440", "r442", "r445", "r446", "r447", "r448", "r449", "r452", "r453", "r454", "r455", "r457", "r458", "r459", "r460", "r461", "r463", "r467", "r468", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r484", "r538" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r187", "r297", "r569", "r570", "r588" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r174", "r175", "r176", "r204", "r386", "r413", "r432", "r435", "r436", "r437", "r438", "r439", "r440", "r442", "r445", "r446", "r447", "r448", "r449", "r452", "r453", "r454", "r455", "r457", "r458", "r459", "r460", "r461", "r463", "r467", "r468", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r484", "r538" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Conversion of debt and liabilities, shares", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r9", "r23", "r49", "r113", "r264" ] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of units for services, shares", "verboseLabel": "Shares issued for consultant services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r9", "r84", "r85", "r113", "r414", "r484", "r502" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://biontech.com/role/StockholdersEquityDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercised, options", "verboseLabel": "Shares issued for cashless exercise", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r9", "r84", "r85", "r113", "r309" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Conversion of debt and liabilities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r9", "r24", "r113" ] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of units for services", "verboseLabel": "Shares issued for consultant services, value", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares issued, value", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r9", "r84", "r85", "r113", "r421", "r484", "r502", "r546" ] }, "us-gaap_StockRepurchaseProgramExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramExpirationDate", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expiry date", "documentation": "Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the YYYY-MM-DD format." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Bion's stockholders\u2019 equity (deficit)", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r85", "r88", "r89", "r102", "r444", "r462", "r485", "r486", "r533", "r547", "r584", "r592", "r630", "r650" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://biontech.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/CondensedConsolidatedBalanceSheets", "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity (deficit)", "periodStartLabel": "Beginning balance, value", "periodEndLabel": "Ending balance, value", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r59", "r60", "r63", "r139", "r140", "r155", "r174", "r175", "r176", "r178", "r184", "r224", "r225", "r292", "r333", "r334", "r335", "r342", "r343", "r352", "r353", "r354", "r355", "r356", "r357", "r359", "r363", "r364", "r368", "r376", "r407", "r408", "r419", "r444", "r462", "r485", "r486", "r506", "r546", "r584", "r592", "r630", "r650" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://biontech.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY:", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r110", "r168", "r275", "r277", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r289", "r292", "r358", "r487", "r488", "r507" ] }, "bnet_SubscriptionReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biontech.com/20231231", "localname": "SubscriptionReceivableTextBlock", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-Affiliates" ], "lang": { "en-us": { "role": { "label": "SUBSCRIPTION RECEIVABLE - AFFILIATES:" } } }, "auth_ref": [] }, "bnet_SubscriptionsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "SubscriptionsReceivableMember", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Subscriptions Receivable [Member]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r369", "r381" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r369", "r381" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r369", "r381" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r369", "r381" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r369", "r381" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://biontech.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS:", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r380", "r382" ] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowElementsAbstract", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "bnet_Techwastage": { "xbrltype": "decimalItemType", "nsuri": "http://biontech.com/20231231", "localname": "Techwastage", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tech wastage" } } }, "auth_ref": [] }, "bnet_The2020ConvertibleObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "The2020ConvertibleObligationsMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "The 2020 Convertible Obligations [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r591", "r631" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "auth_ref": [] }, "bnet_TotalProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "TotalProceeds", "crdr": "credit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total proceeds" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayableDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r344" ] }, "bnet_UndiscountedCashFlow": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "UndiscountedCashFlow", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Undiscounted cash flow" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of estimates:", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r37", "r38", "r39", "r127", "r128", "r131", "r132" ] }, "bnet_VestingOfOptionsForEmployeesAndServices": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "VestingOfOptionsForEmployeesAndServices", "crdr": "debit", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Vesting of options for employees and services" } } }, "auth_ref": [] }, "bnet_VestingOfWarrantsForEmployeesAndServices": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "VestingOfWarrantsForEmployeesAndServices", "crdr": "credit", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Vesting of warrants for employees and services" } } }, "auth_ref": [] }, "us-gaap_WarrantExercisePriceIncrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantExercisePriceIncrease", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant exercise price per share", "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision." } } }, "auth_ref": [ "r291" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r535", "r536", "r539", "r540", "r541", "r542" ] }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMaturityDate", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Effective period", "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format." } } }, "auth_ref": [ "r629" ] }, "bnet_WarrantsAndRightsOutstandingShares": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20231231", "localname": "WarrantsAndRightsOutstandingShares", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants and rights outstanding" } } }, "auth_ref": [] }, "bnet_WarrantsExercisedForCommonShares": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "WarrantsExercisedForCommonShares", "crdr": "credit", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Warrants exercised for common shares" } } }, "auth_ref": [] }, "bnet_WarrantsExercisedForCommonSharesShares": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20231231", "localname": "WarrantsExercisedForCommonSharesShares", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Warrants exercised for common shares , shares" } } }, "auth_ref": [] }, "bnet_WarrantsExercisedForCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "WarrantsExercisedForCommonStock", "crdr": "credit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant Exercised for Common Stock" } } }, "auth_ref": [] }, "bnet_WarrantsExercisedUnderCashlessExercise": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "WarrantsExercisedUnderCashlessExercise", "crdr": "credit", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Warrants exercised under cashless exercise" } } }, "auth_ref": [] }, "bnet_WarrantsExercisedUnderCashlessExerciseShares": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20231231", "localname": "WarrantsExercisedUnderCashlessExerciseShares", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Warrants exercised under cashless exercise , shares" } } }, "auth_ref": [] }, "bnet_WarrantsExpiringOnDecember312025Member": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "WarrantsExpiringOnDecember312025Member", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring On December 312025 [Member]" } } }, "auth_ref": [] }, "bnet_WarrantsHeldByTrustOwnedShares": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20231231", "localname": "WarrantsHeldByTrustOwnedShares", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants held by trust owned" } } }, "auth_ref": [] }, "bnet_WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants Issued In Connection With Sale Of Units In Exchange For Salary [Member]" } } }, "auth_ref": [] }, "bnet_WarrantsIssuedSubscriptionReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "WarrantsIssuedSubscriptionReceivableMember", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants Issued Subscription Receivable [Member]" } } }, "auth_ref": [] }, "bnet_WarrantsIssusedSubscriptionReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "WarrantsIssusedSubscriptionReceivableMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants Issused Subscription Receivable [Member]" } } }, "auth_ref": [] }, "bnet_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "WarrantsMember", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } } }, "auth_ref": [] }, "bnet_WeightedAverageNumberOfDilutedShareOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20231231", "localname": "WeightedAverageNumberOfDilutedShareOutstanding", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "lang": { "en-us": { "role": { "label": "Diluted weighted average shares \u2013 \u00a0\u00a0\u00a0\u00a0end of period" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" ], "lang": { "en-us": { "role": { "label": "Weighted-average number of common shares outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r190", "r201" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://biontech.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" ], "lang": { "en-us": { "role": { "label": "Weighted-average number of common shares outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r188", "r201" ] }, "bnet_WeightedAverageSharesIssuedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20231231", "localname": "WeightedAverageSharesIssuedDuringPeriod", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average shares issued \u00a0\u00a0\u00a0\u00a0during the period" } } }, "auth_ref": [] }, "bnet_WilliamONeillMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "WilliamONeillMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "William O Neill [Member]" } } }, "auth_ref": [] }, "bnet_WorkingCapitalDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20231231", "localname": "WorkingCapitalDeficit", "crdr": "credit", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Working capital deficit" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r566" ] }, "bnet_YearsOneThroughFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "YearsOneThroughFiveMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Years One Through Five [Member]" } } }, "auth_ref": [] }, "bnet_YearsSixThroughMaturityMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20231231", "localname": "YearsSixThroughMaturityMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Years Six Through Maturity [Member]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "270", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-8" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-11" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "25", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-11" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-9" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "932", "SubTopic": "235", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-18" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "980", "SubTopic": "835", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482064/980-835-45-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.13)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-9" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-14" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3A" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3A" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1B" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r512": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r514": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r515": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r516": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r517": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r518": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r519": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r520": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r521": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r522": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r523": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r524": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r525": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r526": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r527": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r528": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r529": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r532": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r533": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480191/946-405-45-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "39", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480228/946-830-45-39" }, "r545": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r547": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r549": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r550": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r568": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r569": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r570": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(g))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 56 0001079973-24-000236-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-24-000236-xbrl.zip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end XML 57 bion_10q_htm.xml IDEA: XBRL DOCUMENT 0000875729 2023-07-01 2023-12-31 0000875729 2024-02-01 0000875729 2023-12-31 0000875729 2023-06-30 0000875729 2023-10-01 2023-12-31 0000875729 2022-10-01 2022-12-31 0000875729 2022-07-01 2022-12-31 0000875729 bnet:SeriesAPreferredStocksMember 2022-09-30 0000875729 bnet:SeriesCPreferredStocksMember 2022-09-30 0000875729 us-gaap:CommonStockMember 2022-09-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000875729 bnet:SubscriptionsReceivableMember 2022-09-30 0000875729 us-gaap:RetainedEarningsMember 2022-09-30 0000875729 us-gaap:NoncontrollingInterestMember 2022-09-30 0000875729 2022-09-30 0000875729 bnet:SeriesAPreferredStocksMember 2023-09-30 0000875729 bnet:SeriesCPreferredStocksMember 2023-09-30 0000875729 us-gaap:CommonStockMember 2023-09-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000875729 bnet:SubscriptionsReceivableMember 2023-09-30 0000875729 us-gaap:RetainedEarningsMember 2023-09-30 0000875729 us-gaap:NoncontrollingInterestMember 2023-09-30 0000875729 2023-09-30 0000875729 bnet:SeriesAPreferredStocksMember 2022-06-30 0000875729 bnet:SeriesCPreferredStocksMember 2022-06-30 0000875729 us-gaap:CommonStockMember 2022-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000875729 bnet:SubscriptionsReceivableMember 2022-06-30 0000875729 us-gaap:RetainedEarningsMember 2022-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2022-06-30 0000875729 2022-06-30 0000875729 bnet:SeriesAPreferredStocksMember 2023-06-30 0000875729 bnet:SeriesCPreferredStocksMember 2023-06-30 0000875729 us-gaap:CommonStockMember 2023-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000875729 bnet:SubscriptionsReceivableMember 2023-06-30 0000875729 us-gaap:RetainedEarningsMember 2023-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2023-06-30 0000875729 bnet:SeriesAPreferredStocksMember 2022-10-01 2022-12-31 0000875729 bnet:SeriesCPreferredStocksMember 2022-10-01 2022-12-31 0000875729 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0000875729 bnet:SubscriptionsReceivableMember 2022-10-01 2022-12-31 0000875729 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2022-10-01 2022-12-31 0000875729 bnet:SeriesAPreferredStocksMember 2023-10-01 2023-12-31 0000875729 bnet:SeriesCPreferredStocksMember 2023-10-01 2023-12-31 0000875729 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0000875729 bnet:SubscriptionsReceivableMember 2023-10-01 2023-12-31 0000875729 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2023-10-01 2023-12-31 0000875729 bnet:SeriesAPreferredStocksMember 2022-07-01 2022-12-31 0000875729 bnet:SeriesCPreferredStocksMember 2022-07-01 2022-12-31 0000875729 us-gaap:CommonStockMember 2022-07-01 2022-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-12-31 0000875729 bnet:SubscriptionsReceivableMember 2022-07-01 2022-12-31 0000875729 us-gaap:RetainedEarningsMember 2022-07-01 2022-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-12-31 0000875729 bnet:SeriesAPreferredStocksMember 2023-07-01 2023-12-31 0000875729 bnet:SeriesCPreferredStocksMember 2023-07-01 2023-12-31 0000875729 us-gaap:CommonStockMember 2023-07-01 2023-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-12-31 0000875729 bnet:SubscriptionsReceivableMember 2023-07-01 2023-12-31 0000875729 us-gaap:RetainedEarningsMember 2023-07-01 2023-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-12-31 0000875729 bnet:SeriesAPreferredStocksMember 2022-12-31 0000875729 bnet:SeriesCPreferredStocksMember 2022-12-31 0000875729 us-gaap:CommonStockMember 2022-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000875729 bnet:SubscriptionsReceivableMember 2022-12-31 0000875729 us-gaap:RetainedEarningsMember 2022-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2022-12-31 0000875729 2022-12-31 0000875729 bnet:SeriesAPreferredStocksMember 2023-12-31 0000875729 bnet:SeriesCPreferredStocksMember 2023-12-31 0000875729 us-gaap:CommonStockMember 2023-12-31 0000875729 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000875729 bnet:SubscriptionsReceivableMember 2023-12-31 0000875729 us-gaap:RetainedEarningsMember 2023-12-31 0000875729 us-gaap:NoncontrollingInterestMember 2023-12-31 0000875729 bnet:SEBFarmsLLCMember 2023-09-28 0000875729 bnet:BridgeLoanAgreementsMember 2023-09-28 0000875729 bnet:BridgeLoanAgreementsMember 2023-10-31 0000875729 2023-10-03 2023-10-05 0000875729 bnet:Gen3TechMember 2023-07-01 2023-12-31 0000875729 2022-01-27 2022-01-28 0000875729 2022-06-01 2022-06-30 0000875729 2023-01-16 2023-01-17 0000875729 2023-04-23 2023-04-24 0000875729 2023-05-01 2023-05-02 0000875729 2023-07-25 2023-07-26 0000875729 2021-07-01 2022-06-30 0000875729 2022-07-01 2023-06-30 0000875729 2023-11-01 2023-11-30 0000875729 2017-07-01 2018-06-30 0000875729 srt:MinimumMember 2023-12-31 0000875729 srt:MaximumMember 2023-12-31 0000875729 us-gaap:WarrantMember 2023-07-01 2023-12-31 0000875729 us-gaap:WarrantMember 2022-07-01 2022-12-31 0000875729 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-12-31 0000875729 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-12-31 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2023-07-01 2023-12-31 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2022-07-01 2022-12-31 0000875729 us-gaap:ComputerEquipmentMember 2023-12-31 0000875729 us-gaap:ComputerEquipmentMember 2023-06-30 0000875729 us-gaap:ConstructionInProgressMember 2023-12-31 0000875729 us-gaap:ConstructionInProgressMember 2023-06-30 0000875729 bnet:PropertyPlantAndEquipmentOfPA1Member 2023-07-01 2023-12-31 0000875729 bnet:WilliamONeillMember 2023-12-31 0000875729 srt:ChiefExecutiveOfficerMember 2023-12-31 0000875729 srt:ChiefOperatingOfficerMember 2023-12-31 0000875729 bnet:BassaniMember 2022-12-31 0000875729 bnet:SmithMember 2022-12-31 0000875729 bnet:ConsultantsMember 2023-12-31 0000875729 bnet:ConsultantsMember 2022-12-31 0000875729 srt:ChiefExecutiveOfficerMember 2023-07-01 2023-12-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2023-10-01 2023-12-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2022-10-01 2022-12-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2023-07-01 2023-12-31 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2022-07-01 2022-12-31 0000875729 bnet:PennvestLoanMember 2023-12-31 0000875729 2021-09-30 0000875729 2021-12-29 0000875729 bnet:YearsOneThroughFiveMember bnet:PennvestLoanMember 2023-07-01 2023-12-31 0000875729 bnet:YearsSixThroughMaturityMember bnet:PennvestLoanMember 2023-07-01 2023-12-31 0000875729 bnet:PennvestLoanMember 2021-07-01 2022-06-30 0000875729 bnet:PennvestLoanMember 2020-07-01 2021-06-30 0000875729 2021-06-30 0000875729 bnet:PA1Member 2014-09-25 0000875729 bnet:PA1Member 2022-06-14 2022-06-15 0000875729 bnet:MarkASmithMember 2023-12-31 0000875729 bnet:DominicBassaniMember 2023-12-31 0000875729 bnet:EdSchaferMember 2023-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember bnet:SmithMember 2023-02-02 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember bnet:BassaniFamilyTrustsMember 2023-02-02 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember bnet:SchaferMember 2023-02-02 0000875729 bnet:BassaniMember srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember 2023-02-02 0000875729 bnet:EdSchaferMember srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember 2023-02-02 0000875729 bnet:BassaniMember bnet:The2020ConvertibleObligationsMember 2023-12-31 0000875729 bnet:SmithMember bnet:The2020ConvertibleObligationsMember 2023-12-31 0000875729 bnet:EdwardSchaferMember bnet:The2020ConvertibleObligationsMember 2023-12-31 0000875729 bnet:BassaniMember bnet:The2020ConvertibleObligationsMember 2023-06-30 0000875729 bnet:SmithMember bnet:The2020ConvertibleObligationsMember 2023-06-30 0000875729 bnet:EdwardSchaferMember bnet:The2020ConvertibleObligationsMember 2023-06-30 0000875729 bnet:BassaniMember bnet:September2015ConvertibleNotesMember 2023-12-31 0000875729 bnet:EdwardSchaferMember bnet:September2015ConvertibleNotesMember 2023-12-31 0000875729 bnet:BassaniMember bnet:September2015ConvertibleNotesMember 2023-06-30 0000875729 bnet:EdwardSchaferMember bnet:September2015ConvertibleNotesMember 2023-06-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-01-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-12-31 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-12-31 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-12-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-12-31 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member 2023-07-01 2023-12-31 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member 2023-12-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-07-01 2023-12-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-07-01 2022-12-31 0000875729 2023-02-02 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2023-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniMember 2023-12-31 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember bnet:SchaferMember 2023-12-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember bnet:ShareholderMember 2023-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniMember 2022-12-31 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember bnet:SchaferMember 2022-12-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember bnet:ShareholderMember 2022-12-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2023-07-01 2023-12-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2022-07-01 2022-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniFamilyTrustsMember 2023-12-31 0000875729 bnet:ConvertibleBridgeLoanDefaultMember 2023-09-28 0000875729 bnet:ConvertibleBridgeLoanDefaultMember 2023-10-31 0000875729 bnet:ConvertibleBridgeLoanDefaultMember us-gaap:ConvertibleDebtMember 2023-07-01 2023-12-31 0000875729 bnet:RestrictedCommonSharesMember bnet:September2015ConvertibleNotesMember 2023-12-31 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-01 0000875729 us-gaap:SeriesBPreferredStockMember 2014-06-30 2014-07-01 0000875729 us-gaap:SeriesBPreferredStockMember 2023-07-01 2023-12-31 0000875729 us-gaap:SeriesBPreferredStockMember 2023-12-31 0000875729 us-gaap:SeriesBPreferredStockMember 2022-07-01 2023-06-30 0000875729 us-gaap:SeriesBPreferredStockMember 2021-07-01 2022-06-30 0000875729 bnet:RestrictedCommonStockMember 2023-07-01 2023-12-31 0000875729 bnet:RestrictedCommonStockMember 2023-12-31 0000875729 bnet:RestrictedCommonStock1Member 2023-07-01 2023-12-31 0000875729 bnet:RestrictedCommonStock1Member 2023-12-31 0000875729 bnet:RestrictedCommonStock2Member 2023-07-01 2023-12-31 0000875729 bnet:RestrictedCommonStock2Member 2023-12-31 0000875729 bnet:PrincipalMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-07-01 2023-12-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2023-07-01 2023-12-31 0000875729 bnet:ConsultantServiceMember 2023-07-01 2023-12-31 0000875729 bnet:ConsultantServiceMember 2023-12-31 0000875729 bnet:ConsultantService1Member 2023-07-01 2023-12-31 0000875729 bnet:ConsultantService1Member 2023-12-31 0000875729 bnet:ConsultantService2Member 2023-07-01 2023-12-31 0000875729 bnet:ConsultantService2Member 2023-12-31 0000875729 bnet:ConsultantService3Member 2023-07-01 2023-12-31 0000875729 bnet:ConsultantService3Member 2023-12-31 0000875729 bnet:ConsultantService4Member 2023-07-01 2023-12-31 0000875729 bnet:ConsultantService4Member 2023-12-31 0000875729 bnet:WarrantsMember 2023-12-31 0000875729 bnet:WarrantsMember 2023-07-01 2023-12-31 0000875729 bnet:PrincipalMember bnet:The2020ConvertibleObligationsMember us-gaap:WarrantMember 2023-07-01 2023-12-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2023-07-01 2023-12-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2023-12-31 0000875729 bnet:RestrictedCommonStockMember us-gaap:WarrantMember 2023-07-01 2023-12-31 0000875729 bnet:RestrictedCommonStockMember us-gaap:WarrantMember 2023-12-31 0000875729 2023-09-25 2023-09-26 0000875729 2023-09-26 0000875729 us-gaap:WarrantMember 2023-07-01 2023-12-31 0000875729 bnet:ConsultantService4Member us-gaap:WarrantMember 2023-07-01 2023-12-31 0000875729 bnet:ConsultantService1Member us-gaap:WarrantMember 2023-07-01 2023-12-31 0000875729 srt:ChiefExecutiveOfficerMember 2022-05-01 0000875729 bnet:ConsultantsMember us-gaap:WarrantMember 2023-12-31 0000875729 bnet:ConsultantsMember us-gaap:WarrantMember 2023-07-01 2023-12-31 0000875729 us-gaap:EmployeeStockOptionMember bnet:EquityIncentivePlanMember 2022-04-07 0000875729 us-gaap:EmployeeStockOptionMember 2023-12-31 0000875729 bnet:Plan2006Member 2023-03-14 2023-03-15 0000875729 bnet:Plan2006Member 2023-05-08 2023-05-09 0000875729 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-12-31 0000875729 bnet:BassaniMember bnet:SecuredPromissoryNoteMember 2023-12-31 0000875729 bnet:SecuredPromissoryNoteMember 2023-12-31 0000875729 srt:PresidentMember bnet:SecuredPromissoryNoteMember 2023-12-31 0000875729 srt:PresidentMember bnet:WarrantsIssuedSubscriptionReceivableMember 2023-12-31 0000875729 bnet:SmithsMember bnet:SecuredPromissoryNoteMember 2023-12-31 0000875729 bnet:FormerEmployeeMember bnet:SecuredPromissoryNoteMember 2023-12-31 0000875729 bnet:FormerEmployeeMember bnet:WarrantsIssuedSubscriptionReceivableMember 2023-12-31 0000875729 srt:PresidentMember 2016-10-09 2016-10-10 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2023-03-31 0000875729 srt:PresidentMember bnet:WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember 2023-03-31 0000875729 2022-04-27 2022-05-02 0000875729 bnet:SmithMember 2023-10-01 2023-12-31 0000875729 bnet:SmithMember 2022-10-01 2022-12-31 0000875729 bnet:SmithMember 2023-07-01 2023-12-31 0000875729 bnet:SmithMember 2022-07-01 2022-12-31 0000875729 srt:ChiefExecutiveOfficerMember 2015-02-03 2015-02-10 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2016-10-31 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2017-04-27 0000875729 bnet:BassaniMember 2018-02-28 0000875729 bnet:BassaniMember 2018-07-28 2018-08-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsExpiringOnDecember312025Member 2018-08-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2023-10-01 2023-12-31 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2022-10-01 2022-12-31 0000875729 srt:ChiefExecutiveOfficerMember 2023-10-01 2023-12-31 0000875729 bnet:WilliamONeillMember 2022-04-27 2022-05-02 0000875729 srt:ChiefExecutiveOfficerMember 2022-10-01 2022-12-31 0000875729 2022-03-01 2022-03-31 0000875729 2023-05-02 0000875729 2022-04-29 2022-04-30 0000875729 2022-03-22 2022-03-23 0000875729 2023-06-22 2023-06-23 0000875729 bnet:SEBFarmsLLCMember 2023-09-29 0000875729 bnet:BridgeLoanAgreementsMember 2023-09-29 0000875729 2023-12-29 2024-01-02 0000875729 us-gaap:SubsequentEventMember 2024-01-01 2024-01-02 0000875729 us-gaap:SubsequentEventMember 2024-01-02 0000875729 us-gaap:SubsequentEventMember 2024-01-17 2024-01-18 0000875729 us-gaap:SubsequentEventMember 2024-01-18 0000875729 us-gaap:SubsequentEventMember 2024-02-13 0000875729 bnet:SmithMember us-gaap:SubsequentEventMember 2024-02-13 iso4217:USD shares iso4217:USD shares pure bnet:Decimal false --06-30 2024 Q2 0000875729 10-Q true 2023-12-31 false 000-19333 Bion Environmental Technologies, Inc. CO 84-1176672 9 East Park Court Old Bethpage NY 11804 516 586-5643 Common Stock BNET Yes Yes Non-accelerated Filer true false false 56201815 384735 625964 3394 16785 6000 6000 394129 648749 66090 93875 9110640 6851009 9570859 7593633 2648005 677136 1225226 864781 255407 71091 75000 4199729 1616917 29068 1740083 1715970 5939812 3361955 0 0 250000000 250000000 50611962 48044790 49907653 47340480 132798923 131935418 504650 504650 -128700799 -127236663 3593474 4194105 37573 37573 3631047 4231678 9570859 7593633 636017 630542 1302272 1497036 460 394 921 724 7431 15148 15730 43591 643908 646084 1318923 1541351 -643908 -646084 -1318923 -1541351 109 1375 504 3310 74790 85285 145717 111380 -74681 -83910 -145213 -108070 -718589 -729994 -1464136 -1649421 -718589 -729994 -1464136 -1649421 -0.01 -0.01 -0.02 -0.02 -0.03 -0.03 -0.04 -0.04 48748554 48748554 43620051 43620051 49321180 49321180 43533789 43533789 44303654 124300604 -504650 -124966975 37573 -1133448 226230 226230 226230 32250 32250 68088 68088 -729994 -729994 44529884 124627172 -504650 -125696969 37573 -1536874 49485556 132197829 -504650 -127982210 37573 3748542 375000 375000 375000 265639 36506 48334 48334 5000 5000 52378 52378 3281 3281 -8430 -8430 449261 42500 42500 89031 89031 -6000 -6000 -718589 -718589 50611962 132798923 -504650 -128700799 37573 3631047 43758820 123620046 -504650 -124047548 37573 -894579 546230 546230 546230 74834 88375 88375 50000 80000 80000 15000 15000 100000 50000 50000 227521 227521 -1649421 -1649421 44529884 124627172 -504650 -125696969 37573 -1536874 48880237 131935418 -504650 -127236663 37573 4231678 403589 420742 420742 38000 28500 28500 265639 56759 76320 76320 5000 5000 107487 107487 6563 6563 -16861 -16861 967738 91548 91548 150206 150206 -6000 -6000 -1464136 -1464136 50611962 132798923 -504650 -128700799 37573 3631047 -1464136 -1649421 921 724 145717 43292 129048 223021 81321 127250 -13391 -80062 220699 -949097 -5192 32308 427583 170000 -450648 -1921861 483823 739486 -483823 -739486 420742 546230 6000 250000 28500 56125 693242 602355 -241229 -2058992 625964 3160442 384735 1101450 49048 50000 23943 80767 60000 91548 1750170 135673 <p id="xdx_80E_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zCcqnmtRzlti" style="margin-top: 0; margin-bottom: 0"><b>1.       <span id="xdx_82B_zxvx8qQp7ETg">ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS:</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Organization and nature of business: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>DUE TO THE RECENT DEATH (FOLLOWING EXTENDED ILLNESS) OF DOMINIC BASSANI (WHO MOST RECENTLY SERVED AS OUR COO (FROM MAY 2022) AFTER SERVING AS OUR CEO FOR THE PRIOR DECADE) AND DIFFICULTIES IN RAISING NEEDED FUNDS (WHICH RE-EMERGED DURING THE 2023 FISCAL YEAR AND HAVE CONTINUED THROUGH THE CURRENT QUARTER TO DATE), THE COMPANY IS FACING INCREASED CAPITAL NEEDS AND THE NEED TO TRANSITION TO A YOUNGER MANAGEMENT TEAM (MARK A. SMITH, THE COMPANY’S PRESIDENT AND GENERAL COUNSEL, PROVIDED NOTICE DURING EARLY 2023 OF HIS INTENT TO PHASE OUT HIS MANAGEMENT ROLES EARLY THIS CALENDAR YEAR). THESE ITEMS HAVE BEEN PREVIOUSLY DISCLOSED BUT THE COMPANY BELIEVES IT IS IMPORTANT TO FEATURE THEM ‘UPFRONT’ AT THIS POINT. PLEASE NOTE:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>A: </b>The Company is not generating any significant revenues. Further, the Company’s anticipated revenues, if any, from existing Projects, JVs and proposed Projects will not be sufficient to meet the Company’s anticipated operational and capital expenditure needs for many years. <b>See “Going Concern and Management’s Plans” below. </b>Current liabilities were approximately $<span id="xdx_90A_eus-gaap--LiabilitiesCurrent_iI_pn5n6_c20231231_zTYRsqv4UEnj" title="Current liabilities">4.2</span> million at December 31, 2023. There was an increase of approximately $<span id="xdx_906_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_pn5n6_c20230701__20231231_zN5ceeAJh5mg" title="Increase in current liabilities">2.6</span> million from a year earlier (which was largely due to an increase in ‘accounts payable and accrued expenses’ totaling approximately $2.0 million and an increase in ‘deferred compensation’ of approximately $.35 million) as a result of the Company’s limited success in raising new financing (equity and/or debt) during the recent period in combination with continued expenses (including those related to the Initial Project); and <b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>B: </b>On September 28, 2023 the Company entered into an agreement for a $<span id="xdx_900_eus-gaap--ConvertibleDebt_iI_pp0p0_c20230928__srt--TitleOfIndividualAxis__custom--SEBFarmsLLCMember_zemhtpCBH8f8" title="Bridge loan">1,500,000</span> bridge loan and executed documents including a convertible promissory note (“Note”) and a binding subscription agreement (“Subscription”) (collectively the Note and the Subscription are the “Bridge Loan Agreements”) with SEB LLC, a non-affiliated party (“Lender”). The Bridge Loan Agreements require the Lender to loan the Company $<span id="xdx_908_eus-gaap--ConvertibleDebt_iI_pp0p0_c20230928__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementsMember_z2HXHDfN1DTf" title="Bridge loan">1,500,000</span> in six monthly tranches of $<span id="xdx_902_eus-gaap--ConvertibleDebt_iI_pp0p0_c20231031__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementsMember_zLbh1ASe59c4" title="Bridge loan">250,000</span> commencing October 2023. All sums advanced under the Bridge Loan Agreements (and accrued interest thereon) would due and payable (with interest accrued at <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20230928__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementsMember_zZceHomx43s9" title="Interest accrued percentage">9</span>% per annum) on October 1, 2024 if not previously converted into securities of the Company. The Note is convertible at $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230928__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementsMember_zL9WXGTnWrcf" title="Convertible price">1.00</span> per unit, at the sole election of the Lender, into units consisting of one share of the Company’s common stock and a warrant to purchase one half share. The initial $<span id="xdx_90D_ecustom--InitialTranche_pp0p0_c20231003__20231005_zJQMUiDxADKa" title="Initial tranche">250,000</span> tranche was received by the Company on October 5, 2023. However, no further funds were received by the Company from the Lender. During early November 2023 the Lender informed the Company verbally that it did not intend to fulfill its obligations pursuant to the Bridge Loan Agreements and since such time the Lender has been in default (“Default”). The Default (which is continuing) has exacerbated the Company’s exiting problems and materially damaged the Company and rendered the Company unable to meet its creditor obligations on a timely basis. The Company is currently evaluating its rights regarding the Default by the Lender. <b>See Notes re Bridge Loan/Default. </b>This situation has contributed to the substantial increase in the Company’s ‘Current Liabilities’ including ‘accounts payable’ over recent periods. <b>See Consolidated Financial Statements </b>and <b>‘Management’s Discussion and Analysis’. </b>The Company is in discussion/negotiation with its larger creditors (including its largest creditor--- the primary contractor on the Initial Project) and anticipates reaching agreements re payments during the current quarter (or soon thereafter).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to make livestock production more sustainable, profitable and transparent. We intend to accomplish this by deploying our Gen3Tech platform/business model (discussed below) in ventures focused on the ‘feeder’ space of the livestock production/value chain to provide the consumer with verifiably sustainable premium meat products (together with environmentally friendly, sustainable and/or organic co-products from the production process).  Bion believes this approach can create extraordinary value for our shareholders and employees (all of whom own securities in the Company) and for livestock/agriculture industry ‘partners’ who join us in our ventures. We anticipate pursuing the opportunity created by our third generation technology (“Gen3Tech”) and business/technology platform in conjunction with other industry practices (“Gen3Tech Platform” or “Platform”) utilizing a joint venture/strategic partner model. We believe our approach will improve the well-being of farmers, ranchers, feeders, etc. that we work with and create value for our shareholders while improving the environment.  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our Gen3Tech” can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These waste ‘assets’ – nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate surface groundwater, and exacerbate climate change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms) (“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). To accomplish Bion’s goals, we anticipate the we will ‘partner’ with other technology companies who provide solutions for different links of the beef (and other livestock) value chain and with strategic partners up and down the supply chain<b>.</b> We anticipate this will result in substantial long-term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent one of the largest enhanced revenue contributors provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion’s Gen3Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the animal raising and waste treatment process will be third-party verified, providing the basis for additional revenues, including carbon and/or renewable energy-related credits and, eventually, payment for a range of ecosystem services, including nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the first half of calendar 2022 Bion began pre-marketing our sustainable beef opportunity to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During our 2023 fiscal year, Bion entered into three (3) letters of intent (“LOIs”): a) July 2022 letter of intent to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch (“Ribbonwire LOI”), in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”), (b) January 2023 letter of intent to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Olson Feeders and TD Angus (“Olson LOI”), near North Platte, Nebraska (with a provision to expand to 45,000 head or more) (“Olson Project”) and c)April 2023 letter of intent to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with Dakota Valley Growers (“DVG LOI”) near Bathgate, North Dakota (“DVG Project”). The Company is in discussions with additional parties regarding potential further LOIs. Based on our experience to date, we believe we will not have difficulty in securing participation in our Projects from additional feeders/cattlemen. The Olson, Dalhart and DVG Projects (and subsequent Projects) will be developed to produce blockchain-verified, sustainable beef in customized covered barns (resulting in reduced stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) with ongoing manure transfer (through slatted floors) to anaerobic digesters (AD) to capture nitrogen from the manure stream before loss to the atmosphere and generate renewable natural gas (RNG) for sale while remediating the environmental/carbon impacts usually associated with cattle feedlots and CAFOs. Bion’s patented Gen3Tech platform will refine the waste stream into valuable coproducts that include clean water, RNG, photovoltaic solar electricity and fertilizer (‘climate smart’ and/or organic) products. We anticipate converting tone or more of these LOIs into definitive JV agreements and creating related distribution agreements with key retailers and food service distributors during the current calendar year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our business plan is focused on executing multiple agreements and letters of intent related to additional sustainable beef JV projects over the next twenty-four (24) months while continuing our work at the Initial Project (see below) and commencing development of one or more of the Dalhart/Olson/DVG Projects (“LOI Projects”)(and/or other Gen3Tech beef JV projects) while pursuing other opportunities in the livestock industry enabled by our Gen3Tech business model.  The LOI announcements have generated significant interest within the livestock industry (among ranchers, feedlot operators, farmers and other AG industry parties) and has led to and assisted our discussions with many major of the larger agriculture/livestock industry companies (including those involved with distribution and/or sales of meat products) in the country which are ongoing at this date. We believe that this interest, combined with consumer interest in ‘sustainable products’ and growing enthusiasm among some livestock industry parties for environmental/sustainable/regenerative practices, may provide Bion (and its partners/venturers) with an opportunity to move forward with a truly sustainable solution in this industry segment at a rapid pace. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the 2023 calendar year, the Company has constructed (construction is largely completed) our 3GTech Ammonia Recovery System (‘ARS’) located near Fair Oaks, Indiana and begun operations of phase 1 of our Initial Project (our commercial scale demonstration facility) located near Fair Oaks, Indiana. The Initial Project has been deemed ‘placed in service’ effective January 1, 2024. Operating results to date at Fair Oaks indicate ARS performance will exceed initial expectations for ammonia recovery and related economics. The Company recently announced that we have achieved key objectives in the optimization of its ARS and will now begin the final design process for full-scale systems based on results to date (and testing over the remainder of this fiscal year) at the Initial Project. The ARS has achieved and maintained controlled steady-state operations under a variety of conditions. When operated at steady state, the system produces an ammonium distillate (solution), the base of Bion’s nitrogen fertilizer products. Bion has begun optimizing the ARS’s operating parameters with the goal of meeting and/or exceeding the results needed for Bion’s economic models for large-scale commercial projects. The Company expects the current optimization phase will continue during the next quarter (or longer) and provide data required to support final design/engineering for commercial project modules. We believe this data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, distributors, retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below). Final economic and energy efficiency models will be validated during the final design process. The Company intends to engage a third party engineering firm during the next quarter to prepare a third-party evaluation of the ARS while also moving forward on final commercial design process.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The patented ARS is the core of Bion’s Gen3Tech platform. It recovers and upcycles problem ammonia contained in the effluent from anaerobic digestion (where methane is captured and more ammonia is released) of the livestock manure waste stream. The ARS captures the ammonia, minimizing its environmental impacts and creating low-carbon and/or organic nitrogen fertilizer products with it. During the last three (3) months,, the Company has produced ammonium distillate and ammonium bicarbonate solutions at the Initial Project in several concentrations and plans to initiate the application process for organic certification for each concentration of liquid fertilizer product. Multiple applications to OMRI (Organic Materials Review Institute) and CDFA (California Department of Food and Agriculture) are being prepared for listing/certification of new organic products. Bion received an OMRI-Listing in 2020 for its initial product. Bion will continue producing liquid and crystal fertilizers at the Initial Project to support testing and life-cycle analysis, product trials, and ongoing organic initiatives. Bion will produce a solid/granular nitrogen fertilizer product at the Initial Project (when the crystalizer module is ready for operation) which we believe will be both ‘Climate-Smart’ and ‘Water-Smart’ – a pure nitrogen fertilizer with a low carbon footprint, that is water soluble and readily available to plants. Samples of the granular product will also be utilized to support organic certification applications. See <b>Fertilizer---Organic and ‘ClimateSmart’ </b>below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b>Bion expects the Initial Project data will document the effectiveness of our Gen3Tech in a commercial-scale setting during the current fiscal year and support development of one or more of the LOI Projects (and/or other Gen3Tech beef JV projects) commencing later this fiscal year.  We do not presently know the order in which the JV Projects will be developed as that decision will be made based on many factors not yet in place. We believe the Initial Project data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, food distributors and retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 6pt">Note that Bion recently announced its intention to establish strategic partnerships to market the ARS as a stand-alone addition to anaerobic digestion (“AD”) nitrogen control solution in two sectors:</p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">A)</span><span style="font-size: 7pt">     </span><span style="font-size: 10pt"><b>INDUSTRIAL AND MUNICIPAL WASTEWATER. </b>AD is now used at 1,269 water resource recovery facilities in the U.S., with another 102 stand-alone systems that digest food waste. The American Biogas Council estimates an additional 8,600 sites with development potential. Germany, by comparison, has almost 10,000 operating AD sites. In the U.S., wastewater and AD digestate from industrial and municipal sources is already regulated for ammonia and nitrates. The EPA recently proposed tougher standards for slaughter facilities. Bion believes ARS ammonia treatment costs will be competitive in these markets and that its unique premium fertilizer byproducts will create an advantage, especially with waste streams that are still considered ‘organic’, like slaughter and food waste. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">B)</span><span style="font-size: 7pt">     </span><span style="font-size: 10pt"><b>ANIMAL WASTE.</b> According to the American Biogas Council here are 473 animal waste digesters operating in the U.S. today, most on dairy operations. The American Biogas Council and USDA’s AgSTAR program estimate more than 8,000 additional sites with development potential. The ARS was designed specifically for this purpose: control ammonia from livestock waste and produce the highest value byproducts with it. Digestate from animal waste AD has enjoyed the same reduced regulatory requirements as land applying raw manure. Recent trends in Michigan and California indicate they will treat animal waste digestate as any industrial source, subject to groundwater permitting requirements. Bion believes its proven technology and value-added fertilizers will give it a significant competitive advantage in this evolving market.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion is now focused primarily on: i) operation and further testing at the Initial Project, our initial commercial-scale Gen3Tech installation, for support of design/feasibility studies/reports related to our initial JV Projects (and further optimization of its operational parameters), ii) pre-development planning of the LOI Projects (and/or other Gen3Tech beef JV projects) including steps toward distribution agreements, iii) developing applications and markets for its low carbon ‘ClimateSmart’ and organic fertilizer products (including listings/certifications of multiple liquid and solid products) and its sustainable (conventional and organic) animal protein products, and iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed herein) (and related Projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), (v) exploring JVs re stand-alone ARS markets, while (vi) continuing to pursue business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&amp;D activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>HISTORY, BACKGROUND AND CURRENT ACTIVITIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since the Company’s inception, Bion has designed and developed advanced waste treatment systems for livestock. The first and second generations of Bion’s technology platform were biological systems, primarily focused on nutrient control. Over 30 of these systems were deployed at New York dairies, Florida food processing facilities and dairies, North Carolina hog farms, a Texas dairy and a Pennsylvania dairy (“Kreider 1 Project”). The systems were highly effective at their intended purpose: capturing nitrogen and phosphorus. They produced BionSoil as a byproduct, which was a remarkably effective soil amendment/ fertilizer product, but whose value was not enough to support a viable business model. As such, these early technology iterations were entirely dependent on either implementation of new regulations requiring waste treatment, or subsidy/ incentive programs that would provide ‘payment for ecosystem services’. By the mid-2010’s, it became apparent that neither of these options were imminent or even assured, so the Company initiated the steps to reimagine and redesign its technology.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From 2016 to 2021 fiscal years, the Company focused most of its activities and resources on developing, testing and demonstrating the third generation of its technology and technology platform (“Gen3Tech”) that was developed with an emphasis producing more valuable co-products from the waste treatment process, including renewable natural gas and ammonium bicarbonate, a low-carbon, organic ’pure’ nitrogen fertilizer product, while raising sustainable livestock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The $175 billion U.S. livestock industry is under intense scrutiny for its environmental and public health impacts – its ‘environmental sustainability’-- at the same time it is struggling with declining revenues and margins (derived in part from clinging to its historic practices and resulting limitations and impacts) which threaten its ‘economic sustainability’. Its failure to adequately respond to consumer concerns including food safety, environmental impacts, and inhumane treatment of animals have provided impetus for plant-based alternatives such as Beyond Meat and Impossible Burger (and many others) being marketed as “sustainable” alternatives for this growing consumer segment of the market (despite the lack of verifiably sustainable attributes).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company believes that its Gen3Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of i) verifiably sustainable-branded conventional livestock products and ii) verifiably sustainable organic-branded livestock products, both of which will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a production/marketing opportunity for Bion (but the former is far larger). Our Gen3Tech will also produce (as co-products) biogas, solar photovoltaic electricity in appropriate locations, and valuable low carbon/organic fertilizer products, which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects) and/or marketed to the growing organic fertilizer market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2022-23, the Company entered into 3 LOIs setting forth the parties’ intention to negotiate joint venture agreement (“JVA”) and enter into joint ventures (“JV”) to develop and operate 15,000 head integrated, sustainable beef facilities (with future expansion under consideration) including:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; width: 96px"> </td> <td style="font: 12pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">a)</span></td> <td style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 10pt">innovative cattle barns (with slatted floors to facilitate movement of manure to the anaerobic digester and potentially solar PV generation on the rooftops which barns will improve the living conditions of the animals while increasing feeding/weight gain efficiency,</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 96px"> </td> <td style="width: 24px"><span style="font-size: 10pt">b)</span></td> <td><span style="font-size: 10pt">‘customized’ anaerobic digestion systems (including pretreatment to increase renewable natural gas (‘RNG’) production and an RNG cleaning system (which will include capture/recycling of the CO2) to allow pipeline sales and monetization of related environmental credits,</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 96px"> </td> <td style="width: 24px"><span style="font-size: 10pt">c)</span></td> <td><span style="font-size: 10pt">a Bion Gen3Tech module (which will utilize the recycled CO2 to increase ammonia nitrogen/ammonium bicarbonate recovery) for the production of ammonia nitrogen fertilizer for use in organic and/or ‘ClimateSmart’ low carbon crop production (plus residual organic solids and clean water),</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 96px"> </td> <td style="width: 24px"><span style="font-size: 10pt">d)</span></td> <td><span style="font-size: 10pt">which will produce verifiably sustainable beef products with USDA certified branding.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify">The opportunity presented by the LOIs to commercialize the Company’s Gen3Tech and business model matured more quickly than anticipated (reflecting strong industry and public momentum in favor of verifiably sustainable food ventures). As a result, we have shifted our plans to focus resources and make our initial <span id="xdx_90B_ecustom--Techwastage_uDecimal_c20230701__20231231__srt--CounterpartyNameAxis__custom--Gen3TechMember_zms2ZQ1fUAad" title="Tech wastage">15,000</span> head operation a reality as soon as possible.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To place the LOI Projects in the context of Company’s business plan (and our prior public disclosure), if the contemplated ventures move forward on the timelines currently contemplated, active development of the initial LOI Project will commence during 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a pre-cursor to such activity, the Company has constructed and commenced operations of the initial phase of our previously discussed Gen3Tech demonstration project near Fair Oaks, Indiana (“Initial Project”): i) to validate our existing data and modeling at commercial scale and ii) to optimize the Bion Gen3Tech module for finalization of design parameters and fabrication details of our planned 15,000 head commercial facilities (including the LOI Projects). For the purposes of this initial phase, the Company, in order to accelerate the data acquisition phase, is utilizing anaerobic digester effluent from the nearby/contiguous Fair Oaks dairy. Thereafter, the Company will evaluate what, if any, additional facilities and testing will take place at that location.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During late September 2021, Bion entered into a lease for the development site of the Initial Project, our initial commercial scale Gen3Tech project, which Initial Project will be located on approximately four (4) acres of leased land near Fair Oaks, Indiana, and a related agreement regarding disposal of certain manure effluent with the Curtis Creek Dairy unit of Fair Oaks Farms (“FOF”). Design and pre-development work commenced during August 2021 and preliminary surveying, site engineering and other work is now underway along with site-specific engineering and design work. The Initial Project was initially planned to be an environmentally sustainable beef cattle feeding facility, equipped with state-of-the-art housing and Bion’s 3G-Tech platform to provide waste treatment and resource recovery. Bion has designed the project to house and feed approximately 300 head of beef cattle. If all phases of the Initial Project are constructed, the facility will include Bion’s Gen3Tech platform including: i) covered barns (possibly including roof top solar photovoltaic generation), ii) anaerobic digestion for renewable energy recovery, iii) livestock waste treatment and resource recovery technology, iv) Bion’s ammonium bicarbonate recovery and crystallization technology and iv) data collection software to document system efficiencies and environmental benefits (with the Bion Gen3Tech facilities capable of treating the waste from approximately <span id="xdx_90E_ecustom--Techwastage_uDecimal_c20230701__20231231_z66h6lZ4Y2P9" title="Tech wastage">1,500</span> head). The facility is large enough to demonstrate engineering capabilities of Bion’s Gen3Tech at commercial scale, but small enough that it can be constructed and commissioned relatively quickly. Originally, construction and onsite assembly operations were targeted to commence sometime late in 2022, however, supply chain backlogs (many pandemic-associated) delayed delivery dates for core modules of the Bion system to the site until during January 2023. Construction has been substantially completed related to Phase 1 of the Initial Project, shakedown operations undertaken and the operation is now focused on optimization of operation parameters. See Note 3 “Property and Equipment” and Note 12 “Subsequent Events” (for activities since the start of the first quarter of the 2024 fiscal year).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Specifically, the Initial Project was designed/developed to provide and/or accomplish the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: right"><span style="font-size: 10pt">i.</span></td> <td style="width: 24px"> </td> <td style="text-align: justify"><span style="font-size: 10pt">Proof of Gen3Tech platform scalability</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px"> </td> <td style="width: 12px"><span style="font-size: 10pt">-</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Document system efficiency and environmental benefits and enable final engineering modifications to optimize each unit process within the Bion Gen3Technology platform. </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px"> </td> <td style="width: 12px"><span style="font-size: 10pt">-</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Environmental benefits will include (without limitation) renewable energy production (natural gas recovery from AD and solar electric from integrated roof top photovoltaic generation); nutrient recovery and conversion to stable organic fertilizer; pathogen destruction; water recovery and reuse; air emission reductions.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: right"><span style="font-size: 10pt">ii.</span></td> <td style="width: 24px"> </td> <td style="text-align: justify"><span style="font-size: 10pt">Use Bion’s data collection system to support 3<sup>rd</sup> party verified system efficiency requirement to qualify for USDA Process-Verified-Program (PVP): certification of sustainable branded beef (and potentially pork) product metrics.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: right"><span style="font-size: 10pt">iii.</span></td> <td style="width: 24px"> </td> <td style="text-align: justify"><span style="font-size: 10pt">Produce sufficient ammonium bicarbonate nitrogen fertilizer (“AD Nitrogen”) in liquid and solid forms for commercial testing by potential joint venture partners and/or purchasers, for university growth trials and to provide samples (and related documentation) to support applications for organic and/or ‘ClimateSmart’ certifications.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: right"><span style="font-size: 10pt">iv.</span></td> <td style="width: 24px"> </td> <td style="text-align: justify"><span style="font-size: 10pt">Produce sustainable beef products for initial test marketing efforts.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $<span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20220127__20220128_zdc0uBydlrK2" title="Debt instrument paid amount">2,665,500</span> (and made the initial <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220127__20220128_zDysdoylDpG2" title="Percentage of initial amount">25</span>% payment ($<span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20220127__20220128_zhtVPFl22lnb" title="Principal, interest">666,375</span>) for the core of the ‘Bion System’ portion (without the crystallization modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. The Company received progress billing in March 2022 and June 2022 for the second and third <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220601__20220630_z2Td14yiWy0f" title="Percentage of initial amount">25</span>% installments, both of which have been paid as of the filing date. On January 17, 2023 the Company received an invoice from Buflovak for $<span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20230116__20230117_zsEBIFwXD7X7" title="Principal, interest">533,100</span> which was paid on March 1, 2023 and on April 24, 2023 the Company received an invoice from Buflovak for $<span id="xdx_902_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20230423__20230424_zgbK19aKyzNg" title="Principal, interest">83,275</span> which was paid on May 2, 2023 bringing the aggregate payments to $<span id="xdx_90A_ecustom--AggregatePayment_pp0p0_c20230501__20230502_ziwi8qgt0gFg" title="Aggregate payment">2,615,500</span> as of the date of this filing. There remains $<span id="xdx_903_ecustom--PurchaseOrder_pp0p0_c20230725__20230726_zrvM0RlYYwkb" title="Purchase order">50,000</span> open on the Purchase Order has been billed on July 26, 2023. In addition to the Purchase Order, through December 31, 2023 the Company has incurred additional costs of $<span id="xdx_901_ecustom--AdditionalInterestCostsIncurredCapitalized_pp0p0_c20230701__20231231_zMKSyde3XRGg" title="Additional incurred additional costs">6,442,812</span> on the Initial Project for capitalized interest and costs, non-cash compensation, equipment and consulting fees. $<span id="xdx_903_ecustom--InterestCostsCapitalizedPaid_pp0p0_c20230701__20231231_zcAuk8DVqK3c" title="Capitalized labour and interest costs paid">6,983954</span> has been paid and $<span id="xdx_90A_eus-gaap--InterestCostsCapitalizedAdjustment_pp0p0_c20230701__20231231_zPEfp1wxTsE8" title="Capitalized labour and interest costs yet to pay">1,750,170</span> has been billed and not yet paid.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Buflovak has worked with the Company on design and testing of its 3G Tech over several years. The basic design for the Initial Project’s Bion System is complete, fabrication and delivery of equipment from Buflovak from the Purchase Order Agreement has been largely completed and assembly/construction is in process.  3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, utilities, etc.) for work related to the Initial Project. The Company has incurred costs of $<span id="xdx_909_eus-gaap--InterestCostsIncurred_pp0p0_c20230701__20231231_zMmbBNvNjM3k" title="Incurred costs">8,177,452</span> on the Initial Project, not including capitalized labor and interest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Initial Project will be carried out in stages with phase one focused largely on portions of items i. and iii. set forth above.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon completing the primary goals of phase 1 of the Initial Project (coupled with obtaining organic certifications(s) for our liquid and/or solid ammonium bicarbonate fertilizer product lines), Bion expects to be ready to move forward with its plans for development of much larger facilities including the LOI Projects, including final design of its Gen3Tech modules. The Company anticipates that discussions and negotiations it has begun (together with additional opportunities that will be generated over the next 12-24 months) regarding potential JVs with strategic partners in the financial, livestock and food distribution industries to develop large scale projects will continue during the optimization operations of the Initial Project with a 2024 goal of establishing multiple JV’s for large scale projects that will produce sustainable and/or sustainable-organic corn-fed beef. These products will be supported by a USDA PVP-certified sustainable brand that will, initially, highlight reductions in carbon and nutrient footprint, as well as pathogen reductions associated with foodborne illness and antibiotic resistance, along with the organic designation where appropriate. Bion has successfully navigated the USDA PVP application process previously, having received conditional approval of its 2G Tech platform (pending resubmission and final site audits), and is confident it will be successful in qualifying its Gen3Tech platform.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After the basic technology start-up milestones of the Initial Project (primarily optimization and steady-state operations of the core modules of our Gen3Tech platform) have been met, the Company will determine whether to complete the entire Initial Project as originally designed at that location or the relocate the core modules to an alternative permanent location. The Company has engaged in discussion with the University of Nebraska-Lincoln to jointly develop an integrated beef facility based on Bion’s Gen3Tech and business model at its Klosterman Feedyard Innovation Center (“KFIC”) (or other mutually agreed upon location) which facility would include innovative barns, an anaerobic digester and a Bion Gen3Tech system to conduct ongoing research and development related thereto and the KFIC is a possible site for the long-term re-location of the core modules. This venture, if it moves forward, is anticipated to include joint preparation of applications for grants and other funding from the USDA (‘climate smart’ program, rural development, etc.) and other sources. The Company will also evaluate re-locating the core module of the Initial Project to Dalhart, Texas, where it might be integrated into the first phases of the Dalhart Project and/or other locations. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020. Applications for our first solid ammonium bicarbonate product line have been filed with OMRI and the California Department of Food &amp; Agriculture (“CDFA”) without success to date , in part due to the novel nature of our Gen3Tech in the context of organic certifications). The Company anticipates filing multiple new applications with OMRI and CDFA (and possible others) for higher concentration liquid products and solid products based on production from the Initial Project over the next several months. See “<b>Fertilizer– Organic and ‘ClimateSmart’</b>” below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, the Company believes there will also be opportunities to proceed with selected ‘retrofit projects’ of existing facilities (see ‘<b><span style="text-decoration: underline">Gen3Tech Kreider 2 Poultry Project’</span></b> below as an example) in the swine, dairy and poultry industries utilizing our Gen3Tech.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion believes that substantial unmet demand currently exists– potentially very large – for ‘real’ meat/dairy/egg products that offer the verifiable/believable sustainability consumers seek, but with the taste and texture they have come to expect from American beef and pork, dairy and poultry. Numerous studies demonstrate the U.S. consumers’ preferences for sustainability. For example, 2019 NYU Stern’s Center for Sustainable Business study found that ‘products marketed as sustainable grew 5.6 times faster than those that were not…’ and that ‘…in more than 90 percent of consumer-packaged-goods (CPG) categories, sustainability-marketed products grew faster than their conventional counterparts.’ Sales growth of plant-based alternatives, including both dairy and more recently ground meat (Beyond Meat, Impossible Foods, etc.) have shown that a large, but apparently limited, segment of consumers is choosing seemingly sustainable offering, and are also willing to pay a premium for it. Tyson Foods, in the context of launching its Brazen beef initiative, recently said, “consumers would be willing to pay at least 24 percent more for environmentally friendly, sustainable options at retail.” Numerous studies also support the consumers’ ‘willingness-to-pay’ (WTP) for sustainable choices, including a recent meta-analysis of 80 worldwide studies with results that calculate the overall WTP premium for sustainability is <span id="xdx_907_ecustom--PercentageOfSustainable_dp_c20230701__20231231_zMr5xjUydwDg" title="Percentage of sustainable">29.5</span> percent on average.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As one of the largest contributors to some of the greatest air and water quality problems in America, it is clear that livestock waste cleanup, at scale, represents one of the greatest opportunities we have to reduce negative environmental impacts of the food supply chain on air and water quality. Bion’s Gen3Tech platform, along with its business model, will enable the cleanup of one of the ‘dirtiest’ parts of the food supply chain: animal protein production and creates the opportunity to produce and market verifiably sustainable organic and conventional ‘real meat’ products that can participate in the growth and premium pricing that appears to be readily available for the ‘right’ products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion believes that at least a premium segment of the U.S. beef industry (and potentially other livestock industry groups) is at the doorstep of a transformative opportunity to address the growing demand for sustainable food product offerings, while pushing back against today’s anti-meat messaging. At $66 billion/year (2021 wholesale/farmgate value), the beef industry is a fragmented, commodity industry whose practices date back decades. In 1935 inflation-adjusted terms, beef was 63% more expensive in 2021, while pork and chicken, which are now primarily raised in covered barns at CAFOs with highly integrated supply chains, were 12% and 62% cheaper, respectively. In recent years, the beef industry has come under increasing fire from advocacy groups, regulatory agencies, institutional investors, and ultimately, their own consumers, over concerns that include climate change, water pollution, food safety, and the treatment of animals and workers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advocacy groups targeting livestock and the beef industry have recently been joined by competitors that produce animal protein alternatives in seeking to exploit the industry’s environmental and economic weaknesses. Their global anti-meat messaging has had a substantial chilling effect on the relationships the beef industry has with its institutional investors; retail distributors, such as fast-food restaurants; and mostly, its consumers. Led by the United Nations Food and Agriculture Organization, a coordinated anti-meat messaging campaign has targeted consumers worldwide, primarily focused on the industry’s impacts on climate change. A 2018 NielsenIQ Homescan survey last year found that 39% of Americans are actively trying to eat more plant-based foods. Some of the recent growth in plant-based proteins results from increasing lactose intolerance and other health concerns; however, most of that growth is attributed to consumers’ growing concerns for the environmental impacts of real meat and dairy. Several large US companies that have traditionally focused on livestock production, including Cargill, ADM, Perdue Foods, and Tyson, have also recently entered the plant protein space. While meat alternatives, especially plant-based protein producers like Beyond Meat and Impossible Foods, have been heavily promoted (by themselves and the media) and enjoyed remarkable initial sales growth, recently, sales have flattened and/or declined over the past 18 months. It should be noted that these plant-based protein producers are primarily expected to be able to serve the ground/ processed meat market, which represents only about 10 percent of the overall animal protein market. Further, there has recently been pushback to these plant-based products, focusing on their highly processed nature and unproven health benefits, scalability/ pricing, and their uncertain carbon footprint---and market growth rates have substantially slowed and may have already plateaued and/or peaked. There have also been several companies recently enter the cellular and 3D-printed meat arena. While facing myriad challenges and further out on the development timeline, some people believe cellular agriculture (aka cultured, clean, lab-grown, cultivated) meat may have the potential to service a much larger percentage of the market than plant-based protein, including cuts like steaks, chops and roasts, but the likely cost remains very uncertain at this point.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In terms of changing customer preferences, ‘saving the planet’ has proven to be a more compelling argument than the traditional animal activism/ welfare pitch. To date, the primary beef ‘industry response’ to this has been grass-fed beef, which is regarded as a generally more sustainable offering than grain-fed (largely without empirical evidence). However grass-fed beef has had only limited acceptance in U.S. markets, because it is less flavorful and tougher than the traditional corn-fed beef consumers have grown to enjoy. Sustainability initiatives have been launched by large US livestock producers (including Tyson’s very recent ‘Brazen’ program), but it is not yet possible to determine the extent the attributes of such products will be substantive and verifiable rather than completely ‘modeled’ and largely public relations ‘greenwashing’.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each of these items supports Bion’s belief that there is a potentially very large opportunity to supply premium sustainable beef products that satisfy consumer concerns. We believe that the real meat/beef products that can be cost-effectively produced today using our Gen3Tech platform, both sustainable and/or organic, can provide an affordable product that satisfies the consumer’s desire for sustainability, but with the superior taste and texture those consumers have grown to prefer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Sustainable Beef</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion’s goal is to be one of the ‘first to market’ with meaningfully verified sustainable beef products that can be produced at sufficient scale to service national market demand. The cattle produced at Bion facilities will have a substantially lower carbon footprint, dramatically reduced nutrient impacts to water, and an almost total pathogen kill in the waste stream. Further, the economics of producing these cattle (including the cost of the facility/technology upgrade) will be greatly enhanced by the revenue realized from the recovery of valuable resources, including renewable energy, high-value fertilizer products, and clean water.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A Bion sustainable beef facility will be comprised of covered barns with slotted floors (allowing the waste to pass through) which will reduce ammonia and greenhouse gas volatilization and loss, as well as odors, thereby improving animal health and human working conditions while preventing air/soil pollution. The manure will be collected and moved directly to anaerobic digestion facilities which will produce renewable natural gas (and re-cycle CO2 from the gas cleaning process). Covered barns will reduce weather impacts on the livestock and have been demonstrated to promote improved general health and weight gain in the cattle housed in them. The barns’ very large roof surface area will be utilized (in geographical locations with adequate sunshine and appropriate ‘tariffs’) for the installation of photovoltaic solar generation systems to produce electricity for the facility, as well as export to the grid. The barn roofs will also be configured to capture rainwater, which, coupled with the water recovered from the treatment process, will reduce the projects’ reliance on current water supplies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Waste treatment and resource recovery will be provided by Bion’s advanced Gen3Tech platform, which Bion believes offers the most comprehensive solution for livestock waste available today. In addition to direct environmental benefits, every pound of nitrogen that is captured, upcycled, and returned to the agricultural nitrogen cycle as high-quality fertilizer (vs lost to contaminate downstream waters), is also a pound of nitrogen that will not have to be produced as synthetic urea or anhydrous ammonia, with their tremendous carbon cost. System performance and environmental benefits will be monitored and verified through third parties, with USDA PVP certification of the sustainable brand that Bion also believes will be the most comprehensive available in the market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Recently there have been efforts to establish sustainable brands (including USDA PVP certification) for a number of small-scale livestock producers (largely in the grass-fed beef category). To date, the reach and extent of such efforts is limited and it is difficult to determine their effectiveness. Additionally, there have been public announcements of initiatives related to beef sustainability (largely focused on the ‘cow-calf’ segment of the livestock chain) in procurement by major beef processing companies (including Tyson’s very recent ‘Brazen’ program), but a closer look finds that many have consisted largely of ‘green washing’ public proclamations in the wake of environmental and social criticism that re-package prior initiatives and lack any significant new substance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Sustainable Organic Beef</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion also believes it may also have a unique opportunity to produce, at scale, affordable corn-fed organic beef that is also certified as sustainable. In addition to the sustainable practices described above, organic-sourced beef cows would be finished on organic corn, which would be produced using the ammonium bicarbonate fertilizer captured by the Gen3Tech platform. Bion believes its meat products will meet consumer demands with respect to sustainability and safety (organic) and provide the tenderness and taste American consumers have come to expect from premium conventional American beef. Such products are largely unavailable in the market today. We believe Bion’s unique ability to produce the fertilizer needed to grow a supply of relatively low-cost organic corn, and the resulting opportunity to produce organic beef, will dramatically differentiate us from potential competitors. This organic opportunity is dependent on successfully establishing Bion’s fertilizer products as acceptable for use in organic grain production.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Today, organic beef demand is limited and mostly supplied with grass-fed cattle. While organic ground/ chopped meat has enjoyed success in U.S. markets, grass-fed steaks have seen limited acceptance, mostly resulting from consumer issues with taste and texture. In other words, it’s tough. Regardless, such steaks sell for a significant premium over conventional beef. A grain-finished organic beef product is largely unavailable in the marketplace today due to the higher costs of producing organic corn and grain. The exception is offerings that are very expensive from small ‘boutique’ beef producers. Like all plants, corn requires nitrogen to grow. Corn is especially sensitive to a late-season application of readily available nitrogen – the key to maximizing yields. With non-organic field corn, this nitrogen is supplied by an application of a low-cost synthetic fertilizer, such as urea or anhydrous ammonia. However, the cost for suitable nitrogen fertilizer that can be applied late-season in organic corn production is so high that the late-season application becomes uneconomical, resulting in substantially lower yields – a widely recognized phenomena known as the ‘yield gap’ in organic production. The yield gap results in higher costs for organic corn that, in turn, make it uneconomical to feed that corn to livestock. As is the case for sustainable but not organic beef, Bion believes there is a potentially large unmet demand for affordable beef products that are both sustainable AND organic, but with the taste and texture consumers have come to expect from American beef. Bion’s ability to produce the low-cost nitrogen fertilizer that can close the organic yield (and affordability) gap puts the Company in a unique, if not exclusive at this time, position to participate in JV’s that will benefit from this opportunity starting next year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The demonstrated willingness of consumers to purchase sustainable products (along with numerous research and marketing studies confirming consumers are seeking, and are willing to pay a premium for, sustainable products)---in combination with the threat to the livestock industry market (primarily beef and pork) posed by plant-based alternatives (heightened by pandemic conditions)--- has succeeded in focusing the large scale livestock industry on how to meet the plant-based market challenge by addressing the consumer sustainability issues. The consumer demand for sustainability appears to be a real and lasting trend, but consumers remain skeptical of generalized claims of ‘sustainability’. To date, a large portion of the industry responses to this trend have been at a superficial level or consist of ‘green washing’, a deceptive marketing practice where companies promote non-substantive initiatives. Real sustainability for the livestock industry will require implementation of advanced waste treatment technology at or near the CAFOs – where most of the negative environmental impacts take place.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fertilizer: Organic and ‘Climate Smart’ </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“Gen3Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of low carbon and/or organically certified soluble nitrogen fertilizer products. The Company’s low concentration ammonium bicarbonate liquid product successfully completed its Organic Materials Review Institute (“OMRI”) application and review process with listing approval during May 2020. During the next 2 months the Company intends to file applications with OMRI and the California Department of Food &amp; Agriculture (“CDFA”) for a line of higher concentration liquid ammonium nitrogen products (ranging from 4% up to 16% (or higher)) based on production of liquid samples during operation of the Initial Project. The Company anticipates applying for and obtaining one or more listings/certifications for higher concentration products in our liquid ammonium nitrogen fertilizer line well prior to operational dates for the Company’s initial large-scale JV Gen3Tech Sustainable Beef Projects.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, the Company intends to explore the market potential for its fertilizer (in liquid and/or solid forms) to be a verifiably ‘ClimateSmart’ product (potentially a much larger market than the organic market) with focus on higher value specialty crops. This will require working with industry and academic entities to develop appropriate metrics and producing a ‘life cycle assessment’ (LCA) for Bion’s ammonium nitrogen fertilizer product which can be compared to conventional nitrogen fertilizer products. Bion’s processes will capture and utilize CO2 in the waste stream (including CO2 produced with the renewable natural gas (RNG) by anaerobic digestion that is usually vented to the atmosphere) as stabilizing agent thereby potentially creating carbon offsets compared to natural gas utilized as feedstock in chemical ammonia production which reduction will be reflected in the LCA. This LCA will assess environmental impacts associated with fertilizer production in support of the beef cattle supply chain for both the existing conventional approach (primarily fossil fuel-based Haber-Bosch production methods) and the largely decarbonized Bion production approach. We believe a series of coincident yet significant LCA benefits accrue from Bion’s patented fertilizer production approach including the reduced loss of ammonia to the environment via air (volatilized) and water (nitrate in groundwater) pathways, recycled/reused water, elimination of pathogens, the production of renewable natural gas, the production solar energy from photovoltaic panels on barn roofs, enhanced animal welfare practices and reduced animal husbandry risks from extreme weather events. Bion believes that current evaluations of the carbon impact from feedlot operations materially underestimate the negative impacts because existing models do not properly include significant ‘downstream’ carbon impacts of required energy intensive waste water treatment for re-deposited ammonia nitrogen. If the Company determines there is a significant ‘ClimateSmart’ opportunity for our fertilizer products, such an LCA can be completed (based in part on data from the Initial Project) and support marketing efforts well prior to operational dates for the Company’s initial large scale JV Gen3Tech projects.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ammonium bicarbonate, manufactured using thermal and mechanical processes, has a long history of use as a fertilizer. In addition to liquid ammonium nitrogen fertilizer, Bion’s Gen3Tech is capable of recovering nitrogen in the form of solid ammonium bicarbonate products containing up to 18%-22% (or higher) nitrogen in a crystalline form that is easily transported (while producing liquids with various percentages of ammonium bicarbonate nitrogen during interim stages of the process). This solid product is water soluble and provides a readily available nitrogen source for crops. It will contain virtually none of the other salt, iron and mineral constituents of the livestock waste stream that often accompany other organic fertilizers. This product is being developed to fertilizer industry standards so that it that can be precision-applied to crops using existing equipment. Bion believes that this product will potentially have broad applications in the production of organic and/or ClimateSmart grains for livestock feed, row crops, horticulture, greenhouse and hydroponic production, and potentially retail lawn and garden products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ammonium bicarbonate products (liquid and solid) produced by Bion’s Gen3Tech platform will enjoy a dramatically lower carbon footprint than synthetic nitrogen fertilizers. Much of the reactive nitrogen captured and upcycled into our fertilizer products was going to be lost through volatilization and runoff, and that loss would generally need to be offset with a synthetic nitrogen fertilizer, such as anhydrous ammonia or urea. These synthetic nitrogen products are produced through the Haber-Bosch (and other) synthetic processes, which converts hydrogen and atmospheric nitrogen to ammonia, with methane from fossil fuels as the energy source. It is an extremely energy-intensive process with a carbon footprint that, while not yet fully understood, is widely accepted to by very large. While a complete Life Cycle Assessment (LCA) of carbon impacts from synthetic fertilizer production is not yet available, according to the Institute for Industrial Productivity, its production alone is responsible for approximately 1 percent of total global CO2 emissions. To the extent that Bion can capture and repurpose the nitrogen traditionally lost from livestock waste, that carbon cost will no longer need to be paid by the environment/climate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Applications for our first solid form of concentrated ammonia, soluble nitrogen fertilizer product line were filed with OMRI (filed during May 2021) and CDFA (filed during May 2022) without success to date. After an extended review processes (which was largely opaque), the OMRI application proceeded through multiple stages without receiving a positive result. We have initiated an informal dialogue with CDFA regarding the basis for and re-consideration of its initial determination and have submitted additional supplemental supporting materials to CDFA. The Company’s solid product line is novel (in the context of organic certification) in part due to the fact that no formal listing category currently in the organic space for a solid form of concentrated ammonia, soluble nitrogen fertilizers and there is no clear guidance at present from internal policy manuals on how to categorize this product and the process that produces it. There is also no clear guidance at present from either the NOP or the National Organic Standards Board (“NOSB”) (which is currently involved in a related review and recommendations process regarding ‘high nitrogen liquid fertilizers’ derived from ammonia from manure). The Company and its representatives, along with a number of other organic fertilizer stakeholders, are involved in discussions regarding resolution of these matters at all three levels. The Company intends to continue efforts to obtain listing/certification for its solid nitrogen fertilizer line over the course of this fiscal year.</p> <p style="font: 10pt/110% Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Gen3Tech Kreider 2 Poultry Project</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_901_ecustom--DescriptionOfKreider2PoultryProject_c20230701__20231231_zXP9evHK6pna" title="Description of kreider 2 poultry project">Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) (‘Kreider Renewable Energy Facility’ or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). Now that development of the Company’s Gen3Tech is being deployed, the Company has commenced discussions with KF regarding updating and amending the JV agreement and anticipates executing an amended joint venture agreement during 2023. During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2<sup>nd</sup> generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA).</span> Note that this Project may also be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). The Company anticipates if and when PA2 re-commences work on the Kreider 2 Project, it will submit a new application based on our Gen3Tech. Site specific design and engineering work for this facility have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during the following calendar year. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its proposed use of Bion’s Gen3Tech for increased recovery of marketable by-products and sustainable branding, are based in material part the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. However, liquidity in the Pennsylvania nutrient credit market has not yet developed significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Note that while Bion believes that the Kreider 2 Project and/or subsequent Bion Projects in PA and the Chesapeake Bay Watershed will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees/premiums related to a ‘sustainable brand’, the Covid-19 pandemic has delayed legislative efforts needed to commence its development. However, the Company is currently engaged in dialogue with the regional EPA office and the Chesapeake Bay Program Office regarding the potential of the Company’s Gen3Tech Kreider2 Project (and other potential projects) to enable Pennsylvania to move forward toward meeting its Chesapeake Bay clean-up goals. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Technology Deployment: Bion Gen3Tech</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the absence of firm regulatory mandates, widespread deployment of waste treatment technology, and the sustainability it enables, is largely dependent upon generating sufficient additional revenues to offset the capital and operating costs associated with technology adoption. Bion’s Gen3Tech business platform has been developed to create opportunities for such augmented revenue streams, while providing third party verification of sustainability claims. The Gen3Tech platform has been designed to maximize the value of co-products produced during the waste treatment/recovery processes, including pipeline-quality renewable natural gas (biogas) and commercial fertilizer products approved for organic production and/or certified as ‘ClimateSmart’. All processes will be verifiable by third parties (including regulatory authorities and certifying boards) to comply with environmental regulations and trading programs and meet the requirements for: a) renewable energy and carbon credits, b) organic certification of the fertilizer coproducts and c) USDA PVP certification of an ‘Environmentally Sustainable’ brand (see discussion above and below), and d) payment for verified ecosystem services. The Company’s first patent on its Gen3Tech was issued during 2018. In August 2020, the Company received a Notice of Allowance on its third patent which significantly expands the breadth and depth of the Company’s Gen3Tech coverage. The Company has additional applications pending and/or planned. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In parallel with technology development, Bion has worked (which work continues) to implement market-driven strategies designed to stimulate private-sector participation in the overall U.S. nutrient and carbon reduction strategy. These market-driven strategies can generate “payment for ecosystem services”, in which farmers or landowners are rewarded for managing their land and operations to provide environmental benefits that will generate additional revenues. Existing renewable energy credits for the production and use of biogas are an example of payment for ecosystem services. Another such strategy is nutrient trading (or water quality trading), which will potentially create markets (in Pennsylvania and other states) that will utilize taxpayer funding for the purchase of verified pollution reductions from agriculture (“nutrient credits”) by the state (or others) through competitively-bid procurement programs. Such credits can then be used as a ‘qualified offset’ by an individual state (or municipality) to meet its federal clean water mandates at significantly lower cost to the taxpayer. Market-driven strategies, including competitive procurement of verified credits, is supported by U.S. EPA, the Chesapeake Bay Commission, national livestock interests, and other key stakeholders. Legislation in Pennsylvania to establish the first such state competitive procurement program passed the Pennsylvania Senate by a bi-partisan majority during March 2019 but has not yet crossed the hurdles required for actual adoption. The Covid-19 pandemic and related financial/budgetary crises have slowed progress for this and other policy initiatives and, as a result, it is not currently possible to project the timeline for completion (or meaningful progress) of this and other similar initiatives (see discussion below).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The livestock industry and its markets are already changing. With our commercial-ready technology and business model, Bion believes it has a ‘first-mover advantage’ over others that will seek to exploit the opportunities that will arise from the industry’s inevitable transformation. Bion anticipates moving forward with the development process of its initial commercial installations utilizing its Gen3Tech, during the current 2024 fiscal year. We believe that Bion’s Gen3Tech platform and business model can provide a pathway to true economic and environmental sustainability with ‘win-win’ benefits for at least a premium sector of the livestock industry, the environment, and the consumer, an opportunity which the Company intends to pursue.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">The Livestock Problem</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The livestock industry is under tremendous pressure from regulatory agencies, a wide range of advocacy groups, institutional investors and the industry’s own consumers, to adopt sustainable practices. Environmental cleanup is inevitable and has already begun — and policies have already begun to change, as well. Bion’s Gen3Tech was developed for implementation on large scale livestock production facilities, where scale drives both lower treatment costs and efficient co-products production, as well as dramatic environmental improvements. We believe that scale, coupled with Bion’s verifiable treatment technology platform, will create a transformational opportunity to integrate clean production practices at (or close to) the point of production—the primary source of the industry’s environmental impacts. Bion intends to assist the forward-looking segment of the livestock industry to bring animal protein production in line with 21<sup>st</sup> Century consumer demands for meaningful sustainability.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the U.S. (according to the USDA’s 2017 agricultural census) there are over 9 million dairy cows, 90 million beef cattle, 60 million swine and more than 2 billion poultry which provides an indication of both the scope of the problem addressed by Bion’s technology, as well as the size of Bion’s opportunity. Environmental impacts from livestock production include surface and groundwater pollution, greenhouse gas emissions, ammonia, and other air pollution, excess water use, and pathogens related to foodborne illnesses and antibiotic resistance. While the most visible and immediate problems are related to nutrient runoff and its effects on water quality, the industry has recently been targeted by various stakeholder groups for its impacts on climate change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Estimates of total annual U.S. livestock manure waste vary widely, but start around a billion tons, between 100 and 130 times greater than human waste. However, while human waste is generally treated by septic or municipal wastewater plants, livestock waste – raw manure – is spread on our nation’s croplands for its fertilizer value. Large portions of U.S. feed crop production (and most organic crop production) are fertilized, in part, in this manner. Under current manure management practices, 80% or more of total nitrogen from manure, much of it in the form of ammonia, escapes during storage, transportation, and during and after soil application, representing both substantial lost value and environmental costs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">More than half of the nitrogen impacts from livestock waste come from airborne ammonia emissions, which are extremely volatile, reactive and mobile. Airborne ammonia nitrogen eventually settles back to the ground through atmospheric deposition — it ‘rains’ everywhere. While some of this nitrogen is captured and used by plants, most of it runs off and enters surface waters or percolates down to groundwater. It is now well-established that most of the voluntary conservation practices, such as vegetated buffers that ‘filter’ runoff (often referred to as “BMPs” or “Best Management Practices” that have traditionally been implemented to attempt to mitigate nutrient runoff), are considerably less effective than was previously believed to be the case. This is especially true with regard to addressing the volatile and mobile nitrogen from ammonia emissions, because BMPs are primarily focused on surface water runoff, directly from farm fields in current production, versus the re-deposition that takes place everywhere or groundwater flow.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Runoff from livestock waste has been identified in most of our major watersheds as a primary source of excess nutrients that fuel algae blooms in both fresh and saltwater. Over the last several years, algae blooms have become increasingly toxic to both humans and animals, such as the Red Tides on the Florida and California coasts, and the Lake Erie algae bloom that cut off the water supply to Toledo, Ohio, residents in 2014. When the nutrient runoff subsides, it leaves the algae blooms with no more ‘food’ and the blooms die. The algae’s decomposition takes oxygen from the water, leading to ‘dead zones’ in local ponds, lakes, and ultimately, the Great Lakes, as well as the Chesapeake Bay, Gulf of Mexico, and other estuary waters. Both the toxic algae blooms and the low/no-oxygen dead zones devastate marine life, from shrimp and fish to higher mammals, including dolphins and manatees. U.S. EPA already considers excess nutrients “one of America’s most widespread, costly and challenging environmental problems”. Nutrient runoff is expected to worsen dramatically in the coming decades due to rising temperatures and increasing rainstorm intensity as a result of climate change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nitrate-contaminated groundwater is of growing concern in agricultural regions nationwide, where it has been directly correlated with nutrient runoff from upstream agricultural operations using raw manure as fertilizer. Pennsylvania, Wisconsin, California and Washington, and others, now have regions where groundwater nitrate levels exceed EPA standards for safe drinking water. High levels of nitrate can cause blue baby syndrome (methemoglobinemia) in infants and affect women who are or may become pregnant, and it has been linked to thyroid disease and colon cancer. EPA has set an enforceable standard called a maximum contaminant level (MCL) in water for nitrates at 10 parts per million (ppm) (10 mg/L) and for nitrites at 1 ppm (1 mg/L). Federal regulations require expensive pretreatment for community water sources that exceed the MCL; however, private drinking water wells are not regulated, and it is the owners’ responsibility to test and treat their wells. Additionally, groundwater flows also transport this volatile nitrogen downstream where, along its way, it intermixes with surface water, further exacerbating the runoff problem. Like atmospheric deposition, the current conservation practices we rely on to reduce agricultural runoff are largely bypassed by this subsurface flow.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, in arid climates, such as California, airborne ammonia emissions from livestock manure contribute to air pollution as a precursor to PM2.5 formation, small inhalable particulate matter that is a regulated air pollutant with significant public health risks. Whether airborne or dissolved in water, ammonia can only be cost-effectively controlled and treated at the source—before it has a chance to escape into the environment where it becomes extremely expensive to ‘chase’, capture, and treat.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">High phosphorus concentrations in soils fertilized with raw manure are another growing problem. The ratio of nitrogen to phosphorus in livestock waste is fixed, and because manure application rates are calculated based on nitrogen requirements, often phosphorus is overapplied as an unintended consequence. Phosphorus accumulation in agricultural soils reduces its productivity, increases the risk of phosphorus runoff, and represents a waste of a finite resource. Decoupling the nitrogen from the phosphorus would allow them to be precision-applied, independently of each other, when and where needed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The livestock industry has recently come under heavy fire for its impacts on climate change, which has become a rallying cry for the anti-meat campaign discussed above. Estimates of the magnitude of those impacts vary widely, but the general consensus is that globally, livestock account for 14.5 percent of greenhouse emissions. In the U.S. however, that number drops to 4.2 percent, due to the increased efficiencies of American beef production. The greatest impacts come from direct emissions of methane from enteric fermentation (belches), methane and nitrous oxide emissions from the manure, with arguably the largest being the massive carbon footprint of the synthetic nitrogen fertilizers used to grow the grains to feed the livestock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For decades the livestock industry has overlooked and/or socialized its environmental problems and costs. Today, the impacts of livestock production on public health and the environment can no longer be ignored and are coming under increasing scrutiny from environmental groups and health organizations, regulatory agencies and the courts, the media, consumers, and activist institutional investors. The result has been a significant and alarming loss of market share to plant-based protein and other alternative products. Bion’s Gen3Tech platform was designed to resolve these environmental issues and bring the industry in line with twenty-first century consumer expectations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Going Concern and Management’s Plans:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company incurred a net loss of $<span id="xdx_909_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pp0p0_c20230701__20231231_zXt3sM2uH0cc" title="Net loss">1,464,000</span> and $<span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pp0p0_c20220701__20221231_zWNoCYbA7Wi4" title="Net loss">1,649,000</span> for the six months ended December 31, 2023 and 2022, respectively. At December 31, 2023, the Company has a working deficit and a stockholders’ equity of approximately $<span id="xdx_90A_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20231231_zpb1h0vOXAff" title="Working capital deficit">3,806,000</span> and $3,593,000, respectively. The Company has not generated significant revenues (even though it earned a net income of $<span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pp0p0_c20210701__20220630_zp6us1En4i82" title="Net Income (loss)">8,291,000</span> for the year ended June 30, 2022) and incurred a net loss of approximately ($<span id="xdx_90C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pp0p0_c20220701__20230630_zpJesnKQGPki" title="Net loss">3,189,000</span>) during the year ended June 30, 2023. The net income for the year ended June 30, 2022 was largely due to a one-time, non-cash event of the dissolution of Bion PA-1, LLC (“PA-1”) resulting in a gain of approximately $<span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperations_pp0p0_c20210701__20220630_zI9HZRzPyXF8" title="Gain in non-cash event">10,235,000</span> as well as a one-time gain of $<span id="xdx_903_ecustom--GainOnSaleOfDomainAmount_c20210701__20220630_pp0p0" title="Gain on sale of domain">902,000</span> from the sale of the Company’s ‘biontech.com’ domain pursuant to a purchase agreement during the period. During the year ended June 30, 2023 the Company had debt modifications that resulted in a reduction of debt of $<span id="xdx_901_ecustom--ReductionOfDebt_pp0p0_c20220701__20230630_zWvMDJfuSCX6" title="Reduction of debt">3,516,000</span> and an increase in equity. The Company’s lack of revenue and/or operating profits, together with the low likelihood of generating positive cash flow and/or net income during the next 12-24 months, raise substantial doubt about the Company’s ability to continue as a going concern. <b>The Company is not currently generating any significant revenues. Further, the Company’s anticipated revenues, if any, from existing projects, JVs and proposed projects will not be sufficient to meet the Company’s anticipated operational and capital expenditure needs for many years. As previously noted, the Company is currently not generating significant revenue and accordingly has not generated cash flows from operations. The Company does not anticipate generating sufficient revenues to offset operating and capital costs (for Projects) for a minimum of two to five years. While there are no assurances that the Company will be successful in its efforts to develop and construct its Projects and market its Systems, it is certain that the Company will require substantial funding from external sources. Given the unsettled state of the current credit and capital markets for companies such as Bion, there is no assurance the Company will be able to raise the funds it needs on reasonable terms.</b> The aggregate effect of these factors raises substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. The following paragraphs describe management’s plans with regard to these conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Current liabilities were approximately $<span id="xdx_90A_eus-gaap--LiabilitiesCurrent_iI_pn5n6_c20231231_zINXn1zkQRlh" title="Current liabilities">4.2</span> million and $<span id="xdx_902_eus-gaap--LiabilitiesCurrent_iI_pn5n6_c20221231_zo0pdkCvXfvj" title="Current liabilities">1.6</span> million at December 31, 2023 and 2022, respectively. There was an increase of approximately $<span id="xdx_904_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_pn5n6_c20230701__20231231_z5wdDyt5133a" title="Increase in current liabilities">2.6</span> million (which was largely due to an increase in ‘accounts payable and accrued expenses’ totaling approximately $2.0 million and an increase in ‘deferred compensation’ of approximately $.35 million) as a result of the Company’s limited success in raising new financing (equity and/or debt) during the recent period combined with continued expenses (including those related to the Initial Project).</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>The Company continues to explore sources of additional financing to satisfy its current operating requirements as it is not currently generating any significant revenues. </b>During fiscal years 2023 and 2022 (as a whole), the Company faced less difficulty in raising equity funding (but was subject to substantial equity dilution from the larger amounts of equity financing during the periods) than was experienced in the prior 3 years. <b>However, this positive trend did not continue during the last quarter of the 2023 fiscal year and first and second quarters of the current fiscal year (and the third quarter through the date of this report). The Company raised only raised very limited equity funds during such periods to meet its some of its immediate needs, and therefore, the Company needs to raise substantial additional funds in the upcoming periods. The Company has faced substantial increases in demand for capital and operating expenditures for the fiscal year 2024 to date (and we anticipate such increased demands will continue during the remainder of the 2024 fiscal year and periods thereafter) as it moves toward commercial implementation of its 3G Tech and development of JVs (including costs associated with additions of personnel to carry out the business activities of the Company) and, therefore, is likely to continue to face, significant cash flow management issues due to limited capital resources and working capital constraints which had only recently begun to be alleviated. As a result, the Company has faced, and continues to face, significant cash flow management challenges due to material working capital constraints. To partially mitigate these working capital constraints, the Company's core senior management and some key employees and consultants have been deferring most of their cash compensation and/or are accepting compensation in the form of securities of the Company and members of the Company's senior management have from time-to-time made loans to the Company in the past and may do so in future periods. </b>The Company continues to explore sources of additional financing (including potential agreements with strategic partners – both financial and ag-industry) to satisfy its current and future operating and capital expenditure requirements as it is not currently generating any significant revenues.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended June 30, 2023 and 2022, the Company received gross proceeds of approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20220701__20230630_z1oy86lAfJyc" title="Gross proceeds">4,038,000</span> and $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20210701__20220630_zBDaYZF5Ffxl" title="Gross proceeds">1,737,000</span>, respectively, from the sale of its debt and equity securities. The Company paid commissions on the exercise of warrants in the amount of $<span id="xdx_90D_ecustom--PaymentsToWarrantExercisesCommissions_pp0p0_c20230701__20231231_z29kKats0Zv2" title="Payments to exercise of warrants">86,000</span> and $<span id="xdx_90F_ecustom--PaymentsToWarrantExercisesCommissions_pp0p0_c20220701__20221231_zI4XRF5J74Ql" title="Payments to exercise of warrants">19,000</span> in 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31, 2023 and 2022 the Company received total proceeds of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20230701__20231231_zE9hkMpqMFx3" title="Gross proceeds">443,000</span> and $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20220701__20221231_zioc85OByECa" title="Gross proceeds">602,000</span>, respectively, from the sale of its debt and equity securities. During the six months ended December 31, 2023 the Company received proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20230701__20231231_zNnSAxbS1vn4" title="Gross convertible loan">250,000</span> from a convertible bridge loan <b>but the provider of the bridge loan breached its contractual obligation/binding subscription agreement to fund an additional $<span id="xdx_903_ecustom--DeferredCompensationLiabilityAmountCancelled_pp0p0_c20231101__20231130_zkk2kv4fybmi" title="Total of aggregate amount">1,250,000</span> to the Company during November 2023 (and on an ongoing basis since such time), which breach (combined with management stresses related to the final illness and passing of Dominic Bassani, Bion’s COO and former CEO, and required management transitions) has created a substantial cash flow difficulties for the Company which are ongoing. See Note 6 and Note 9, E4) Bridge Loan/Default below.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company anticipates substantial increases in demand for capital and operating expenditures for the balance of fiscal year 2024 (and we anticipate such increased demands will continue during the 2025 fiscal year and periods thereafter) as it moves toward commercial implementation of its 3G Tech and development of JVs (including costs associated with additions of personnel to carry out the business activities of the Company) and, therefore, is likely to continue to face, significant cash flow management issues due to limited capital resources and working capital constraints which had only recently begun to be alleviated during the 2023 fiscal year. As a result, the Company has faced, and continues to face, significant cash flow management challenges due to material working capital constraints. To partially mitigate these working capital constraints, the Company's core senior management and some key employees and consultants have been deferring most of their cash compensation and/or are accepting compensation in the form of securities of the Company and members of the Company's senior management have from time-to-time made loans to the year ended June 30, 2018, senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $<span id="xdx_905_ecustom--DeferredCompensationLiabilityAmountCancelled_pp0p0_c20170701__20180630_zcxH1z13f06i" title="Total of aggregate amount">2,404,000</span>. Additionally, the Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again during the year ended June 30, 2018. As set forth in detail elsewhere herein, during the year ended June 30, 2023 senior management (and family members) who held convertible obligations of the Company adjusted the terms of their outstanding notes and agreed to debt modifications that reduced of the Company’s debt by $<span id="xdx_901_ecustom--ReductionOfDebt_pp0p0_c20230701__20231231_zz8ZGVyrGMZc" title="Increased shareholders equity">3,516,000</span> and increased shareholders equity by the same amount.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>The constraints on available resources have had, and continue to have, negative effects on the pace and scope of the Company’s efforts to operate and develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. </b>If the Company is able to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and/or curtailment of ongoing activities including research and development activities. The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including the Initial Project, JV Projects (including the Dalhart, Olson and DVG Projects), and the Kreider 2 facility) and CAFO Retrofit waste remediation systems. The Company anticipates that it will seek to raise from $<span id="xdx_90A_eus-gaap--CapitalRequiredForCapitalAdequacy_iI_pp0p0_c20231231__srt--RangeAxis__srt--MinimumMember_zqxkDRyU0pbb" title="Capital required for capital adequacy">20,000,000</span> to $<span id="xdx_901_eus-gaap--CapitalRequiredForCapitalAdequacy_iI_pp0p0_c20231231__srt--RangeAxis__srt--MaximumMember_zYAcs3PBRwY6" title="Capital required for capital adequacy">80,000,000</span> or more debt and/or equity through joint ventures, strategic partnerships and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) and/or through other means during the next twelve months. <b>However, as discussed above, there is no assurance, especially in light of the difficulties the Company has experienced in many recent years and the extremely unsettled capital markets that presently exist for small companies like us, that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and Projects.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>There is no realistic likelihood that funds required during the next twelve months (or in the periods immediately thereafter) for the Company’s basic operations, the Initial Project and/or proposed JVs and/or Projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company’s existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for small companies like Bion.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Covid-19 pandemic related matters:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 4200000 2600000 1500000 1500000 250000 0.09 1.00 250000 15000 1500 2665500 0.25 666375 0.25 533100 83275 2615500 50000 6442812 6983954 1750170 8177452 0.295 Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) (‘Kreider Renewable Energy Facility’ or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). Now that development of the Company’s Gen3Tech is being deployed, the Company has commenced discussions with KF regarding updating and amending the JV agreement and anticipates executing an amended joint venture agreement during 2023. During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA). 1464000 1649000 3806000 8291000 3189000 10235000 902000 3516000 4200000 1600000 2600000 4038000 1737000 86000 19000 443000 602000 250000 1250000 2404000 3516000 20000000 80000000 <p id="xdx_808_eus-gaap--SignificantAccountingPoliciesTextBlock_zbnurz4vTb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2.       <span id="xdx_826_zf521VL9TOdg">SIGNIFICANT ACCOUNTING POLICIES</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zzHo9hrwLxd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86C_z1gXMXXq2h52">Principles of consolidation:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying condensed consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at December 31, 2023, the results of operations and cash flows of the Company for the three and six months ended December 31, 2023 and 2022. Operating results for the three and six months ended December 31, 2023 are not necessarily indicative of the results that may be expected for the year ending June 30, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zlqT0pWPoUf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86F_zerecxK32hc1">Cash and cash equivalents:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of December 31, 2023 and June 30, 2023 there are <span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20231231_z7ZPGbLb4hOj" title="Cash equivalents"><span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20230630_zyIOpFsFBsLj" title="Cash equivalents">no</span></span> cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zcnEbMabu5Kc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><span id="xdx_86C_zZaZmDf2yxRc">Property and equipment:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects such as consulting fees, internal salaries and benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_849_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zNTFORPX0Bdf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_869_zr9KzwkIKWnc">Patents:</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s condensed consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_843_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zXQrBUl2wk72" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_869_z5sYTV8b7DQg">Stock-based compensation:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zppm87KNd4ef" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_866_z0kY04E6xa22">Derivative Financial Instruments:</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_z383rLuPmGP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86E_zxuinzs1ke33">Options:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_ecustom--EquityIssuancesWarrantsPolicyPolicyTextBlock_zRhjO2YdDITj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_860_z8JItu1vn7ib">Warrants:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zUVU9AdDhdck" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_867_zFlYHc1REXEk">Concentrations of credit risk:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_843_ecustom--MinorityInterestPolicyPolicyTextBlock_zJ7LOD4jQvNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_862_zSOl0UQn1dag">Noncontrolling interests:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the condensed consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the condensed consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_845_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zeiKV2iwmvF5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86F_zuBRyrYalXo8">Fair value measurements:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 – assets and liabilities whose significant value drivers are unobservable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_843_eus-gaap--LessorLeasesPolicyTextBlock_zKrQSW9Osrw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86E_z3CA3xyMT4Wg">Lease Accounting:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">The Company accounts for leases under ASC 842, <i>Leases</i> (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the condensed consolidated statements of operations over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84D_eus-gaap--RevenueRecognitionPolicyTextBlock_zjXdlaJtPa2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_z4VicVoKLAb7">Revenue Recognition:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zl8zYnYI8MF" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_zwoDacj1uY08">Income (Loss) per share:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise, or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the three and six months ended December 31, 2023 and 2022, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zRpOQGigRYml" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B4_zChHfDCjgJec" style="display: none">Schedule of warrants and option and convertible securities</span></td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">December 31, <br/> 2023</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">December 31, <br/> 2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: justify">Warrants</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zfXf0TMewh9e" style="width: 14%; font-size: 10pt; text-align: right" title="Antidilutive securities">23,905,539</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zQU6M5CfLU27" style="width: 14%; font-size: 10pt; text-align: right" title="Antidilutive securities">20,660,031</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Options</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zBF3FMc7rPb5" style="font-size: 10pt; text-align: right" title="Antidilutive securities">12,006,600</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zIAdOzkc1dKi" style="font-size: 10pt; text-align: right" title="Antidilutive securities">11,201,600</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify">Convertible debt</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zxqZivpjNEpj" style="font-size: 10pt; text-align: right" title="Antidilutive securities">9,754,772</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zQzCO0kRdfde" style="font-size: 10pt; text-align: right" title="Antidilutive securities">11,010,012</td><td style="font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zV4djE1swgdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the three and six months ended December 31, 2023 and 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zTmbbOaHE55j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: justify"><span id="xdx_8BE_zPp0Y8P28BK3" style="display: none">Schedule of basic and diluted income (loss) per share</span></td><td style="font-size: 12pt"> </td> <td colspan="2" id="xdx_49F_20231001__20231231_zf6K79Z65gBh" style="font-size: 12pt; text-align: center"> </td><td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td colspan="2" id="xdx_498_20221001__20221231_zStHbqPNyilg" style="font-size: 12pt; text-align: center"> </td><td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td colspan="2" id="xdx_49F_20230701__20231231_z7lui7EQB4w3" style="font-size: 12pt; text-align: center"> </td><td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td colspan="2" id="xdx_495_20220701__20221231_zMzHplT0JfS3" style="font-size: 12pt; text-align: center"> </td><td style="font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: justify"> </td><td style="font-size: 12pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>Three months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>2023</b></span></p></td><td style="padding-bottom: 1pt; font-size: 12pt"> </td><td style="font-size: 12pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>Three months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>2022</b></span></p></td><td style="padding-bottom: 1pt; font-size: 12pt"> </td><td style="font-size: 12pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>Six months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>2023</b></span></p></td><td style="padding-bottom: 1pt; font-size: 12pt"> </td><td style="font-size: 12pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>Six months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>2022</b></span></p></td><td style="padding-bottom: 1pt; font-size: 12pt"> </td></tr> <tr id="xdx_40E_ecustom--SharesIssuedBeginningOfPeriod_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left; text-indent: 0in">Shares issued – beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">49,485,556</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">44,303,654</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">48,880,237</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">43,758,820</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--SharesHeldBySubsidiaries_i_pdd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0in">Shares held by subsidiaries (Note 7)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--SharesOutstandingBeginningOfPeriod_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in">Shares outstanding – beginning of period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48,781,247</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,599,345</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48,175,928</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,054,511</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--WeightedAverageSharesIssuedDuringPeriod_zZkjqceEijM9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 0in">Weighted average shares issued <br/>    during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">98,186</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">20,706</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">572,626</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">479,278</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--WeightedAverageNumberOfDilutedShareOutstanding_zDh2Tr21cJee" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Diluted weighted average shares – <br/>    end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">48,879,433</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">43,620,051</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">48,748,554</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">43,533,789</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_8AD_ze5aCNMDDZti" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--UseOfEstimates_zxWXfYRtx0Qe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_860_z0JnsqRZ7rx2">Use of estimates:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In preparing the Company’s condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zr32fkPddpn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_zcVjTe2nrYE">Recent Accounting Pronouncements:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its condensed consolidated financial statements and assures that there are proper controls in place to ascertain that the Company’s condensed consolidated financial statements properly reflect the change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zzHo9hrwLxd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86C_z1gXMXXq2h52">Principles of consolidation:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying condensed consolidated financial statements have been prepared without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements reflect all adjustments (consisting of only normal recurring entries) that, in the opinion of management, are necessary to present fairly the financial position at December 31, 2023, the results of operations and cash flows of the Company for the three and six months ended December 31, 2023 and 2022. Operating results for the three and six months ended December 31, 2023 are not necessarily indicative of the results that may be expected for the year ending June 30, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zlqT0pWPoUf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86F_zerecxK32hc1">Cash and cash equivalents:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of December 31, 2023 and June 30, 2023 there are <span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20231231_z7ZPGbLb4hOj" title="Cash equivalents"><span id="xdx_90D_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20230630_zyIOpFsFBsLj" title="Cash equivalents">no</span></span> cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 0 0 <p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zcnEbMabu5Kc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><span id="xdx_86C_zZaZmDf2yxRc">Property and equipment:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects such as consulting fees, internal salaries and benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_849_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zNTFORPX0Bdf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_869_zr9KzwkIKWnc">Patents:</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s condensed consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_843_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zXQrBUl2wk72" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_869_z5sYTV8b7DQg">Stock-based compensation:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zppm87KNd4ef" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_866_z0kY04E6xa22">Derivative Financial Instruments:</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_z383rLuPmGP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86E_zxuinzs1ke33">Options:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_ecustom--EquityIssuancesWarrantsPolicyPolicyTextBlock_zRhjO2YdDITj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_860_z8JItu1vn7ib">Warrants:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zUVU9AdDhdck" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_867_zFlYHc1REXEk">Concentrations of credit risk:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_843_ecustom--MinorityInterestPolicyPolicyTextBlock_zJ7LOD4jQvNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_862_zSOl0UQn1dag">Noncontrolling interests:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the condensed consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the condensed consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_845_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zeiKV2iwmvF5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86F_zuBRyrYalXo8">Fair value measurements:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 – assets and liabilities whose significant value drivers are unobservable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_843_eus-gaap--LessorLeasesPolicyTextBlock_zKrQSW9Osrw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86E_z3CA3xyMT4Wg">Lease Accounting:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">The Company accounts for leases under ASC 842, <i>Leases</i> (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the condensed consolidated statements of operations over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84D_eus-gaap--RevenueRecognitionPolicyTextBlock_zjXdlaJtPa2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_z4VicVoKLAb7">Revenue Recognition:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zl8zYnYI8MF" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_zwoDacj1uY08">Income (Loss) per share:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise, or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the three and six months ended December 31, 2023 and 2022, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zRpOQGigRYml" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B4_zChHfDCjgJec" style="display: none">Schedule of warrants and option and convertible securities</span></td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">December 31, <br/> 2023</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">December 31, <br/> 2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: justify">Warrants</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zfXf0TMewh9e" style="width: 14%; font-size: 10pt; text-align: right" title="Antidilutive securities">23,905,539</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zQU6M5CfLU27" style="width: 14%; font-size: 10pt; text-align: right" title="Antidilutive securities">20,660,031</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Options</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zBF3FMc7rPb5" style="font-size: 10pt; text-align: right" title="Antidilutive securities">12,006,600</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zIAdOzkc1dKi" style="font-size: 10pt; text-align: right" title="Antidilutive securities">11,201,600</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify">Convertible debt</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zxqZivpjNEpj" style="font-size: 10pt; text-align: right" title="Antidilutive securities">9,754,772</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zQzCO0kRdfde" style="font-size: 10pt; text-align: right" title="Antidilutive securities">11,010,012</td><td style="font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zV4djE1swgdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the three and six months ended December 31, 2023 and 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zTmbbOaHE55j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: justify"><span id="xdx_8BE_zPp0Y8P28BK3" style="display: none">Schedule of basic and diluted income (loss) per share</span></td><td style="font-size: 12pt"> </td> <td colspan="2" id="xdx_49F_20231001__20231231_zf6K79Z65gBh" style="font-size: 12pt; text-align: center"> </td><td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td colspan="2" id="xdx_498_20221001__20221231_zStHbqPNyilg" style="font-size: 12pt; text-align: center"> </td><td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td colspan="2" id="xdx_49F_20230701__20231231_z7lui7EQB4w3" style="font-size: 12pt; text-align: center"> </td><td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td colspan="2" id="xdx_495_20220701__20221231_zMzHplT0JfS3" style="font-size: 12pt; text-align: center"> </td><td style="font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: justify"> </td><td style="font-size: 12pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>Three months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>2023</b></span></p></td><td style="padding-bottom: 1pt; font-size: 12pt"> </td><td style="font-size: 12pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>Three months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>2022</b></span></p></td><td style="padding-bottom: 1pt; font-size: 12pt"> </td><td style="font-size: 12pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>Six months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>2023</b></span></p></td><td style="padding-bottom: 1pt; font-size: 12pt"> </td><td style="font-size: 12pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>Six months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>2022</b></span></p></td><td style="padding-bottom: 1pt; font-size: 12pt"> </td></tr> <tr id="xdx_40E_ecustom--SharesIssuedBeginningOfPeriod_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left; text-indent: 0in">Shares issued – beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">49,485,556</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">44,303,654</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">48,880,237</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">43,758,820</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--SharesHeldBySubsidiaries_i_pdd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0in">Shares held by subsidiaries (Note 7)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--SharesOutstandingBeginningOfPeriod_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in">Shares outstanding – beginning of period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48,781,247</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,599,345</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48,175,928</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,054,511</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--WeightedAverageSharesIssuedDuringPeriod_zZkjqceEijM9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 0in">Weighted average shares issued <br/>    during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">98,186</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">20,706</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">572,626</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">479,278</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--WeightedAverageNumberOfDilutedShareOutstanding_zDh2Tr21cJee" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Diluted weighted average shares – <br/>    end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">48,879,433</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">43,620,051</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">48,748,554</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">43,533,789</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_8AD_ze5aCNMDDZti" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zRpOQGigRYml" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B4_zChHfDCjgJec" style="display: none">Schedule of warrants and option and convertible securities</span></td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">December 31, <br/> 2023</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 8pt"> </span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">December 31, <br/> 2022</span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"><span style="font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: justify">Warrants</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zfXf0TMewh9e" style="width: 14%; font-size: 10pt; text-align: right" title="Antidilutive securities">23,905,539</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zQU6M5CfLU27" style="width: 14%; font-size: 10pt; text-align: right" title="Antidilutive securities">20,660,031</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Options</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zBF3FMc7rPb5" style="font-size: 10pt; text-align: right" title="Antidilutive securities">12,006,600</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zIAdOzkc1dKi" style="font-size: 10pt; text-align: right" title="Antidilutive securities">11,201,600</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify">Convertible debt</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zxqZivpjNEpj" style="font-size: 10pt; text-align: right" title="Antidilutive securities">9,754,772</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zQzCO0kRdfde" style="font-size: 10pt; text-align: right" title="Antidilutive securities">11,010,012</td><td style="font-size: 10pt; text-align: left"> </td></tr> </table> 23905539 20660031 12006600 11201600 9754772 11010012 <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zTmbbOaHE55j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: justify"><span id="xdx_8BE_zPp0Y8P28BK3" style="display: none">Schedule of basic and diluted income (loss) per share</span></td><td style="font-size: 12pt"> </td> <td colspan="2" id="xdx_49F_20231001__20231231_zf6K79Z65gBh" style="font-size: 12pt; text-align: center"> </td><td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td colspan="2" id="xdx_498_20221001__20221231_zStHbqPNyilg" style="font-size: 12pt; text-align: center"> </td><td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td colspan="2" id="xdx_49F_20230701__20231231_z7lui7EQB4w3" style="font-size: 12pt; text-align: center"> </td><td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td colspan="2" id="xdx_495_20220701__20221231_zMzHplT0JfS3" style="font-size: 12pt; text-align: center"> </td><td style="font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: justify"> </td><td style="font-size: 12pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>Three months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>2023</b></span></p></td><td style="padding-bottom: 1pt; font-size: 12pt"> </td><td style="font-size: 12pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>Three months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>2022</b></span></p></td><td style="padding-bottom: 1pt; font-size: 12pt"> </td><td style="font-size: 12pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>Six months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>2023</b></span></p></td><td style="padding-bottom: 1pt; font-size: 12pt"> </td><td style="font-size: 12pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>Six months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: center; text-indent: -0.25in"><span style="font-size: 8pt"><b>2022</b></span></p></td><td style="padding-bottom: 1pt; font-size: 12pt"> </td></tr> <tr id="xdx_40E_ecustom--SharesIssuedBeginningOfPeriod_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left; text-indent: 0in">Shares issued – beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">49,485,556</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">44,303,654</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">48,880,237</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">43,758,820</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--SharesHeldBySubsidiaries_i_pdd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0in">Shares held by subsidiaries (Note 7)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(704,309</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--SharesOutstandingBeginningOfPeriod_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0in">Shares outstanding – beginning of period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48,781,247</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,599,345</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48,175,928</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,054,511</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--WeightedAverageSharesIssuedDuringPeriod_zZkjqceEijM9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 0in">Weighted average shares issued <br/>    during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">98,186</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">20,706</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">572,626</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">479,278</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--WeightedAverageNumberOfDilutedShareOutstanding_zDh2Tr21cJee" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Diluted weighted average shares – <br/>    end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">48,879,433</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">43,620,051</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">48,748,554</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">43,533,789</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 49485556 44303654 48880237 43758820 -704309 -704309 -704309 -704309 48781247 43599345 48175928 43054511 98186 20706 572626 479278 48879433 43620051 48748554 43533789 <p id="xdx_841_eus-gaap--UseOfEstimates_zxWXfYRtx0Qe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_860_z0JnsqRZ7rx2">Use of estimates:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In preparing the Company’s condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zr32fkPddpn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_zcVjTe2nrYE">Recent Accounting Pronouncements:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its condensed consolidated financial statements and assures that there are proper controls in place to ascertain that the Company’s condensed consolidated financial statements properly reflect the change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_801_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zlmfWa6fRqJ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>3.       <span id="xdx_826_zJVzVM8EPUx6">PROPERTY AND EQUIPMENT:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zcPLSyEuLC5j" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; font-weight: bold"><span id="xdx_8B0_z1eqDaoZXX0j" style="display: none">Schedule of property and equipment</span></td><td> </td> <td colspan="2" id="xdx_49A_20231231_zsvgL7KpgX2d" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49C_20230630_zuGLLh5Ln2lg" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 8pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 8pt"><b>June 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: left">Computers and office equipment</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 14%; font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zKZ3OBAYYVQl" title="Property and equipment, gross">15,156</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 14%; font-size: 10pt; text-align: right"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zuShigBAZ2r4" title="Property and equipment, gross">15,156</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Initial Project: construction in process</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zOWg8z3oafN8" title="Property and equipment, gross">9,108,312</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zlWG4hbfuIKd" title="Property and equipment, gross">6,847,760</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_maCzWwk_z0MSIR3bH2zg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Property and equipment, gross</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">9,123,468</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">6,862,916</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msCzWwk_zC9X4lQ5VCUf" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(12,828</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(11,907</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_zTXZyHf9URFb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"> Property and equipment, net</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">9,110,640</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,851,009</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 3G1 project (“Initial Project”) began in July of 2021, with a lease signed on land October 1, 2021 (Note 9). Once the lease commenced the Company moved into construction phase. The balance for the Initial Project construction in process includes $<span id="xdx_901_eus-gaap--InterestCostsCapitalized_c20230701__20231231_zvMVEYu0PZuc" title="Capitalized interest">238,540</span> and $<span id="xdx_907_eus-gaap--InterestCostsCapitalized_c20220701__20221231_z7fn3eQ4E2nd" title="Capitalized interest">98,104</span> for capitalized interest and $<span id="xdx_904_ecustom--NonCashCompensation_c20230701__20231231_zKhXSFS5drE7" title="Non cash compensation">135,648</span> and $<span id="xdx_90C_ecustom--NonCashCompensation_c20220701__20221231_zv1WHnc9jJvl" title="Non cash compensation">135,648</span> in non-cash compensation as of December 31, 2023 and 2022, respectively. On January 1, 2024 the Initial Project was deemed to have been ‘placed in service’ (Note 10).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has reviewed the remaining property and equipment for impairment as of December 31, 2023 and believes that <span id="xdx_90D_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_do_c20230701__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--PropertyPlantAndEquipmentOfPA1Member_zBmoCegJB3H8" title="Impairment of long lived assets">no</span> impairment exists.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense was $<span id="xdx_903_eus-gaap--Depreciation_c20231001__20231231_z4gzZJ3C9Rg8" title="Depreciation expense">460</span> and $<span id="xdx_900_eus-gaap--Depreciation_c20221001__20221231_z38QkWG1i8i4" title="Depreciation expense">394</span> for the three months ended December 31, 2023 and 2022, respectively and $<span id="xdx_904_eus-gaap--Depreciation_c20230701__20231231_zVPJtabqvnDf" title="Depreciation expense">921</span> and $<span id="xdx_90B_eus-gaap--Depreciation_c20220701__20221231_zuKNkRe2O7kb" title="Depreciation expense">724</span> for the six months ended December 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zcPLSyEuLC5j" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; font-weight: bold"><span id="xdx_8B0_z1eqDaoZXX0j" style="display: none">Schedule of property and equipment</span></td><td> </td> <td colspan="2" id="xdx_49A_20231231_zsvgL7KpgX2d" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49C_20230630_zuGLLh5Ln2lg" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 8pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 8pt"><b>June 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: left">Computers and office equipment</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 14%; font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zKZ3OBAYYVQl" title="Property and equipment, gross">15,156</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 14%; font-size: 10pt; text-align: right"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zuShigBAZ2r4" title="Property and equipment, gross">15,156</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Initial Project: construction in process</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zOWg8z3oafN8" title="Property and equipment, gross">9,108,312</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zlWG4hbfuIKd" title="Property and equipment, gross">6,847,760</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_maCzWwk_z0MSIR3bH2zg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Property and equipment, gross</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">9,123,468</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">6,862,916</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msCzWwk_zC9X4lQ5VCUf" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(12,828</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(11,907</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentOtherNet_iI_zTXZyHf9URFb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"> Property and equipment, net</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">9,110,640</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,851,009</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> 15156 15156 9108312 6847760 9123468 6862916 12828 11907 9110640 6851009 238540 98104 135648 135648 0 460 394 921 724 <p id="xdx_80E_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z6hiJtshmXE" style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify"><b>4.       <span id="xdx_824_zCdQrMdYZMp1">DEFERRED COMPENSATION:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">The Company owes deferred compensation to various employees, former employees and consultants totaling $<span id="xdx_90B_eus-gaap--DeferredCompensationLiabilityCurrent_iI_c20231231_zhR33ik1eur3" title="Deferred compensation liability">1,225,226</span> and $<span id="xdx_904_eus-gaap--DeferredCompensationLiabilityCurrent_iI_c20221231_zJETQwghrc02" title="Deferred compensation liability">714,222</span> as of December 31, 2023 and 2022, respectively. Included in the deferred compensation balances as of December 31, 2023, are $<span id="xdx_907_eus-gaap--DeferredCompensationLiabilityCurrent_iI_c20231231__srt--TitleOfIndividualAxis__custom--WilliamONeillMember_z2O9MaqF0T4b" title="Deferred compensation liability">255,000</span>, $<span id="xdx_90A_eus-gaap--DeferredCompensationLiabilityCurrent_iI_c20231231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_znV9a9MHXxTk" title="Deferred compensation liability">652,252</span> and $<span id="xdx_90F_eus-gaap--DeferredCompensationLiabilityCurrent_iI_c20231231__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zs2yNM34eyb6" title="Deferred compensation liability">70,450</span> owed William O’Neill (“O’Neill”), the Company’s CEO, Dominic Bassani (“Bassani”), the Company’s recently deceased Chief Operating Officer (who was Chief Executive Officer for a decade through April 30, 2022) (NOTE: Dominic Bassani passed away on October 11, 2023.), and Mark A. Smith (“Smith”), the Company’s President, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">The sums owed to Bassani and Smith are owed pursuant to extension agreements effective January 1, 2015, whereby unpaid compensation earned after January 1, 2015, accrues interest at <span id="xdx_90B_ecustom--InterestRateOnDeferredCompensation_iI_dp_c20231231_zUfD9HOgIdu8" title="Accrued interest rate">4</span>% per annum and can be converted into shares of the Company’s common stock at the election of the employee during the first five calendar days of any month. The conversion price shall be the average closing price of the Company’s common stock for the last <span id="xdx_90C_ecustom--DeferredCompensationConsecutiveTradingDays_dtD_c20230701__20231231_zyWZvyf1Hm0e" title="Deferred compensation consecutive trading days">10</span> trading days of the immediately preceding month. The deferred compensation owed Bassani and Smith as of December 31, 2022 was $<span id="xdx_90E_eus-gaap--DeferredCompensationLiabilityCurrent_iI_c20221231__srt--CounterpartyNameAxis__custom--BassaniMember_zMHxN2oYQnL6" title="Deferred compensation liability"><span id="xdx_904_eus-gaap--DeferredCompensationLiabilityCurrent_iI_c20221231__srt--CounterpartyNameAxis__custom--SmithMember_zzR77ZF58v78" title="Deferred compensation liability">481,972</span></span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">O’Neill is owed balance of $<span id="xdx_909_eus-gaap--DeferredCompensationLiabilityCurrentAndNoncurrent_iI_c20231231_zOtdEPsCASzj" title="Deferred compensation">255,000</span> and $<span id="xdx_90D_eus-gaap--DeferredCompensationLiabilityCurrentAndNoncurrent_iI_c20221231_zzsCNo35zZja" title="Deferred compensation">80,000</span> at December 31, 2023 and 2022, respectively, pursuant to his 2021 employment agreement There is no interest accrual or conversion rights related to the deferred balance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">The Company also owes various consultants and an employee, pursuant to various agreements, for deferred compensation of $<span id="xdx_90E_eus-gaap--DeferredCompensationLiabilityCurrent_pp0p0_c20231231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zuHwqp3K1O4" title="Deferred compensation liability">175,024</span> and $<span id="xdx_903_eus-gaap--DeferredCompensationLiabilityCurrent_iI_c20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zyFZVb381yxa" title="Deferred compensation liability">79,750</span> as of December 31, 2023 and 2022, respectively, with similar conversion terms as those described above for Bassani and Smith, with the exception that the interest accrues at <span id="xdx_904_ecustom--InterestRateOnDeferredCompensation_iI_dp_c20231231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zAQpzyiLjSv3" title="Interest rate on deferred compensation">0</span>% to <span id="xdx_90B_ecustom--InterestRateOnDeferredCompensation_iI_dp_c20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zeWs8KokZPef" title="Interest rate on deferred compensation">3</span>% per annum. The Company also owes a former employee $72,500, which is not convertible and is non-interest bearing. Bassani and Smith have each been granted the right to convert up to $<span id="xdx_90D_ecustom--DeferredCompensationConvertibleToCommonStock_c20230701__20231231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zcxFUNcF6FW8" title="Deferred compensation balance">300,000</span> of deferred compensation balances at a price of $<span id="xdx_900_ecustom--DeferredCompensationConvertibleToCommonStockPricePerShare_iI_c20231231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z543nvdbWse4" title="Deferred compensation, Price per share">0.75</span> per share until June 30, 2024 into common shares (to be issued pursuant to the 2006 Plan). Smith also has the right to convert all or part of his deferred compensation balance into the Company’s securities (to be issued pursuant to the 2006 Plan) “at market” and/or on the same terms as the Company is selling or has sold its securities in its then current (or most recent if there is no current) private placement. Smith also received the right to transfer future deferred compensation to his 2020 Convertible Obligation at his election but such right is no longer in force.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0; text-align: justify">The Company recorded interest expense of $<span id="xdx_900_eus-gaap--InterestExpense_c20231001__20231231__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_zjKFdOEuHAU7" title="Interest expense">7,201</span> ($<span id="xdx_900_ecustom--InterestExpenseRelatedParties_c20231001__20231231__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_z0TDhHdSyaGe" title="Interest expense related party">6,875</span> with related parties) and $<span id="xdx_906_eus-gaap--InterestExpense_c20221001__20221231__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_zjRpeIpazazk" title="Interest expense">4,873</span> ($<span id="xdx_908_ecustom--InterestExpenseRelatedParties_c20221001__20221231__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_zgOlMHeihnV9" title="Interest expense related party">4,345</span> with related parties) for the three months ended December 31, 2023 and 2022, respectively and $<span id="xdx_90C_eus-gaap--InterestExpense_c20230701__20231231__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_zN74CaCLGm64" title="Interest expense">13,629</span> ($<span id="xdx_906_ecustom--InterestExpenseRelatedParties_c20230701__20231231__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_zSUdUPnFf0Za" title="Interest expense related party">12,511</span> with related parties) and $<span id="xdx_903_eus-gaap--InterestExpense_c20220701__20221231__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_zRM067rVidy3" title="Interest expense">9,424</span> ($<span id="xdx_900_ecustom--InterestExpenseRelatedParties_c20220701__20221231__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_zy2DrKEKzVPf" title="Interest expense related party">8,464</span> with related parties) for the six months ended December 31, 2023 and 2022, respectively.</p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> 1225226 714222 255000 652252 70450 0.04 P10D 481972 481972 255000 80000 175024 79750 0 0.03 300000 0.75 7201 6875 4873 4345 13629 12511 9424 8464 <p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_zu7jTfVdojgg" style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b>5.       <span id="xdx_828_zWPs2Hio8Uye">LOANS PAYABLE:</span></b></p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $<span id="xdx_90E_eus-gaap--ConstructionLoan_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_z0hN9moLqb0l" title="Construction loan">10,010,000</span> under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $<span id="xdx_90F_ecustom--AccruedInterestAndLateChargesPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zjPs3II0jAp3" title="Accrued interest and late charges payable">2,255,802</span> as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s condensed consolidated balance sheet. At September 30, 2021, PA1’s total assets were $<span id="xdx_909_eus-gaap--Assets_iI_c20210930_zHIQrH2FyHX8" title="Total assets">297</span> and its total liabilities were $<span id="xdx_90C_eus-gaap--Liabilities_iI_c20210930_zTe8Z2UBiBJ3" title="Total liabilities">10,154,334</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_909_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pp0p0_c20210930_zIm3ZAp8pCc5" title="Accounts payable and accrued liabilities">9,939,148</span>, accounts payable of $<span id="xdx_903_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20210930_zMnu4XxSUYSl" title="Accounts payable">214,235</span> and accrued liabilities of $<span id="xdx_905_eus-gaap--AccruedLiabilitiesCurrent_iI_c20210930_zx21US42pIR7" title="Accrued liabilities, current">950</span>) which sums were included in the Company’s condensed consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $<span id="xdx_900_eus-gaap--Liabilities_iI_c20211229_zsCJuWe4nYsd" title="Total liabilities">10,234,501</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_90F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_c20211229_ztdD8aiZzSul" title="Accounts payable and accrued liabilities">10,009,802</span>, accounts payable of $<span id="xdx_906_eus-gaap--AccountsPayableCurrent_iI_c20211229_ztpwNjU8iAAf" title="Accounts payable">212,263</span> and accrued liabilities of $<span id="xdx_902_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20211229_zmw9Dr8oKqG2" title="Accrued liabilities, current">12,436</span>). The net amount of $<span id="xdx_90A_eus-gaap--GainOrLossOnSaleOfStockInSubsidiary_c20230701__20231231_zrQLr0a61Ck9" title="Gain on legal dissolution of subsidiary">10,234,501</span> was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As background, the terms of the Pennvest Loan provided for funding of up to $<span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zKiItePC8Gfi" title="Repayments of loans">7,754,000</span> which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20230701__20231231__srt--StatementScenarioAxis__custom--YearsOneThroughFiveMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zz2epgxUtvVb" title="Debt instrument interest rate">2.547</span>% per annum for years 1 through 5 and <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20230701__20231231__srt--StatementScenarioAxis__custom--YearsSixThroughMaturityMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zW9mbxbrdbd2" title="Debt instrument interest rate">3.184</span>% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $<span id="xdx_90B_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zDRlmJ74yXc5" title="Principal payment">5,886,000</span> in fiscal years 2013 through 2021, and $<span id="xdx_90F_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zRU8Dn2lL1I3" title="Long term debt maturity year two">846,000</span> in fiscal year 2022, $<span id="xdx_903_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zBiVki2JVu3i" title="Long term debt maturity year three">873,000</span> in fiscal year 2023 and $<span id="xdx_902_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zMUUclcv37cd" title="Long term debt maturity year four">149,000</span> in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $<span id="xdx_905_eus-gaap--InterestExpenseDebt_c20210701__20220630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_ztzuqlmQm5ub" title="Interest expense, debt">123,444</span> and $<span id="xdx_90C_eus-gaap--InterestExpenseDebt_pp0p0_c20200701__20210630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zqD8nXBtQEVh" title="Interest expense, debt">246,887</span> for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s condensed consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $<span id="xdx_908_eus-gaap--LinesOfCreditCurrent_iI_c20210630_zRLb4TeBCt32" title="Loans as a liability">9,868,495</span> despite the fact that the obligation (if any) was solely an obligation of PA1<b>. </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $<span id="xdx_90F_eus-gaap--DebtDefaultLongtermDebtAmount_iI_c20140925__dei--LegalEntityAxis__custom--PA1Member_zKS6KVkbsmC7" title="Debt instrument debt default amount">8,137,117</span> (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $<span id="xdx_90F_eus-gaap--GainLossOnSecuritizationOfFinancialAssets_pp0p0_c20220614__20220615__dei--LegalEntityAxis__custom--PA1Member_z4brdrl2Wl9e" title="Realized from the asset sale">104,725</span> was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest described above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.</p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 10010000 2255802 297 10154334 9939148 214235 950 10234501 10009802 212263 12436 10234501 7754000 0.02547 0.03184 5886000 846000 873000 149000 123444 246887 9868495 8137117 104725 <p id="xdx_803_ecustom--ConvertibleDebtTextBlock_zTZup8AHcm16" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>6.       <span id="xdx_827_z7qhqW61FaKl">CONVERTIBLE NOTES PAYABLE:</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes --- see below) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $3.47 million, in aggregate –See Note 7 below, <b>‘Debt Modification to Additional Paid in Capital’) </b>while equitably maintaining existing conversion rights.  The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mark A. Smith (the Company’s President)(“Smith”), Dominic Bassani (the Company’s Chief Operating Officer) (“Bassani”) (<b>NOTE</b>: Dominic Bassani passed away on October 11, 2023.) and Ed Schafer (Director)(“Schafer”), adjusted/reduced the principal owed to them by $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__srt--CounterpartyNameAxis__custom--MarkASmithMember_zoAeMTfk1yob" title="Principal owed">1,109,649</span>, $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231__srt--CounterpartyNameAxis__custom--DominicBassaniMember_z3cvYHgOAD13" title="Principal owed">1,939,670</span> and $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231__srt--CounterpartyNameAxis__custom--EdSchaferMember_zpBR769NAOVg" title="Principal owed">424,873</span>, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations and the adjusted portion of the September 2015 Convertible Notes were renamed Adjusted September 2015 Convertible Notes. The Adjusted 2020 Convertible Obligations of Smith, Bassani and Schafer are convertible into Units (consisting of 1 share and from one half (1/2) to one (1) warrant) at prices of $<span id="xdx_908_ecustom--ConversionPricePerUnit_iI_c20231231__srt--CounterpartyNameAxis__custom--MarkASmithMember_z3QHZj5594ug" title="Convertible price">.0946</span>, $<span id="xdx_90A_ecustom--ConversionPricePerUnit_iI_c20231231__srt--CounterpartyNameAxis__custom--DominicBassaniMember_zs6FdAH6gKVg" title="Convertible price">.0953</span>, and $<span id="xdx_90B_ecustom--ConversionPricePerUnit_iI_c20231231__srt--CounterpartyNameAxis__custom--EdSchaferMember_zotblrUhmwal" title="Convertible price">.0953</span>, respectively, and the Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.115 per share. The adjusted conversion prices slightly reduce the securities to be issued on conversion of each instrument from the amount receivable under the unadjusted instruments. The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). After the adjustment, the Company owed Smith, Bassani (and trust) and Schafer $<span id="xdx_901_eus-gaap--ConvertibleNotesPayable_iI_c20230202__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--RelatedPartyTransactionAxis__custom--SmithMember_zQHELn2uD0ua" title="Convertible notes">262,154</span>, $<span id="xdx_903_eus-gaap--ConvertibleNotesPayable_iI_c20230202__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--RelatedPartyTransactionAxis__custom--BassaniFamilyTrustsMember_zvHJPQVAGOb4" title="Convertible notes">434,016</span> and $<span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_c20230202__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--RelatedPartyTransactionAxis__custom--SchaferMember_zPxTlmY438Y9" title="Convertible notes">96,364</span>, respectively, of Adjusted 2020 Convertible Obligations and Bassani and Schafer, respectively, $<span id="xdx_90A_eus-gaap--ConvertibleNotesPayable_iI_c20230202__srt--CounterpartyNameAxis__custom--BassaniMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember_zkuSG5HQ8gf8" title="Convertible notes">24,230</span> and $<span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_c20230202__srt--CounterpartyNameAxis__custom--EdSchaferMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember_zRUJ5abOGsC5" title="Convertible notes">4,012</span> of Adjusted September 2015 Convertible Notes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2023, the Adjusted 2020 Convertible Obligation balances, including accrued interest, owed Bassani (and his donees), Smith and Edward Schafer were $<span id="xdx_909_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20231231__srt--CounterpartyNameAxis__custom--BassaniMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_zTpF9EDTIDF9" title="Convertible obligation balances">450,361</span>, $<span id="xdx_907_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20231231__srt--CounterpartyNameAxis__custom--SmithMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_zp2pp8XzCcXk" title="Convertible obligation balances">44,017</span> and $<span id="xdx_908_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20231231__srt--CounterpartyNameAxis__custom--EdwardSchaferMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_zd7QATDzbLn3" title="Convertible obligation balances">99,993</span>, respectively. As of June 30 2023, the Adjusted 2020 Convertible Obligation balances, including accrued interest, owed Bassani (and his donees), Smith and Edward Schafer were $<span id="xdx_905_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20230630__srt--CounterpartyNameAxis__custom--BassaniMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_zf7HA0t4mht5" title="Convertible obligation balances">441,446</span>, $<span id="xdx_908_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20230630__srt--CounterpartyNameAxis__custom--SmithMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_z8AzrHNY6PKg" title="Convertible obligation balances">130,180</span> and $<span id="xdx_907_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20230630__srt--CounterpartyNameAxis__custom--EdwardSchaferMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_z9qv3k4ZnSZa" title="Convertible obligation balances">98,014</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2023 the Adjusted September 2015 Convertible Notes balances, including accrued interest, owed Bassani Family Trusts and Schafer were $<span id="xdx_90E_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20231231__srt--CounterpartyNameAxis__custom--BassaniMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember_zdgwP0aKmdfk">25,143</span> and $<span id="xdx_90C_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20231231__srt--CounterpartyNameAxis__custom--EdwardSchaferMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember_zaeyGWK0SFR8">4,163</span>, respectively. As of June 30, 2023 the Adjusted September 2015 Convertible Notes balances, including accrued interest, owed Bassani Family Trusts and Schafer were $<span id="xdx_90B_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20230630__srt--CounterpartyNameAxis__custom--BassaniMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember_z67WoJsxhgga" title="Convertible notes balances">24,645</span> and $<span id="xdx_902_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20230630__srt--CounterpartyNameAxis__custom--EdwardSchaferMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember_zKxECBQk7Hrh" title="Convertible notes balances">4,081</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2020 Convertible Obligations </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2020 Convertible Obligations (which combined/replaced prior convertible instruments dating to 2017 (or earlier), which accrue interest at either <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20200101__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zE7O7piWK9Ji" title="Debt instrument interest rate">4</span>% per annum or <span id="xdx_901_ecustom--DebtInstrumentInterestRateStatedPercentageQuarterly_iI_dp_c20200101__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zi2SgZbe2Axk" title="Debt instrument interest rate quarterly">4</span>% compounded quarterly and effective January 1, 2020 are due and payable on July 1, 2024. The 2020 Convertible Obligations (including accrued interest, plus all future deferred compensation added subsequently), are convertible, at the sole election of the holder, into Units consisting of one share of the Company’s common stock and one half to one warrant to purchase a share of the Company’s common stock, at a price of $<span id="xdx_907_ecustom--ConversionPricePerUnit_c20200101__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pdd" title="Conversion price per unit">0.50</span> per Unit until July 1, 2024. The original conversion price of $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231231_zydSTa9YzYKj" title="Original conversion price">0.50</span> per Unit approximated the fair value of the Units at the date of the agreements; therefore, no beneficial conversion feature exists. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC 815-15 “Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are not “clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was not required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is not readily convertible to cash in accordance with ASC 815-10, “Derivatives and Hedging”. Effective February 1, 2023, a large portion of the 2020 Convertible Obligations were adjusted as set forth herein.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2023, the remaining unadjusted portion of the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts (and his donees) and Smith, were $<span id="xdx_902_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20231231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zw5uUIAPPbkg" title="Convertible notes payable, noncurrent">367,660</span> and $<span id="xdx_902_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20231231__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zeNG7vznMGrb" title="Convertible notes payable, noncurrent">118,732</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2022, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts, Smith and Schafer were $<span id="xdx_903_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20221231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zxuB4FkMp6ih" title="Convertible notes payable, noncurrent">2,644,553</span>, $<span id="xdx_907_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20221231__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zInFmpW14SWk" title="Convertible notes payable, noncurrent">1,388,421</span> and $<span id="xdx_904_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20221231__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z7uw8htNAOcb" title="Convertible notes payable, noncurrent">508,352</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December, 2023, Smith elected to convert $<span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20230701__20231231__us-gaap--DebtInstrumentAxis__custom--PrincipalMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member_zqCoiPnmvTZ4" title="Debt conversion value">91,548</span> of his Adjusted 2020 Convertible Obligation into <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230701__20231231__us-gaap--DebtInstrumentAxis__custom--PrincipalMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member_zzIyzTr7omvh" title="Debt conversion shares">967,738</span> units at $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--PrincipalMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member_zhchFwrRLeQ2" title="Debt instrument convertible price per share">0.0946</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until July 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded interest expense of $<span id="xdx_905_eus-gaap--InterestExpense_c20230701__20231231__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z6mGJmhnspoa" title="Interest expense">7,875</span> and $<span id="xdx_901_eus-gaap--InterestExpense_c20220701__20221231__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zxJq3SSnXR25" title="Interest expense">82,740</span> for the six months ended December 31, 2023 and 2022, respectively. The Company capitalized $<span id="xdx_903_eus-gaap--CostsIncurredDevelopmentCosts_c20230701__20231231_zE6gV4ERB8sh" title="Capitalized amount">26,559</span> and $<span id="xdx_909_eus-gaap--CostsIncurredDevelopmentCosts_c20220701__20221231_zdNaPNEVCaOd" title="Capitalized amount">66,104</span> related to the Initial Project for the six months ended December 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long-term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $<span id="xdx_901_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn4n6_c20230202_zHSYNkpgBSZk" title="Convertible note">3.47</span> million, in aggregate) while equitably maintaining existing conversion rights. Because the modifications where with affiliates that are related parties, the debt modification was treated as an equity transaction. The Company recorded a deemed dividend for the reductions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mark A. Smith (the Company’s President) (“Smith”), Dominic Bassani (the Company’s Chief Operating Officer) (“Bassani”) (NOTE: Dominic Bassani passed away on October 11, 2023. See Note 10) and Ed Schafer (Director) (“Schafer”), adjusted/reduced the principal owed to them by $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__srt--CounterpartyNameAxis__custom--MarkASmithMember_z2dtTyMAmsZ" title="Principal amount">1,109,649</span>, $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__srt--CounterpartyNameAxis__custom--DominicBassaniMember_z7W8EtBwTQ6c" title="Principal amount">1,939,670</span> and $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__srt--CounterpartyNameAxis__custom--EdSchaferMember_zFdrvUtw3jWa" title="Principal amount">424,873</span>, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations (see above and Note 7.). The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>September 2015 Convertible Notes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2016, the Company entered into September 2015 Convertible Notes with Bassani, Schafer and a Shareholder which replaced previously issued promissory notes. The September 2015 Convertible Notes bear interest at 4% per annum, have maturity dates of July 1, 2024, and may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $<span id="xdx_900_ecustom--ConversionPricePerUnit_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zj4wYvmZDd41" title="Conversion price per unit">0.60</span> per share. As the conversion price of $0.60 approximated the fair value of the common shares at the date of the September 2015 Convertible Notes, no beneficial conversion feature exists.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The balances of the September 2015 Convertible Notes as of December 31, 2023, including accrued interest owed Bassani, Schafer and Shareholder, are $<span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20231231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--BassaniMember_z34hfgl3oCr9" title="Convertible notes payable">186,725</span>, $<span id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_c20231231__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--SchaferMember_zdzFzaZGYlUj" title="Convertible notes payable">4,163</span> and $<span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20231231__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ShareholderMember_zeg1t6awzna3" title="Convertible notes payable">468,431</span>, respectively. The balances of the September 2015 Convertible Notes as of December 31, 2022, including accrued interest, were $<span id="xdx_90F_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20221231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--BassaniMember_zyAgTGO5LTX7" title="Convertible notes payable">284,211</span>, $<span id="xdx_90A_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20221231__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--SchaferMember_zx3AzcGbSwOh" title="Convertible notes payable">21,173</span> and $<span id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_c20221231__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ShareholderMember_zPAHaanIZ0i5" title="Convertible notes payable">453,314</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded interest expense of $<span id="xdx_902_eus-gaap--InterestExpense_c20230701__20231231__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zwUbm7QFZiG3" title="Interest expense">10,158</span> and $<span id="xdx_90A_eus-gaap--InterestExpense_c20220701__20221231__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zeSKfK7EP1sh" title="Interest expense">12,731</span> for the six months ended December 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including the September 2015 Convertible Notes owned by Bassani and Schafer) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $3.52 million, in aggregate) while equitably maintaining existing conversion rights.  Mark A. Smith (the Company’s President), Dominic Bassani (the Company’s Chief Operating Officer)(and a family Trust) and Ed Schafer (Director), adjusted/reduced the principal owed to them by $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231__srt--CounterpartyNameAxis__custom--MarkASmithMember_zE3yjK4g7KZ2" title="Principal amount">1,109,649</span>, $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231__srt--CounterpartyNameAxis__custom--DominicBassaniMember_z9DrPVxoXHw" title="Principal amount">1,939,670</span> and $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231__srt--CounterpartyNameAxis__custom--EdSchaferMember_zR1FtkzCUB97" title="Principal amount">424,873</span>, respectively. Subsequent to the adjustment, the adjusted portion of the Notes were renamed Adjusted September 2015 Convertible Notes. The Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.115 per share. As of December 31, 2023 the Adjusted September 2015 Convertible Notes balances, including accrued interest, owed Bassani Family Trusts and Schafer were $<span id="xdx_900_eus-gaap--ConvertibleNotesPayable_iI_c20231231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--BassaniFamilyTrustsMember_zqDIREJ1XR0i" title="Convertible notes payable">25,143</span> and $<span id="xdx_909_eus-gaap--ConvertibleNotesPayable_iI_c20231231__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--SchaferMember_zw34blt3Xyse" title="Convertible notes payable">4,163</span>, respectively. The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties. See above.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Convertible Bridge Loan/Default </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 28, 2023 the Company entered into an agreement for a $<span id="xdx_901_eus-gaap--ConvertibleDebt_iI_pp0p0_c20230928__srt--TitleOfIndividualAxis__custom--SEBFarmsLLCMember_zO8ThDVmomC5" title="Bridge loan">1,500,000</span> Bridge Loan and executed documents including a convertible promissory note (“Note”) and a binding subscription agreement (“Subscription”) (collectively the Note and the Subscription are the “Bridge Loan Agreements”) with SEB LLC, a non-affiliated party (“Lender”). The Bridge Loan Agreements require the Lender to loan the Company $<span id="xdx_907_eus-gaap--ConvertibleDebt_iI_pp0p0_c20230928__us-gaap--TypeOfArrangementAxis__custom--ConvertibleBridgeLoanDefaultMember_zNj7RSDqy4n9" title="Bridge loan">1,500,000</span> in six monthly tranches of $<span id="xdx_90A_eus-gaap--ConvertibleDebt_iI_pp0p0_c20231031__us-gaap--TypeOfArrangementAxis__custom--ConvertibleBridgeLoanDefaultMember_zHd27jEjfnw" title="Bridge loan">250,000</span> commencing October 2023. All sums advanced under the Bridge Loan Agreements (and accrued interest thereon) would due and payable (with interest accrued at <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20230928__us-gaap--TypeOfArrangementAxis__custom--ConvertibleBridgeLoanDefaultMember_zF0wvuU1Kfoa" title="Interest accrued percentage">9</span>% per annum) on October 1, 2024 if not previously converted into securities of the Company. The Note is convertible at $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230928__us-gaap--TypeOfArrangementAxis__custom--ConvertibleBridgeLoanDefaultMember_ziVXg9E1bRs1" title="Convertible price">1.00</span> per unit, at the sole election of the Lender, into units consisting of one share of the Company’s Common Stock and a warrant to purchase one-half share. The initial $<span id="xdx_906_ecustom--InitialTranche_pp0p0_c20231003__20231005_zBs6jLLwjDf7" title="Initial tranche">250,000 </span>tranche was received by the Company on October 5, 2023. However, no further funds were received by the Company from the Lender. During early November 2023 the Lender informed the Company verbally that it did not intend to fulfill its obligations pursuant to the Bridge Loan Agreements and since such time the Lender has been in default (“Default”). The Default (which is continuing) has created substantial problems for and materially damaged the Company and rendered the Company unable to meet its current creditor obligations on a timely basis. The Company is currently evaluating its rights regarding the Default by the Lender. See Note 10.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded interest expense of $<span id="xdx_90F_eus-gaap--InterestExpense_c20230701__20231231__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeLoanDefaultMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_ztQ9xmIQWpQd" title="Interest expense">5,407</span> and nil for the six months ended December 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 1109649 1939670 424873 0.0946 0.0953 0.0953 262154 434016 96364 24230 4012 450361 44017 99993 441446 130180 98014 25143 4163 24645 4081 0.04 0.04 0.50 0.50 367660 118732 2644553 1388421 508352 91548 967738 0.0946 7875 82740 26559 66104 3470000 1109649 1939670 424873 0.60 186725 4163 468431 284211 21173 453314 10158 12731 1109649 1939670 424873 25143 4163 1500000 1500000 250000 0.09 1.00 250000 5407 <p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zdGdLjsxPGNg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>7.       <span id="xdx_822_zEjMsGWg0qvd">STOCKHOLDERS’ EQUITY:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Debt Modification to Additional paid in capital </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes --- see below) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $<span id="xdx_903_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn4n6_c20230202_z74EfcK6etIf" title="Convertible note">3.47</span> million, in aggregate<b>) </b>while equitably maintaining existing conversion rights. Because the modifications where with affiliates that are related parties, the debt modification was treated as an equity transaction. The Company recorded a deemed dividend for the reductions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mark A. Smith (the Company’s President)(“Smith”), Dominic Bassani (then the Company’s Chief Operating Officer)(“Bassani”) (NOTE: Dominic Bassani passed away on October 11, 2023.) and Ed Schafer (Director)(“Schafer”), adjusted/reduced the principal owed to them by $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231__srt--CounterpartyNameAxis__custom--MarkASmithMember_zEOrnTnS8qGi" title="Principal amount">1,109,649</span>, $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231__srt--CounterpartyNameAxis__custom--DominicBassaniMember_zanMkr83F7Bg" title="Principal amount">1,939,670</span> and $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20231231__srt--CounterpartyNameAxis__custom--EdSchaferMember_zadUEKoWq8xj" title="Principal amount">424,873</span>, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations and the adjusted portion of the September 2015 Convertible Notes were renamed Adjusted September 2015 Convertible Notes. The Adjusted 2020 Convertible Obligations of Smith, Bassani and Schafer are convertible into Units at prices of $<span id="xdx_907_ecustom--ConversionPricePerUnit_iI_c20231231__srt--CounterpartyNameAxis__custom--MarkASmithMember_znD4NMqlQaS8" title="Conversion price per unit">.0946</span>, $<span id="xdx_900_ecustom--ConversionPricePerUnit_iI_c20231231__srt--CounterpartyNameAxis__custom--DominicBassaniMember_z1b2zLD0Vrle" title="Conversion price per unit">.0953</span>, and $<span id="xdx_90F_ecustom--ConversionPricePerUnit_iI_c20231231__srt--CounterpartyNameAxis__custom--EdSchaferMember_zO6lHrNHWpkh" title="Conversion price per unit">.0953</span>, respectively, and the Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $<span id="xdx_908_ecustom--ConversionPricePerUnit_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--AwardTypeAxis__custom--RestrictedCommonSharesMember_z36EwgMygE7e" title="Conversion price per unit">0.115</span> per share. The adjusted conversion prices slightly reduce the securities to be issued on conversion of each instrument from the amount receivable under the unadjusted instruments. The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). After the adjustment, the Company owed Smith, Bassani (and trust) and Schafer $262,154, $434,016 and $96,364, respectively, of Adjusted 2020 Convertible Obligations and Bassani and Schafer, respectively, $24,230 and $4,012 of Adjusted September 2015 Convertible Notes. The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). The Company treated this as an equity transaction and recorded the reduction of debt through additional paid in capital at the net present value of the modified debt agreements. This resulted in an increase to Additional Paid in Capital of $<span id="xdx_90D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_pp0p0_c20220701__20230630_zNTSTnAH3uu6" title="Increase to additional paid in capital">3,522,000</span> at the modification date and a reduction of additional paid in capital of $<span id="xdx_904_ecustom--ReductionOfAdditionalPaidInCapital_pp0p0_c20220701__20230630_zXmeNxPTdHQc" title="Reduction of additional paid in capital">14,051</span> for the year ended June 30, 2023 and $<span id="xdx_90E_ecustom--DebtModifications_pp0p0_c20230701__20231231_zhUTunJIXCjc" title="Debt modified">16,861</span> for the six months ended December 31, 2023 for the adjustment to the net present value of the modified debt agreements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Series B Preferred stock:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since July 1, 2014, the Company had <span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_c20140701__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKZgcuLw0Aq" title="Preferred stock, shares outstanding">200</span> shares of Series B redeemable convertible Preferred stock outstanding with a par value of $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20140701__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ziV5mCAopam7" title="Preferred stock, par value">0.01</span> per share, convertible at the option of the holder at $<span id="xdx_905_ecustom--PreferredStockConvertibleOptionPerShare_iI_c20140701__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zCFs9ENfquAg" title="Preferred stock, convertible option per share">2.00</span> per share, with dividends accrued and payable at <span id="xdx_902_eus-gaap--PreferredStockDividendRatePercentage_pip0_dp_c20140630__20140701__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zyjirVKY2Lh7" title="Preferred stock dividend rate percentage">2.5</span>% per quarter. The Series B Preferred stock is mandatorily redeemable at $<span id="xdx_90A_eus-gaap--PreferredStockRedemptionPricePerShare_iI_c20140701__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z1FCcMGmOHo8" title="Preferred stock, redemption price per share">100</span> per share by the Company three years after issuance and accordingly was classified as a liability. The 200 shares had reached their redemption date and the Company approved the redemption of the Series B preferred stock during the year ended June 30, 2022. The 200 shares of Series B redeemable convertible Preferred stock were redeemed for $<span id="xdx_90F_ecustom--RedemptionOfConvertiblePreferredStock_pp0p0_c20230701__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zM1FicQlUH2g" title="Redemption of convertible preferred stock">41,000</span>, which included the $<span id="xdx_909_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zF3DeDGm7KEk" title="Dividends payable">21,000</span> in accrued dividend payable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended June 30, 2023, and 2022, the Company declared dividends of nil and $<span id="xdx_90B_eus-gaap--DividendsPreferredStock_pp0p0_c20220701__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8gC3lv5r2W8" title="Dividends, preferred stock"><span id="xdx_904_eus-gaap--DividendsPreferredStock_pp0p0_c20210701__20220630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zpiNFIfi2sy" title="Dividends, preferred stock">1,000</span></span> respectively. The dividends are classified as a component of operations as the Series B Preferred stock is presented as a liability in these financial statements. There is <span id="xdx_90F_eus-gaap--LiabilitiesCurrent_iI_pp0p0_do_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zrzx7F032qSa" title="Liability">no</span> liability at December 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common stock:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Holders of common stock are entitled to one vote per share on all matters to be voted on by common stockholders. In the event of liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to share in all assets remaining after liabilities have been paid in full or set aside and the rights of any outstanding preferred stock have been satisfied. Common stock has no preemptive, redemption or conversion rights. The rights of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of any outstanding series of preferred stock or any series of preferred stock the Company may designate in the future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Centerpoint holds <span id="xdx_904_ecustom--SharesHeldBySubsidiaries_iN_di_c20230701__20231231_zdyGGOCQ96B7" title="Shares Held by Subsidiaries">704,309</span> shares of the Company’s common stock. These shares of the Company’s common stock held by Centerpoint are for the benefit of its shareholders without any beneficial interest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31, 2023, the Company entered into subscription agreements to sell <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230701__20231231__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zpxhHMPcw4s3" title="Sale of stock, shares">28,589</span> units at a price of $<span id="xdx_90D_ecustom--SaleOfUnitPricePerUnit_iI_c20231231__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zKHWyRgX9z58" title="Sale of units">1.60</span>, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_907_eus-gaap--SharePrice_iI_c20231231__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zbvLbE6F7xId" title="Sell units">2.40</span> per share with an expiry date of June 30, 2024, and pursuant thereto, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230701__20231231__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zbTL5aaKbOa6" title="Number of shares issued">28,589</span> units for total proceeds of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20230701__20231231__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zQC82o0hdV3f" title="Number of shares issued, value">45,742</span>. See ‘<b>Warrants</b>’ below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31, 2023, the Company entered into subscription agreements to sell <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230701__20231231__us-gaap--AwardTypeAxis__custom--RestrictedCommonStock1Member_zL0obkOvfjBd" title="Sale of stock, shares">75,000</span> units at a price of $<span id="xdx_902_ecustom--SaleOfUnitPricePerUnit_iI_c20231231__us-gaap--AwardTypeAxis__custom--RestrictedCommonStock1Member_zmKLBlz1yG6d" title="Sale of units">1.00</span>, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20231231__us-gaap--AwardTypeAxis__custom--RestrictedCommonStock1Member_zXGlouf8snd1" title="Sell units">1.25</span> per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230701__20231231__us-gaap--AwardTypeAxis__custom--RestrictedCommonStock1Member_z5Ek0aEkBCel" title="Number of shares issued">75,000</span> units for total proceeds of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20230701__20231231__us-gaap--AwardTypeAxis__custom--RestrictedCommonStock1Member_zR798xIZ0tl3" title="Number of shares issued, value">75,000</span>. See ‘<b>Warrants</b>’ below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31, 2023, the Company entered into subscription agreements to sell <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230701__20231231__us-gaap--AwardTypeAxis__custom--RestrictedCommonStock2Member_z2iI3qGzABTf" title="Sale of stock, shares">300,000</span> units at a price of $<span id="xdx_90A_ecustom--SaleOfUnitPricePerUnit_iI_c20231231__us-gaap--AwardTypeAxis__custom--RestrictedCommonStock2Member_z3LSqqNX62jd" title="Sale of units">1.00</span>, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_908_eus-gaap--SharePrice_iI_c20231231__us-gaap--AwardTypeAxis__custom--RestrictedCommonStock2Member_zrHeufpK7ip9" title="Sell units">1.25</span> per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230701__20231231__us-gaap--AwardTypeAxis__custom--RestrictedCommonStock2Member_zcSFHgcPtOFf" title="Number of shares issued">300,000</span> units for total proceeds of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20230701__20231231__us-gaap--AwardTypeAxis__custom--RestrictedCommonStock2Member_zPwB1yayfuEc" title="Number of shares issued, value">300,000</span>. See ‘<b>Warrants</b>’ below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31, 2023, <span id="xdx_90B_ecustom--ClassOfWarrantOrRightExercisedDuringPeriod_c20230701__20231231_zZ3Mdkj1WWrb" title="Warrants were exercised">38,000</span> warrants were exercised to purchase <span id="xdx_907_ecustom--CommonStockSharesIssuedUponExerciseOfWarrants_c20230701__20231231_zi7Ce7BqTia1" title="Purchase of warrants">38,000</span> shares of the Company’s common stock at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoI4bdlqbslj" title="Warrants exercisable per share">0.75</span> per share for total proceeds of $<span id="xdx_908_ecustom--TotalProceeds_pp0p0_c20230701__20231231_znshqsdTf74c" title="Total proceeds">28,500</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31,2023, Smith elected to converted $<span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20230701__20231231__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__srt--TitleOfIndividualAxis__custom--PrincipalMember_zMfCEtYtlGjc" title="Debt conversion value">91,548</span> of principal from his Adjusted 2020 Convertible note into <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230701__20231231__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgzIjTZfapqk" title="Debt conversion value">967,738</span> Units; each unit consisting of one share and one warrant with the exercise price of $.75 until July 21, 2026. Each of these warrants carry an exercise bonus of <span id="xdx_90E_ecustom--ExerciseBonus_iI_dp_c20231231_zyTUcuUDBlo" title="Exercise bonus">75</span>%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31, 2023, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230701__20231231__srt--TitleOfIndividualAxis__custom--ConsultantServiceMember_zoDfW3AjXVBk" title="Shares issued for consultant services">7,500</span> shares of the Company’s common stock to a consultant for services. The shares were issued at $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__srt--TitleOfIndividualAxis__custom--ConsultantServiceMember_zKLkbFX57pe3" title="Share price">1.20</span> per share for a total value of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20230701__20231231__srt--TitleOfIndividualAxis__custom--ConsultantServiceMember_zq2OMqLu09uk" title="Shares issued for consultant services, value">9,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31, 2023, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230701__20231231__srt--TitleOfIndividualAxis__custom--ConsultantService1Member_ztLpB09N7eP1" title="Shares issued for consultant services">10,753</span> shares of the Company’s common stock to a consultant for services. The shares were issued at $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__srt--TitleOfIndividualAxis__custom--ConsultantService1Member_zyi5cNda2Ozd" title="Share price">1.55</span> per share for a total value of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20230701__20231231__srt--TitleOfIndividualAxis__custom--ConsultantService1Member_zSJN9S0mRnhl" title="Shares issued for consultant services, value">16,667</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31, 2023, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230701__20231231__srt--TitleOfIndividualAxis__custom--ConsultantService2Member_zQukvqIWu1s3" title="Shares issued for consultant services">2,000</span> shares of the Company’s common stock to a consultant for services. The shares were issued at $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__srt--TitleOfIndividualAxis__custom--ConsultantService2Member_zECP3O2pvmS7" title="Share price">1.16</span> per share for a total value of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20230701__20231231__srt--TitleOfIndividualAxis__custom--ConsultantService2Member_zTdRT8tlOqH1" title="Shares issued for consultant services, value">2,320</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31, 2023, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230701__20231231__srt--TitleOfIndividualAxis__custom--ConsultantService3Member_zjk5MI7iTLDl" title="Shares issued for consultant services">15,000</span> shares of the Company’s common stock to a consultant for services. The shares were issued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__srt--TitleOfIndividualAxis__custom--ConsultantService3Member_zjfu8QSmteXh" title="Share price">1.00</span> per share for a total value of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20230701__20231231__srt--TitleOfIndividualAxis__custom--ConsultantService3Member_zbB4q2h3R9P9" title="Shares issued for consultant services, value">15,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31, 2023, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230701__20231231__srt--TitleOfIndividualAxis__custom--ConsultantService4Member_zJpfRLD2mpUk" title="Shares issued for consultant services">21,506</span> shares of the Company’s common stock to a consultant for services. The shares were issued at $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__srt--TitleOfIndividualAxis__custom--ConsultantService4Member_zSvfXdJOilnj" title="Share price">1.55</span> per share for a total value of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20230701__20231231__srt--TitleOfIndividualAxis__custom--ConsultantService4Member_z90CuPfei6te" title="Shares issued for consultant services, value">33,334</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31, 2023, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230701__20231231__srt--TitleOfIndividualAxis__custom--ConsultantServiceMember_zWuuR4Ueqp04" title="Shares issued for cashless exercise">265,639</span> shares of the Company’s common stock upon cashless exercise of ____ outstanding warrants held by non-affiliates of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Warrants:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2023, the Company had approximately <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pn6n6_c20231231_z0uIHntQQuwh" title="Warrant outstanding">24</span> million warrants outstanding, with exercise prices from $0.60 to $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__srt--RangeAxis__srt--MaximumMember_z6cGQBafzh33" title="Warrants exercise price per share">2.40</span> and expiring on various dates through November 9, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted-average exercise price for the outstanding warrants is $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20231231__us-gaap--AwardTypeAxis__custom--WarrantsMember_zBp9Z1KcgDz6" title="Weighted average exercise price">0.64</span>, and the weighted-average remaining contractual life as of December 31, 2023 is <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230701__20231231__us-gaap--AwardTypeAxis__custom--WarrantsMember_zyMHjFVsqIg1" title="Remaining contractual life">1</span> years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31, 2023, Smith elected to converted $<span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20230701__20231231__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__srt--TitleOfIndividualAxis__custom--PrincipalMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDG1pU9O9NZh" title="Debt conversion value">91,548</span> of principal from his Adjusted 2020 Convertible note into <span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230701__20231231__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjYWxW6cVlDf" title="Debt conversion shares">967,738</span> Units; each unit consisting of one share and one warrant with the exercise price of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqvhd03YTKak" title="Conversion price per share">.75</span> until July 21, 2026. Each of these warrants carry an exercise bonus of <span id="xdx_903_ecustom--ExerciseBonus_iI_dp_c20231231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYeJ2udFzs63" title="Exercise bonus">75</span>%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31, 2023, the Company entered into subscription agreements to sell <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zB8EMzkv2o06" title="Sale of stock, shares">28,589</span> units at a price of $<span id="xdx_90F_ecustom--SaleOfUnitPricePerUnit_iI_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zlYgxdaQJ2R1" title="Sale of units">1.60</span>, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_907_eus-gaap--SharePrice_iI_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zah7DpYTTrKi" title="Sell units">2.40</span> per share with an expiry date of June 30, 2024, and pursuant thereto, the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zDrZYFDHDAn5" title="Number of shares issued">28,589</span> units for total proceeds of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20230701__20231231__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZqbD2ULZqhi" title="Number of shares issued, value">45,742</span>. On September 26, the Company’s Board of Directors, due to a misunderstanding related to a private placement (memorandum of March 2023) and the securities sold thereunder, adjusted the units sold in the offering by substituting <span id="xdx_904_ecustom--SaleOfWarrants_c20230925__20230926_zMNZ1woMy9i1" title="Sale of warrants">1,003,590</span> warrants with an exercise price of $<span id="xdx_907_eus-gaap--WarrantExercisePriceIncrease_c20230925__20230926_zHs9iI7QD4tj" title="Warrant exercise price per share">1.25</span> per share for <span id="xdx_900_eus-gaap--SharesIssued_iI_c20230926_zzWOWo1eaNBg" title="Shares issued">501,795</span> previously issued warrants effective <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230926_zwqVBO5euWPc" title="Effective period">October 1, 2023</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">During the six months ended December 31, 2023, the Company approved the modification of existing warrants held by brokers, which extended certain expiration dates. The modifications resulted in interest  expenses of $<span id="xdx_90F_ecustom--InterestExpenses_pp0p0_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJJNYfPrM9ri" title="Interest expenses">135,207</span> and non-cash compensation of $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn7mKjAAJHqe" title="Non-cash compensation">15,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31, 2023, <span id="xdx_900_ecustom--ClassOfWarrantOrRightExercisedDuringPeriod_c20230701__20231231_zTx3jH0bnBX7" title="Class of warrant or right, exercised">38,000</span> warrants were exercised to purchase <span id="xdx_90F_ecustom--CommonStockSharesIssuedUponExerciseOfWarrants_c20230701__20231231_zXwdOT29DdCk" title="Common Stock Shares Issued upon Exercise of Warrants">38,000</span> shares of the Company’s common stock at $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyKCn621AmRc" title="Warrants exercisable per share">0.75</span> per share for total proceeds of $<span id="xdx_900_ecustom--WarrantsExercisedForCommonStock_pp0p0_c20230701__20231231_zgVwfiKhrHEa" title="Warrant Exercised for Common Stock">28,500</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31, 2023, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230701__20231231__srt--TitleOfIndividualAxis__custom--ConsultantService4Member__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zb7sjaNK0V2k" title="Shares issued for consultant services">50,000</span> warrants to a consultant for services. The warrants were issued for a total value of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20230701__20231231__srt--TitleOfIndividualAxis__custom--ConsultantService1Member__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zMRSExdUyfvb" title="Shares issued for consultant services, value">5,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended December 31, 2023, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230701__20231231__srt--TitleOfIndividualAxis__custom--ConsultantService4Member__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zA6vnhxzTBAa" title="Shares issued for cashless exercise">265,639</span> shares of the Company’s common stock upon cashless exercise of outstanding warrants held by non-affiliates of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective May 1, 2022, an entity affiliated with William O’Neill (“O’Neill”) was issued <span id="xdx_900_eus-gaap--SharesIssued_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zliQBL4Xcvt9" title="Number of shares issued">1,000,000</span> Incentive Warrants exercisable at $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pdd" title="Warrants exercisable per share">1.00</span> per share until April 30, 2026 of which up to <span id="xdx_908_ecustom--CancellationOfWarrants_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zHzGxmk7MQlk" title="Cancellation of warrants">700,000</span> Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a <span id="xdx_909_ecustom--ExercisePrice_iI_dp_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zKKu4g5QGnb4" title="Exercise price">75</span>% exercise price adjustment provision if the terms set forth therein are met. <span id="xdx_904_eus-gaap--SharesIssued_iI_c20231231__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJrpaqfXJRd" title="Number of shares issued">700,000</span> of the warrants are vesting through <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230701__20231231__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8SnaVDUOWfb" title="Vesting period">May 1, 2023</span>  and 2024. The vesting resulted in non-cash compensation of $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230701__20231231__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKLR5cVsUrah" title="Non cash compensation">6,563</span> for the six months ended December 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Stock options: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 7, 2022 the Company’s shareholders approved the Bion Environmental Technologies, Inc. 2021 Equity Incentive Award Plan (the “<span style="text-decoration: underline">Equity Plan</span>”). The Equity Plan provides for the issuance of options (and/or other securities) to purchase up to <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20220407__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zTjkAMAPJ6B5" title="Stock options, authorized">30,000,000</span> shares of the Company’s common stock. The Equity Plan was adopted and ratified by Board of Directors on April 8, 2022. Terms of exercise and expiration of options/securities granted under the Equity Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. No grants have been made pursuant to the Equity Plan as of the date of this report.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s 2006 Consolidated Incentive Plan, as amended during the year ended June 30, 2021 (the “2006 Plan”), provides for the issuance of options (and/or other securities) to purchase up to <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwkRfw0AP2A3" title="Stock options, authorized">36,000,000</span> shares of the Company’s common stock. Terms of exercise and expiration of options/securities granted under the 2006 Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. The 2006 Plan will be maintained to service grants already made thereunder (together with new grants, if any, to employees and consultants who already has received grants pursuant to its terms).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 15, 2023, the Company granted <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230314__20230315__us-gaap--PlanNameAxis__custom--Plan2006Member_zuVhMH2L1J9b" title="Number of shares granted">30,000</span> options under the 2006 Plan to two consultants. The options vested equally in thirds on March 20, 2023, June 20, 2023 and September 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 9, 2023, the Company granted <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230508__20230509__us-gaap--PlanNameAxis__custom--Plan2006Member_zfN5pDGhv49e" title="Number of shares granted">500,000</span> options under the 2006 Plan to Bill O’Neill. 250,000 of these options vest on June 1, 2024 and 250,000 options vest on June 1, 2025; all options expire on June 30, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded compensation expense related to employee stock options of $<span id="xdx_90A_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pp0p0_c20230701__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zj4kKaPe33D2" title="Compensation expense">107,487</span> and nil for the six months ended December 31, 2023 and 2022, respectively. The Company granted nil and nil options for the six months ended December 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">A summary of option activity under the 2006 Plan for six months ended December 31, 2023 is as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zLABFm6FxGn4" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left"><span id="xdx_8BA_zecn0t46zZ0c" style="display: none">Schedule of option activity</span> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left; font-size: 8pt"> </td><td style="padding-bottom: 1pt; font-size: 8pt"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Weighted- <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Weighted- <br/> Average <br/> Remaining <br/> Contractual <br/> Life</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 46%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Outstanding at July 1, 2023</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230701__20231231_zGTHXXBHc3Jk" style="width: 10%; font-size: 10pt; text-align: right" title="Options outstanding, beginning">12,006,600</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230701__20231231_zjKUXEFXvCfk" style="width: 10%; font-size: 10pt; text-align: right" title="Options outstanding, beginning weighted-average exercise price">0.85</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 10%; font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20220630_zNZa2FUYOg72" title="Outstanding, weighted-average remaining contractual life (Year)">1.83</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230701__20231231_z2xjibiG8dCf" style="width: 10%; font-size: 10pt; text-align: right" title="Outstanding, aggregate intrinsic value beginning">5,085,659</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Granted</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20231231_zHQ38kkHvnm7" title="Granted, options"><span style="-sec-ix-hidden: xdx2ixbrl1523">—</span></span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20231231_pdd" title="Granted, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1525">—</span></span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Exercised</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230701__20231231_pdd" title="Exercised, options"><span style="-sec-ix-hidden: xdx2ixbrl1527">—</span></span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230701__20231231_pdd" title="Exercised, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1529">—</span></span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Forfeited</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230701__20231231_pdd" title="Forfeited, options"><span style="-sec-ix-hidden: xdx2ixbrl1531">—</span></span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230701__20231231_pdd" title="Forfeited, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1533">—</span></span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Expired</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230701__20231231_zyX6w928iCc9" title="Expired, options"><span style="-sec-ix-hidden: xdx2ixbrl1535">—</span></span>  </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230701__20231231_pdd" title="Expired, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1537">—</span></span>  </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Outstanding at December 31, 2023</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230701__20231231_z2VwRdQ8n0eg" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Options outstanding, ending">12,006,600</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230701__20231231_zmhqTBIZmqci" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Options outstanding, ending weighted-average exercise price">0.85</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20231231_zr9WlYsYSD0d" title="Outstanding, weighted-average remaining contractual life (Year)">1.32</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230701__20231231_zR6QieXQA4M7" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Outstanding, aggregate intrinsic value ending">1,778,547</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zxGcsYaZwQy4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The total fair value of stock options that vested during the six months ended December 31, 2023 and 2022 was nil and nil, respectively. As of December 31, 2023, the Company had no unrecognized compensation cost related to stock options.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 3470000 1109649 1939670 424873 0.0946 0.0953 0.0953 0.115 3522000 14051 16861 200 0.01 2.00 0.025 100 41000 21000 1000 1000 0 -704309 28589 1.60 2.40 28589 45742 75000 1.00 1.25 75000 75000 300000 1.00 1.25 300000 300000 38000 38000 0.75 28500 91548 967738 0.75 7500 1.20 9000 10753 1.55 16667 2000 1.16 2320 15000 1.00 15000 21506 1.55 33334 265639 24000000 2.40 0.64 P1Y 91548 967738 0.75 0.75 28589 1.60 2.40 28589 45742 1003590 1.25 501795 2023-10-01 135207 15000 38000 38000 0.75 28500 50000 5000 265639 1000000 1.00 700000 0.75 700000 2023-05-01 6563 30000000 36000000 30000 500000 107487 <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zLABFm6FxGn4" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left"><span id="xdx_8BA_zecn0t46zZ0c" style="display: none">Schedule of option activity</span> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left; font-size: 8pt"> </td><td style="padding-bottom: 1pt; font-size: 8pt"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Weighted- <br/> Average <br/> Exercise <br/> Price</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Weighted- <br/> Average <br/> Remaining <br/> Contractual <br/> Life</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 46%; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Outstanding at July 1, 2023</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230701__20231231_zGTHXXBHc3Jk" style="width: 10%; font-size: 10pt; text-align: right" title="Options outstanding, beginning">12,006,600</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230701__20231231_zjKUXEFXvCfk" style="width: 10%; font-size: 10pt; text-align: right" title="Options outstanding, beginning weighted-average exercise price">0.85</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 10%; font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20220630_zNZa2FUYOg72" title="Outstanding, weighted-average remaining contractual life (Year)">1.83</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230701__20231231_z2xjibiG8dCf" style="width: 10%; font-size: 10pt; text-align: right" title="Outstanding, aggregate intrinsic value beginning">5,085,659</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Granted</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20231231_zHQ38kkHvnm7" title="Granted, options"><span style="-sec-ix-hidden: xdx2ixbrl1523">—</span></span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20231231_pdd" title="Granted, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1525">—</span></span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Exercised</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230701__20231231_pdd" title="Exercised, options"><span style="-sec-ix-hidden: xdx2ixbrl1527">—</span></span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230701__20231231_pdd" title="Exercised, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1529">—</span></span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Forfeited</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20230701__20231231_pdd" title="Forfeited, options"><span style="-sec-ix-hidden: xdx2ixbrl1531">—</span></span>  </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230701__20231231_pdd" title="Forfeited, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1533">—</span></span>  </td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">  Expired</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230701__20231231_zyX6w928iCc9" title="Expired, options"><span style="-sec-ix-hidden: xdx2ixbrl1535">—</span></span>  </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230701__20231231_pdd" title="Expired, weighted-average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1537">—</span></span>  </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 10pt">Outstanding at December 31, 2023</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230701__20231231_z2VwRdQ8n0eg" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Options outstanding, ending">12,006,600</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230701__20231231_zmhqTBIZmqci" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Options outstanding, ending weighted-average exercise price">0.85</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20231231_zr9WlYsYSD0d" title="Outstanding, weighted-average remaining contractual life (Year)">1.32</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230701__20231231_zR6QieXQA4M7" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Outstanding, aggregate intrinsic value ending">1,778,547</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> 12006600 0.85 P1Y9M29D 5085659 12006600 0.85 P1Y3M25D 1778547 <p id="xdx_806_ecustom--SubscriptionReceivableTextBlock_z4jT3ahj2PP" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>8.       <span id="xdx_82A_ztSb6aO0Jsh5">SUBSCRIPTION RECEIVABLE - AFFILIATES:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2023, the Company has three interest bearing, secured promissory notes with an aggregate principal amount of $<span id="xdx_90D_ecustom--FinancingReceivablePrincipalAmount_iI_pp0p0_c20231231__srt--CounterpartyNameAxis__custom--BassaniMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zFT7IK1JNRA1" title="Aggregate principal amount">428,250</span> ($<span id="xdx_905_eus-gaap--NotesReceivableNet_iI_pp0p0_c20231231__srt--CounterpartyNameAxis__custom--BassaniMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zyvwU8EgowAc" title="Notes receivable interest">526,142</span>, including interest) from Bassani which were received as consideration for purchases of warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zJD1WEKpAFoc" title="Purchases of warrants">5,565,000</span> shares, in aggregate, of the Company’s restricted common stock, which warrants have an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zkq2C0jgKsWh" title="Exercise price">0.75</span> (with a 75% exercise price adjustment provision) and have expiry dates ranging from December 31, 2024 to December 31, 2025 (subject to extension rights) secured by portions of Bassani Family Trust’s 2020 Convertible Obligation and Bassani Family Trust’s September 2015 Convertible Notes. The secured promissory notes are payable July 1, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> As of December 31, 2023, the Company has an interest bearing, secured promissory note for $<span id="xdx_90B_ecustom--FinancingReceivablePrincipalAmount_iI_pp0p0_c20231231__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zqmr6xSMvcJh" title="Aggregate principal amount">30,000</span> ($<span id="xdx_906_eus-gaap--NotesReceivableNet_iI_pp0p0_c20231231__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_ze6EOjzJEM58" title="Notes receivable interest">36,487</span> including interest) from Smith as consideration to purchase warrants to purchase 300,000 shares of the Company’s restricted common stock, which warrants are exercisable at $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssuedSubscriptionReceivableMember_zUjCgNAWaVLi" title="Exercise price">0.60</span> (with a 75% exercise price adjustment provision) and have expiry dates of December 31, 2024 (subject to extension rights) The promissory note bears interest at <span id="xdx_90C_ecustom--FinancingReceivableInterestRateStatedPercentage_iI_dp_c20231231__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zWda9Xl3cMUg" title="Financing receivable interest rate stated percentage">4</span>% per annum, and is secured by $<span id="xdx_907_ecustom--FinancingReceivablePrincipalAmount_iI_pp0p0_c20231231__srt--TitleOfIndividualAxis__custom--SmithsMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zNutdpTJutEa" title="Aggregate principal amount">30,000</span> original principal ($<span id="xdx_906_eus-gaap--NotesReceivableNet_iI_pp0p0_c20231231__srt--TitleOfIndividualAxis__custom--SmithsMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zYLMAmxmAwE5" title="Notes receivable interest">37,157</span> including interest) of Smith’s 2020 Convertible Obligations. The secured promissory note is payable on July 1, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2023, the Company has two interest bearing, secured promissory notes with an aggregate principal amount of $<span id="xdx_90D_ecustom--FinancingReceivablePrincipalAmount_pp0p0_c20231231__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zZOYl0WW8xXk" title="Aggregate principal amount">46,400</span> ($<span id="xdx_902_eus-gaap--NotesReceivableNet_pp0p0_c20231231__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_z9f9L33obASg" title="Notes receivable interest">57,790</span> including interest) from two employee/consultants as consideration to acquire warrants to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssuedSubscriptionReceivableMember_zrHnZhFj1N4l" title="Purchases of warrants">928,000</span> shares of the Company’s restricted common stock, which warrants are exercisable at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssuedSubscriptionReceivableMember_zlTz70Csscdg" title="Exercise price">0.75</span> (with a 90% exercise price adjustment provision) and have expiry dates of December 31, 2024. (The promissory notes bear interest at <span id="xdx_906_ecustom--FinancingReceivableInterestRateStatedPercentage_iI_dp_c20231231__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_z2ZMJmxGbP6e" title="Financing receivable interest rate stated percentage">4</span>% per annum, are secured by a perfected security interest in the warrants, and are payable on July 1, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify">These secured promissory notes are recorded as “Subscription receivable—affiliates” on the Company’s balance sheet pending payment.</p> 428250 526142 5565000 0.75 30000 36487 0.60 0.04 30000 37157 46400 57790 928000 0.75 0.04 <p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zbYTpb9nN6hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>9.       <span id="xdx_82A_z6wvex7KlVaa">COMMITMENTS AND CONTINGENCIES:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>A: Employment and consulting agreements:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Smith has held the positions of Director, Executive Chairman, President and General Counsel of Company and its subsidiaries under various agreements (and extensions) and terms since March 2003. On October 10, 2016, the Company approved a month-to-month contract extension with Smith which included provisions for i) a monthly salary of $<span id="xdx_901_ecustom--MonthlyOfficersCashCompensation_c20161009__20161010__srt--TitleOfIndividualAxis__srt--PresidentMember_zedDs9XhXaxj" title="Monthly officers cash compensation">18,000</span> ( deferred until the Board of Directors re-instated cash payments to all employees and consultants who are deferring compensation), ii) the right to convert up to $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230331__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_zKDYntDPv8B1" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">300,000</span> of his deferred compensation, at his sole election, at $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember_zstPB24euD3c" title="Warrants exercisable per share">0.75</span> per share, until December 31, 2024, and iii) the right to convert his deferred compensation in whole or in part, at his sole election, at any time in any amount at “market” or into securities sold in the Company’s current/most recent private offering at the price of such offering to third parties. Smith agreed effective July 29, 2018 to continue to serve the Company under the same basic terms on a month-to-month basis. On May 1, 2022 Smith’s compensation was increased to $<span id="xdx_90B_ecustom--CompensationIncreased_c20220427__20220502_z6UCbvRmZ9Ld" title="Compensation increased">25,000</span> per month of which $5,000 per month is deferred. Currently Smith is deferring all of his monthly compensation to help the Company conserve cash. For the three months ended December 31, 2023 and 2022, Smith was paid $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20231001__20231231__srt--CounterpartyNameAxis__custom--SmithMember_zeDnI9spGGT6" title="Cash compensation paid">5,000</span> and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20221001__20221231__srt--CounterpartyNameAxis__custom--SmithMember_zsuQwzDo25i9" title="Cash compensation paid">60,000</span>, respectively, of cash compensation. For the six months ended December 31, 2023 and 2022, Smith was paid $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20230701__20231231__srt--CounterpartyNameAxis__custom--SmithMember_zrCjq3UlycKl" title="Cash compensation paid">20,000</span> and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20221231__srt--CounterpartyNameAxis__custom--SmithMember_zlUUIGsvZH83" title="Cash compensation paid">100,000</span>, respectively, of cash compensation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since March 31, 2005, the Company has had various agreements with Dominic Bassani (and/or Brightcap which provided his services during some of the years) <b>(NOTE: Dominic Bassani passed away on October 11, 2023.</b>) who was serving as the Company’s Chief Operating Officer (‘COO’) at the time of his passing and formerly served as the Company’s Chief Executive Officer (‘CEO’) for the prior decade (any reference to Brightcap or Bassani for all purposes are referring to the same individual). The Board appointed Bassani as the Company's CEO effective May 13, 2011. On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017 (with the Company having an option to extend the term an additional six months.) Pursuant to the Extension Agreement, Bassani continued to defer his cash compensation ($<span id="xdx_909_ecustom--MonthlyOfficersCashCompensation_pp0p0_c20150203__20150210__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zNhIkAt4x8j2" title="Monthly officers cash compensation">31,000</span> per month) until the Board of Directors re-instated cash payments to all employees and consultants who were deferring their compensation. During October 2016 Bassani was granted the right to convert up to $<span id="xdx_908_ecustom--DeferredCompensationMaximumConvertibleAmount_iI_pp0p0_c20161031__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_zIGtO2zfnSk3" title="Deferred compensation">125,000</span> of his deferred compensation, at his sole election, at $<span id="xdx_900_ecustom--DeferredCompensationStockConversionPricePerShare_iI_c20161031__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_zMaqLheSPEhc" title="Deferred compensation, price per share">0.75</span> per share, until March 15, 2018 (which was expanded on April 27, 2017 to the right to convert up to $<span id="xdx_90A_ecustom--DeferredCompensationMaximumConvertibleAmount_iI_pp0p0_c20170427__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_zdGoryzN2oD8" title="Deferred compensation">300,000</span> of his deferred compensation, at his sole election, at $<span id="xdx_906_ecustom--DeferredCompensationStockConversionPricePerShare_c20170427__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_pdd" title="Deferred compensation, price per share">0.75</span> per share, until June 30, 2024 (including extensions). During February 2018, the Company agreed to the material terms for a binding two-year extension agreement for Bassani’s services as CEO. Bassani’s salary remained $<span id="xdx_90C_eus-gaap--AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent_c20180228__srt--TitleOfIndividualAxis__custom--BassaniMember_pp0p0" title="Salaries and wages">31,000</span> per month, which will continue to be accrued in part during periods when the Board determines there is not adequate cash available. Additionally, the Company agreed to pay or accrue $<span id="xdx_90D_eus-gaap--OtherAdditionalCapital_c20180228__srt--TitleOfIndividualAxis__custom--BassaniMember_pp0p0" title="Additional paid amount">2,000</span> per month to be applied to life insurance premiums (which sums have been accrued as liabilities). On August 1, 2018, in the context of extending his agreement to provide services to the Company on a full-time basis through December 31, 2022) plus 2 years after that on a part-time basis, the Company received an interest bearing secured promissory note for $<span id="xdx_90D_ecustom--InterestBearingSecuredPromissoryNote_pp0p0_c20180728__20180801__srt--TitleOfIndividualAxis__custom--BassaniMember_zplKuVQ0sNGd" title="Interest bearing secured promissory note">300,000</span> from Bassani as consideration to purchase warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20180801__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsExpiringOnDecember312025Member_zpglGdpUyeWa" title="Warrants purchase">3,000,000</span> shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of June 30, 2025. The promissory note is secured by a portion of Bassani’s 2020 Convertible Obligations and as of June 30, 2023, the principal and accrued interest was $<span id="xdx_90C_eus-gaap--NotesReceivableNet_iI_pp0p0_c20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member_zTAj7qhFzikk" title="Principal and accrued interest">364,490</span>. For the three months ended December 31, 2023 and 2022, Brightcap was paid $<span id="xdx_904_eus-gaap--RepaymentsOfLongTermDebt_pp0p0_c20231001__20231231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member_zmg1iLgVaq25" title="Repayments of compensation">5,000</span> and $<span id="xdx_902_eus-gaap--RepaymentsOfLongTermDebt_pp0p0_c20221001__20221231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member_zpuNbJhEOry1" title="Repayments of compensation">75,500</span>, respectively, of cash compensation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">William O’Neill (“O’Neill”) was hired as the Company’s Chief Executive Officer (“CEO”) effective May 1, 2022.  O’Neill had previously been working with the Company as a consultant and had been employed by the Company as its CEO during 2010-2011. (Upon the hiring of O’Neill, Bassani, CEO of the Company since 2011, assumed the position of COO while retaining existing operational management responsibilities and working with O’Neill on ‘commercialization’ of the Company’s technology and work related to JVs (and other transactions) based on the Company’s Gen3 Technology and related matters until his recent death. Bassani’s compensation arrangements with the Company were not altered in the context of the change of positions.) The Company and O’Neill entered into a thirty-seven (37) month employment agreement with compensation of $<span id="xdx_90C_ecustom--MonthlyOfficersCashCompensation_pp0p0_c20231001__20231231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zXLy1me2dvJ" title="Monthly officers cash compensation">25,000</span> cash and $<span id="xdx_90F_ecustom--DeferredCompensationMaximumConvertibleAmount_iI_pp0p0_c20231231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z3iofK6BoEXl" title="Deferred Compensation, Maximum Convertible Amount">10,000</span> deferred compensation per month. The cash payment is paid $<span id="xdx_900_eus-gaap--PaymentsForFees_c20220427__20220502__srt--CounterpartyNameAxis__custom--WilliamONeillMember_zbteU8ZLwft1" title="Payment for cash">12,500</span> to O’Neill and $12,500 to an entity affiliated with O’Neill. An entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share (a 75% exercise price adjustment provision if the terms set forth therein are met) until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. Currently O’Neill is deferring all of his monthly compensation to help the Company conserve cash. For the three months ended December 31, 2023 and 2022, O’Neill and the entity affiliated with O’Neill were paid $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_pp0p0_c20231001__20231231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zOvGmeJpxjf2" title="Cash compensation paid">42,500</span> and $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20221001__20221231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zsV6lp2BvZge" title="Cash compensation paid">75,000</span>, respectively, of cash compensation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>B: Exercise Price Adjustments/Extension Rights:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of agreements the Company entered into with Bassani and Smith effective May 15, 2013, they were each granted the following: a) a 50% execution/exercise price adjustment provision (exercise bonus in the context of options) which shall be applied upon the effective date of the notice of intent to exercise (for options and warrants) or issuance event, as applicable, of any currently outstanding and/or subsequently acquired options, warrants and/or contingent stock bonuses owned by each (and/or their donees) as follows: i) in the case of exercise by payment of cash, the bonus shall take the form of reduction of the exercise price; ii) in the case of cashless exercise, the adjustment shall be applied to reduce the exercise price prior to the cashless exercise calculations; and iii) with regard to contingent stock adjustments, issuance shall be triggered upon the Company’s common stock reaching a closing price equal to 50% of currently specified price; and b) the right to extend the exercise period of all or part of the applicable options and warrants for up to five years (one year at a time) by annual payments of $.05 per option or warrant to the Company on or before a date during the three months prior to expiration of the exercise period at least three business days before the end of the expiration period. Effective January 1, 2016 such annual payments to extend warrant exercise periods were reduced to $.01 per option or warrant. These exercise adjustments were subsequently increased to 75%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2021, the Company added a <span id="xdx_906_ecustom--ExerciseBonus_iI_dp_c20210630_zch7UBISubxj" title="Exercise bonus">75</span>% exercise price adjustment to the terms of <span id="xdx_903_ecustom--WarrantsHeldByTrustOwnedShares_iI_pp0p0_c20210630_zlDUqNKshiL" title="Warrants held by trust owned">3,000,000</span> warrants held by a trust owned by Bassani.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2023, exercise price adjustment provisions ranging from <span id="xdx_90D_ecustom--ExerciseBonus_iI_dp_c20231231__srt--RangeAxis__srt--MinimumMember_zBmztnXV0Sp7" title="Exercise bonus">50</span>-<span id="xdx_902_ecustom--ExerciseBonus_iI_dp_c20231231__srt--RangeAxis__srt--MaximumMember_zWINiyfnIbK1" title="Exercise bonus">90</span>% were applicable to 11,771,600 of the Company’s outstanding options and <span id="xdx_90C_ecustom--WarrantsAndRightsOutstandingShares_iI_pp0p0_c20231231_za8FoWpMvcPc" title="Warrants and rights outstanding">20,415,408</span> of the Company’s outstanding warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective May 1, 2022, an entity affiliated with O’Neill was issued <span id="xdx_903_eus-gaap--SharesIssued_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_za5mPEdsaWOc" title="Number of shares issued">1,000,000</span> Incentive Warrants exercisable at $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zIaWZSS7YdTk" title="Warrants exercisable per share">1.00</span> per share until April 30, 2026 of which up to <span id="xdx_904_ecustom--CancellationOfWarrants_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zP48wHj3vxre" title="Cancellation of warrants">700,000</span> Incentive Warrants were cancellable if O’Neill was not renewed at 13 months (renewal has happened) and/or fails to serve the entire contract term thereafter. These warrants each have a <span id="xdx_905_ecustom--ExerciseBonus_iI_dp_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zzbt8Qep5Y27" title="Exercise bonus">75</span>% exercise price adjustments if the terms set forth therein are met.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>C: Initial Project:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"><span style="background-color: white">On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $<span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20220127__20220128_zqvluKPqSesa" title="Debt instrument paid amount">2,665,500</span> (and made the initial <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220127__20220128_zXNlXpBgEuwb" title="Debt instrument, interest rate">25</span>% payment ($<span id="xdx_903_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20220127__20220128_zfg7NjZDeUuh" title="Principal, interest">666,375</span>) for the core of the ‘Bion System’ portion (without the crystallization modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. The Company received progress billing in March 2022 and June 2022 for the second and third <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220301__20220331_zQhUfXYdcBLk" title="Debt instrument, interest rate"><span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220601__20220630_zi9ocvKphCdl" title="Debt instrument, interest rate">25</span></span>% installments, both of which have been paid as of the filing date. On January 17, 2023 the Company received an invoice from Buflovak for $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20230116__20230117_zyKT7JIII1G6" title="Principal, interest">533,100</span> which was paid on March 1, 2023 and on April 24, 2023 the Company received an invoice from Buflovak for $<span id="xdx_901_eus-gaap--PrepaidExpenseAndOtherAssets_iI_c20230502_zXHet1GTYP0i" title="Paid invoice amount">83,275</span> which was paid on May 2, 2023 bringing the aggregate payments to $<span id="xdx_905_ecustom--AggregatePayment_pp0p0_c20230501__20230502_zvBRfmJ4X9J8" title="Aggregate payment">2,615,500</span> as of the date of this filing. There remains $<span id="xdx_903_ecustom--PurchaseOrder_pp0p0_c20220429__20220430_zQb1135JPiI8" title="Purchase order">50,000</span> open on the Purchase Order has been billed on July 26, 2023. In addition to the Purchase Order, through December 31, 2023 the Company has incurred additional costs of <span id="xdx_90C_eus-gaap--InterestCostsIncurredCapitalized_pp0p0_c20230701__20231231_zYDy8TLIOJig" title="Capitalized labour and interest costs">6,442,812</span> on the Initial Project for capitalized interest and costs, non-cash compensation, equipment and consulting fees. $<span id="xdx_905_ecustom--InterestCostsCapitalizedPaid_pp0p0_c20230701__20231231_zbssEO4FChp9" title="Capitalized labour and interest costs paid">6,983,954</span> has been paid and $<span id="xdx_90E_eus-gaap--InterestCostsCapitalizedAdjustment_pp0p0_c20230701__20231231_z567ik9ymfT8" title="Capitalized labour and interest costs yet to pay">1,750,170</span> has been billed and not yet paid. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"><span style="background-color: white">Buflovak has worked with the Company on design and testing of its 3G Tech over several years. The basic design for the Initial Project’s Bion System is complete, fabrication and delivery of equipment from Buflovak from the Purchase Order Agreement has been largely completed and assembly/construction is in process.  3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, utilities, etc.) for work related to the Initial Project. The Company has incurred costs </span>of $<span id="xdx_909_ecustom--InterestsCostsIncurredCapitalized_pp0p0_c20230701__20231231_zbvJYD2wr8i3" title="Interests costs incurred capitalized">8,177,452</span> on t<span style="background-color: white">he Initial Project, not including capitalized labor and interest.</span></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"><span style="background-color: white">The Initial Project was deemed to have been ‘placed in service’ on January 1, 2024 (Note 10).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>D: Lease:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The future minimum lease payment under noncancelable operating lease with terms greater than one year as of December 31, 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--ScheduleOfFutureMinimumLeasePaymentsForCapitalLeaseTableTextBlock_z1w5cJzjfIfj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8B6_z5jE9fTKfPo4" style="display: none">Schedule of future minimum lease payment</td><td> </td> <td id="xdx_494_20231231_zPFohLi4ZcDa" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--OperatingLeasesFutureMinimumPaymentReceivableInTwoYears_iI_pp0p0_zoMCd2zTni49" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; width: 84%">From January 2024 to December 2024</td><td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">75,000</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--UndiscountedCashFlow_iI_pp0p0_zGBLRVvJ14X3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Undiscounted cash flow</td><td> </td> <td style="text-align: right">75,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--LessImputedInterest_iI_pp0p0_zIyMHM5c80Hf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(3,909</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--CapitalLeaseContingentRentalPaymentsDue_iI_pp0p0_zep2bVhoee44" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">71,091</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> <span style="text-underline-style: double"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of December 31, 2023 were 1 years and 10%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>E: Litigation (and related matters):</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">1)  Website: Domain Sale/Resolved Litigation/Hacking/Theft</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 23, 2022 <span id="xdx_901_ecustom--SaleOfDomainDescription_c20220322__20220323_zL0d9B8jqrY6" title="Sale of domain, description">the Company entered into an agreement to sell domain name &lt;biontech.com&gt; and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490.</span> The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name &lt;biontech.com&gt; no longer represented a core asset of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the &lt;biontech.com&gt; domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and &lt;biontech.com&gt;, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name &lt;biontech.com&gt; ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and &lt;biontech.com&gt;, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name &lt;biontech.com&gt; to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations were subjected to disruption and expenses were incurred related to the matter including legal fees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">2)  Pennvest Loan and Dissolution of Bion PA1, LLC (“PA1”)</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $<span id="xdx_904_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pp0p0_c20211229_zMNr8E3ZOUJ9" title="Accrued interest">2,255,802</span> as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $<span id="xdx_90C_eus-gaap--Assets_iI_pp0p0_c20210930_zoJZOzJVCfYb" title="Total assets">297</span> and its total liabilities were $<span id="xdx_900_eus-gaap--Liabilities_iI_pp0p0_c20210930_zxMJpoE5tBbj" title="Total liabilities">10,154,334</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_90B_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pp0p0_c20210930_ztL4XTsKZ9db" title="Accounts payable and accrued liabilities">9,939,148</span>, accounts payable of $<span id="xdx_906_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20210930_zkALb3IJmjn2" title="Accounts payable">214,235</span> and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s consolidated balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $<span id="xdx_90B_eus-gaap--Liabilities_iI_pp0p0_c20211229_zr9Ki1Apin6d" title="Total liabilities">10,234,501</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_908_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pp0p0_c20211229_ztFqgCo7nag6" title="Accounts payable and accrued liabilities">10,009,802</span>, accounts payable of $212,263 and accrued liabilities of $<span id="xdx_90F_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20211229_zDrvlCJZtnaj" title="Accrued liabilities, current">12,436</span>. The net amount of $<span id="xdx_908_eus-gaap--ExtinguishmentOfDebtGainLossNetOfTax_pp0p0_c20230701__20231231_zAcxHN8FLMnb" title="Gain on legal dissolution of subsidiary">10,234,501</span> was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As background, the terms of the Pennvest Loan provided for funding of up to $<span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zbqIrGO7EFn3" title="Line of credit facility, maximum borrowing capacity">7,754,000</span> which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20230701__20231231__srt--StatementScenarioAxis__custom--YearsOneThroughFiveMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zNqhXUweOmEh" title="Debt instrument, interest rate">2.547</span>% per annum for years 1 through 5 and <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20230701__20231231__srt--StatementScenarioAxis__custom--YearsSixThroughMaturityMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zF8Wf2p1vKid" title="Debt instrument, interest rate">3.184</span>% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $<span id="xdx_903_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zUC5ieQLa9ae" title="Principal payment">5,886,000</span> in fiscal years 2013 through 2021, and $<span id="xdx_906_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zEcOhsAMcBYf" title="Long-Term debt, maturity, year two">846,000</span> in fiscal year 2022, $<span id="xdx_900_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_z6Zx6nuUqUs8" title="Long-Term debt, maturity, year three">873,000</span> in fiscal year 2023 and $<span id="xdx_90A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_c20231231__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zPLUj2CmVf99" title="Long-Term debt, maturity, year four">149,000</span> in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $<span id="xdx_90A_eus-gaap--InterestExpenseDebt_pp0p0_c20210701__20220630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zDTvdJu3LGtl" title="Interest expense, debt">123,444</span> and $<span id="xdx_90F_eus-gaap--InterestExpenseDebt_pp0p0_c20200701__20210630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zPHt2TRbcIra" title="Interest expense, debt">246,887</span> for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $<span id="xdx_90C_eus-gaap--LinesOfCreditCurrent_iI_pp0p0_c20210630_zx8SkdCeOonh" title="Loans as a liability">9,868,495</span> despite the fact that the obligation (if any) was solely an obligation of PA1<b>. </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $<span id="xdx_907_eus-gaap--DebtDefaultLongtermDebtAmount_iI_pp0p0_c20140925__dei--LegalEntityAxis__custom--PA1Member_zBewwgOKrIX6" title="Principal amount">8,137,117</span> (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest set forth above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception, and no payment will be made to the Company or any affiliate in connection with the dissolution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>3)  Bank Account Hacking </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 23, 2023, an officer of the Company with personal accounts with Signature Bank was hacked and $<span id="xdx_906_ecustom--BankAccountHackedAmount_c20230622__20230623_zKAfYt3WtJ27" title="Bank account hacked amount">75,000</span> was transferred from the Company’s accounts at Signature Bank to the officer’s personal accounts. The bank was notified and all Company accounts were placed on hold. Subsequently, the funds were released and transferred back to the Company prior to June 30, 2023, the end of the fiscal year, and there were no losses incurred.  The Company has reviewed the authorized individuals on all accounts and further limited access after the hacking incident.  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company currently is not involved in any other material litigation or similar events.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>4)  Bridge Loan/Default</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 29, 2023 the Company entered into an agreement for a $<span id="xdx_907_eus-gaap--ConvertibleDebt_iI_pp0p0_c20230929__srt--TitleOfIndividualAxis__custom--SEBFarmsLLCMember_zCD0lhxYTUF2" title="Bridge loan">1,500,000</span> Bridge Loan and executed documents including a convertible promissory note (“Note”) and a binding subscription agreement (“Subscription”) (collectively the Note and the Subscription are the “Bridge Loan Agreements”) with SEB LLC, a non-affiliated party (“Lender”). The Bridge Loan Agreements require the Lender to loan the Company $<span id="xdx_908_eus-gaap--ConvertibleDebt_iI_pp0p0_c20230929__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementsMember_zrUIxv1q6jpj" title="Bridge loan">1,500,000</span> in six monthly tranches of $<span id="xdx_906_eus-gaap--ConvertibleDebt_iI_c20231031__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementsMember_zSdzztn7hsC5" title="Bridge loan">250,000</span> commencing October 2023. All sums advanced under the Bridge Loan Agreements (and accrued interest thereon) would due and payable (with interest accrued at <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20230929__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementsMember_zSuumOm2Djvk" title="Interest accrued percentage">8</span>% per annum) on October 1, 2024 if not previously converted into securities of the Company. The Note is convertible at $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230929__us-gaap--TypeOfArrangementAxis__custom--BridgeLoanAgreementsMember_zPHcQXJeZ1j7" title="Convertible price">1.00</span> per unit, at the sole election of the Lender, into units consisting of one share of the Company’s Common Stock and a warrant to purchase one-half share. The initial $<span id="xdx_907_ecustom--InitialTranche_pp0p0_c20231003__20231005_zfDbEMBaWQrf" title="Initial tranche">250,000</span> tranche was received by the Company on October 5, 2023. However, no further funds were received by the Company from the Lender. During early November 2023 the Lender informed the Company verbally that it did not intend to fulfill its obligations pursuant to the Bridge Loan Agreements and since such time the lender has been in default (“Default”). The Default (which is continuing) has created substantial problems for and materially damaged the Company and rendered the Company unable to meet its current creditor obligations on a timely basis. The Company is currently evaluating its rights regarding the Default by the Lender.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 18000 300000 0.75 25000 5000 60000 20000 100000 31000 125000 0.75 300000 0.75 31000 2000 300000 3000000 364490 5000 75500 25000 10000 12500 42500 75000 0.75 3000000 0.50 0.90 20415408 1000000 1.00 700000 0.75 2665500 0.25 666375 0.25 0.25 533100 83275 2615500 50000 6442812 6983954 1750170 8177452 <table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--ScheduleOfFutureMinimumLeasePaymentsForCapitalLeaseTableTextBlock_z1w5cJzjfIfj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8B6_z5jE9fTKfPo4" style="display: none">Schedule of future minimum lease payment</td><td> </td> <td id="xdx_494_20231231_zPFohLi4ZcDa" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--OperatingLeasesFutureMinimumPaymentReceivableInTwoYears_iI_pp0p0_zoMCd2zTni49" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; width: 84%">From January 2024 to December 2024</td><td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">75,000</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--UndiscountedCashFlow_iI_pp0p0_zGBLRVvJ14X3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Undiscounted cash flow</td><td> </td> <td style="text-align: right">75,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--LessImputedInterest_iI_pp0p0_zIyMHM5c80Hf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(3,909</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--CapitalLeaseContingentRentalPaymentsDue_iI_pp0p0_zep2bVhoee44" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">71,091</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 75000 75000 -3909 71091 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. 2255802 297 10154334 9939148 214235 10234501 10009802 12436 10234501 7754000 0.02547 0.03184 5886000 846000 873000 149000 123444 246887 9868495 8137117 75000 1500000 1500000 250000 0.08 1.00 250000 <p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zAQsPeLzrrSg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>10.       <span id="xdx_829_z6xD1aNQOjRl">SUBSEQUENT EVENTS:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #500050"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">The Company is in discussion/negotiation with its largest creditor--the primary contractor on the Initial Project-- and anticipates reaching agreement regarding payment of its accrued obligations during the current quarter. The Company is also involved in discussions and negotiations with other creditors.   </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On January 1, 2024 the Initial Project was ‘placed into service’ with a total capitalized cost of $<span id="xdx_90D_eus-gaap--CapitalizedContractCostAmortization_c20231229__20240102_zj9tRkVhvlMd" title="Capitalized cost">9,108,312</span>. During the current quarter the Company will commence depreciation of this asset.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">On January 1, 2024, Smith elected to convert the $<span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20240101__20240102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcsnpsFpbfyj" title="Debt conversion value">49,403</span> remaining balance of his Adjusted 2020 Convertible note into <span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20240101__20240102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgmRdglWIfm8" title="Debt conversion shares">522,231</span> units (each unit consisting of one share and one warrant with the exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8PmNOqF0dZ7" title="Exercise price">.75</span> until July 21, 2026). Smith made gifts/donations of 122,231 units and 200,000 to his spouse. </p> <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white; color: #222222"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On January 18, 2024, the Company entered into a subscription agreement to sell <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240117__20240118__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkmNVNC0suhf" title="Sale of units">10,000</span> units at a price of $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_c20240118__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUBWP00feSd6" title="Sale of units, price per unit">1.00</span>, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20240118__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWSvGRhwseB1" title="Sale of units, price per share">1.25</span> per share with an expiry date of <span id="xdx_90D_eus-gaap--StockRepurchaseProgramExpirationDate_dd_c20240117__20240118__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkt4SYWbB8Jl" title="Expiry date">December 31, 2024</span>, and pursuant thereto, the Company issued 10,000 units for total proceeds of $<span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240117__20240118__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zbQPlt7Op30h" title="Proceeds from sale of units">10,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #222222"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="color: #222222">From January 1, 2024 to February 13, 2024, the Company issued </span><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240213__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2TeOA4H9Tlc" title="Number of warrants or rights outstanding">3,307,516</span> <span style="color: #222222">shares of the Company’s common stock upon cashless exercise of outstanding warrants held by non-affiliates of the Company.</span></p> <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0; background-color: white; color: #222222"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="color: #222222">From January 1, 2024 to February 13, 2024, the Company issued </span><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240213__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--CounterpartyNameAxis__custom--SmithMember_ziBD34MTVqL5" title="Number of warrants or rights outstanding">2,439,428</span> <span style="color: #222222">shares of the Company’s common stock upon cashless exercise of outstanding warrants held by Mark Smith (which includes</span> 700,062<span style="color: #222222"> by his wife.)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: yellow"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 9108312 49403 522231 0.75 10000 1.00 1.25 2024-12-31 10000 3307516 2439428